
<html lang="en"     class="pb-page"  data-request-id="da333b5f-5224-4290-99fc-48a6d139e3af"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2018.61.issue-24;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00876;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles" /></meta><meta name="dc.Creator" content="Michael&#xA;D.  Delost" /></meta><meta name="dc.Creator" content="David T.  Smith" /></meta><meta name="dc.Creator" content="Benton J.  Anderson" /></meta><meta name="dc.Creator" content="Jon T.  Njardarson" /></meta><meta name="dc.Description" content="Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our databas..." /></meta><meta name="Description" content="Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our databas..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 19, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00876" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00876" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00876" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00876" /></link>
        
    
    

<title>From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00876" /></meta><meta property="og:title" content="From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0001.jpeg" /></meta><meta property="og:description" content="Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00876"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00876">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00876&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00876&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00876&amp;href=/doi/10.1021/acs.jmedchem.8b00876" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10996-11020</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00588" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01291" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael D. Delost</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Delost</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael%0AD.++Delost">Michael D. Delost</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David T. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David T. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+T.++Smith">David T. Smith</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benton J. Anderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benton J. Anderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benton+J.++Anderson">Benton J. Anderson</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jon T. Njardarson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon T. Njardarson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 520-626-0754. E-mail: <a href="/cdn-cgi/l/email-protection#147a7e756670756667547179757d783a75667d6e7b7a753a717061"><span class="__cf_email__" data-cfemail="701e1a11021411020330151d11191c5e1102190a1f1e115e151405">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+T.++Njardarson">Jon T. Njardarson</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2268-1479" title="Orcid link">http://orcid.org/0000-0003-2268-1479</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00876&amp;href=/doi/10.1021%2Facs.jmedchem.8b00876" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10996–11020</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 June 2018</li><li><span class="item_label"><b>Published</b> online</span>19 July 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 December 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00876" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00876</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10996%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMichael%250AD.%2BDelost%252C%2BDavid%2BT.%2BSmith%252C%2BBenton%2BJ.%2BAnderson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D24%26contentID%3Dacs.jmedchem.8b00876%26title%3DFrom%2BOxiranes%2Bto%2BOligomers%253A%2BArchitectures%2Bof%2BU.S.%2BFDA%2BApproved%2BPharmaceuticals%2BContaining%2BOxygen%2BHeterocycles%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11020%26publicationDate%3DDecember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00876"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5460</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">85</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00876" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael\nD.&quot;,&quot;last_name&quot;:&quot;Delost&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;T. Smith&quot;},{&quot;first_name&quot;:&quot;Benton&quot;,&quot;last_name&quot;:&quot;J. Anderson&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;T. Njardarson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10996-11020&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00876&quot;},&quot;abstract&quot;:&quot;Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00876&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00876" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00876&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00876" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00876&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00876" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00876&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00876&amp;href=/doi/10.1021/acs.jmedchem.8b00876" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00876" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00876" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00876%26sid%3Dliteratum%253Aachs%26pmid%3D30024747%26genre%3Darticle%26aulast%3DDelost%26date%3D2018%26atitle%3DFrom%2BOxiranes%2Bto%2BOligomers%253A%2BArchitectures%2Bof%2BU.S.%2BFDA%2BApproved%2BPharmaceuticals%2BContaining%2BOxygen%2BHeterocycles%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D24%26spage%3D10996%26epage%3D11020%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290921" title="Heterocyclic compounds">Heterocyclic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292534" title="Oxygen">Oxygen</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/jmcmar.2018.61.issue-24/20181227/jmcmar.2018.61.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes rounding off the top five. The main body of this Perspective is organized according to ring size, commencing with three- and four-membered rings and ending with macrocycles, polymers, and unusual oxygen-containing heterocycles. For each section, all oxygen heterocycle-containing drugs are presented along with a brief discussion about structural and drug application patterns.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inspired by how much was learned by assembling and analyzing the 640 small molecule drugs containing nitrogen heterocycles<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> as well as other educational endeavors,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> a similar study for oxygen heterocycles has now been completed. Analysis of our drug database (through 2017) unearthed a total of 311 unique oxygen heterocycle-containing pharmaceuticals, which is a significant representation (about 27% of unique approved small molecules and 15% of all approved drugs). In comparison, our group’s 2016 top 200 pharmaceutical prescription and retail sales posters reveal 17% and 16% representation of oxygen-heterocycle containing pharmaceuticals, respectively.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Many of these drugs contain more than one oxygen heterocycle with a total of 389 oxygen heterocycles being part of these 311 drugs. For example, recently approved eteplirsen and mipomersen contain 30 and 20 oxygen heterocycles, respectively. In the context of the evolutionarily selected structures carbohydrates and nucleosides, it is unsurprising that pyranoses and furanoses are the top two most frequently employed oxygen heterocycles. In this Perspective, all 311 U.S. FDA approved drugs containing oxygen heterocycles are presented, analyzed, and discussed in sections organized according to ring size or unique common structural features.</div><div class="NLM_p">The breakdown of the 389 oxygen heterocycles that are components of the 311 identified oxygen heterocyclic drugs is presented according to ring size and presence or absence of aromaticity in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The majority (89%) of the oxygen heterocycles are nonaromatic; 95% of aromatic are five-membered rings. These numbers are significantly higher than for their nitrogen heterocyclic counterparts where 70% are nonaromatic and 60% of the aromatic heterocycles are five-membered rings. With respect to ring size, five- and six-membered rings reign supreme (84% total) with 46% and 38% representation, respectively. Rounding off the top five are macrocycles (10%) followed by three-membered (3%), seven-membered (2%), and four-membered (1%) rings.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of oxygen heterocycles according to ring size and aromaticity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A closer look at the 311 unique oxygen heterocycle containing U.S. FDA approved drugs reveals the majority (71%) are substituted with only one oxygen heterocycle (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), with 13% and 6% consisting of two and three oxygen heterocycles, respectively. A decent number (3%) of these drugs are decorated with greater than eight oxygen heterocycles. Although the atomic composition of the rings of these oxygen heterocycles primarily comprises one oxygen atom and carbon atoms (64%) as one would find in pyranoses, furanoses, etc., a large number (26%) also contain nitrogen, sulfur, boron, and even metal atoms, and 10% contain a second oxygen atom. The most common of these are rings composed of one oxygen and one nitrogen atom, which are represented by members such as oxazoles and morpholines and their isomeric variants. Finally, most (75%) of these oxygen heterocycles are chiral.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Frequency and structural content of oxygen heterocycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our analysis led us to identify the top 27 most frequently occurring oxygen heterocycles in the FDA pharmaceutical library (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Analysis of the 389 oxygen heterocycles contained within the 311 unique oxygen heterocycle-containing drugs revealed that pyranoses are number 1 with 62 appearances (16%) followed by furanoses in a distant second place (9%). Macrolactones, morpholines, and dioxolanes account for the remaining top five. These data for oxygen heterocycles are far more top heavy in favor of one heterocycle (pyranose) when compared with nitrogen heterocycles, with a 45% decrease between #1 (pyranose) and #2 (furanose) compared to 14% drop between (#1) piperidine and (#2) pyridine. In assembling this top 27 list and deciding how to best convey the diversity of oxygen heterocycles presented in later sections, similar ring types are organized according to their degree and location of unsaturation as well as exact location of heteroatoms within a given ring and fusion with other rings. For example, pyranoses are not the only six-membered rings containing a single oxygen atom in the top 27. Also belonging to this broad category would be tetrahydropyrans, chromenes, chromanes, δ-lactones, and dihydropyrans. Similarly, isoxazole and oxazole were categorized separately. Macrolactones (#3) make it into the top 10, which is in stark contrast to nitrogen heterocycles, for which no macrocycles make it into the top 27. This is perhaps not entirely surprising as macrocyclic drugs are commonly natural products or derivatives that usually contain 14- to 20-membered lactones. Dioxolanes, which chemists typically associate with carbonyl protecting groups, are quite a surprise at #5 being part of 24 approved drugs. Oxiranes appear highly on this list; this is not the case for the three-membered nitrogen heterocycle aziridine, which is only seen in a single U.S. FDA approved drug. Only 5 (19%) of the top 27 oxygen heterocycles are aromatic, with isoxazole (#6) being the most commonly occurring. Two (1,3-oxathiolane and boron–oxygen heterocycles) of these top structures contain atoms other than carbon, oxygen, or nitrogen as part of their rings. Four fused ring types (morphine, chromene, benzofuran, and chromane) are represented, which is far fewer than for nitrogen heterocycles where 11 fused rings are highly ranked. Oxadiazoles are the only oxygen heterocycle in the top 27 with two additional heteroatoms as part of the core ring. Furthermore, 13 (48%) of the top 27 oxygen heterocycles are five-membered; 8 (30%) are six-membered.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Most frequent oxygen heterocycles in U.S. FDA approved drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the sections that follow, all of the 311 unique oxygen heterocycle-containing drugs are presented according to their ring size, from small to large starting with oxiranes and continuing all the way to macrocyclic structures, with the final two sections focused on oxygen oligomers and unusual oxygen heterocycles. To achieve comprehensive coverage of all relevant structures, drugs that contain more than one oxygen heterocycle appear in more than one section. For each section, the oxygen heterocycle of focus is highlighted in blue and drug structures are organized based on common disease indications. For drug families with high structural similarity, alphabetized colored circles are employed to signify structural deviations from the common core.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Three-Membered Oxygen Heterocycles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Oxiranes appear in 13 U.S. FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). With respect to oxirane substitution arrangements, only di- (69%) and trisubstituted oxiranes are represented. Three of the trisubstituted rings are part of fused natural product-type ring systems (eplerenone, trilostane, and picrotoxin), while one (ixabepilone) is nonfused. The disubstituted oxiranes can be further broken down into three categories: 1,1-disubstituted (carfilzomib and troleandomycin), 1,2-trans-disubstituted (natamycin and mupirocin), and 1,2-cis-disubstituted (scopolamine, methyl scopolamine, tiotropium, cerulenin, and fosfomycin). These oxirane-containing drugs are structurally diverse with origins in natural products. Troleandomycin, natamycin, mupirocin, scopolamine, and picrotoxin are natural products, while eplerenone, trilostane, tiotropium, and methyl scopolamine are natural products derived from steroids and tropanes, respectively. Scopolamine, methyl scopolamine, and tiotropium are anticholinergic drugs used to treat a variety of conditions such as nausea, peptic ulcers, irritable bowel syndrome, and chronic obstructive pulmonary disease (COPD).<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> These drugs are easily recognizable by their tropane ring. Fosfomycin, isolated from <i>Streptomyces fradiae</i>, is a broad-spectrum antibiotic effective against both Gram-negative and Gram-positive bacteria. Intriguingly, fosfomycin, with its small size and phosphonic acid substitution at a reactive oxirane site, shares no structural similarities to any other natural product antibiotics.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Cerulenin is an antifungal agent that inhibits fatty acid and sterol biosynthesis. The reactive epoxide interacts with fatty acid synthase through the formation of a covalent adduct with a cysteine residue.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Trilostane, which inhibits steroid biosynthesis, is used to combat Cushing’s syndrome (hyperadrenocorticism) in both humans and dogs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Mupirocin and troleandomycin are both antibiotics, with troleandomycin having also been investigated as an alternative to steroids in the treatment of asthma.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Mupirocin, which is easily hydrolyzed and therefore can only be applied topically, is primarily used to combat streptococcal and staphylococcal infections. Natamycin is an antifungal available as eye drops to treat fungal infections around the eye.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Carfilzomib, a selective proteasome inhibitor, is an analog of the natural product epoxomicin. Epoxomicin and carfilzomib contain a unique pharmacophore epoxyketone that is responsible for the drug’s mechanism of action. The epoxyketone undergoes a double nucleophilic attack by a threonine residue, thereby forming a morpholine ring.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmaceuticals containing oxiranes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Four-Membered Oxygen Heterocycles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Oxetane’s importance as a valuable structural motif in drug discovery has increased in recent years. Oxetanes possess high polarity and the ability to act as hydrogen bond acceptors while contributing to metabolic and chemical stability of their host molecule. As a result of these attractive physiochemical properties, oxetanes have been investigated as isosteres to gem-dimethyl and carbonyl groups.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As depicted in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, four U.S. FDA approved drugs contain an oxetane. Paclitaxel (Taxol) and its two derivatives (docetaxel and cabazitaxel), which are antimitotic agents, contain a trisubstituted oxetane fused to the cyclohexyl C-ring. The paclitaxel family of drugs has proven to be successful in treating cancers like breast, lung, and ovarian. The oxetane ring in this family of drugs orients the adjacent acetyl group in the hydrophobic binding pocket for optimal interactions.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Orlistat, an antiobesity drug, contains a β-lactone ring. Orlistat is a semisynthetic derivative of the natural product lipstatin and acts as an irreversible inhibitor of pancreatic lipase, thereby reducing fatty acid absorption from the GI tract. The reactive electrophilic β-lactone moiety is critical for irreversible acylation of the serine residue in lipase.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmaceuticals containing oxetanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Five-Membered Oxygen Heterocycles: Nonaromatic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Furanose</h3><div class="NLM_p">The furanose ring appears in 34 U.S. FDA approved pharmaceuticals of which 31 contain a single furanose (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) with the remaining being oligomers (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>). The majority (74%) of furanose containing drugs are nucleosides. This number increases to 79% if the nucleoside component of vitamin B12 derivatives is included. A closer look at these nucleosides reveals that 52% of nucleobases contain the pyrimidine core, 36% contain the purine core, while pentostatin and ribavirin contain ring-expanded or ring-contracted nucleobases. Several of the nucleobases are substituted with halogens in the form of iodine (idoxuridine), fluorine (floxuridine, fludarabine, and capecitabine), trifluoromethyl (trifluridine), and a 1-thio-3,3,3-trifluoropropyl (Cangrelor) substituent. With respect to the substitution and stereochemical patterns of the furanose component, all but one of these nucleoside drugs contain a 2,5-cis-substitution with the same stereochemistry. The exception to this is telbivudine, which is the enantiomer of thymidine. Four common furanose cores are highlighted in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, with the rest differing in their substitutions or lack thereof at the 3- and 4-positions. The majority (68%) contain substituents at 3- and 4-positions, with 26% lacking a substituent at the 3-position, two being unsubstituted (didanosine and zalcitabine) and, interestingly, none lacking a substituent at the 4-position. Most fascinating of these are zidovudine, clofarabine, gemcitabine, and sofosbuvir, which are decorated with fluorine atoms or an azide at these positions. Many of these drugs are antimetabolite agents used to combat cancer and viruses. These antimetabolite drugs act as imposter substrates and entice nucleotide biosynthesis enzymes to select them over endogenous substrates. Once this occurs, the antimetabolites irreversibly bind the enzymes, thereby halting DNA synthesis. Cyanocobalamin and hydroxcobalamin, which are synthetic derivatives of vitamin B<sub>12</sub>, are used to treat vitamin B<sub>12</sub> deficiencies as well as related conditions such as pernicious anemia.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Non-nucleoside furanoses appear in five drugs (neomycin, paromomycin, streptomycin, lactulose, and sucralfate). All these furanoses contain at least one highly decorated pyranose component as well. Neomycin, paromomycin, and streptomycin are natural product antibiotics. Lactulose, a disaccharide of fructose and galactose, is used to treat constipation as well as hepatic encephalopathy by lowering ammonia levels. Because it is a synthetic sugar, lactulose is not metabolized by humans.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Sucralfate is most notable for the unique aluminum sulfate decoration of all its hydroxyl groups.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmaceuticals containing furanose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Dioxolane</h3><div class="NLM_p">The dioxolane heterocycle appears in 24 drugs (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Three unique drug families, corticosteroids, podophyllotoxins, and conazoles, all contain dioxolanes. 83% of dioxolanes are part of fused rings, with 38% of those being aromatic (1,3-benzodioxole). Of these nine 1,3-benzodioxoles, only lumacaftor is substituted at the ketal carbon (two fluorine atoms). This is in clear contrast to the cyclic and acyclic alkyl ones, which all contain either one (13%) or two (87%) carbon substituents at the ketal carbon atom. Topiramate is noteworthy as the only drug containing two dioxolanes, while guanadrel is structurally the simplest member of this family. The nine steroids shown contain a dioxolane fused to the D-ring at carbons 16–17 with two methyl groups substituted at the ketal carbon (acetonide) for most members. Otherwise, these steroids differ primarily in their C–F substitutions or if the primary hydroxyl group is acylated. The dioxolane (cyclic ketal) helps increase the lipophilicity and potency of these topical corticosteroids. The conazoles, a class of antifungals, contain a nonfused trisubstituted dioxolane ring with a chiral quaternary center. Ketoconazole was the first oral antifungal azole to be discovered, but as a result of more effective antifungals becoming available, its use is currently limited to shampoos and creams. Podophyllotoxin (podofilox), a natural product extracted from <i>Podophyllum</i> species, is used to treat genital warts. Podofilox functions by destabilizing microtubules. Remarkably, two semisynthetic derivatives of podofilox (etoposide and teniposide) function as topoisomerase II poisons and are prescribed for treatment of numerous cancers.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Guanadrel contains both a spirocyclic dioxolane and guanidine component. Guanadrel is structurally and pharmacologically similar to guanethidine; both are used as antihypertensives.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The dioxolane moiety appears in drugs used to treat a variety of conditions including depressive and anxiety disorders (paroxetine), erectile dysfunction (tadalafil), epilepsy (topiramate), cancer (trabectedin and omacetaxine mepesuccinate), and cystic fibrosis (lumacaftor). Lumacaftor contains cyclopropane and difluoromethylene moieties, both of which are being seen more frequently in pharmaceuticals.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmaceuticals containing dioxolanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Dihydrofuran-2(3<i>H</i>)-one (γ-Lactones)</h3><div class="NLM_p">γ<b>-</b>Lactones appear in 10 U.S. FDA approved pharmaceuticals (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), of which six are fused, three are spiro, and one (pilocarpine) is not attached to a ring. The γ<b>-</b>lactone of mycophenolate mofetil is the only one that contains unsaturation and lacks any stereocenters. Natural product motifs play a key role in this category, with two natural products (podofilox and picrotoxin) and all the rest except pilocarpine being derivatives of natural products. The spirolactone class of steroids contain spirocyclic γ-lactones at the C17 junction. These drugs are mineralocorticoid receptor antagonists that help to increase sodium excretion and potassium retention. Both the lactone ring and enone-decorated A-ring are crucial for activity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Picrotoxin contains an additional γ-lactone as part of its pentacyclic core. Vorapaxar, a derivative of the natural product himbacine, is a thrombin receptor antagonist indicated for patients with past myocardial infarctions.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pilocarpine, a disubstituted cholinergic dihydrofuran-2(3<i>H</i>)-one that contains an additional imidazole component, is used to treat glaucoma and xerostomia (dry mouth).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Mycophenolate mofetil, which is a prodrug of mycophenolic acid, helps prevent transplant rejection.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmaceuticals containing dihydrofuran-2(3<i>H</i>)-one (γ<b>-</b>lactones).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Furan-2(5<i>H</i>)-one (Butenolides)</h3><div class="NLM_p">Butenolides appear in the eight drugs presented in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> of which six are steroids. The digoxin family, indicated for a myriad of heart-related conditions, contains a chiral butenolide attached at C17 on the D-ring of their glycosylated steroid core.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Rofecoxib, an anti-inflammatory, contains a 1,2-diaryl substituted butenolide. Fluorescein is a fluorescent dye that is used as a tracer in a variety of procedures. It is commonly used in the medical field of ophthalmology as a diagnostic tool for corneal conditions.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Pharmaceuticals containing furan-2(5<i>H</i>)-one (butenolides).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Oxazolidinones</h3><div class="NLM_p">Oxazolidinone family members appear in 16 U.S. FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). These 16 oxazolidinones can be broken into four structural categories. Oxazolidine-2-ones are mostly commonly seen in this family, appearing in eight (50%) of these drugs. Most members (tedizolid, linezolid, furazolidone, and telithromycin) are antibiotics. In particular, oxazolidine-2-ones make up a class of antimicrobial drugs that inhibit protein synthesis at the P site of the 50S ribosomal subunit of Gram-positive bacteria.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Within the oxazolidine-2-one family, all but metaxalone have a nitrogen atom substituent. Furazolidone is the least substituted oxazolidine-2-one member, while telithromycin is the most (tetrasubstituted). The isomeric oxazolidine-4-ones appear in four (25%) drugs, which are small components of the ergot alkaloids, which are used to treat migraines. The oxazolidine-2,4-dione moiety is present in three (19%) drugs (pemoline, trimethadione, and paramethadione). Finally, cycloserine, an intriguing constrained version of the amino acid serine, is the lone isoxazolidin-3-one. Cycloserine, a partial NMDA-agonist initially developed to combat tuberculosis, has been investigated for use in treating neuropsychiatric illnesses such as schizophrenia.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmaceuticals containing oxazolidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Tetrahydrofurans</h3><div class="NLM_p">Tetrahydrofuran-containing drugs are prescribed as treatments for various diseases including cardiovascular, infectious, urinary, cancer, and diabetes (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Cyclic ethers have been used in drug design as bioisosteres of amide/peptide bonds in protease inhibitors to help combat drug-resistant viral strains. The ether’s oxygen can form hydrogen bonds (like peptides), thereby enhancing binding affinity. In addition, replacing a peptide bond with a tetrahydrofuran helps increase the bioavailability of the drug, as it will no longer be susceptible to protease degradation.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> These approaches have been shown to be effective with amprenavir and darunavir in treating HIV infection. Our analysis reveals 13 tetrahydrofuran-containing drugs. Four of these drugs contain two tetrahydrofuran units, three of which are fused bis-tetrahydrofurans (darunavir, isosorbide dinitrate, and isosorbide mononitrate). All tetrahydrofurans contain a stereocenter, with terazosin and alfuzosin being sold as racemates. Ivermectin and epoprostenol (prostaglandin I2) are the only bona fide natural products with eribulin being a synthetic analog of the natural product halichondrin B.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Posaconazole, a recent antifungal of the azole family, contains a trisubstituted tetrahydrofuran with a chiral quaternary center. Posaconazole is preferred over earlier azoles such as ketoconazole, as it is effective against <i>Aspergillus</i> as well as other fungal infections resistant to previous antifungals.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pharmaceuticals containing tetrahydrofurans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 1,3-Oxathiolane</h3><div class="NLM_p">Three drugs contain an 1,3-oxathiolane heterocycle (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). All three are chiral and are substituted at C2 and C4 positions. Cevimeline, whose 1,3-oxathioloane is spiro-connected to a quinuclidine, is a muscarinic agonist indicated for treatment of dry mouth.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Lamivudine, a cytidine nucleoside analog, is an antiretroviral medication used to treat HIV/AIDS and hepatitis B. Its fluorinated analog, emtricitabine, is a nucleoside reverse transcriptase inhibitor also utilized for the treatment of HIV.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Emtricitabine is prescribed in combination with tenofovir.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pharmaceuticals containing 1,3-oxathiolane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Five-Membered Oxygen Heterocycles: Aromatic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Furans</h3><div class="NLM_p">The aromatic furan heterocycle appears in 10 drugs (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) of which six (60%) are disubstituted and four (40%) are monosubstituted. All these furans are substituted at C2 with six (67%) being also substituted at C5. Fluticasone furoate is the only furan drug without a benzylic amine/imine in the 2-position. The nitrofurans are a class of drugs almost exclusively used as antibiotics. Nitrofurantoin, available since World War II, is used to treat urinary tract infections.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> However, dantrolene is used as a muscle relaxant.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Lapatinib, a human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) mixed inhibitor, contains a disubstituted furan.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Prazosin, originally used as an antihypertensive, has also been evaluated as candidate for treating nightmares, especially post-traumatic stress disorder (PTSD) related.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Ranitidine, an antacid (histamine H2 receptor antagonist) FDA approved in 1983, became one of the first drugs to total $1 billion in sales.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> At first glance, it may seem surprising that such a common heterocycle only appears in nine drugs. It is worth noting however that both furans and thiophenes can display hepatotoxicity when bioactivated to electrophilic <i>cis</i>-2-butene-1,4-dials in vivo.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Pharmaceuticals containing furans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Isoxazoles</h3><div class="NLM_p">Our database reveals 17 drugs containing an isoxazole (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) of which three (risperidone, paliperidone, and zonisamide) are benzisoxazoles. Substitution pattern analysis reveals that 65% of these isoxazoles are trisubstituted with the rest being disubstituted. All isoxazoles are substituted at C5, and all but two (danazol and leflunomide) are substituted at C3. Isoxazole-containing drugs display a broad range of biological activity as exemplified by the various indications.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> The β-lactam oxacillin family, sulfisoxazole (acetyl) and sulfamethoxazole are all antibiotics. Isoxicam and valdecoxib are anti-inflammatory drugs, while isocarboxazid is an antidepressant of the monoamine oxidase inhibitor (MAOI) class. Leflunoamide is an immunosuppressant, whereas risperidone and paliperidone are antipsychotics. Micafungin is an antifungal natural product of the echinocandin family.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Pharmaceuticals containing isoxazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Oxazoles</h3><div class="NLM_p">In juxtaposition to the 17 isoxazoles approved, its isomer oxazole only appears in two approved drugs oxaprozin and suvorexant (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Also included in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a> are dihydro- (deflazacort) and tetrahydro- (clavulanate) oxazole drugs. Various drug types including anti-inflammatory, sleep agents, antibiotics, and glucocorticoids are represented by these four drugs. Deflazacort, which was approved in 2017 for the treatment of Duchenne muscular dystrophy, contains a dihydrooxazole fused at C16–C17 of its D-ring steroid core. Suvorexant, which contains three types of heterocycles, was approved in 2014 for the treatment of insomnia. Clavulanate, a β-lactamase inhibitor, contains a unique oxa-penam (clavam) core wherein the sulfide common to penams has been replaced with an ether.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pharmaceuticals containing oxazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Oxadiazoles</h3><div class="NLM_p">Oxadiazoles, which are frequently used in drug discovery as bioisosteres of amides and esters as well as to confer solubility benefits,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> are represented by three isomeric forms and appear in four U.S. FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). The antiretroviral remedy raltegravir contains a 1,2,5-oxadiazole core, and the high blood pressure medication isradipine is decorated with a benzo-variant. In naldemedine, which is approved to treat opioid-induced constipation, one of the nitrogen atoms is in a different position (1,2,4-oxadiazole) while in the hypertension drug azilsartan medoxomil the heterocycle is no longer aromatic (1,2,3-oxadiazole-3-one) as a carbonyl group has been added.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Pharmaceuticals containing oxadiazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Six-Membered Oxygen Heterocycles: Nonaromatic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pyranose</h3><div class="NLM_p">The pyranose family constitutes the largest family of U.S. FDA approved drugs containing oxygen heterocycles, with 62 drugs containing at least one pyranose. Natural products, oligosaccharides, and more traditional synthetic drugs are all encompassed in this diverse family. Given the size of this data set and the fact that many of these drugs are large and occupy significant space when drawn, the discussions about the pyranoses are split into three sections. Part 1 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) is focused on chemotherapeutic, cardiovascular, antidiabetic, and antifungal agents, part 2 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) is dedicated to antibiotics, and part 3 (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) covers an assortment of pyranoses.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Pharmaceuticals containing pyranoses (part I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Pharmaceuticals containing pyranoses (part II).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Pharmaceuticals containing pyranoses (part III).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pyranoses in part 1 are components of nine chemotherapeutic, six cardiovascular, five antidiabetic, and four antifungal agents (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Pyranoses in these series are common components of terpenoids, glycosylated macrolactones, and anthracyclines. The anthracycline family is easily recognized by their linearly fused tetracyclic core. These anticancer agents, which are extracted from <i>Streptomyces</i> bacteria, are all decorated with an <span class="smallcaps smallerCapital">l</span>-daunosamine carbohydrate (pyranose). The anthracyclines intercalate with DNA, thereby inhibiting topoisomerase II.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Streptozocin, a glucosamine-nitrosourea compound, is a natural product currently used to treat pancreatic islet cell cancer. As with other nitroso-containing compounds, streptozocin is an alkylating agent, thereby acting as a DNA synthesis inhibitor.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Midostaurin, a derivative of staurosporine, is part of the indolocarbazole family and was recently approved as an anticancer agent.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Bleomycin is a glycopeptide of antitumor antibiotic class used to treat a variety of cancers. The bis-thiazole in bleomycin is involved in intercalating DNA, helping to facilitate the single- and double-stranded breaks.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The digitalis glycosides, isolated from <i>Digitalis</i> (foxglove), are a family of drugs used to treat cardiovascular conditions such as heart failure.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The six approved digitalis glycosides share a common steroid core, notably substituted with a butenolide on its D-ring and glycosides at C3 on the A-ring. Ouabain and digitalin are decorated with one and two glycosides, respectively, while digoxin, digitoxin, and acetyldigitoxin all contain a common triglycoside, and deslanoside is substituted with a tetraglycoside. Glycosylated macrolactones are a significant presence. Amphotericin B, nystatin, candicidin, and natamycin are polyene antifungals with many structural similarities. Five antidiabetic drugs are represented; three are members of the gliflozin family, which are inhibitors of sodium-glucose transport protein 2 (SGLT2), used to treat type 2 diabetes.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> These members, dapagliflozin, canagliflozin, and empagliflozin, share a common pyranose core as well other structural similarities. Acarbose, a trisaccharide linked to an interesting heavily substituted cyclohexene fragment, is an antidiabetic drug of the α-glucosidase inhibitor class used to treat type 2 diabetes.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">Part 2 presents antibiotics which contain pyranoses (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). Natural products and their derivatives are heavily represented in this category with erythromycin, vancomycin, and streptomycin being among the more notable polyketide (macrolactone), nonribosomal peptide, and aminoglycoside members. The glycopeptide vancomycin, produced by fermenting <i>Amycolatopsis orientalis,</i> is a glycosylated hexapeptide effective against Gram-positive bacteria.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Oritavancin and telavancin are natural product derivatives whose structures marginally deviate in the positions shown, while dalbavancin is significantly different. The natural product erythromycin and related macrolide members are used as antibiotics to treat a range of bacterial infections. Most of these macrolide antibiotics contain a characteristic 14-membered ring with two pyranose sugars, usually a cladinose and desosamine, appended at common hydroxyl groups. Unlike erythromycin, josamycin has a 16-membered ring.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Fidaxomicin, which contains an 18-membered ring, is a narrow spectrum antibiotic prescribed for <i>Clostridium difficile</i> infection (CDI).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Eight pyranose containing drugs belong to the aminoglycoside family, which have traditionally been used as antibiotics against Gram-negative bacteria.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> However, aminoglycosides are also effective against Gram-positive bacteria. Aminoglycoside members are easily recognizable by their 1,3-diaminoinositol pharmacophore, usually a 2-deoxystreptamine. Streptomycin contains a streptidine ring instead.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Most (88%) aminoglycosides contain two highly substituted pyranose moieties. Lincomycin and its derivative clindamycin are lincosamide antibiotics that are mostly effective against Gram-positive bacteria. This family functions by binding to rRNA, blocking microbial protein synthesis. Clindamycin has recently found an important use in the treatment of <i>Staphylococcus aureus</i>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p last">Part 3 covers the remaining pyranose-containing drugs (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Sugammadex is the first selective relaxant binding agent (SRBA) indicated to reverse neuromuscular blockage effects of rocuronium in anesthesia. Structurally, sugammadex is a γ-cyclodextrin derivative with eight carboxyl thioether groups substituted at the C6 of the pyranose moieties.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Fondaparinux, a synthetic pentasaccharide structurally similar to low molecular weight heparins, is an anticoagulant. Among the more interesting structures in this category is auranofin, which is an organogold tetra-acetylated pyranose indicated for treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Sucralfate is a sucrose sulfate–aluminum complex used to treat various gastrointestinal conditions. Spinosad, an antiparasitic, is used to treat head lice in humans and fleas in cats and dogs. Interestingly, spinosad is also a widely used insecticide. Spinosad contains a unique tetracyclic core with two pyranoses (<span class="smallcaps smallerCapital">d</span>-forosamine and a tri-<i>O</i>-methyl-<span class="smallcaps smallerCapital">l</span>-rhamnose).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Ivermectin, a member of the avermectin family, is an antiparasitic agent used to treat a wide range of diseases such as head lice, river blindness, strongyloidiasis, and scabies. As a result of ivermectin’s revolutionary impact in the world, it is often referred to as a “wonder drug”.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> A Nobel Prize was awarded in 2015 to William C. Campbell and Satoshi O̅mura for their ivermectin discoveries.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Morpholine</h3><div class="NLM_p">Morpholine, which contains both a secondary amine and a ether, is a valuable building block for synthesizing drug-like molecules. Morpholine also finds utility as common solvent in organic synthesis. With a p<i>K</i><sub>a</sub> of 8.7, morpholine can be readily alkylated at its N4 atom in substitution reactions. Morpholine-containing drugs are used to treat a wide variety of diseases.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, morpholine can fine-tune the physicochemical properties such as polarity and solubility of drugs. The secondary amine on morpholine can enhance selectivity through hydrogen bond donating and accepting; the ether moiety acts as a hydrogen bond acceptor.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Anticancer agents (alectinib, carfilzomib, gefitinib, and sonidegib), antiemetics (aprepitant), stimulants (phenmetrazine), glaucoma (timolol), antivirals (cobicistat), and antibiotics (linezolid) are represented to name a few. Our drug analysis (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) confirms 25 small molecule drugs that contain a morpholine heterocycle. An additional morpholino oligomer (eteplirsen) is shown in <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>. Further inspection of these morpholine substitution patterns reveals that most (84%) are substituted at N4, with the 2-position and 3-positions substituted in 36% and 32% of the drugs, respectively. The majority (64%) are monosubstituted with levofloxacin and ofloxacin being most substituted.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Pharmaceuticals containing morpholines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Dihydropyran</h3><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>, four highly decorated dihydropyrans appear among U.S. FDA approved drugs, including the antivirals tipranavir and zanamivir. Zanamivir is a neuraminidase inhibitor used to combat influenza A and B virus.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Netilimicin is an antibiotic, while etodolac is an anti-inflammatory drug. Etodolac is the only 3,6-dihydropyran of the four and the rest are 3,4-dihydropyrans, which is a reactive group used as a reagent for protecting hydroxyls (THP protecting group).</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Pharmaceuticals containing dihydropyran.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Tetrahydropyran</h3><div class="NLM_p">Tetrahydropyrans appear in 14 U.S. FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Three of these drugs (candicidin, eribulin, and ivermectin) are decorated with multiple tetrahydropyrans, fused in eribulin and spirocyclic in ivermectin. Candicidin, an antifungal, contains two tetrahydropyrans of which one is part of the macrolactone. A variety of diseases are treated by these drugs. For example, the natural products rapamycin (sirolimus) and FK-506 (tacrolimus) and their derivatives are immunosuppressive drugs. In addition to their use as immunosuppressive agents, everolimus and temsirolimus have oncological applications such as in the treatment of advanced renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), mantle cell lymphoma (MCL) as well as hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The prostaglandin derivative lubiprostone is a laxative. Teniposide and eribulin are all chemotherapy agents, while mupirocin and spectinomycin are antibiotics. Venetoclax targets the B-cell lymphoma-2 (Bcl-2) protein and is used to treat chronic lymphocytic leukemia (CLL).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Pharmaceuticals containing tetrahydropyran.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> δ-Lactones</h3><div class="NLM_p">δ-Lactones appear in six drugs (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) all of which are natural products (lovastatin) or are derived or inspired from ones (camptothecin, steroids, and lovastatin). The camptothecin family contains a pentacyclic structural core with the δ-lactone occupying the E-ring. The camptothecin family of drugs are topoisomerase I poisons, which irreversibly damage DNA, so it is unable to be replicated. The parent compound containing the δ-lactone is more active than the hydrolyzed hydroxy acid metabolite. Both topotecan and irinotecan are tetrasubstituted δ-lactones fused to a 2-pyridone.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Lovastatin, the first of the statins to be approved, and its derivative simvastatin both contain disubstituted δ-lactones. The statins are a family of antihyperlipidemics, which act as HMG-CoA reductase inhibitors.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Two steroids contain δ-lactones as replacements for their cyclohexyl A-ring or cyclopentyl D-rings. Testolactone, a modified androstenedione, is an irreversible aromatase inhibitor used to treat late-stage breast cancer,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> while oxandrolone is an anabolic steroid.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Pharmaceuticals containing δ-lactones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1,3-Oxazinanes</h3><div class="NLM_p">Three approved drugs contain a 1,3-oxazinane heterocycle (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). All three drugs are chiral, with the ethereal oxygen atom being part of a secondary or tertiary stereocenter and fused to another ring. Both dolutegravir and efavirenz are antiretrovirals indicated for treatment of HIV/AIDS. Dolutegravir is also used as a combination drug with abacavir and lamivudine for the same indication.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Dirithromycin is an antibiotic of the macrolide glycopeptide family. The oxazinane, which is a hemiaminal, of dirithromycin is hydrolyzed in vivo to form erythromycyclamine.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Pharmaceuticals containing 1,3-oxazinanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Six-Membered Oxygen Heterocycles: Aromatic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chromanes</h3><div class="NLM_p">Seven U.S. FDA approved drugs contain a chromane heterocycle; six are small molecules (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>), and one (crofelemer) is an oligomer (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>). Diverse drug types such as antidiabetic and anti-inflammatory (troglitazone), antiviral (velpatasvir), and synthetic cannabinoids (dronabinol and nabilone) are represented by these structures. Most notable among these is the natural product dronabinol and velpatasvir, which are used in combination with sofosbuvir to treat hepatitis C.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Pharmaceuticals containing chromanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chromenes</h3><div class="NLM_p">The chromenes, of which coumarins and chromones belong, are privileged scaffolds in drug discovery (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). These heterocycles, widely seen in natural products, have been extensively investigated for diverse pharmacological drug properties.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Eleven U.S. FDA approved pharmaceuticals were found to contain a chromene heterocycle, of which six are coumarins. Indications include asthma (cromoglicic acid and pranlukast), blood clots (warfarin family and dicumarol), skin diseases (methoxsalen), and bacterial infections (novobiocin) among others. Warfarin, phenprocoumon, and acenocoumarol are structurally similar, differing slightly in their substitution at the two positions shown. Novobiocin and methoxsalen are also decorated with pyranose and furan oxygen heterocycles, respectively. Cromoglicic acid and dicoumarol are rare examples of drugs that are symmetrical dimers.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0027.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Pharmaceuticals containing chromenes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Morphinan Alkaloids</h3><div class="NLM_p">Sixteen U.S. FDA approved morphinan-type drugs, distinguished by their unique pentacyclic natural product core, are displayed in <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>. The E-ring contains a tetrahydrofuran moiety. Morphine and its methylated version codeine are the only ones that contain a C7–C8 double bond, while 12 derivatives are saturated at C7–C8. Naldemedine is different as it contains a C6–C7 enol. Galantamine, although not a morphinan per se, contains very similar architecture with an azepane in place of the bridged bicyclic piperidine. Galantamine, a natural product alkaloid, is an acetylcholinesterase (AChE) inhibitor indicated to treat cognitive degeneration in Alzheimer’s disease.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> 44% of the morphinans contain a C6 ketone, while the others are either in reduced hydroxy form or contain an olefin (nalmefene). All 16 members are substituted at the core nitrogen atom, with an unusual methylene cyclopropane substituent appearing in five derivatives. Buprenorphine stands out as the most complex approved morphinan with its C14–C6 bridged carbon chain as well as additional substitution at C7.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0028.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Pharmaceuticals containing morphinan alkaloids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Benzofuran Family</h3><div class="NLM_p">Ten U.S. FDA approved benzofuran (five), coumaran (three), and phthalane- (two) containing drugs are presented in <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>. Our coverage of benzofuran<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> is combined with that of its reduced (2,3-dihydrobenzofuran = coumaran and 1,3-dihydroisobenzofuran = phthalane) members. These ten drugs have been approved as antiarrhythmic agents (amiodarone and dronedarone), antidepressants (vilazodone, citalopram, and escitalopram), and sleep agents (ramelteon and tasimelteon) as well as for conditions such as urinary incontinence (darifenacin), skin disease (methoxsalen), and dry eye (lifitegrast). Dronedarone and amiodarone share a common central benzofuran differing slightly in their heteroatom substitutions and amine tether lengths. The same can be said for ramelteon and tasimelteon, whose dihydrobenzofuran core is the same. The two phthalanes are particularly notable as they are the same compound, with one being sold as a racemate (citalopram) and the other (escitalopram) as single enantiomer. Escitalopram, the <i>S</i>-(+)-enantiomer, was developed after studies showed that this enantiomer was responsible for nearly all of the serotonin reuptake inhibition. Furthermore, in vitro studies in rat brains concluded that the <i>S</i>-(+)-enantiomer is 150 times more potent than the <i>R</i>-(−)-enantiomer.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Interestingly, arylnitriles are featured in three (vilazodone, citalopram, and escitalopram) of these drugs.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0029.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Pharmaceuticals containing benzofurans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Various Seven-Membered Rings</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Seven U.S. FDA approved oxygen heterocycle-containing drugs are seven-membered rings (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). Most of these drugs are used for psychiatric conditions. Loxapine, a typical antipsychotic, and amoxapine (N-demethylated version), an antidepressant, both contain a 1,4- oxazepine heterocycle fused between two aryl rings. Asenapine, doxepin, and olopatadine share similar isomeric dibenzooxepine cores as part of their rigid central architecture. Artemether, an artemisinin derivative, is a sesquiterpene lactone, which contains a truly unique seven-membered peroxide bridge as well as a fused oxepane ring. The artemisinin family of drugs is used to treat malaria. The endoperoxide is thought to play a role in killing parasites through a free radical mechanism.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Pharmaceuticals containing various seven-membered rings.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Macro-Lactones</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Macro-lactones are encompassed in 26 U.S. FDA approved drugs, 19 of which are shown in <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>. These drugs are generally natural products or natural-product-derived structures with complex highly substituted architectures. As discussed previously, amphotericin B, nystatin, candicidin, and natamycin are all polyene antifungal agents. The nystatin family contains a 36-membered lactone ring, while natamycin contains a 24-membered lactone ring. Sirolimus (rapamycin) and its derivatives act as immunosuppressants in preventing organ transplant rejection. Temsirolimus is utilized as an anticancer agent.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> The sirolimus (rapamycin) family contains a 29-membered ring with four trans double bonds. Pimecrolimus and tacrolimus are calcineurin inhibitors that act as immunosuppressive agents and contain a 21-membered lactone ring.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The erythromycin family, a class of broad-spectrum antibiotics, contains a 14-membered lactone ring.</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0031.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Pharmaceuticals containing macro-lactones (part I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a> displays the seven additional pharmaceuticals containing a macrolactone. Dactinomycin, a chemotherapeutic agent, contains two separate 16-membered macrolactones. Trabectedin, a chemotherapy agent, contains a structurally unique 10-membered macrolactone.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Romidepsin, another anticancer agent, contains a unique structural moiety in the form of a disulfide in addition to a 16-membered ring. Furthermore, this disulfide linkage is responsible for its mechanism of action. The disulfide is reduced in vivo to a thiol, which reversibly interacts with a zinc atom in the histone deacetylase binding pocket.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Ivermectin, a 16-membered antiparasitic agent, and the antibiotics josamycin (16-membered ring) and fidaxomycin (18 membered ring) each contain highly decorated pyrans as part of their architectures. Dactinomycin, an anticancer agent, contains a unique oxazine ring fused to a benzene ring and a 2,5-cyclohexadienone. It is worth noting that the <i>p</i>-benzoquinone imine component of dactinomycin is reactive and electrophilic. Therefore, dactinomycin is susceptible to NADPH/CYP450 reductase. Furthermore, single-stranded DNA breaks can occur as result of free radicals produced.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0032.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Pharmaceuticals containing macro-lactones (part 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Macrocyclic Ethers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Macrocyclic ethers appear in 12 U.S. FDA approved drugs (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>). The majority of macrocyclic ether drugs are antibiotics, with the 30- and 25-membered ether rings of the vancomycin and rifamycin families representing all eight members. Voxilaprevir, an 18-membered antiviral, and eribulin, a 22-membered anticancer agent, also contain macrocyclic ethers.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Tubocurarine, a benzyl isoquinoline derivative, is a naturally occurring 18-membered quaternary alkaloid that was once used as an arrow poison. Although rarely used currently, tubocurarine was used as a combination drug with an anesthetic for its muscle relaxing properties.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> However, metocurine, a trimethylated analog of tubocurarine, is currently used as a muscle relaxant.</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0033.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Pharmaceuticals containing macrocyclic ethers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Oligomers and Polymers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The U.S. FDA approved oxygen heterocycle-containing oligomers and polymers are shown in <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>. Recently approved mipomersen and nusinersen are antisense oligonucleotides indicated for treatments of familial hypercholesterolemia and spinal muscular atrophy, respectively.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Interestingly, the nucleotides are linked by phosphorothioate linkages as opposed to phosphodiester. This modification aids in its resistance to nuclease degradation. The methoxyethyl substitution helps increase binding affinity and potency.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Mipomersen is a 20-mer, and nusinersen is an 18-mer. Distribution analysis of the nitrogenous bases of mipomersen reveals 5-methylcytosine (m<sup>5</sup>C, 45%) is most prevalent, followed by thymine (T, 25%), guanine (G, 20%), and adenine (A, 10%). However, in the case of nusinersen, thymine (T, 39%) is most prevalent, followed by adenine (A, 22%), 5-methylcytosine (m<sup>5</sup>C, 22%), and guanine (G, 17%). Furthermore, both mipomersen and nusinersen contain predominately pyrimidine architectures at 70% and 61%, respectively. Eteplirsen’s unique and innovative structure stands out from the rest. Eteplirsen, an oligomorpholine, targets regional mutations thought to cause Duchenne muscular dystrophy (DMD). DMD, a recessive X-linked neuromuscular disorder in males, results from mutations of the DMD gene that codes for dystrophin. Dystrophin is a vital protein needed for strengthening muscle structure. Mutations in this protein lead to muscle degeneration, loss of ambulation, and ultimately death, usually in the 20s. Eteplirsen, a 30-mer nucleotide morpholino oligomer, acts as an exon-skipping therapeutic, specifically targeting deletions ending at exon 50 and beginning at exon 52. About 14% of all DMD patients are covered by this exon skipping range.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The heparins are glycosaminoglycans used as anticoagulants. Structurally, heparin contains a sulfated iduronic acid and 6-O-sulfated, N-sulfated glucosamine disaccharide. Dalteparin, enoxaparin, and tinzaparin are additional members of the heparin family also indicated as anticoagulants.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Pentosan polysulfate, a semisynthetic xylan, is a heparin-like, sulfated polysaccharide indicated for thrombus and interstitial cystitis in humans.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Hyaluronic acid, a glycosaminoglycan-like heparin, is commonly used in cosmetic surgery as a dermal filler, for skin care, and as a dietary supplement. However, hyaluronic acid is nonsulfated unlike the heparin family.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Defibrotide is an oligonucleotide used to treat hepatic veno-occlusive disease. Defibrotide is derived from the porcine intestinal mucosa.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0034.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Pharmaceuticals containing oligomers and polymers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Boron, Phosphorus, and Metal Oxacycles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There are nine unique boron, phosphorus, and metal oxacycles (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>), which have received U.S. FDA approval. The pharmaceutical industry has shown increased interest in boron in drugs, with recent developments showing boron-containing drugs having therapeutic effects against a wide range of disease pathologies. A breakthrough with boron-containing drugs was the development of bortezomib as a treatment for multiple myeloma.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Currently, there are three U.S. FDA-approved boron–oxygen containing heterocycles of which two are oxaborolanols and one is an oxaborinanol. Tavaborole is an antifungal. The boron atom of tavaborole binds to cytoplasmic leucyl-transfer ribonucleic acid (tRNA) synthetase, a fungal enzyme needed for protein synthesis.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Crisaborole is a nonsteroidal topical for atopic dermatitis; the boron atom in crisaborole helps to facilitate increased skin penetration. In addition, the boron is critical for the drug’s mechanism of action. The boronate mimics a phosphate of cyclic adenosine monophosphate (cAMP), thereby targeting and inhibiting phosphodiesterase 4 (PDE4).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Vaborbactam is a non-β-lactam β-lactamase inhibitor. The boron atom in vaborbactam is necessary for the drug’s mechanism of action as a tetrahedral transition state mimic targeted against β-lactamases.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Platinum-based drugs continue to find uses as anticancer agents. The electrophilic platinum atom in carboplatin and oxaliplatin is attacked by the nucleophilic DNA.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Cyclophosphoramide and ifosfamide contain a unique oxazaphosphinane heterocycle, which is required for their mechanism of action in generating aziridines in vivo.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Despite the inherit toxicity of arsenic, arsenic-containing drugs have had a major impact over the years. For example, arsphenamine was used to treat syphilis in the past century. Arsenic trioxide, which is an adamantane-type oxygen–arsenic heterocycle, is used as an anticancer agent.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Samarium has found a unique medical use, with samarium lexidronam being used in pain management of cancers which have spread to the bone.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Structurally, this drug contains a unique heterocycle with five different elements.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0035.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Pharmaceuticals containing boron, phosphorus, and metal oxacycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46463" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46463" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, this Perspective offers the first compilation and detailed analysis of oxygen-containing heterocycles in U.S. FDA approved pharmaceuticals. As is evident from the discussion, the 311 drugs containing oxygen heterocycles have a dramatic impact in the treatment of a wide variety of medical conditions. It is quite remarkable how numerous types of oxygen heterocycles appear in approved drug architectures. This comprehensive overview is meant to give the reader an up-to-date analysis of the frequency as well as substitution patterns of all oxygen-heterocycles in drugs using a minimalistic graphical presentation approach. The heterocyclic moieties successfully incorporated into approved drugs should provide some valuable insight for prospective drug hunters. It is our hope that this analysis also serves to inspire the development of novel methods and reactions for constructing oxygen heterocycles, especially underrepresented or yet-to-be synthesized oxygen heterocycles. For example, seeing boron-containing heterocycles incorporated in drugs has been a true testament to the creativity of the synthetic community in pushing the boundaries beyond classically successful oxygen heterocycles such as furanoses and pyranoses.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00876" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon T. Njardarson</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2268-1479" title="Orcid link">http://orcid.org/0000-0003-2268-1479</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84eaeee5f6e0e5f6f7c4e1e9e5ede8aae5f6edfeebeae5aae1e0f1"><span class="__cf_email__" data-cfemail="26484c47544247545566434b474f4a0847544f5c49484708434253">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael
D. Delost</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David T. Smith</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benton J. Anderson</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry and
Biochemistry, University of Arizona, 1306 E. University Boulevard, Tucson, Arizona 85721, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.D.D. and D.T.S. contributed equally to the creation of this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Michael
D. Delost</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=BIO-d7e1027-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Michael D. Delost</b> received a B.S. in Chemistry from Gannon University in 2013. He then earned a M.S in Chemistry (organic synthesis) from Youngstown State University in 2015. Mike joined the research group of Professor Njardarson in the fall 2016.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="36" class="article__inlineFigure"><h2 class="fig-label">David T. Smith</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=BIO-d7e1032-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>David T. Smith</b> received a B.S. in Chemistry from The University of North Carolina at Charlotte in December of 2012. David entered the graduate program in chemistry at The University of Arizona in August of 2013, and in January of 2014 he joined the research group of Professor Njardarson.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Benton J. Anderson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=BIO-d7e1037-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Benton J. Anderson</b> received a B.S. in Biochemistry from the University of Arizona in May of 2017. Benton entered the graduate program in chemistry at the University of Wisconsin—Madison in June of 2018.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Jon T. Njardarson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=BIO-d7e1042-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jon T. Njardarson</b> received his Ph.D. at Yale University in 2001 with Professor John L. Wood. Following postdoctoral training with Professor Samuel J. Danishefsky at The Memorial Sloan-Kettering Cancer Center he started his independent career in 2004 at Cornell University. In 2010, Professor Njardarson moved his research group to The University of Arizona.</p></figure></div><div class="ack" id="ACK-d7e1047-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the National Science Foundation (Grant CHE1565500) for financial support of the pharmaceutical poster outreach projects and the resulting analysis efforts.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquired immunodeficiency syndrome</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">δ</td><td class="NLM_def"><p class="first last">delta</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Federal Drug Administration</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">gastrointestinal</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HMG-CoA reductase</td><td class="NLM_def"><p class="first last">3-hydoxy-3-methylglutaryl-coenzyme A reductase</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">N-heterocycle</td><td class="NLM_def"><p class="first last">nitrogen heterocycle</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartic acid</p></td></tr><tr><td class="NLM_term">O-heterocycle</td><td class="NLM_def"><p class="first last">oxygen heterocycle</p></td></tr><tr><td class="NLM_term">PTSD</td><td class="NLM_def"><p class="first last">post-traumatic stress disorder</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22753" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22753" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 97 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0lgKrPiaw45AlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug Design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+Design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lh2oXzLQh9Z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520Design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brichacek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A Graphical journey of innovative organic architectures that have improved our lives</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1021/ed1003806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed1003806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1348-1349&author=N.+A.+McGrathauthor=M.+Brichacekauthor=J.+T.+Njardarson&title=A+Graphical+journey+of+innovative+organic+architectures+that+have+improved+our+lives&doi=10.1021%2Fed1003806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives</span></div><div class="casAuthors">McGrath, Nicholas A.; Brichacek, Matthew; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1348-1349</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">A new free graphical teaching tool that highlights the beautiful org. architectures of the top selling pharmaceuticals is detailed on two posters.  In addn. to the multitude of teaching and data-mining opportunities these posters offer, they were also created to emphasize the central role org. chemists play in the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPDa7XFu1jBLVg90H21EOLACvtfcHk0lh2oXzLQh9Z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP&md5=abaab52626cc29b94b88389f39727513</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fed1003806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed1003806%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DN.%2BA.%26aulast%3DBrichacek%26aufirst%3DM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520Graphical%2520journey%2520of%2520innovative%2520organic%2520architectures%2520that%2520have%2520improved%2520our%2520lives%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2010%26volume%3D87%26spage%3D1348%26epage%3D1349%26doi%3D10.1021%2Fed1003806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ZuWallack, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ZuWallack, R. L.</span></span> <span> </span><span class="NLM_article-title">Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1517/14656566.5.8.1827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1517%2F14656566.5.8.1827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15264997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Olt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=1827-1835&author=A.+R.+ZuWallackauthor=R.+L.+ZuWallack&title=Tiotropium+bromide%2C+a+new%2C+once-daily+inhaled+anticholinergic+bronchodilator+for+chronic-obstructive+pulmonary+disease&doi=10.1517%2F14656566.5.8.1827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease</span></div><div class="casAuthors">ZuWallack, Alicia R.; ZuWallack, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1827-1835</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Tiotropium bromide is a quaternary ammonium compd. structurally related to ipratropium and has recently been approved in the US for the long-term, once-daily, maintenance treatment of bronchospasm assocd. with chronic-obstructive pulmonary disease (COPD).  It is available in a dry powder form, where 18 mg of the drug is inhaled once-daily through a device, the HandiHaler.  The potency and long duration of effect of this anticholinergic bronchodilator result primarily from a prolonged blockade of the M1 and M3 muscarinic receptors in the airways and a relatively more rapid dissocn. from the M2 receptor (which provides inhibitory feedback).  Multiple studies of up to a duration of 1 yr have demonstrated its effectiveness as a bronchodilator for COPD, with a trough increase (measured ∼ 24 h after administration of the drug) in forced expiratory vol. in 1 s of ∼ 0.12 l and a peak increase of ∼ 0.25 l.  Tiotropium inhalation also leads to a significant redn. in static lung vols. in hyperinflated patients with COPD; this probably contributes to the redn. in dyspnoea that is assocd. with long-term use of this maintenance bronchodilator.  Regular use of the drug was assocd. with clin. meaningful increases in the Transitional Dyspnea Index, which indicate redns. in dyspnea assocd. with daily activities.  Improvement in the respiratory-specific health status questionnaire, the St George's Respiratory Questionnaire component and total scores was also documented.  Finally, pooled data from two 1-yr studies and two 6-mo studies documented 20 and 28% redns. in the no. of exacerbations per patient per yr.  Side effects have been relatively minimal, with dry mouth the most common symptom, ranging 6-16% of patients and rarely leading to discontinuation of the study drug.  Limited comparisons of efficacy with other bronchodilators are available.  Once-daily tiotropium has been demonstrated to be clearly superior to ipratropium four times daily as a bronchodilator for COPD.  Combined results from two studies comparing once-daily tiotropium to twice-daily inhalation of std. doses of salmeterol, indicate a magnitude of the bronchodilator response similar in the two drugs early in the study.  However, by 6 mo, the bronchodilator effect of tiotropium was somewhat greater than that of the long-acting β-agonist.  Preliminary data suggest that combining tiotropium with long-acting β-agonists may produce addnl. bronchodilator action in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYqgepEqrbmLVg90H21EOLACvtfcHk0lh2oXzLQh9Z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Olt7c%253D&md5=90c3f5babe9fbb4436482ececa4569c0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656566.5.8.1827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.5.8.1827%26sid%3Dliteratum%253Aachs%26aulast%3DZuWallack%26aufirst%3DA.%2BR.%26aulast%3DZuWallack%26aufirst%3DR.%2BL.%26atitle%3DTiotropium%2520bromide%252C%2520a%2520new%252C%2520once-daily%2520inhaled%2520anticholinergic%2520bronchodilator%2520for%2520chronic-obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2004%26volume%3D5%26spage%3D1827%26epage%3D1835%26doi%3D10.1517%2F14656566.5.8.1827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grynkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadzikowska, M.</span></span> <span> </span><span class="NLM_article-title">Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=18799813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWgsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=439-463&author=G.+Grynkiewiczauthor=M.+Gadzikowska&title=Tropane+alkaloids+as+medicinally+useful+natural+products+and+their+synthetic+derivatives+as+new+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs</span></div><div class="casAuthors">Grynkiewicz, Grzegorz; Gadzikowska, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-463</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    
            (<span class="NLM_cas:orgname">Polish Academy of Sciences, Institute of Pharmacology</span>)
        </div><div class="casAbstract">A review.  Secondary metabolites of Solanaceae plants sharing a tropane skeleton as a common structural feature are sharply divided into two classes: tropine and ecgonine derivs.  The first group, represented by well known alkaloids: atropine and scopolamine, which are considered to be model anticholinergic drugs (cholinergic antagonists), continues to provide inspiration in the search for more selective muscarinic receptor antagonists.  The second class accommodates one of the principal drugs of abuse, cocaine.  Synthesis of much needed cocaine antagonists, despite extensive research, has not been particularly successful.  Therefore, new concepts of cocaine abuse treatment resort to immunotherapy and biotechnol.  The contemporary pharmaceutical industry manufs. over 20 active pharmaceutical substances contg. tropane moiety in their structure, which are applied as mydriatics (nervous system agents), antiemetics, antispasmodic agents (muscle relaxants, spasmolytics), anesthetics and bronchodilators.  There are two sources of starting materials for this industrial activity: natural products isolated from cultivated transgenic plants (mainly scopolamine and atropine from Australian Duboisia) and chem. synthesis based on common intermediate: tropinone, which can be further transformed by synthetic means to the following classes of compds.: tropine and its esters (tropeines), scopine and nortropine derivs., and tropane quaternary ammonium salts.  This survey focuses on new developments in chem. and pharmacol. of tropane derivs., particularly in view of their prospective industrial applications as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY2vRlzsQ-OLVg90H21EOLACvtfcHk0lirsBiCzhjP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWgsrvO&md5=f59773c74944524fbd41938e15eb3ae7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrynkiewicz%26aufirst%3DG.%26aulast%3DGadzikowska%26aufirst%3DM.%26atitle%3DTropane%2520alkaloids%2520as%2520medicinally%2520useful%2520natural%2520products%2520and%2520their%2520synthetic%2520derivatives%2520as%2520new%2520drugs%26jtitle%3DPharmacol.%2520Rep.%26date%3D2008%26volume%3D60%26spage%3D439%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raz, R.</span></span> <span> </span><span class="NLM_article-title">Fosfomycin: an old–new antibiotic</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1111/j.1469-0691.2011.03636.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1469-0691.2011.03636.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21914036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslyqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4-7&author=R.+Raz&title=Fosfomycin%3A+an+old%E2%80%93new+antibiotic&doi=10.1111%2Fj.1469-0691.2011.03636.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fosfomycin: an old-new antibiotic</span></div><div class="casAuthors">Raz, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-7</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fosfomycin is a broad-spectrum antibiotic discovered in Spain in 1969.  It has bactericidal activity against a wide range of bacteria, including gram-neg. micro-organisms and some gram-pos. bacteria, such as staphylococci.  Initially fosfomycin was administered parenterally and only to patients with severe infections.  Today it is often dispensed as fosfomycin-trometamol, an oral formula recommended in the treatment of urinary tract infections.  Fosfomycin-trometamol in a single dose is indicated for the treatment of women with uncomplicated urinary tract infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFTGAabxBhQLVg90H21EOLACvtfcHk0lirsBiCzhjP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslyqs7Y%253D&md5=b01415c2f4698138f5a00a0cb36f0a6a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2011.03636.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2011.03636.x%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DR.%26atitle%3DFosfomycin%253A%2520an%2520old%25E2%2580%2593new%2520antibiotic%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2012%26volume%3D18%26spage%3D4%26epage%3D7%26doi%3D10.1111%2Fj.1469-0691.2011.03636.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of cerulenin on fatty acid synthetase. Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a133933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1093%2Foxfordjournals.jbchem.a133933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=6749834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaL38Xks1KjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1982&pages=7-12&author=A.+Kawaguchiauthor=H.+Tomodaauthor=S.+Nozoeauthor=S.+Omuraauthor=S.+Okuda&title=Mechanism+of+action+of+cerulenin+on+fatty+acid+synthetase.+Effect+of+cerulenin+on+iodoacetamide-induced+malonyl-CoA+decarboxylase+activity&doi=10.1093%2Foxfordjournals.jbchem.a133933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of cerulenin on fatty acid synthetase.  Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity</span></div><div class="casAuthors">Kawaguchi, Akihiko; Tomoda, Hiroshi; Nozoe, Shigeo; Omura, Satoshi; Okuda, Shigenobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">The antibiotic cerulenin (I)  [17397-89-6] irreversibly inactivates yeast fatty acid synthetase  [9045-77-6].  Of all catalytic activities of the synthetase, only the condensation reaction is inhibited by cerulenin.  At 0° and pH 6.5, the second-order rate const. of k = 88 M-1·s-1 was obtained for the inactivation by cerulenin.  This value was ∼90-times greater than the rate const. for the inactivation of the enzyme by iodoacetamide  [144-48-9].  The enzyme was protected against the action of cerulenin by prior treatment with acetyl-CoA but not malonyl-CoA.  Treatment of the enzyme with iodoacetamide, while impairing the synthetase activity, induced malonyl-CoA decarboxylase  [9024-99-1] activity.  Cerulenin had no effect on the malonyl-CoA decarboxylase activity of the iodoacetamide-treated enzyme.  N-Ethylmaleimide, in contrast, inhibited the iodoacetamide-induced malonyl-CoA decarboxylase activity.  When the enzyme was preincubated with cerulenin, malonyl-CoA decarboxylase activity could not be detected even after treatment of the enzyme with iodoacetamide.  These results indicated that the reaction of cerulenin with the peripheral SH-groups of the synthetase is responsible for the inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgbtzg55-j7Vg90H21EOLACvtfcHk0lirsBiCzhjP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xks1KjtLs%253D&md5=f15e1ebe0efc898afb775f3f375f43cb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a133933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a133933%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DA.%26aulast%3DTomoda%26aufirst%3DH.%26aulast%3DNozoe%26aufirst%3DS.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DOkuda%26aufirst%3DS.%26atitle%3DMechanism%2520of%2520action%2520of%2520cerulenin%2520on%2520fatty%2520acid%2520synthetase.%2520Effect%2520of%2520cerulenin%2520on%2520iodoacetamide-induced%2520malonyl-CoA%2520decarboxylase%2520activity%26jtitle%3DJ.%2520Biochem.%26date%3D1982%26volume%3D92%26spage%3D7%26epage%3D12%26doi%3D10.1093%2Foxfordjournals.jbchem.a133933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arenas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melián, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Alenza, M.
D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily</span>. <i>J. Vet. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1111/jvim.12207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fjvim.12207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=24118316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fkt12qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1478-1485&author=C.+Arenasauthor=C.+Meli%C3%A1nauthor=M.%0AD.+P%C3%A9rez-Alenza&title=Evaluation+of+2+trilostane+protocols+for+the+treatment+of+canine+pituitary-dependent+hyperadrenocorticism%3A+twice+daily+versus+once+daily&doi=10.1111%2Fjvim.12207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily</span></div><div class="casAuthors">Arenas C; Melian C; Perez-Alenza M D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of veterinary internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1478-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Trilostane is the drug of choice to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs, but there is still controversy about which protocol best controls the clinical signs and results of adrenal functioning test.  OBJECTIVES:  To compare the efficacy of twice daily (BID) versus once daily (SID) trilostane administration and to compare the safety of both protocols in the treatment of dogs with PDH.  ANIMALS:  Thirty-two client-owned dogs diagnosed with PDH between 2008 and 2010 and treated with trilostane either BID or SID.  METHODS:  In this prospective randomized study, 2 trilostane protocols were evaluated on the basis of the owner's perception of clinical signs, on the results of laboratory tests, and on the results of the ACTH stimulation test in dogs with PDH.  Dogs were followed up for a period of 1 year.  RESULTS:  During the study, more dogs in the BID group had complete clinical recovery than in the SID group.  However, there was no significant difference in the mean post-ACTH cortisol concentration between groups.  Basal cortisol concentration at 6 months was higher in animals treated SID compared with animals treated BID.  Mean total daily doses of trilostane used to control PDH, as well as adverse effects observed in the course of the study, in both groups were not statistically different.  CONCLUSION AND CLINICAL IMPORTANCE:  Adverse effects were mild using either protocol of treatment.  Using trilostane BID might increase the number of dogs with a good clinical response compared with using trilostane SID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzJn3YTky2dresJRIHUP1ofW6udTcc2ebofupJhfJiZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fkt12qtA%253D%253D&md5=fb425b5fadde0bc5e3e216100e023411</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fjvim.12207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvim.12207%26sid%3Dliteratum%253Aachs%26aulast%3DArenas%26aufirst%3DC.%26aulast%3DMeli%25C3%25A1n%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-Alenza%26aufirst%3DM.%2BD.%26atitle%3DEvaluation%2520of%25202%2520trilostane%2520protocols%2520for%2520the%2520treatment%2520of%2520canine%2520pituitary-dependent%2520hyperadrenocorticism%253A%2520twice%2520daily%2520versus%2520once%2520daily%26jtitle%3DJ.%2520Vet.%2520Intern.%2520Med.%26date%3D2013%26volume%3D27%26spage%3D1478%26epage%3D1485%26doi%3D10.1111%2Fjvim.12207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullinan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geddes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span> <span> </span><span class="NLM_article-title">Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">Cd002987</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2F14651858.CD002987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=Cd002987&author=D.+J.+Evansauthor=P.+Cullinanauthor=D.+M.+Geddesauthor=E.+H.+Waltersauthor=S.+J.+Milanauthor=P.+Jones&title=Troleandomycin+as+an+oral+corticosteroid+steroid+sparing+agent+in+stable+asthma&doi=10.1002%2F14651858.CD002987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002987%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DCullinan%26aufirst%3DP.%26aulast%3DGeddes%26aufirst%3DD.%2BM.%26aulast%3DWalters%26aufirst%3DE.%2BH.%26aulast%3DMilan%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DTroleandomycin%2520as%2520an%2520oral%2520corticosteroid%2520steroid%2520sparing%2520agent%2520in%2520stable%2520asthma%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2000%26volume%3D2%26spage%3DCd002987%26doi%3D10.1002%2F14651858.CD002987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; p  <span class="NLM_fpage">1163</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1163&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1039/c3np20126k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2Fc3np20126k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23575525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=600-604&author=K.+B.+Kimauthor=C.+M.+Crews&title=From+epoxomicin+to+carfilzomib%3A+chemistry%2C+biology%2C+and+medical+outcomes&doi=10.1039%2Fc3np20126k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span></div><div class="casAuthors">Kim, Kyung Bo; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">600-604</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: 1992 to 2012The initial enthusiasm following the discovery of a pharmacol. active natural product is often fleeting due to the poor prospects for its ultimate clin. application.  Despite this, the ever-changing landscape of modern biol. has a const. need for mol. probes that can aid in our understanding of biol. processes.  After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore.  Despite its drawbacks, epoxomicin's pharmacophore was found to provide unprecedented selectivity for the proteasome.  Epoxomicin also served as a scaffold for the generation of a synthetic tetrapeptide epoxyketone with improved activity, YU-101, which became the parent lead compd. of carfilzomib (Kyprolis®), the recently approved therapeutic agent for multiple myeloma.  In this era of rational drug design and high-throughput screening, the prospects for turning an active natural product into an approved therapy are often slim.  However, by understanding the journey that began with the discovery of epoxomicin and ended with the successful use of carfilzomib in the clinic, we may find new insights into the keys for success in natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ZmojYh4VybVg90H21EOLACvtfcHk0ljZDbKATFwAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D&md5=fa9d90ac327e5383f6d80512ecec8db4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1039%2Fc3np20126k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np20126k%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DFrom%2520epoxomicin%2520to%2520carfilzomib%253A%2520chemistry%252C%2520biology%252C%2520and%2520medical%2520outcomes%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D600%26epage%3D604%26doi%3D10.1039%2Fc3np20126k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuitschik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Oxetanes in drug discovery: structural and synthetic insights</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3227</span>– <span class="NLM_lpage">3246</span>, <span class="refDoi"> DOI: 10.1021/jm9018788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3227-3246&author=G.+Wuitschikauthor=E.+M.+Carreiraauthor=B.+Wagnerauthor=H.+Fischerauthor=I.+Parrillaauthor=F.+Schulerauthor=M.+Rogers-Evansauthor=K.+M%C3%BCller&title=Oxetanes+in+drug+discovery%3A+structural+and+synthetic+insights&doi=10.1021%2Fjm9018788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes in Drug Discovery: Structural and Synthetic Insights</span></div><div class="casAuthors">Wuitschik, Georg; Carreira, Erick M.; Wagner, Bjorn; Fischer, Holger; Parrilla, Isabelle; Schuler, Franz; Rogers-Evans, Mark; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3227-3246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of oxetanes as replacements for gem-di-Me or carbonyl groups and their effects on the aq. soly., lipophilicity, metabolic stability, and conformation for various compds. are studied; methods for the prepn. of a variety of substituted oxetanes are given.  The magnitude of changes in properties and in metabolic stability with oxetane substitution depends on the structural context; for example, substitution of a gem-di-Me group with an oxetane, aq. soly. may increase by a factor of 4 to more than 4000 while reducing the rate of metabolic degrdn. in most cases.  Incorporation of an oxetane into an aliph. chain increases in some cases the preference for synclinal conformations rather than antiplanar conformations of the chain.  Spirocyclic oxetanes such as an oxazaspiroheptane resemble commonly used fragments in drug discovery, such as morpholines, and in some cases increase aq. soly. more effectively than morpholines.  An improved chemoselective oxidn. of 3-oxetanol to 3-oxetanone is disclosed; olefination of 3-oxetanone by a variety of methods yields alkylideneoxetanes I [R = (EtO)2P(:O), OHC, O2N, EtO2C, NC, PhO2S, MeCO, 1-(4-chlorophenyl)-1-cyclobutanecarbonyl].  I (R = EtO2C, OHC, O2N) undergo addn. reactions with nucleophiles such as amines, carbonyl compds., and arylboronic acids to give oxetanes such as II.  The crystal structures of a variety of oxetanes are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbJqJGrlPJrVg90H21EOLACvtfcHk0ljZDbKATFwAhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D&md5=e95742d38e933c2fb0d76d638ccc773c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm9018788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018788%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DOxetanes%2520in%2520drug%2520discovery%253A%2520structural%2520and%2520synthetic%2520insights%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3227%26epage%3D3246%26doi%3D10.1021%2Fjm9018788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gueritte, F.</span></span> <span> </span><span class="NLM_article-title">General and recent aspects of the chemistry and structure activity relationships of taxoids</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.2174/1381612013397429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2174%2F1381612013397429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1229-1249&author=F.+Gueritte&title=General+and+recent+aspects+of+the+chemistry+and+structure+activity+relationships+of+taxoids&doi=10.2174%2F1381612013397429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1381612013397429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397429%26sid%3Dliteratum%253Aachs%26aulast%3DGueritte%26aufirst%3DF.%26atitle%3DGeneral%2520and%2520recent%2520aspects%2520of%2520the%2520chemistry%2520and%2520structure%2520activity%2520relationships%2520of%2520taxoids%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2001%26volume%3D7%26spage%3D1229%26epage%3D1249%26doi%3D10.2174%2F1381612013397429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadvary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfer, H.</span></span> <span> </span><span class="NLM_article-title">The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1991&pages=2021-2027&author=P.+Hadvaryauthor=W.+Sidlerauthor=W.+Meisterauthor=W.+Vetterauthor=H.+Wolfer&title=The+lipase+inhibitor+tetrahydrolipstatin+binds+covalently+to+the+putative+active+site+serine+of+pancreatic+lipase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHadvary%26aufirst%3DP.%26aulast%3DSidler%26aufirst%3DW.%26aulast%3DMeister%26aufirst%3DW.%26aulast%3DVetter%26aufirst%3DW.%26aulast%3DWolfer%26aufirst%3DH.%26atitle%3DThe%2520lipase%2520inhibitor%2520tetrahydrolipstatin%2520binds%2520covalently%2520to%2520the%2520putative%2520active%2520site%2520serine%2520of%2520pancreatic%2520lipase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1991%26volume%3D266%26spage%3D2021%26epage%3D2027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Oral vitamin B12 replacement for the treatment of pernicious anemia</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.3389/fmed.2016.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.3389%2Ffmed.2016.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2szotl2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=38&author=C.+Q.+H.+Chanauthor=L.+L.+Lowauthor=K.+H.+Lee&title=Oral+vitamin+B12+replacement+for+the+treatment+of+pernicious+anemia&doi=10.3389%2Ffmed.2016.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia</span></div><div class="casAuthors">Chan Catherine Qiu Hua; Low Lian Leng; Lee Kheng Hock</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">Many patients with pernicious anemia are treated with lifelong intramuscular (IM) vitamin B12 replacement.  As early as the 1950s, there were studies suggesting that oral vitamin B12 replacement may provide adequate absorption.  Nevertheless, oral vitamin B12 replacement in patients with pernicious anemia remains uncommon in clinical practice.  The objective of this review is to provide an update on the effectiveness of oral vitamin B12 for the treatment of pernicious anemia, the recommended dosage, and the required frequency of laboratory test and clinical monitoring.  Relevant articles were identified by PubMed search from January 1, 1980 to March 31, 2016 and through hand search of relevant reference articles.  Two randomized controlled trials, three prospective papers, one systematic review, and three clinical reviews fulfilled our inclusion criteria.  We found that oral vitamin B12 replacement at 1000 μg daily was adequate to replace vitamin B12 levels in patients with pernicious anemia.  We conclude that oral vitamin B12 is an effective alternative to vitamin B12 IM injections.  Patients should be offered this alternative after an informed discussion on the advantages and disadvantages of both treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxUyB8QnYOiTW1zwg2yUK5fW6udTcc2eaNx7trSYM6w7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szotl2msw%253D%253D&md5=ce0b914b7a322260eb064f718be3c578</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2016.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2016.00038%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BQ.%2BH.%26aulast%3DLow%26aufirst%3DL.%2BL.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DOral%2520vitamin%2520B12%2520replacement%2520for%2520the%2520treatment%2520of%2520pernicious%2520anemia%26jtitle%3DFront.%2520Med.%26date%3D2016%26volume%3D3%26spage%3D38%26doi%3D10.3389%2Ffmed.2016.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen</span>. <i>Med. Gas Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1186/2045-9912-2-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2045-9912-2-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22309834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFert7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=3-6&author=X.+Chenauthor=X.+Zhaiauthor=Z.+Kangauthor=X.+Sun&title=Lactulose%3A+an+effective+preventive+and+therapeutic+option+for+ischemic+stroke+by+production+of+hydrogen&doi=10.1186%2F2045-9912-2-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen</span></div><div class="casAuthors">Chen, Xiao; Zhai, Xiao; Kang, Zhimin; Sun, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Medical Gas Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">MGREB2</span>;
        ISSN:<span class="NLM_cas:issn">2045-9912</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Lactulose, a synthetic sugar not able to be digested and absorbed by human beings, is widely used to treat constipation and hepatic encephalopathy clin.  Through fermn. by the bacteria in the gastrointestinal tract, lactulose can produce considerable amt. of hydrogen, which is protective for ischemic stroke as a unique antioxidant.  We propose that lactulose can induce the prodn. of endogenous hydrogen that in turn reduces oxidative stress and ameliorate the stroke damage in human beings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrasvdTF-sfKbVg90H21EOLACvtfcHk0lgaFBSWFFtVtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFert7o%253D&md5=4d6fcd9801efa1cde26d9aa289d36fdd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F2045-9912-2-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-9912-2-3%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DKang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DLactulose%253A%2520an%2520effective%2520preventive%2520and%2520therapeutic%2520option%2520for%2520ischemic%2520stroke%2520by%2520production%2520of%2520hydrogen%26jtitle%3DMed.%2520Gas%2520Res.%26date%3D2012%26volume%3D2%26spage%3D3%26epage%3D6%26doi%3D10.1186%2F2045-9912-2-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp 924, 1165–1168, 1221–1224.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, C. A.</span></span> <span> </span><span class="NLM_article-title">Guanadrel Sulfate: A Postganglionic sympathetic inhibitor for the treatment of mild to moderate hypertension</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1983.tb03257.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fj.1875-9114.1983.tb03257.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1983&pages=220-227&author=J.+D.+Palmerauthor=C.+A.+Nugent&title=Guanadrel+Sulfate%3A+A+Postganglionic+sympathetic+inhibitor+for+the+treatment+of+mild+to+moderate+hypertension&doi=10.1002%2Fj.1875-9114.1983.tb03257.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1983.tb03257.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1983.tb03257.x%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DJ.%2BD.%26aulast%3DNugent%26aufirst%3DC.%2BA.%26atitle%3DGuanadrel%2520Sulfate%253A%2520A%2520Postganglionic%2520sympathetic%2520inhibitor%2520for%2520the%2520treatment%2520of%2520mild%2520to%2520moderate%2520hypertension%26jtitle%3DPharmacotherapy%26date%3D1983%26volume%3D3%26spage%3D220%26epage%3D227%26doi%3D10.1002%2Fj.1875-9114.1983.tb03257.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterfalvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournex, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span> <span> </span><span class="NLM_article-title">Importance of the lactonic ring in the activity of steroidal antialdosterones</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90513-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2F0006-2952%2880%2990513-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=353-357&author=M.+Peterfalviauthor=V.+Torelliauthor=R.+Fournexauthor=G.+Rousseauauthor=M.+Claireauthor=A.+Michaudauthor=P.+Corvol&title=Importance+of+the+lactonic+ring+in+the+activity+of+steroidal+antialdosterones&doi=10.1016%2F0006-2952%2880%2990513-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990513-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990513-4%26sid%3Dliteratum%253Aachs%26aulast%3DPeterfalvi%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26aulast%3DFournex%26aufirst%3DR.%26aulast%3DRousseau%26aufirst%3DG.%26aulast%3DClaire%26aufirst%3DM.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DCorvol%26aufirst%3DP.%26atitle%3DImportance%2520of%2520the%2520lactonic%2520ring%2520in%2520the%2520activity%2520of%2520steroidal%2520antialdosterones%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D353%26epage%3D357%26doi%3D10.1016%2F0006-2952%2880%2990513-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykow, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamanda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agans-Fantuzzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintala, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3061</span>– <span class="NLM_lpage">3064</span>, <span class="refDoi"> DOI: 10.1021/jm800180e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800180e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3061-3064&author=S.+Chackalamannilauthor=Y.+Wangauthor=W.+J.+Greenleeauthor=Z.+Huauthor=Y.+Xiaauthor=H.-S.+Ahnauthor=G.+Boykowauthor=Y.+Hsiehauthor=J.+Palamandaauthor=J.+Agans-Fantuzziauthor=S.+Kurowskiauthor=M.+Grazianoauthor=M.+Chintala&title=Discovery+of+a+novel%2C+orally+active+himbacine-based+thrombin+receptor+antagonist+%28SCH+530348%29+with+potent+antiplatelet+activity&doi=10.1021%2Fjm800180e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity</span></div><div class="casAuthors">Chackalamannil, Samuel; Wang, Yuguang; Greenlee, William J.; Hu, Zhiyong; Xia, Yan; Ahn, Ho-Sam; Boykow, George; Hsieh, Yunsheng; Palamanda, Jairam; Agans-Fantuzzi, Jacqueline; Kurowski, Stan; Graziano, Michael; Chintala, Madhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3061-3064</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described.  Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clin. trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKpr_OJqfuEbVg90H21EOLACvtfcHk0ljXxL449B37Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ghu70%253D&md5=228c224e173cdb77b448943bdbec6838</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm800180e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800180e%26sid%3Dliteratum%253Aachs%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DH.-S.%26aulast%3DBoykow%26aufirst%3DG.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DPalamanda%26aufirst%3DJ.%26aulast%3DAgans-Fantuzzi%26aufirst%3DJ.%26aulast%3DKurowski%26aufirst%3DS.%26aulast%3DGraziano%26aufirst%3DM.%26aulast%3DChintala%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520orally%2520active%2520himbacine-based%2520thrombin%2520receptor%2520antagonist%2520%2528SCH%2520530348%2529%2520with%2520potent%2520antiplatelet%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3061%26epage%3D3064%26doi%3D10.1021%2Fjm800180e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arev-Fishelzon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, Y.</span></span> <span> </span><span class="NLM_article-title">The effect of a single dose of oral pilocarpine (Salagen) on the intraocular pressure and pupil diameter in glaucoma Patients</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=448&author=O.+Geyerauthor=A.+Wolfauthor=T.+Arev-Fishelzonauthor=E.+Levingerauthor=Y.+Wolfson&title=The+effect+of+a+single+dose+of+oral+pilocarpine+%28Salagen%29+on+the+intraocular+pressure+and+pupil+diameter+in+glaucoma+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DO.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DArev-Fishelzon%26aufirst%3DT.%26aulast%3DLevinger%26aufirst%3DE.%26aulast%3DWolfson%26aufirst%3DY.%26atitle%3DThe%2520effect%2520of%2520a%2520single%2520dose%2520of%2520oral%2520pilocarpine%2520%2528Salagen%2529%2520on%2520the%2520intraocular%2520pressure%2520and%2520pupil%2520diameter%2520in%2520glaucoma%2520Patients%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2006%26volume%3D47%26spage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eugui, E. M.</span></span> <span> </span><span class="NLM_article-title">Mycophenolate mofetil and its mechanisms of action</span>. <i>Immunopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/S0162-3109(00)00188-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS0162-3109%2800%2900188-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10878285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=85-118&author=A.+C.+Allisonauthor=E.+M.+Eugui&title=Mycophenolate+mofetil+and+its+mechanisms+of+action&doi=10.1016%2FS0162-3109%2800%2900188-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mycophenolate mofetil and its mechanisms of action</span></div><div class="casAuthors">Allison, A. C.; Eugui, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">85-118</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with many refs.  Mycophenolate mofetil (MMF, CellCept) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase (IMPDH).  This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides.  T- and B-lymphocytes are more dependent on this pathway than other cell types are.  Moreover, MPA is a fivefold more potent inhibitor of the type II isoform of IMPDH, which is expressed in activated lymphocytes, than of the type I isoform of IMPDH, which is expressed in most cell types.  MPA has therefore a more potent cytostatic effect on lymphocytes than on other cell types.  This is the principal mechanism by which MPA exerts immunosuppressive effects.  Three other mechanisms may also contribute to the efficacy of MPA in preventing allograft rejection and other applications.  First, MPA can induce apoptosis of activated T-lymphocytes, which may eliminate clones of cells responding to antigenic stimulation.  Second, by depleting guanosine nucleotides, MPA suppresses glycosylation and the expression of some adhesion mols., thereby decreasing the recruitment of lymphocytes and monocytes into sites of inflammation and graft rejection.  Third, by depleting guanosine nucleotides MPA also depletes tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase (iNOS).  MPA therefore suppresses the prodn. by iNOS of NO, and consequent tissue damage mediated by peroxynitrite.  CellCept suppresses T-lymphocytic responses to allogeneic cells and other antigens.  The drug also suppresses primary, but not secondary, antibody responses.  The efficacy of regimes including CellCept in preventing allograft rejection, and in the treatment of rejection, is now firmly established.  CellCept is also efficacious in several exptl. animal models of chronic rejection, and it is hoped that the drug will have the same effect in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLog1LqM9WU7Vg90H21EOLACvtfcHk0ljXxL449B37Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7o%253D&md5=0d254ab2a991bf5be727fcf8e38371e3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900188-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900188-0%26sid%3Dliteratum%253Aachs%26aulast%3DAllison%26aufirst%3DA.%2BC.%26aulast%3DEugui%26aufirst%3DE.%2BM.%26atitle%3DMycophenolate%2520mofetil%2520and%2520its%2520mechanisms%2520of%2520action%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D85%26epage%3D118%26doi%3D10.1016%2FS0162-3109%2800%2900188-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauptman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. A.</span></span> <span> </span><span class="NLM_article-title">Digitalis</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1265</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.99.9.1265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1161%2F01.CIR.99.9.1265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=1265-1270&author=P.+J.+Hauptmanauthor=R.+A.+Kelly&title=Digitalis&doi=10.1161%2F01.CIR.99.9.1265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.9.1265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.9.1265%26sid%3Dliteratum%253Aachs%26aulast%3DHauptman%26aufirst%3DP.%2BJ.%26aulast%3DKelly%26aufirst%3DR.%2BA.%26atitle%3DDigitalis%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D1265%26epage%3D1270%26doi%3D10.1161%2F01.CIR.99.9.1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bozdogan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, P. C.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones: activity, mode of action, and mechanism of resistance</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2003.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ijantimicag.2003.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=113-119&author=B.+Bozdoganauthor=P.+C.+Appelbaum&title=Oxazolidinones%3A+activity%2C+mode+of+action%2C+and+mechanism+of+resistance&doi=10.1016%2Fj.ijantimicag.2003.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones: activity, mode of action, and mechanism of resistance</span></div><div class="casAuthors">Bozdogan, Bulent; Appelbaum, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-119</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Oxazolidinones are a new group of antibiotics.  These synthetic drugs are active against a large spectrum of Gram-pos. bacteria, including methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes.  Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit.  Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, assocd. with 23S rRNA alterations during treatment were reported.  Linezolid, the 1st oxazolidinone available, has already taken its place in the clinic for treatment of Gram-pos. infections.  Pharmacokinetic properties as well as its good penetration and accumulation in the tissue including bone, lung, vegetations, hematoma and cerebrospinal fluid, allow its use for surgical infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjtJXxgnCjTbVg90H21EOLACvtfcHk0ljXxL449B37Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOnug%253D%253D&md5=3ce55290e07811bb846ba5a8fcc99073</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2003.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2003.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DBozdogan%26aufirst%3DB.%26aulast%3DAppelbaum%26aufirst%3DP.%2BC.%26atitle%3DOxazolidinones%253A%2520activity%252C%2520mode%2520of%2520action%252C%2520and%2520mechanism%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2004%26volume%3D23%26spage%3D113%26epage%3D119%26doi%3D10.1016%2Fj.ijantimicag.2003.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, W.</span></span> <span> </span><span class="NLM_article-title">D-Cycloserine in neuropsychiatric diseases: a systematic review</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyv102</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1093%2Fijnp%2Fpyv102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26364274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyv102&author=S.+Schadeauthor=W.+Paulus&title=D-Cycloserine+in+neuropsychiatric+diseases%3A+a+systematic+review&doi=10.1093%2Fijnp%2Fpyv102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv102%26sid%3Dliteratum%253Aachs%26aulast%3DSchade%26aufirst%3DS.%26aulast%3DPaulus%26aufirst%3DW.%26atitle%3DD-Cycloserine%2520in%2520neuropsychiatric%2520diseases%253A%2520a%2520systematic%2520review%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyv102%26doi%3D10.1093%2Fijnp%2Fpyv102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4155%2Ffmc.11.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21806380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1181-1197&author=A.+K.+Ghoshauthor=D.+D.+Anderson&title=Tetrahydrofuran%2C+tetrahydropyran%2C+triazoles+and+related+heterocyclic+derivatives+as+HIV+protease+inhibitors&doi=10.4155%2Ffmc.11.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors</span></div><div class="casAuthors">Ghosh, Arun K.; Anderson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1181-1197</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  HIV/AIDS remains a formidable disease with millions of individuals inflicted worldwide.  Although treatment regimens have improved considerably, drug resistance brought on by viral mutation continues to erode their effectiveness.  Intense research efforts are currently underway in search of new and improved therapies.  This review is concerned with the design of novel HIV-1 protease inhibitors that incorporate heterocyclic scaffolds and which have been reported within the recent literature (2005--2010).  Various examples in this review showcase the essential role heterocycles play as scaffolds and bioisosteres in HIV-1 protease inhibitor drug development.  This review will hopefully stimulate the widespread application of these heterocycles in the design of other therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWRpKhwnPK7LVg90H21EOLACvtfcHk0lioqZLlXyNo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFeisbw%253D&md5=c5c7ac273b57adae7b8c18cabaee2c49</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.68%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DAnderson%26aufirst%3DD.%2BD.%26atitle%3DTetrahydrofuran%252C%2520tetrahydropyran%252C%2520triazoles%2520and%2520related%2520heterocyclic%2520derivatives%2520as%2520HIV%2520protease%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1181%26epage%3D1197%26doi%3D10.4155%2Ffmc.11.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramu Sridhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaragurubaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fcmdc.200600103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16927344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=939-950&author=A.+K.+Ghoshauthor=P.+Ramu+Sridharauthor=N.+Kumaragurubaranauthor=Y.+Kohauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Bis-tetrahydrofuran%3A+a+privileged+ligand+for+darunavir+and+a+new+generation+of+hiv+protease+inhibitors+that+combat+drug+resistance&doi=10.1002%2Fcmdc.200600103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Sridhar, Perali Ramu; Kumaragurubaran, Nagaswamy; Koh, Yasuhiro; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-950</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The structure-based design of bis-tetrahydrofuranyl urethane has emerged as a privileged nonpeptide P2 ligand for a variety of highly potent HIV-1 protease inhibitors.  Incorporation of this ligand provided HIV protease inhibitors with exceedingly potent antiviral activity and superior activity against multi-PI-resistant variants relative to other FDA-approved PIs.  Recently, TMC-114 (darunavir) was approved by the FDA for treatment of drug-resistant HIV.  GW640385 (brecanavir), which incorporates bis-THF as the P2 ligand, is currently in Phase-III clin. development.  The bis-THF ligand was specifically designed to fill in the hydrophobic S2 pocket effectively and to promote extensive hydrogen bonding with the protein backbone in the enzyme S2 site.  The protein-ligand x-ray crystal structures with TMC-114 and other inhibitors with the bis-THF ligand revealed extensive interactions with the backbone of residues Asp29 and Asp30 at the S2 site.  The current design concept targeting the protein backbone may serve as an important guide to combat drug resistance.  Further design and synthesis of conceptually novel inhibitors are in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpT49sY24kLVg90H21EOLACvtfcHk0lioqZLlXyNo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVCmu7w%253D&md5=e9826330e807476b916d69e86ff55a40</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600103%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DRamu%2BSridhar%26aufirst%3DP.%26aulast%3DKumaragurubaran%26aufirst%3DN.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DBis-tetrahydrofuran%253A%2520a%2520privileged%2520ligand%2520for%2520darunavir%2520and%2520a%2520new%2520generation%2520of%2520hiv%2520protease%2520inhibitors%2520that%2520combat%2520drug%2520resistance%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D939%26epage%3D950%26doi%3D10.1002%2Fcmdc.200600103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. K.</span></span> <span> </span><span class="NLM_article-title">Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.2146/ajhp110237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2146%2Fajhp110237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22517020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOmsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=745-755&author=A.+McBrideauthor=S.+K.+Butler&title=Eribulin+mesylate%3A+a+novel+halichondrin+B+analogue+for+the+treatment+of+metastatic+breast+cancer&doi=10.2146%2Fajhp110237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer</span></div><div class="casAuthors">McBride, Ali; Butler, Sara K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose. The pharmacol., pharmacokinetics, clin. efficacy, safety, and administration of eribulin in patients with metastatic breast cancer are reviewed.  Summary. Classical chemotherapeutic agents for breast cancer have dominated treatment regimens even in the era of targeted therapy.  Disease progression through these agents is often due to the development of resistance or lack of efficacy with these agents.  Recently, a new nontaxane agent, eribulin mesylate, was approved for the treatment of metastatic breast cancer in patients who have received at least two prior chemotherapeutic agents.  Eribulin is a member of a new class of synthetic cytotoxic agents derived from the Japanese sea sponge Halichondria okadai.  Eribulin differs from other antimicrotubule agents in that it can bind to the microtubule cap and inhibit tubulin polymn., leading to microtubule arrest.  In Phase II clin. trials, eribulin demonstrated activity in extensively pretreated patients who had previously received an anthracycline, taxane, and capecitabine and had shown disease progression within the last six months of treatment.  In a pivotal Phase III clin. trial of heavily pretreated patients, patients who received eribulin vs. the physician's treatment of choice showed a significant increase in overall and progression-free survival.  Eribulin has a manageable adverse-effect profile, consisting mainly of neutropenia and fatigue.  Eribulin has been assocd. with a low incidence of peripheral neuropathy.  Conclusion. Eribulin, a novel synthetic antimicrotubule agent that binds to the vinca domain of tubulin and inhibits the polymn. of tubulin, offers a new treatment option for metastatic breast cancer or locally advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolsBGRs5gqkLVg90H21EOLACvtfcHk0lioqZLlXyNo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOmsb%252FL&md5=26be9deaf43ca2950e61b2371d6fa4bb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2146%2Fajhp110237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp110237%26sid%3Dliteratum%253Aachs%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DS.%2BK.%26atitle%3DEribulin%2520mesylate%253A%2520a%2520novel%2520halichondrin%2520B%2520analogue%2520for%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D745%26epage%3D755%26doi%3D10.2146%2Fajhp110237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachem, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontoyiannis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raad, I. I.</span></span> <span> </span><span class="NLM_article-title">Posaconazole: a broad-spectrum triazole antifungal</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(05)70297-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS1473-3099%2805%2970297-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16310149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlelu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=775-785&author=H.+A.+Torresauthor=R.+Y.+Hachemauthor=R.+F.+Chemalyauthor=D.+P.+Kontoyiannisauthor=I.+I.+Raad&title=Posaconazole%3A+a+broad-spectrum+triazole+antifungal&doi=10.1016%2FS1473-3099%2805%2970297-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Posaconazole: A broad-spectrum triazole antifungal</span></div><div class="casAuthors">Torres, Harrys A.; Hachem, Ray Y.; Chemaly, Roy F.; Kontoyiannis, Dimitrios P.; Raad, Issam I.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Posaconazole is a new triazole drug being investigated in phase III clin. trials for the treatment and prevention of invasive fungal infections.  In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi.  Posaconazole is given orally two to four times daily.  This triazole is widely distributed in the body, metabolized mainly by the liver, and is well tolerated, even in long-term courses.  Adverse events are generally mild and include headache and gastrointestinal complaints.  Posaconazole has shown promising clin. efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies-eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4X-P2eEDtKbVg90H21EOLACvtfcHk0lhf_pw9Cqn5qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlelu7jE&md5=e762181fe91a9df86697eb42d7e574be</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2805%2970297-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252805%252970297-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DH.%2BA.%26aulast%3DHachem%26aufirst%3DR.%2BY.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DKontoyiannis%26aufirst%3DD.%2BP.%26aulast%3DRaad%26aufirst%3DI.%2BI.%26atitle%3DPosaconazole%253A%2520a%2520broad-spectrum%2520triazole%2520antifungal%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2005%26volume%3D5%26spage%3D775%26epage%3D785%26doi%3D10.1016%2FS1473-3099%2805%2970297-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, H.</span></span> <span> </span><span class="NLM_article-title">Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with sjogren’s syndrome</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.2165/00044011-200222020-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00044011-200222020-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23315394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XitV2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=67-73&author=H.+Yasudaauthor=H.+Niki&title=Review+of+the+pharmacological+properties+and+clinical+usefulness+of+muscarinic+agonists+for+xerostomia+in+patients+with+sjogren%E2%80%99s+syndrome&doi=10.2165%2F00044011-200222020-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjogren's syndrome</span></div><div class="casAuthors">Yasuda, Hiroshi; Niki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The anti-xerostomia effects of muscarinic agonists (cholinomimetics) are reviewed.  Cevimeline (cevimeline monohydrochloride hemihydrate) is a novel muscarinic agonist that stimulates salivary secretion in animals and humans both with normal salivary gland function and with impaired salivary secretion (xerostomia or oral dryness) as effectively as pilocarpine.  Other classic and non-selective muscarinic agonists, such as arecoline, carbachol, muscarine and oxotremorine, as well as acetylcholine, failed to exhibit a sufficient salivation effect even at sublethal doses in animals.  Oral administration of cevimeline 30mg to humans induces a moderate and lasting increase in salivary flow, and the effect is maintained for at least 4 to 6 h, longer than with pilocarpine.  Mean increases in salivary flow rates after cevimeline treatment were 2-fold higher than after placebo, and no evidence of tolerance of the pharmacol. effect has been obsd. during prolonged administration for up to 12 mo.  The clin. efficacy of cevimeline in relieving symptoms of xerostomia, including oral dryness and difficulties in chewing, swallowing and speaking, has been demonstrated by placebo-controlled, double-blind, randomized clin. trials in the USA and Japan.  In these studies, cevimeline 30mg three times daily increased salivary flow and improved the symptoms of xerostomia in a significantly higher percentage of patients compared with placebo.  Some patients receiving cevimeline therapy for xerostomia experienced adverse events such as sweating, gastrointestinal symptoms (nausea, diarrhea, abdominal pain and vomiting), dizziness and rigors; these effects were related to muscarinic activity and were generally mild and tolerable in comparison with those of pilocarpine.  These findings suggest that muscarinic M3 agonists are suitable for the treatment of xerostomia.  Cevimeline in particular has a long-lasting salivation effect with fewer adverse events than pilocarpine, and so is expected to be more useful for the treatment of xerostomia in patients with Sjogren's syndrome, reducing symptom severity and improving their quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTTV8eQzUMt7Vg90H21EOLACvtfcHk0lhf_pw9Cqn5qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitV2htLg%253D&md5=1e1ce23c558ae2c0f692b72e1af1e890</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F00044011-200222020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00044011-200222020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DH.%26atitle%3DReview%2520of%2520the%2520pharmacological%2520properties%2520and%2520clinical%2520usefulness%2520of%2520muscarinic%2520agonists%2520for%2520xerostomia%2520in%2520patients%2520with%2520sjogren%25E2%2580%2599s%2520syndrome%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2002%26volume%3D22%26spage%3D67%26epage%3D73%26doi%3D10.2165%2F00044011-200222020-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubber, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitoria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span> <span> </span><span class="NLM_article-title">comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e79981</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0079981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1371%2Fjournal.pone.0079981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e79981&author=N.+Fordauthor=Z.+Shubberauthor=A.+Hillauthor=M.+Vitoriaauthor=M.+Dohertyauthor=E.+J.+Millsauthor=A.+Gray&title=comparative+efficacy+of+lamivudine+and+emtricitabine%3A+a+systematic+review+and+meta-analysis+of+randomized+trials&doi=10.1371%2Fjournal.pone.0079981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0079981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0079981%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DN.%26aulast%3DShubber%26aufirst%3DZ.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DVitoria%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DE.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26atitle%3Dcomparative%2520efficacy%2520of%2520lamivudine%2520and%2520emtricitabine%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520randomized%2520trials%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De79981%26doi%3D10.1371%2Fjournal.pone.0079981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvaris, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of urinary infections with nitrofurantoin (furadantin)</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.1958.tb03521.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1464-410X.1958.tb03521.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1958&pages=303-309&author=M.+Salvaris&title=Treatment+of+urinary+infections+with+nitrofurantoin+%28furadantin%29&doi=10.1111%2Fj.1464-410X.1958.tb03521.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.1958.tb03521.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.1958.tb03521.x%26sid%3Dliteratum%253Aachs%26aulast%3DSalvaris%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520urinary%2520infections%2520with%2520nitrofurantoin%2520%2528furadantin%2529%26jtitle%3DBJU%2520Int.%26date%3D1958%26volume%3D30%26spage%3D303%26epage%3D309%26doi%3D10.1111%2Fj.1464-410X.1958.tb03521.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P.</span></span> <span> </span><span class="NLM_article-title">Lapatinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fnrd2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17633789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=431&author=B.+Moyauthor=P.+Kirkpatrickauthor=S.+Karauthor=P.+Goss&title=Lapatinib&doi=10.1038%2Fnrd2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib</span></div><div class="casAuthors">Moy, Beverly; Kirkpatrick, Peter; Kar, Santwana; Goss, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">431-432</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lapatinib is a small-mol. kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2).  In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2hpzYynvxLbVg90H21EOLACvtfcHk0lh_Fu51oPz21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVSmur8%253D&md5=e1fc2433a41b935d4dcfd72e8e12be59</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2332%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DGoss%26aufirst%3DP.%26atitle%3DLapatinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D431%26doi%3D10.1038%2Fnrd2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinel, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapid, M. I.</span></span> <span> </span><span class="NLM_article-title">Treatment of nightmares with prazosin: A systematic review</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/j.mayocp.2012.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.mayocp.2012.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22883741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=890-900&author=S.+Kungauthor=Z.+Espinelauthor=M.+I.+Lapid&title=Treatment+of+nightmares+with+prazosin%3A+A+systematic+review&doi=10.1016%2Fj.mayocp.2012.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of nightmares with prazosin: a systematic review</span></div><div class="casAuthors">Kung, Simon; Espinel, Zelde; Lapid, Maria I.</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">890-900</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Nightmares, frequently assocd. with posttraumatic stress disorder and clin. relevant in today's world of violence, are difficult to treat, with few pharmacol. options.  We performed a systematic review to evaluate the evidence for the use of prazosin in the treatment of nightmares.  A comprehensive search was performed using the databases EMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systematic Reviews, from their inception to March 9, 2012, using keywords prazosin and nightmares/PTSD or assocd. terms (see text).  Two authors independently reviewed titles and abstrs. and selected relevant studies.  Descriptive data and outcomes of interest from eligible studies were extd. by 1 author, and checked by 2 others.  The risk of bias of randomized controlled trials (RCTs) was assessed independently by 2 reviewers.  Articles met criteria for inclusion if prazosin was used to treat nightmares, and outcome measures included nightmares or related symptoms of sleep disorders.  Our search yielded 21 studies, consisting of 4 RCTs, 4 open-label studies, 4 retrospective chart reviews, and 9 single case reports.  The prazosin dose ranged from 1 to 16 mg/d.  Results were mixed for the 4 RCTs: 3 reported significant improvement in the no. of nightmares, and 1 found no redn. in the no. of nightmares.  Reduced nightmare severity with use of prazosin was consistently reported in the open-label trials, retrospective chart reviews, and single case reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFs7_H89PSJ7Vg90H21EOLACvtfcHk0lh_Fu51oPz21w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlaqsA%253D%253D&md5=fe853863fd7f14c86ff51077b7739bbf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2012.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2012.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DS.%26aulast%3DEspinel%26aufirst%3DZ.%26aulast%3DLapid%26aufirst%3DM.%2BI.%26atitle%3DTreatment%2520of%2520nightmares%2520with%2520prazosin%253A%2520A%2520systematic%2520review%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2012%26volume%3D87%26spage%3D890%26epage%3D900%26doi%3D10.1016%2Fj.mayocp.2012.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R.</span></span> <span> </span><span class="NLM_article-title">How Zantac became the best-selling drug in history</span>. <i>J. Health Care Mark.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10169076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADyaK2svgsFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=24-29&author=R.+Wright&title=How+Zantac+became+the+best-selling+drug+in+history"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">How Zantac became the best-selling drug in history</span></div><div class="casAuthors">Wright R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of health care marketing</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">24-9</span>
        ISSN:<span class="NLM_cas:issn">0737-3252</span>.
    </div><div class="casAbstract">Glaxo's Zantac began its dominance of the acid/peptic marketplace with a launch strategy, taking advantage of the established Roche sales force to rapidly promote the product.  Educational symposia for physicians were instrumental in disseminating both disease and product information to primary care physicians and specialists.  This technique not only pleased physicians (more referrals), but also increased public awareness of gastrointestinal disease, further expanding the patient market.  Several novel marketing strategies contributed to Zantac's success, including the public-service announcements, celebrity media tours, and consumer-awareness bulletins, which brought the drug to the lay public and encouraged individuals to seek advice from their physicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUKOV4dA-MuEodMGTatQ7LfW6udTcc2eZDiwGoHOIp1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2svgsFGmsA%253D%253D&md5=74637455d07a98f3bf713e35a7e65765</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DR.%26atitle%3DHow%2520Zantac%2520became%2520the%2520best-selling%2520drug%2520in%2520history%26jtitle%3DJ.%2520Health%2520Care%2520Mark.%26date%3D1996%26volume%3D16%26spage%3D24%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schauer, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mally, A.</span></span> <span> </span><span class="NLM_article-title">Hepatobiliary toxicity of furan: identification of furan metabolites in bile of male f344/n rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.031781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1124%2Fdmd.109.031781" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1698-1706&author=C.+Hambergerauthor=M.+Kellertauthor=U.+M.+Schauerauthor=W.+Dekantauthor=A.+Mally&title=Hepatobiliary+toxicity+of+furan%3A+identification+of+furan+metabolites+in+bile+of+male+f344%2Fn+rats&doi=10.1124%2Fdmd.109.031781"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.031781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.031781%26sid%3Dliteratum%253Aachs%26aulast%3DHamberger%26aufirst%3DC.%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DSchauer%26aufirst%3DU.%2BM.%26aulast%3DDekant%26aufirst%3DW.%26aulast%3DMally%26aufirst%3DA.%26atitle%3DHepatobiliary%2520toxicity%2520of%2520furan%253A%2520identification%2520of%2520furan%2520metabolites%2520in%2520bile%2520of%2520male%2520f344%252Fn%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1698%26epage%3D1706%26doi%3D10.1124%2Fdmd.109.031781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. A.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolites in the biotransformation of molecules containing a furan ring</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/tx3003824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=6-25&author=L.+A.+Peterson&title=Reactive+metabolites+in+the+biotransformation+of+molecules+containing+a+furan+ring&doi=10.1021%2Ftx3003824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span></div><div class="casAuthors">Peterson, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-25</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many xenobiotics contg. a furan ring are toxic and/or carcinogenic.  The harmful effects of these compds. require furan ring oxidn.  This reaction generates an electrophilic intermediate.  Depending on the furan ring substituents, the intermediate is either an epoxide or a cis-enedione with more ring substitution favoring epoxide formation.  Either intermediate reacts with cellular nucleophiles such as protein or DNA to trigger toxicities.  The reactivity of the metabolite dets. which cellular nucleophiles are targeted.  The toxicity of a particular furan is also influenced by the presence of competing metabolic pathways or efficient detoxification routes.  GSH plays an important role in modulating the harmful effects of this class of compd. by reacting with the reactive metabolite.  However, this may not represent a detoxification step in all cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp4Dr5stLUSrVg90H21EOLACvtfcHk0lhv5LvcEN4SLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN&md5=fe3a280d0b7a99a436ec619abc1e1fa0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Ftx3003824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003824%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DReactive%2520metabolites%2520in%2520the%2520biotransformation%2520of%2520molecules%2520containing%2520a%2520furan%2520ring%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D6%26epage%3D25%26doi%3D10.1021%2Ftx3003824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barmade, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murumkar, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry perspective of fused isoxazole derivatives</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2883</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160506145700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2174%2F1568026616666160506145700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=27150366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWht7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2863-2883&author=M.+A.+Barmadeauthor=P.+R.+Murumkarauthor=M.+K.+Sharmaauthor=M.+R.+Yadav&title=Medicinal+chemistry+perspective+of+fused+isoxazole+derivatives&doi=10.2174%2F1568026616666160506145700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry Perspective of Fused Isoxazole Derivatives</span></div><div class="casAuthors">Barmade, Mahesh A.; Murumkar, Prashant R.; Sharma, Mayank Kumar; Yadav, Mange Ram</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2863-2883</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitrogen contg. heterocyclic rings with an oxygen atom is considered as one of the best combination in medicinal chem. due to their diversified biol. activities.  Isoxazole, a five membered heterocyclic azole ring is found in naturally occurring ibetonic acid along with some of the marketed drugs such as valdecoxib, flucloxacillin, cloxacillin, dicloxacillin, and danazol.  It is also significant for showing antipsychotic activity in risperidone and anticonvulsant activity in zonisamide, the marketed drugs.  This review article covers research articles reported till date covering biol. activity along with SAR of fused isoxazole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB2RkEKpFxPbVg90H21EOLACvtfcHk0lhv5LvcEN4SLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWht7zF&md5=774b6118d2b3440f33c52fa3cc93584d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160506145700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160506145700%26sid%3Dliteratum%253Aachs%26aulast%3DBarmade%26aufirst%3DM.%2BA.%26aulast%3DMurumkar%26aufirst%3DP.%2BR.%26aulast%3DSharma%26aufirst%3DM.%2BK.%26aulast%3DYadav%26aufirst%3DM.%2BR.%26atitle%3DMedicinal%2520chemistry%2520perspective%2520of%2520fused%2520isoxazole%2520derivatives%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2863%26epage%3D2883%26doi%3D10.2174%2F1568026616666160506145700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.-H.</span></span> <span> </span><span class="NLM_article-title">Recent advance in oxazole-based medicinal chemistry</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ejmech.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29288945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=444-492&author=H.-Z.+Zhangauthor=Z.-L.+Zhaoauthor=C.-H.+Zhou&title=Recent+advance+in+oxazole-based+medicinal+chemistry&doi=10.1016%2Fj.ejmech.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advance in oxazole-based medicinal chemistry</span></div><div class="casAuthors">Zhang, Hui-Zhen; Zhao, Zhi-Long; Zhou, Cheng-He</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">444-492</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Oxazole compds. contg. nitrogen and oxygen atoms in the five-membered arom. ring are readily able to bind with a variety of enzymes and receptors in biol. systems via diverse non-covalent interactions, and thus display versatile biol. activities.  The related researches in oxazole-based derivs. including oxazoles, isoxazoles, oxazolines, oxadiazoles, oxazolidones, benzoxazoles and so on, as medicinal drugs have been an extremely active topic, and numerous excellent achievements have been acquired.  Noticeably, a large no. of oxazole compds. as clin. drugs or candidates have been frequently employed for the treatment of various types of diseases, which have shown their large development value and wide potential as medicinal agents.  This work systematically reviewed the recent researches and developments of the whole range of oxazole compds. as medicinal drugs, including antibacterial, antifungal, antiviral, antitubercular, anticancer, anti-inflammatory and analgesic, antidiabetic, antiparasitic, anti-obesitic, anti-neuropathic, antioxidative as well as other biol. activities.  The perspectives of the foreseeable future in the research and development of oxazole-based compds. as medicinal drugs are also presented.  It is hoped that this review will serve as a stimulant for new thoughts in the quest for rational designs of more active and less toxic oxazole medicinal drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0ZFICNzJ_LVg90H21EOLACvtfcHk0lhv5LvcEN4SLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kluw%253D%253D&md5=4b4b3a3db4b5bdae78aa385db3c6f263</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-Z.%26aulast%3DZhao%26aufirst%3DZ.-L.%26aulast%3DZhou%26aufirst%3DC.-H.%26atitle%3DRecent%2520advance%2520in%2520oxazole-based%2520medicinal%2520chemistry%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D444%26epage%3D492%26doi%3D10.1016%2Fj.ejmech.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinàs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&author=J.+Bostr%C3%B6mauthor=A.+Hognerauthor=A.+Llin%C3%A0sauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2eYaVnNgLwbKHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlin%25C3%25A0s%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellon, D. M.</span></span> <span> </span><span class="NLM_article-title">Anthracycline chemotherapy and cardiotoxicity</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1007/s10557-016-6711-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs10557-016-6711-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28185035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=63-75&author=J.+V.+McGowanauthor=R.+Chungauthor=A.+Maulikauthor=I.+Piotrowskaauthor=J.+M.+Walkerauthor=D.+M.+Yellon&title=Anthracycline+chemotherapy+and+cardiotoxicity&doi=10.1007%2Fs10557-016-6711-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Anthracycline Chemotherapy and Cardiotoxicity</span></div><div class="casAuthors">McGowan, John V.; Chung, Robin; Maulik, Angshuman; Piotrowska, Izabela; Walker, J. Malcolm; Yellon, Derek M.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.  Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality.  The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways.  Cardioprotective treatments are few and those that have been examd. include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane.  New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon.  Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD-ITlhJanQbVg90H21EOLACvtfcHk0lho4I6v1FdIRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlOqtLs%253D&md5=a13263360269429a434337fb46c44b23</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs10557-016-6711-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-016-6711-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DJ.%2BV.%26aulast%3DChung%26aufirst%3DR.%26aulast%3DMaulik%26aufirst%3DA.%26aulast%3DPiotrowska%26aufirst%3DI.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26aulast%3DYellon%26aufirst%3DD.%2BM.%26atitle%3DAnthracycline%2520chemotherapy%2520and%2520cardiotoxicity%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D31%26spage%3D63%26epage%3D75%26doi%3D10.1007%2Fs10557-016-6711-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eleazu, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleazu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chukwuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essien, U. N.</span></span> <span> </span><span class="NLM_article-title">Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans</span>. <i>J. Diabetes Metab. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/2251-6581-12-60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2251-6581-12-60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=24364898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSgtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=60&author=C.+O.+Eleazuauthor=K.+C.+Eleazuauthor=S.+Chukwumaauthor=U.+N.+Essien&title=Review+of+the+mechanism+of+cell+death+resulting+from+streptozotocin+challenge+in+experimental+animals%2C+its+practical+use+and+potential+risk+to+humans&doi=10.1186%2F2251-6581-12-60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans</span></div><div class="casAuthors">Eleazu, Chinedum Ogbonnaya; Eleazu, Kate Chinedum; Chukwuma, Sonia; Essien, Udeme Nelson</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes and Metabolic Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60/1-60/7, 7</span>CODEN:
                <span class="NLM_cas:coden">JDMDAL</span>;
        ISSN:<span class="NLM_cas:issn">2251-6581</span>.
    
            (<span class="NLM_cas:orgname">Tehran University of Medical Sciences, Endocrinology & Metabolism Research Center</span>)
        </div><div class="casAbstract">A review.  Streptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose) is a naturally occurring diabetogenic compd., produced by the soil bacterium streptomyces achromogenes, that exhibits broad spectrum of antibacterial properties.  Streptozotocin functions as a DNA synthesis inhibitor in both bacterial and mammalian cells.  In mammalian cells, the actual mechanism and metabolic targets of STZ toxicity that results in cell death is not known.  This review identifies four key areas that explain the mechanism of the cytotoxicity of STZ in mammalian cell lines, investigates the practical aspects of using STZ in exptl. animals and the potential risks of its exposure to human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKMm4ggmSHRrVg90H21EOLACvtfcHk0lho4I6v1FdIRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSgtrvL&md5=7b5fa0bad8c6e07c9eec53201cfc507d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F2251-6581-12-60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2251-6581-12-60%26sid%3Dliteratum%253Aachs%26aulast%3DEleazu%26aufirst%3DC.%2BO.%26aulast%3DEleazu%26aufirst%3DK.%2BC.%26aulast%3DChukwuma%26aufirst%3DS.%26aulast%3DEssien%26aufirst%3DU.%2BN.%26atitle%3DReview%2520of%2520the%2520mechanism%2520of%2520cell%2520death%2520resulting%2520from%2520streptozotocin%2520challenge%2520in%2520experimental%2520animals%252C%2520its%2520practical%2520use%2520and%2520potential%2520risk%2520to%2520humans%26jtitle%3DJ.%2520Diabetes%2520Metab.%2520Disord.%26date%3D2013%26volume%3D12%26spage%3D60%26doi%3D10.1186%2F2251-6581-12-60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, J. A.</span></span> <span> </span><span class="NLM_article-title">Indolocarbazole natural products: occurrence, biosynthesis, and biological activity</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1039/B601930G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2FB601930G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17119643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivFahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1007-1045&author=C.+Sanchezauthor=C.+Mendezauthor=J.+A.+Salas&title=Indolocarbazole+natural+products%3A+occurrence%2C+biosynthesis%2C+and+biological+activity&doi=10.1039%2FB601930G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Indolocarbazole natural products: occurrence, biosynthesis, and biological activity</span></div><div class="casAuthors">Sanchez, Cesar; Mendez, Carmen; Salas, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1007-1045</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The indolocarbazole family of natural products, including the biosynthetically related bisindolylmaleimides, is reviewed (with 316 refs. cited).  The isolation of indolocarbazoles from natural sources and the biosynthesis of this class of compds. are thoroughly reviewed, including recent developments in mol. genetics, enzymol. and metabolic engineering.  The biol. activities and underlying modes of action displayed by natural and synthetic indolocarbazoles is also presented, with an emphasis on the development of analogs that have entered clin. trials for its future use against cancer or other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYX-bxZmjEA7Vg90H21EOLACvtfcHk0lifiBT-mc5ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivFahsQ%253D%253D&md5=7634cd7a7078adbeb5be7bd6fa12a862</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FB601930G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB601930G%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DMendez%26aufirst%3DC.%26aulast%3DSalas%26aufirst%3DJ.%2BA.%26atitle%3DIndolocarbazole%2520natural%2520products%253A%2520occurrence%252C%2520biosynthesis%252C%2520and%2520biological%2520activity%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2006%26volume%3D23%26spage%3D1007%26epage%3D1045%26doi%3D10.1039%2FB601930G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, M. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of DNA-bound Co(III)·bleomycin B(2): Insights on intercalation and minor groove binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">5052</span>– <span class="NLM_lpage">5056</span>, <span class="refDoi"> DOI: 10.1073/pnas.0708143105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1073%2Fpnas.0708143105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5052-5056&author=K.+D.+Goodwinauthor=M.+A.+Lewisauthor=E.+C.+Longauthor=M.+M.+Georgiadis&title=Crystal+structure+of+DNA-bound+Co%28III%29%C2%B7bleomycin+B%282%29%3A+Insights+on+intercalation+and+minor+groove+binding&doi=10.1073%2Fpnas.0708143105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708143105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708143105%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DK.%2BD.%26aulast%3DLewis%26aufirst%3DM.%2BA.%26aulast%3DLong%26aufirst%3DE.%2BC.%26aulast%3DGeorgiadis%26aufirst%3DM.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520DNA-bound%2520Co%2528III%2529%25C2%25B7bleomycin%2520B%25282%2529%253A%2520Insights%2520on%2520intercalation%2520and%2520minor%2520groove%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D5052%26epage%3D5056%26doi%3D10.1073%2Fpnas.0708143105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">705</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=701-705&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D701%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J. P. H.</span></span> <span> </span><span class="NLM_article-title">Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1210/jc.2009-0473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1210%2Fjc.2009-0473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=19892839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=34-42&author=S.+Nairauthor=J.+P.+H.+Wilding&title=Sodium+glucose+cotransporter+2+inhibitors+as+a+new+treatment+for+diabetes+mellitus&doi=10.1210%2Fjc.2009-0473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus</span></div><div class="casAuthors">Nair, Sunil; Wilding, John P. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-42</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Sodium-glucose cotransporter 2 (SGLT2) expressed in the proximal renal tubules accounts for about 90% of the reabsorption of glucose from tubular fluid.  Genetic defects of SGLT2 result in a benign familial renal glucosuria.  Pharmacol. agents that block SGLT2 are being tested as potential treatment for type 2 diabetes mellitus.  A Pubmed search was used to identify all relevant articles on the physiol. of SGLTs as well as published preclin. and clin. exptl. studies with SGLT2 inhibitors; a ref. search of all retrieved articles was also undertaken.  SGLT2 is almost exclusively expressed in the proximal renal tubules.  Preclin. studies with selective SLGT2 inhibitors show dose-dependent glucosuria and lowering of blood glucose in models of type 2 diabetes.  Preliminary clin. studies of ≤ 3-mo duration show dose-dependent lowering of glycosylated Hb ≤ 0.9% along with modest wt. loss.  Side effects include an increase in genital fungal infection compared to placebo, increased urine vol. (300-400 mL/24 h), and evidence of vol. depletion consistent with mild diuretic effect.  SGLT2 inhibitors are showing promise as a useful addn. to the current therapeutic options in type 2 diabetes mellitus.  Results of ongoing phase III clin. trials are awaited and will det. whether the risk-benefit ratio will allow approval of this new class of drug for the management of type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVmHLfjABp1bVg90H21EOLACvtfcHk0lifiBT-mc5ZSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGhsr0%253D&md5=d99ac28d42f3b3869b61fb98d53587f6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1210%2Fjc.2009-0473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2009-0473%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DS.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DSodium%2520glucose%2520cotransporter%25202%2520inhibitors%2520as%2520a%2520new%2520treatment%2520for%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2010%26volume%3D95%26spage%3D34%26epage%3D42%26doi%3D10.1210%2Fjc.2009-0473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanefeld, M.</span></span> <span> </span><span class="NLM_article-title">The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus</span>. <i>J. Diabetes Complicat.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/S1056-8727(97)00123-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS1056-8727%2897%2900123-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=9647342" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=228-237&author=M.+Hanefeld&title=The+role+of+acarbose+in+the+treatment+of+non-insulin-dependent+diabetes+mellitus&doi=10.1016%2FS1056-8727%2897%2900123-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS1056-8727%2897%2900123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8727%252897%252900123-2%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520acarbose%2520in%2520the%2520treatment%2520of%2520non-insulin-dependent%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Diabetes%2520Complicat.%26date%3D1998%26volume%3D12%26spage%3D228%26epage%3D237%26doi%3D10.1016%2FS1056-8727%2897%2900123-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruniera, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviolli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacci, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Luz Goncalves Pedreira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorgini
Peterlini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzalis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos Junqueira, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, F. L.</span></span> <span> </span><span class="NLM_article-title">The use of vancomycin with its therapeutic and adverse effects: a review</span>. <i>Eur. Rev. Med. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25753888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2MnislSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=694-700&author=F.+R.+Brunieraauthor=F.+M.+Ferreiraauthor=L.+R.+Saviolliauthor=M.+R.+Bacciauthor=D.+Federauthor=M.+da+Luz+Goncalves+Pedreiraauthor=M.+A.+Sorgini%0APeterliniauthor=L.+A.+Azzalisauthor=V.+B.+Campos+Junqueiraauthor=F.+L.+Fonseca&title=The+use+of+vancomycin+with+its+therapeutic+and+adverse+effects%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The use of vancomycin with its therapeutic and adverse effects: a review</span></div><div class="casAuthors">Bruniera F R; Ferreira F M; Saviolli L R M; Bacci M R; Feder D; da Luz Goncalves Pedreira M; Sorgini Peterlini M A; Azzalis L A; Campos Junqueira V B; Fonseca F L A</div><div class="citationInfo"><span class="NLM_cas:title">European review for medical and pharmacological sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">694-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Vancomycin (VCM) is a tricyclic glycopeptide antibiotic produced by Streptococcus orientalis.  Widely used in hospitals, it is indicated to fight severe infections caused by Gram-positive bacteria, especially with the advent of MRSA (methicillin-resistant Staphylococcus aureus), penicillin-resistant pneumococci among others.  Furthermore, it is indicated for the treatment of patients allergic to penicillins and cephalosporins.  Dose recommendations, dilution rates and types of infusion are controversial and also result in toxic effects.  Aim of this paper was to perform a literature review showing the therapeutic and adverse effects of vancomycin.  MATERIALS AND METHODS:  This is a literature review of recent articles published on MEDLINE and SciELO databases in English, Portuguese and Spanish.  RESULTS:  The main adverse effects of vancomycin are: hypotension, phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red man syndrome, neutropenia, chills, fever, interstitial nephritis.  CONCLUSIONS:  The use of vancomycin is still very common; however, inadequate doses and prolonged therapy pose a risk of increasing minimum inhibitory concentrations (MICs), resulting in subtherapeutic levels, treatment failures and toxicity.  Therefore, further studies should be conducted to optimize the administration of vancomycin, monitoring treatments from the beginning in order to ensure a safe and effective use of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlQswSuSEi7MSzjBFCN0BJfW6udTcc2eaA9dLQtxiHYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnislSlsQ%253D%253D&md5=b257c0b6ed5eb2984b2ef531c51814c7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruniera%26aufirst%3DF.%2BR.%26aulast%3DFerreira%26aufirst%3DF.%2BM.%26aulast%3DSaviolli%26aufirst%3DL.%2BR.%26aulast%3DBacci%26aufirst%3DM.%2BR.%26aulast%3DFeder%26aufirst%3DD.%26aulast%3Dda%2BLuz%2BGoncalves%2BPedreira%26aufirst%3DM.%26aulast%3DSorgini%2BPeterlini%26aufirst%3DM.%2BA.%26aulast%3DAzzalis%26aufirst%3DL.%2BA.%26aulast%3DCampos%2BJunqueira%26aufirst%3DV.%2BB.%26aulast%3DFonseca%26aufirst%3DF.%2BL.%26atitle%3DThe%2520use%2520of%2520vancomycin%2520with%2520its%2520therapeutic%2520and%2520adverse%2520effects%253A%2520a%2520review%26jtitle%3DEur.%2520Rev.%2520Med.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D19%26spage%3D694%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arsic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladenovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, P.</span></span> <span> </span><span class="NLM_article-title">16-membered macrolide antibiotics: a review</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2017.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ijantimicag.2017.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28668674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12iu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=283-298&author=B.+Arsicauthor=J.+Barberauthor=A.+Cikosauthor=M.+Mladenovicauthor=N.+Stankovicauthor=P.+Novak&title=16-membered+macrolide+antibiotics%3A+a+review&doi=10.1016%2Fj.ijantimicag.2017.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">16-Membered macrolide antibiotics: a review</span></div><div class="casAuthors">Arsic, Biljana; Barber, Jill; Cikos, Ana; Mladenovic, Milan; Stankovic, Nevena; Novak, Predrag</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-298</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 16-membered macrolide antibiotics (e.g. tylosin A and josamycin) are mainly used in veterinary medicine, and are much less studied than their 14- and 15-membered erythromycin-based cousins.  Although these antibiotics have similar antibacterial profiles, with activity primarily against Gram-pos. and a limited range of Gram-neg. organisms, the 16-membered macrolides show some advantages.  These include better gastrointestinal tolerance, lack of drug-drug interactions, and activity against certain resistant bacterial strains by extension of the peptide tunnel reach allowing addnl. interactions.  In addn. to antibacterial activity, the most famous representative of the class, tylosin A, as well as some derivs. of desmycosin (tylosin B), have shown antimalarial activity.  Such activity has also been obsd. in the 14-membered macrolide antibiotics, azithromycin, solithromycin and clindamycin.  This antimalarial activity provides the opportunity to investigate these drugs as cheap and effective antimalarials.  This is an overview of the latest research on biosynthesis, structure, chem. properties and mode of action of 16-membered macrolides, with special emphasis on their most explored members: tylosin A and josamycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiw9SfzlKkx7Vg90H21EOLACvtfcHk0lim00_mM-wQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12iu74%253D&md5=b58e545077ba9ed63b3d5494766141c8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2017.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2017.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DArsic%26aufirst%3DB.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DCikos%26aufirst%3DA.%26aulast%3DMladenovic%26aufirst%3DM.%26aulast%3DStankovic%26aufirst%3DN.%26aulast%3DNovak%26aufirst%3DP.%26atitle%3D16-membered%2520macrolide%2520antibiotics%253A%2520a%2520review%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2018%26volume%3D51%26spage%3D283%26epage%3D298%26doi%3D10.1016%2Fj.ijantimicag.2017.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Fidaxomicin: A novel agent for the treatment of clostridium difficile infection</span>. <i>Can. J. Infect. Dis. Med. Micriobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1155/2015/934594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1155%2F2015%2F934594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26744587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=305-312&author=G.+G.+Zhanelauthor=A.+J.+Walktyauthor=J.+A.+Karlowsky&title=Fidaxomicin%3A+A+novel+agent+for+the+treatment+of+clostridium+difficile+infection&doi=10.1155%2F2015%2F934594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1155%2F2015%2F934594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F934594%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DWalkty%26aufirst%3DA.%2BJ.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DFidaxomicin%253A%2520A%2520novel%2520agent%2520for%2520the%2520treatment%2520of%2520clostridium%2520difficile%2520infection%26jtitle%3DCan.%2520J.%2520Infect.%2520Dis.%2520Med.%2520Micriobiol.%26date%3D2015%26volume%3D26%26spage%3D305%26epage%3D312%26doi%3D10.1155%2F2015%2F934594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, T.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside antibiotics: old drugs and new therapeutic approaches</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1852</span>, <span class="refDoi"> DOI: 10.1007/s00018-007-7034-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs00018-007-7034-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17447006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFagtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=1841-1852&author=T.+Hermann&title=Aminoglycoside+antibiotics%3A+old+drugs+and+new+therapeutic+approaches&doi=10.1007%2Fs00018-007-7034-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside antibiotics: old drugs and new therapeutic approaches</span></div><div class="casAuthors">Hermann, T.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1841-1852</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Aminoglycoside antibiotics kill bacteria by binding to the ribosomal decoding site and reducing fidelity of protein synthesis.  Since the discovery of these natural products over 50 years ago, aminoglycosides have provided a mainstay of antibacterial therapy of serious Gram-neg. infections.  In recent years, aminoglycosides have become important tools to study mol. recognition of RNA (RNA).  In an ingenious exploitation of the aminoglycosides' mechanism of action, it has been speculated that drug-induced readthrough of premature stop codons in mutated mRNAs might be used to treat patients suffering from certain heritable genetic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEI1QmZiN5qbVg90H21EOLACvtfcHk0lim00_mM-wQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFagtLg%253D&md5=64e217c8a48b551551d3278fa203d8f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00018-007-7034-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-007-7034-x%26sid%3Dliteratum%253Aachs%26aulast%3DHermann%26aufirst%3DT.%26atitle%3DAminoglycoside%2520antibiotics%253A%2520old%2520drugs%2520and%2520new%2520therapeutic%2520approaches%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2007%26volume%3D64%26spage%3D1841%26epage%3D1852%26doi%3D10.1007%2Fs00018-007-7034-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busscher, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutjes, F. P. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Delft, F. L.</span></span> <span> </span><span class="NLM_article-title">2-Deoxystreptamine: central scaffold of aminoglycoside antibiotics</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/cr0404085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0404085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=775-792&author=G.+F.+Busscherauthor=F.+P.+J.+T.+Rutjesauthor=F.+L.+van+Delft&title=2-Deoxystreptamine%3A+central+scaffold+of+aminoglycoside+antibiotics&doi=10.1021%2Fcr0404085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">2-Deoxystreptamine: Central Scaffold of Aminoglycoside Antibiotics</span></div><div class="casAuthors">Busscher, Guuske F.; Rutjes, Floris P. J. T.; Van Delft, Floris L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-791</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses mechanism of action, toxicity, synthesis and resistance to aminoglycoside antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBApxOro0DKrVg90H21EOLACvtfcHk0lim00_mM-wQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsrg%253D&md5=531133e96e3397673a084b60341b04fe</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fcr0404085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0404085%26sid%3Dliteratum%253Aachs%26aulast%3DBusscher%26aufirst%3DG.%2BF.%26aulast%3DRutjes%26aufirst%3DF.%2BP.%2BJ.%2BT.%26aulast%3Dvan%2BDelft%26aufirst%3DF.%2BL.%26atitle%3D2-Deoxystreptamine%253A%2520central%2520scaffold%2520of%2520aminoglycoside%2520antibiotics%26jtitle%3DChem.%2520Rev.%26date%3D2005%26volume%3D105%26spage%3D775%26epage%3D792%26doi%3D10.1021%2Fcr0404085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Structure and mechanism of the lincosamide antibiotic adenylyltransferase LinB</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1016/j.str.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.str.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=20004168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFantbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1649-1659&author=M.+Morarauthor=K.+Bhullarauthor=D.+W.+Hughesauthor=M.+Junopauthor=G.+D.+Wright&title=Structure+and+mechanism+of+the+lincosamide+antibiotic+adenylyltransferase+LinB&doi=10.1016%2Fj.str.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Mechanism of the Lincosamide Antibiotic Adenylyltransferase LinB</span></div><div class="casAuthors">Morar, Mariya; Bhullar, Kirandeep; Hughes, Donald W.; Junop, Murray; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1649-1659</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Lincosamides make up an important class of antibiotics used against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus.  Predictably, lincosamide-resistant microorganisms have emerged with antibiotic modification as one of their major resistance strategies.  Inactivating enzymes LinB/A catalyze adenylylation of the drug; however, little is known about their mechanistic and structural properties.  We detd. two x-ray structures of LinB: ternary substrate- and binary product-bound complexes.  Structural and kinetic characterization of LinB, mutagenesis, solvent isotope effect, and product inhibition studies are consistent with a mechanism involving direct in-line nucleotidyl transfer.  The characterization of LinB enabled its classification as a member of a nucleotidyltransferase superfamily, along with nucleotide polymerases and aminoglycoside nucleotidyltransferases, and this relationship offers further support for the LinB mechanism.  The LinB structure provides an evolutionary link to ancient nucleotide polymerases and suggests that, like protein kinases and acetyltransferases, these are proto-resistance elements from which drug resistance can evolve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTfPk0pQXU7Vg90H21EOLACvtfcHk0lg3ayodBvGe7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFantbrL&md5=16a3b5173a48a5b1492e541d835331c6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DMorar%26aufirst%3DM.%26aulast%3DBhullar%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DD.%2BW.%26aulast%3DJunop%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DStructure%2520and%2520mechanism%2520of%2520the%2520lincosamide%2520antibiotic%2520adenylyltransferase%2520LinB%26jtitle%3DStructure%26date%3D2009%26volume%3D17%26spage%3D1649%26epage%3D1659%26doi%3D10.1016%2Fj.str.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetti, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivashanmugam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parthasarathy, S.</span></span> <span> </span><span class="NLM_article-title">Sugammadex: A revolutionary drug in neuromuscular pharmacology</span>. <i>Anesth. Essays Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.4103/0259-1162.123211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4103%2F0259-1162.123211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25885973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlsVeqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=302-306&author=K.+Nagauthor=D.+R.+Singhauthor=A.+N.+Shettiauthor=H.+Kumarauthor=T.+Sivashanmugamauthor=S.+Parthasarathy&title=Sugammadex%3A+A+revolutionary+drug+in+neuromuscular+pharmacology&doi=10.4103%2F0259-1162.123211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Sugammadex: A revolutionary drug in neuromuscular pharmacology</span></div><div class="casAuthors">Nag Kusha; Singh Dewan Roshan; Kumar Hemanth; Sivashanmugam T; Parthasarathy S; Shetti Akshaya N</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia, essays and researches</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-6</span>
        ISSN:<span class="NLM_cas:issn">0259-1162</span>.
    </div><div class="casAbstract">Sugammadex (ORG 25969) is a unique neuromuscular reversal drug; a novel cyclodextrin, the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade (NMB) with the aminosteroid non-depolarizing muscle relaxants rocuronium and vecuronium.  Sugammadex can reverse moderate or deep NMB.  The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQEv8ir77jTc25P7XSLhESfW6udTcc2eaVOZ2P4AqC_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlsVeqtQ%253D%253D&md5=ffdf88b898eb1f4578b0929929010aaf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4103%2F0259-1162.123211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0259-1162.123211%26sid%3Dliteratum%253Aachs%26aulast%3DNag%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%2BR.%26aulast%3DShetti%26aufirst%3DA.%2BN.%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DSivashanmugam%26aufirst%3DT.%26aulast%3DParthasarathy%26aufirst%3DS.%26atitle%3DSugammadex%253A%2520A%2520revolutionary%2520drug%2520in%2520neuromuscular%2520pharmacology%26jtitle%3DAnesth.%2520Essays%2520Res.%26date%3D2013%26volume%3D7%26spage%3D302%26epage%3D306%26doi%3D10.4103%2F0259-1162.123211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, M. J.</span></span> <span> </span><span class="NLM_article-title">Auranofin: repurposing an old drug for a golden new age</span>. <i>Drugs R&D</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1007/s40268-015-0083-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs40268-015-0083-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25698589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2htL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=13-20&author=C.+Roderauthor=M.+J.+Thomson&title=Auranofin%3A+repurposing+an+old+drug+for+a+golden+new+age&doi=10.1007%2Fs40268-015-0083-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin: Repurposing an Old Drug for a Golden New Age</span></div><div class="casAuthors">Roder, Christine; Thomson, Melanie J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Drug discovery, development and registration is an expensive and time-consuming process assocd. with a high failure rate [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Woodcock and Woosley (Annu Rev Med 59:1-12, 2008)].  Drug 'repurposing' is the identification of new therapeutic purposes for already approved drugs and is more affordable and achievable than novel drug discovery [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013)].  Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a no. of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)].  The main mechanism of action of auranofin is through the inhibition of redn./oxidn. (redox) enzymes that are essential for maintaining intracellular levels of reactive oxygen species.  Inhibition of these enzymes leads to cellular oxidative stress and intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Fan et al. (Cell Death Dis 5:e1191, 2014), Fiskus et al. (Cancer Res 74:2520-2532, 2014), Marzano et al. (Free Radic Biol Med 42:872-881, 2007)].  Drugs such as auranofin that have already been approved for human use [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)] can be brought into clin. use for other diseases relatively quickly and for a fraction of the cost of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqitmjCdCXIoLVg90H21EOLACvtfcHk0lg3ayodBvGe7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2htL8%253D&md5=86020bc2c56f02d36384f65a5062de35</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40268-015-0083-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-015-0083-y%26sid%3Dliteratum%253Aachs%26aulast%3DRoder%26aufirst%3DC.%26aulast%3DThomson%26aufirst%3DM.%2BJ.%26atitle%3DAuranofin%253A%2520repurposing%2520an%2520old%2520drug%2520for%2520a%2520golden%2520new%2520age%26jtitle%3DDrugs%2520R%2526D%26date%3D2015%26volume%3D15%26spage%3D13%26epage%3D20%26doi%3D10.1007%2Fs40268-015-0083-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gissendanner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruthers, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. R.</span></span> <span> </span><span class="NLM_article-title">Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs</span>. <i>Vet. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1016/j.vetpar.2007.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.vetpar.2007.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17980490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGjtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2007&pages=345-351&author=D.+E.+Snyderauthor=J.+Meyerauthor=A.+G.+Zimmermannauthor=M.+Qiaoauthor=S.+J.+Gissendannerauthor=L.+R.+Cruthersauthor=R.+L.+Sloneauthor=D.+R.+Young&title=Preliminary+studies+on+the+effectiveness+of+the+novel+pulicide%2C+spinosad%2C+for+the+treatment+and+control+of+fleas+on+dogs&doi=10.1016%2Fj.vetpar.2007.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs</span></div><div class="casAuthors">Snyder, Daniel E.; Meyer, Jeffery; Zimmermann, Alan G.; Qiao, Meihua; Gissendanner, Sonya J.; Cruthers, Larry R.; Slone, Robyn L.; Young, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Parasitology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-351</span>CODEN:
                <span class="NLM_cas:coden">VPARDI</span>;
        ISSN:<span class="NLM_cas:issn">0304-4017</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spinosad is a novel mode-of-action insecticide produced from a family of natural products derived from fermn. of the actinomycete, Saccharopolyspora spinosa.  Sep. studies were undertaken to det. the min. ED of spinosad given orally for the treatment of exptl. induced flea infestations (Ctenocephalides felis) on dogs, and to assess any potential impacts of feeding canned or dry food at the time of dosing.  Both were randomized block (blocked by gender and pre-treatment flea counts), blinded parallel-arm studies, with dogs selected on health and ability to maintain pre-treatment flea populations.  For dose selection, 48 dogs were allocated among six groups (8 dogs/group; 4 males, 4 females): placebo-treated neg. control, spinosad in gelatin capsules at 15, 20, 30 and 40 mg/kg administered per os; and topical imidacloprid (10 mg/kg) as a pos. control.  Placebo and spinosad treatments were administered on Days 0, 30 and 60, imidacloprid only on Day 0.  In a second study to assess the impact of food type at the time of dosing, three groups were formed: placebo-treated control (8 dogs; 4 males, 4 females), spinosad (30 mg/kg) administered with canned food (8 male dogs, 8 females); and spinosad (30 mg/kg) with dry food (8 males, 8 females).  Treatments were administered on Days 0 and 30.  To assess post-treatment persistent efficacy, flea infestations were repeated at regular post-treatment intervals, beginning on Day 5 through Day 89 in the dose selection study and Day 58 in the impact of food type and dosing study.  Flea counts were performed 48 h post-infestation by study personnel who were blinded to treatments.  In the dose selection study, compared to geometric mean live flea counts in the control group, each spinosad dose was highly effective (99.8-100%) at 7, 14 and 21 days after treatment.  Only the 30 and 40 mg/kg doses maintained high efficacy (97.2-100%) until 30 days after treatment, with no difference between the two.  Imidacloprid was highly effective at Day 30, with significant difference only from the 15 mg/kg spinosad group.  Because there was no significant difference between the higher spinosad rates, 30 mg/kg was selected as the optimal min. ED.  In the second study, spinosad was highly effective at all post-treatment flea counts (98-100%).  Taken together, these studies demonstrate that repeated monthly oral treatments with spinosad at 30 mg/kg provide sustained control of C. felis on dogs.  There were no treatment-related adverse events in either study, indicating that spinosad has potential to be used monthly as a safe and effective flea adulticide, providing sustained activity that matches that of currently used topical products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgbO7Qe47X4rVg90H21EOLACvtfcHk0lgomyg4pq6AdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGjtr%252FM&md5=a2369bbcce41576611189b4e29f47494</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.vetpar.2007.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vetpar.2007.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DD.%2BE.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DA.%2BG.%26aulast%3DQiao%26aufirst%3DM.%26aulast%3DGissendanner%26aufirst%3DS.%2BJ.%26aulast%3DCruthers%26aufirst%3DL.%2BR.%26aulast%3DSlone%26aufirst%3DR.%2BL.%26aulast%3DYoung%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520studies%2520on%2520the%2520effectiveness%2520of%2520the%2520novel%2520pulicide%252C%2520spinosad%252C%2520for%2520the%2520treatment%2520and%2520control%2520of%2520fleas%2520on%2520dogs%26jtitle%3DVet.%2520Parasitol.%26date%3D2007%26volume%3D150%26spage%3D345%26epage%3D351%26doi%3D10.1016%2Fj.vetpar.2007.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crump, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Ivermectin, “wonder drug” from Japan: the human use perspective</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2183/pjab.87.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2183%2Fpjab.87.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2011&pages=13-28&author=A.+Crumpauthor=S.+Omura&title=Ivermectin%2C+%E2%80%9Cwonder+drug%E2%80%9D+from+Japan%3A+the+human+use+perspective&doi=10.2183%2Fpjab.87.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ivermectin 'Wonder drug' from Japan: the human use perspective</span></div><div class="casAuthors">Crump, Andy; Omura, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">13-28</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro deriv. of avermectin-originating solely from a single microorganism isolated at the Kitasato Institute, Tokyo, Japan from Japanese soil-has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world.  Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in com. livestock and companion animals.  It was quickly discovered to be ideal in combating two of the world's most devastating and disfiguring diseases which have plagued the world's poor throughout the tropics for centuries.  It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally.  It has also been used to successfully overcome several other human diseases and new uses for it are continually being found.  This paper looks in depth at the events surrounding ivermectin's passage from being a huge success in Animal Health into its widespread use in humans, a development which has led many to describe it as a "wonder" drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgTCraCUeJ7Vg90H21EOLACvtfcHk0lgomyg4pq6AdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL4%253D&md5=6eabcfcd3ef1a97aa7165b35d9eb0eef</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2183%2Fpjab.87.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.87.13%26sid%3Dliteratum%253Aachs%26aulast%3DCrump%26aufirst%3DA.%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DIvermectin%252C%2520%25E2%2580%259Cwonder%2520drug%25E2%2580%259D%2520from%2520Japan%253A%2520the%2520human%2520use%2520perspective%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2011%26volume%3D87%26spage%3D13%26epage%3D28%26doi%3D10.2183%2Fpjab.87.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khater, E. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergquist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. N.</span></span> <span> </span><span class="NLM_article-title">Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty</span>. <i>Infect. Dis. Poverty</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1186/s40249-015-0091-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2Fs40249-015-0091-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26708575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsFajtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=58-65&author=E.+Tamboauthor=E.+I.+M.+Khaterauthor=J.+H.+Chenauthor=R.+Bergquistauthor=X.+N.+Zhou&title=Nobel+prize+for+the+artemisinin+and+ivermectin+discoveries%3A+a+great+boost+towards+elimination+of+the+global+infectious+diseases+of+poverty&doi=10.1186%2Fs40249-015-0091-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty</span></div><div class="casAuthors">Tambo Ernest; Tambo Ernest; Tambo Ernest; Tambo Ernest; Khater Emad I M; Zhou Xiao-Nong; Khater Emad I M; Zhou Xiao-Nong; Chen Jun-Hu; Zhou Xiao-Nong; Chen Jun-Hu; Chen Jun-Hu; Bergquist Robert</div><div class="citationInfo"><span class="NLM_cas:title">Infectious diseases of poverty</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58</span>
        ISSN:<span class="NLM_cas:issn">2095-5162</span>.
    </div><div class="casAbstract">The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to inflict a disproportionate global public health burden with associated consequences, thereby contributing to the vicious cycle of poverty and inequity.  However, the effectiveness and large-scale coverage of artemisinin combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives.  The paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the Nobel Prize in Physiology or Medicine in 2015.  However, the story would not be complete without mentioning praziquantel.  The huge contribution of this drug in modernizing the control of schistosomiasis and also some intestinal helminth infections had already shifted the focus from control to potential elimination of this disease.  Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious diseases that humans have lived with since time immemorial.  These drugs all have broad-spectrum effects, yet they are very safe and can even be packaged together in various combinations.  The strong effect on so many of the great infectious scourges in the developing countries has not only had a remarkable influence on many endemic diseases, but also contributed to improving the cost structure of healthcare.  Significant benefits include improved quality of preventive and curative medicine, promotion of community-based interventions, universal health coverage and the fostering of global partnerships.  The laudable progress and benefits achieved are indispensable in championing, strengthening and moving forward elimination of the IDoPs.  However, there is an urgent need for further innovative, contextual and integrated approaches along with the advent of the Sustainable Development Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzwIcPiz2m6Fw2ofyr07jXfW6udTcc2ebq9hHpDzFMwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsFajtw%253D%253D&md5=b9c00c0d744d3216ea9404ed73d56850</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs40249-015-0091-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40249-015-0091-8%26sid%3Dliteratum%253Aachs%26aulast%3DTambo%26aufirst%3DE.%26aulast%3DKhater%26aufirst%3DE.%2BI.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DBergquist%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DX.%2BN.%26atitle%3DNobel%2520prize%2520for%2520the%2520artemisinin%2520and%2520ivermectin%2520discoveries%253A%2520a%2520great%2520boost%2520towards%2520elimination%2520of%2520the%2520global%2520infectious%2520diseases%2520of%2520poverty%26jtitle%3DInfect.%2520Dis.%2520Poverty%26date%3D2015%26volume%3D4%26spage%3D58%26epage%3D65%26doi%3D10.1186%2Fs40249-015-0091-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava, N.</span></span> <span> </span><span class="NLM_article-title">A review on pharmacological profile of Morpholine derivatives</span>. <i>Int. J. Pharmacol. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=40-51&author=M.+Naimauthor=O.+Alamauthor=J.+Alamauthor=P.+Alamauthor=N.+Shrivastava&title=A+review+on+pharmacological+profile+of+Morpholine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaim%26aufirst%3DM.%26aulast%3DAlam%26aufirst%3DO.%26aulast%3DAlam%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DP.%26aulast%3DShrivastava%26aufirst%3DN.%26atitle%3DA%2520review%2520on%2520pharmacological%2520profile%2520of%2520Morpholine%2520derivatives%26jtitle%3DInt.%2520J.%2520Pharmacol.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D3%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rupak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulichi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suman, K.</span></span> <span> </span><span class="NLM_article-title">Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance</span>. <i>Int. J. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1777</span>– <span class="NLM_lpage">1788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=1777-1788&author=K.+Rupakauthor=S.+R.+Vulichiauthor=K.+Suman&title=Emphasizing+morpholine+and+its+derivatives+%28MAID%29%3A+typical+candidate+of+pharmaceutical+importance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance</span></div><div class="casAuthors">Rupak, Kumar; Vulichi, Srinivasa R.; Suman, Kapur</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chemical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1777-1788</span>CODEN:
                <span class="NLM_cas:coden">IJCSIL</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sadguru Publications</span>)
        </div><div class="casAbstract">The use of chems. (drugs) for both medical and recreational purposes is hardly new.  In fact, drug use seems to have been a part of human science prehistory.  Morpholine (C4H9NO, 1-oxa-4-azacyclohexane) is a synthetic simple heterocyclic org. compd. having characteristic functional groups of amine and ether and great industrial importance.  Chem. manipulations on morpholine based mols. through structure - activity relationship strategy could help developing many interesting candidates of therapeutic significance to tackle broad range of medical ailments.  Feasible physicochem. properties (polarity and soly.), low cost and wide availability make it a suitable candidate for the synthesis of many potent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT0rs1eUYwRbVg90H21EOLACvtfcHk0lgDQHEF19GpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFantLs%253D&md5=5ebc0d446a0813a9ff55edccb0ef62ee</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRupak%26aufirst%3DK.%26aulast%3DVulichi%26aufirst%3DS.%2BR.%26aulast%3DSuman%26aufirst%3DK.%26atitle%3DEmphasizing%2520morpholine%2520and%2520its%2520derivatives%2520%2528MAID%2529%253A%2520typical%2520candidate%2520of%2520pharmaceutical%2520importance%26jtitle%3DInt.%2520J.%2520Chem.%2520Sci.%26date%3D2016%26volume%3D14%26spage%3D1777%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiver, G.</span></span> <span> </span><span class="NLM_article-title">The treatment of influenza with antiviral drugs</span>. <i>Can. Med. Assoc. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12515786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FgvFCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2003&pages=49-57&author=G.+Stiver&title=The+treatment+of+influenza+with+antiviral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The treatment of influenza with antiviral drugs</span></div><div class="casAuthors">Stiver Grant</div><div class="citationInfo"><span class="NLM_cas:title">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-56</span>
        ISSN:<span class="NLM_cas:issn">0820-3946</span>.
    </div><div class="casAbstract">Influenza vaccination with current inactivated vaccines homologous to the prevalent wild-type virus can reduce influenza illness in 75%-80% of healthy adults.  Vaccine is recommended for all individuals with chronic underlying diseases and for those aged 65 years or older.  Although influenza vaccination is still advocated for patients with blunted immunity, protection rates are not as high, running at 40% for frail institutionalized elderly people.  The influenza antiviral agents amantadine or rimantadine, zanamivir and oseltamivir can modify the severity of illness and reduce the duration of illness by about 1.5-2.5 days.  Amantadine inhibits only influenza A.  Resistant virus may emerge in up to 33% of amantadine-treated patients in the first 5 days of treatment and be transmitted to susceptible close contacts.  Side effects are usually mild in short courses of treatment.  The neuraminidase inhibitor drugs zanamivir and oseltamivir act on both influenza A and B.  Treatment is most effective when given within 30-36 hours after the onset of illness, and the earlier the better.  Influenza should be treated with antiviral drugs in unvaccinated and vaccinated high-risk patients, as well as immunosuppressed patients with influenza-like illness, in periods of confirmed influenza prevalence.  These drugs may be of great value in the event of a major viral antigenic shift that causes pandemic influenza, if an adequate supply can be sustained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8Urfbou99qTEwO064Z95rfW6udTcc2eaChOVPYy9H0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FgvFCmtQ%253D%253D&md5=8343e074c01f0ffdcfeed864852cff50</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStiver%26aufirst%3DG.%26atitle%3DThe%2520treatment%2520of%2520influenza%2520with%2520antiviral%2520drugs%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2003%26volume%3D168%26spage%3D49%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buontempo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting the mTOR pathway</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1042/CS20171158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1042%2FCS20171158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29523752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Gnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=543-568&author=A.%0AM.+Martelliauthor=F.+Buontempoauthor=J.+A.+McCubrey&title=Drug+discovery+targeting+the+mTOR+pathway&doi=10.1042%2FCS20171158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery targeting the mTOR pathway</span></div><div class="casAuthors">Martelli, Alberto M.; Buontempo, Francesca; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-568</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. mTORC1 and mTORC2 play key physiol. roles as they control anabolic and catabolic processes in response to external cues in a variety of tissues and organs.  However, mTORC1 and mTORC2 activities are deregulated in widespread human diseases, including cancer.  Cancer cells take advantage of mTOR oncogenic signaling to drive their proliferation, survival, metabolic transformation, and metastatic potential.  Therefore, mTOR lends itself very well as a therapeutic target for innovative cancer treatment. mTOR was initially identified as the target of the antibiotic rapamycin that displayed remarkable antitumor activity in vitro.  Promising preclin. studies using rapamycin and its derivs. (rapalogs) demonstrated efficacy in many human cancer types, hence supporting the launch of numerous clin. trials aimed to evaluate the real effectiveness of mTOR-targeted therapies.  However, rapamycin and rapalogs have shown very limited activity in most clin. contexts, also when combined with other drugs.  Thus, novel classes of mTOR inhibitors with a stronger antineoplastic potency have been developed.  Nevertheless, emerging clin. data suggest that also these novel mTOR-targeting drugs may have a weak antitumor activity.  Here, we summarize the current status of available mTOR inhibitors and highlight the most relevant results from both preclin. and clin. studies that have provided valuable insights into both their efficacy and failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyW8DmOPSirrVg90H21EOLACvtfcHk0lgDQHEF19GpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Gnsrk%253D&md5=4cb101292276ef49baefa197915e306e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1042%2FCS20171158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171158%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DBuontempo%26aufirst%3DF.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DDrug%2520discovery%2520targeting%2520the%2520mTOR%2520pathway%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D543%26epage%3D568%26doi%3D10.1042%2FCS20171158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner
Enschede, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span> <span> </span><span class="NLM_article-title">The bcl2 selective inhibitor venetoclax induces rapid onset apoptosis of cll cells in patients via a tp53-independent mechanism</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3215</span>– <span class="NLM_lpage">3224</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-01-688796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1182%2Fblood-2016-01-688796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=3215-3224&author=M.+A.+Andersonauthor=J.+Dengauthor=J.+F.+Seymourauthor=C.+Tamauthor=S.+Y.+Kimauthor=J.+Feinauthor=L.+Yuauthor=J.+R.+Brownauthor=D.+Westermanauthor=E.+G.+Siauthor=I.+J.+Majewskiauthor=D.+Segalauthor=S.+L.+Heitner%0AEnschedeauthor=D.+C.+S.+Huangauthor=M.+S.+Davidsauthor=A.+Letaiauthor=A.+W.+Roberts&title=The+bcl2+selective+inhibitor+venetoclax+induces+rapid+onset+apoptosis+of+cll+cells+in+patients+via+a+tp53-independent+mechanism&doi=10.1182%2Fblood-2016-01-688796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-01-688796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-01-688796%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DWesterman%26aufirst%3DD.%26aulast%3DSi%26aufirst%3DE.%2BG.%26aulast%3DMajewski%26aufirst%3DI.%2BJ.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DHeitner%2BEnschede%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26atitle%3DThe%2520bcl2%2520selective%2520inhibitor%2520venetoclax%2520induces%2520rapid%2520onset%2520apoptosis%2520of%2520cll%2520cells%2520in%2520patients%2520via%2520a%2520tp53-independent%2520mechanism%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D3215%26epage%3D3224%26doi%3D10.1182%2Fblood-2016-01-688796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirumurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bal, T. R.</span></span> <span> </span><span class="NLM_article-title">Camptothecin and its analogues: a review on their chemotherapeutic potential</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1080/14786410412331299005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1080%2F14786410412331299005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15938148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFajsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=393-412&author=D.+Sriramauthor=P.+Yogeeswariauthor=R.+Thirumuruganauthor=T.+R.+Bal&title=Camptothecin+and+its+analogues%3A+a+review+on+their+chemotherapeutic+potential&doi=10.1080%2F14786410412331299005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin and its analogues: a review on their chemotherapeutic potential</span></div><div class="casAuthors">Sriram, Dharmarajan; Yogeeswari, Perumal; Thirumurugan, Rathinasabapathy; Ratan Bal, Tanushree</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-412</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Topoisomerase I (Topo-I) is a major target for anticancer drug discovery and design.  As a result, Topo-I inhibitors constitute an important class of the current anticancer drugs.  To date, all of the Topo-I inhibitors that have been clin. evaluated are analogs of camptothecin (CPT), an ext. of the Chinese tree Camptotheca acuminata.  CPT has shown significant antitumor activity to lung, ovarian, breast, pancreas and stomach cancers.  In this article the, phytochem. aspect, and various structural modifications are comprehensively reviewed as in rings A, B, C, D and E. Biol. activity of camptothecin, other than anticancer, reported till the year 2003 has also been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6NIkdIrNjA7Vg90H21EOLACvtfcHk0lhPG7jHOiXWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFajsrY%253D&md5=7149d979a0e7915678cce4ba5ea8aabb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1080%2F14786410412331299005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786410412331299005%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DThirumurugan%26aufirst%3DR.%26aulast%3DBal%26aufirst%3DT.%2BR.%26atitle%3DCamptothecin%2520and%2520its%2520analogues%253A%2520a%2520review%2520on%2520their%2520chemotherapeutic%2520potential%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2005%26volume%3D19%26spage%3D393%26epage%3D412%26doi%3D10.1080%2F14786410412331299005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzeeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashikumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullangi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies</span>. <i>Biomed. Chromatogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1002/bmc.561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fbmc.561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16143964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=282-293&author=M.+K.+Pashaauthor=S.+Muzeebauthor=S.+J.+Bashaauthor=D.+Shashikumarauthor=R.+Mullangiauthor=N.+R.+Srinivas&title=Analysis+of+five+HMG-CoA+reductase+inhibitors%2D%2D+atorvastatin%2C+lovastatin%2C+pravastatin%2C+rosuvastatin+and+simvastatin%3A+pharmacological%2C+pharmacokinetic+and+analytical+overview+and+development+of+a+new+method+for+use+in+pharmaceutical+formulations+analysis+and+in+vitro+metabolism+studies&doi=10.1002%2Fbmc.561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of 5 HMG-CoA reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies</span></div><div class="casAuthors">Pasha, Md. Khalid; Muzeeb, Syed; Basha, Shaik Jafar Sadik; Shashikumar, Dhanya; Mullangi, Ramesh; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A specific, accurate, precise and reproducible high-performance liq. chromatog. (HPLC) method was developed and validated for the simultaneous quantitation of 5 3-hydroxy-3-methyglutaryl CoA (HMG-CoA) reductase inhibitors, viz. atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin, in pharmaceutical formulations and extended the application to in vitro metab. studies of these statins.  Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 × 250 mm, 5 μm) at ambient temp.  The mobile phase consisted of 0.01 M ammonium acetate (pH 5.0), acetonitrile and methanol.  Theophylline was used as an internal std. (IS).  The HMG-CoA reductase inhibitors and their metabolites were monitored at a wavelength of 237 nm.  Drugs were found to be 89.6-105.6% of their label's claim in the pharmaceutical formulations.  For in vitro metab. studies the reaction mixts. were extd. with simple liq.-liq. extn. using Et acetate.  Baseline sepn. of statins and their metabolites along with IS free from endogenous interferences was achieved.  Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5, and 35.5 min, resp.  The proposed method is simple, selective, and could be applicable for routine anal. of HMG-CoA reductase inhibitors in pharmaceutical prepns. as well as in vitro metab. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwmedQVQ007Vg90H21EOLACvtfcHk0lhPG7jHOiXWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlKlsr8%253D&md5=b095fd040f79ebdf5fa3bff5e9d51e30</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fbmc.561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.561%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DMuzeeb%26aufirst%3DS.%26aulast%3DBasha%26aufirst%3DS.%2BJ.%26aulast%3DShashikumar%26aufirst%3DD.%26aulast%3DMullangi%26aufirst%3DR.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DAnalysis%2520of%2520five%2520HMG-CoA%2520reductase%2520inhibitors--%2520atorvastatin%252C%2520lovastatin%252C%2520pravastatin%252C%2520rosuvastatin%2520and%2520simvastatin%253A%2520pharmacological%252C%2520pharmacokinetic%2520and%2520analytical%2520overview%2520and%2520development%2520of%2520a%2520new%2520method%2520for%2520use%2520in%2520pharmaceutical%2520formulations%2520analysis%2520and%2520in%2520vitro%2520metabolism%2520studies%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2006%26volume%3D20%26spage%3D282%26epage%3D293%26doi%3D10.1002%2Fbmc.561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunkel, L.</span></span> <span> </span><span class="NLM_article-title">Use of aromatase inhibitors to increase final height</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>254–255</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2006.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.mce.2006.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16766117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254%E2%80%93255&publication_year=2006&pages=207-216&author=L.+Dunkel&title=Use+of+aromatase+inhibitors+to+increase+final+height&doi=10.1016%2Fj.mce.2006.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Use of aromatase inhibitors to increase final height</span></div><div class="casAuthors">Dunkel, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">254-255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During puberty in both sexes, the mechanism involved in epiphyseal fusion is mediated by the action of estrogen through a cascade of events including proliferation, differentiation, and apoptosis of chondrocytes.  The enzyme P 450 aromatase catalyzes the aromatization of C19 androgens (androstenedione and testosterone) to C18 estrogens (estrone and estradiol).  Inhibition of estrogen action by aromatase inhibitors (AIs) appears to decelerate the process of growth plate fusion, and thus AIs may be used therapeutically to increase adult height.  The clin. experience with AIs in the pediatric setting is limited to testolactone, fadrozole, letrozole, and anastrozole.  Testolactone, a nonselective steroidal AI, was used successfully as an adjunct to antiandrogen and gonadotropin-releasing hormone analog (GnRHa), therapy for children with familial male-limited precocious puberty (FMPP) and congenital adrenal hyperplasia (CAH), and with some success in girls with McCune-Albright syndrome.  The limitations of testolactone include its relatively low potency and the need for frequent dosing.  Results of a randomized placebo-controlled trial in boys with delayed puberty treated with letrozole, a selective nonsteroidal AI, found that boys treated with letrozole + testosterone experienced delayed bone maturation and good growth response and achieved an increase in predicted adult height.  In this study, only minor differences in bone d. were seen between the placebo and letrozole treatment groups, both of which were receiving concomitant testosterone therapy.  No adverse effects on testis size or inhibin B concn. were noted.  The therapeutic value of AIs in growth promotion now remains to be substantiated in future controlled clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd6lh7ASnlPLVg90H21EOLACvtfcHk0lhPG7jHOiXWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSjtro%253D&md5=c5294ae019b717b8619e84367f7fdd33</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2006.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2006.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DL.%26atitle%3DUse%2520of%2520aromatase%2520inhibitors%2520to%2520increase%2520final%2520height%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2006%26volume%3D254%25E2%2580%2593255%26spage%3D207%26epage%3D216%26doi%3D10.1016%2Fj.mce.2006.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandel, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span> <span> </span><span class="NLM_article-title">Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3547</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S84850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FDDDT.S84850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26185421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3547-3555&author=C.+E.+Kandelauthor=S.+L.+Walmsley&title=Dolutegravir+%E2%80%93+a+review+of+the+pharmacology%2C+efficacy%2C+and+safety+in+the+treatment+of+HIV&doi=10.2147%2FDDDT.S84850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV</span></div><div class="casAuthors">Kandel, Christopher E.; Walmsley, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3547-3555</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection.  Dolutegravir is equiv. or superior to existing treatment regimens in both treatment-na.ovrddot.ive and treatment-experienced patients including those with previous raltegravir or elvitegravir failure.  The consistent efficacy coupled with excellent tolerability and infrequent drug-drug interactions makes the co-formulation of dolutegravir with two nucleotide reverse-transcriptase inhibitors an attractive treatment option.  This review summarizes the pharmacokinetics, adverse event profile, and efficacy of dolutegravir in the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDC2XTWz-H7Vg90H21EOLACvtfcHk0lirSpZfYUFHNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOjtLs%253D&md5=3c19253c813435554b78db89949fbb13</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S84850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S84850%26sid%3Dliteratum%253Aachs%26aulast%3DKandel%26aufirst%3DC.%2BE.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26atitle%3DDolutegravir%2520%25E2%2580%2593%2520a%2520review%2520of%2520the%2520pharmacology%252C%2520efficacy%252C%2520and%2520safety%2520in%2520the%2520treatment%2520of%2520HIV%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3547%26epage%3D3555%26doi%3D10.2147%2FDDDT.S84850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D. H.</span></span> <span> </span><span class="NLM_article-title">(1994). Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.2165/00003495-199448040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-199448040-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1994&pages=599-616&author=R.+N.+Brogdenauthor=D.+H.+Peters&title=%281994%29.+Dirithromycin.+A+review+of+its+antimicrobial+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy&doi=10.2165%2F00003495-199448040-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2165%2F00003495-199448040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199448040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DPeters%26aufirst%3DD.%2BH.%26atitle%3D%25281994%2529.%2520Dirithromycin.%2520A%2520review%2520of%2520its%2520antimicrobial%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1994%26volume%3D48%26spage%3D599%26epage%3D616%26doi%3D10.2165%2F00003495-199448040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhazes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Chromone as a privileged scaffold in drug discovery: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7941</span>– <span class="NLM_lpage">7957</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1ylsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7941-7957&author=J.+Reisauthor=A.+Gasparauthor=N.+Milhazesauthor=F.+Borges&title=Chromone+as+a+privileged+scaffold+in+drug+discovery%3A+recent+advances&doi=10.1021%2Facs.jmedchem.6b01720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances</span></div><div class="casAuthors">Reis, Joana; Gaspar, Alexandra; Milhazes, Nuno; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7941-7957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of privileged structures in drug discovery has proven to be an effective strategy allowing the generation of innovative hits/leads and successful optimization processes.  Chromone is actually recognized as a privileged structure and a valid template for the design of novel compds. with potential pharmacol. interest, particularly in the field of neurodegenerative, inflammatory and infectious diseases as well as diabetes and cancer.  Within this framework, this review provides the reader with a literature update following the preceding article entitled Chromone: a valid scaffold in Medicinal Chem.  The review is mainly focused on the biol. interest of chromones, including those isolated from natural sources.  Moreover, as drug repurposing is becoming an attractive drug discovery approach, the opening repurposing studies on chromone-based drugs are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLXpaiKTmA7Vg90H21EOLACvtfcHk0lirSpZfYUFHNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1ylsbY%253D&md5=bb722a050abe9c6203d9d891818d06eb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01720%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DMilhazes%26aufirst%3DN.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DChromone%2520as%2520a%2520privileged%2520scaffold%2520in%2520drug%2520discovery%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7941%26epage%3D7957%26doi%3D10.1021%2Facs.jmedchem.6b01720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goa, K. L.</span></span> <span> </span><span class="NLM_article-title">Galantamine: a review of its use in Alzheimer’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060050-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-200060050-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1095-1122&author=L.+J.+Scottauthor=K.+L.+Goa&title=Galantamine%3A+a+review+of+its+use+in+Alzheimer%E2%80%99s+disease&doi=10.2165%2F00003495-200060050-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060050-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060050-00008%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DGoa%26aufirst%3DK.%2BL.%26atitle%3DGalantamine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26spage%3D1095%26epage%3D1122%26doi%3D10.2165%2F00003495-200060050-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevagi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. N.</span></span> <span> </span><span class="NLM_article-title">Biological and medicinal significance of benzofuran</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ejmech.2014.10.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26015069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=561-581&author=R.+J.+Nevagiauthor=S.+N.+Digheauthor=S.+N.+Dighe&title=Biological+and+medicinal+significance+of+benzofuran&doi=10.1016%2Fj.ejmech.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and medicinal significance of benzofuran</span></div><div class="casAuthors">Nevagi, Reshma J.; Dighe, Santosh N.; Dighe, Satish N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  This article emphasizes on the importance of benzofuran as a biol. relevant heterocycle.  It covers most of the physiol. as well as medicinally important compds. contg. benzofuran rings.  This article also covers clin. approved drugs contg. benzofuran scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmk0ugoH_1xLVg90H21EOLACvtfcHk0lirSpZfYUFHNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWisr3F&md5=d3395a58c2eaf4c068d8e7465a2014d2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DNevagi%26aufirst%3DR.%2BJ.%26aulast%3DDighe%26aufirst%3DS.%2BN.%26aulast%3DDighe%26aufirst%3DS.%2BN.%26atitle%3DBiological%2520and%2520medicinal%2520significance%2520of%2520benzofuran%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D561%26epage%3D581%26doi%3D10.1016%2Fj.ejmech.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiremathad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K. R., C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, R. S.</span></span> <span> </span><span class="NLM_article-title">Benzofuran: an emerging scaffold for antimicrobial agents</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">96809</span>– <span class="NLM_lpage">96828</span>, <span class="refDoi"> DOI: 10.1039/C5RA20658H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2FC5RA20658H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=96809-96828&author=A.+Hiremathadauthor=M.+R.+Patilauthor=C.+K.+R.author=K.+Chandauthor=M.+A.+Santosauthor=R.+S.+Keri&title=Benzofuran%3A+an+emerging+scaffold+for+antimicrobial+agents&doi=10.1039%2FC5RA20658H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Benzofuran: an emerging scaffold for antimicrobial agents</span></div><div class="casAuthors">Hiremathad, Asha; Patil, Mahadeo R.; Chethana, K. R.; Chand, Karam; Santos, M. Amelia; Keri, Rangappa S.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">117</span>),
    <span class="NLM_cas:pages">96809-96828</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Resistance to antibiotics is a major global problem and there is an urgent need to develop new therapeutic agents.  Although many classes of active compds. have been established as efficient derivs. in diverse fields of antimicrobial therapy, they have not yet found wide application against a few deadly microbes.  In recent years, compds. have been developed that have solved some of the problems posed; for example improved bioavailability is one of the targets achieved with most of the more recent compds., allowing for once-daily dosing.  Benzofuran and its derivs. are found to be suitable structures, existing widely in natural products and unnatural compds. with a wide range of biol. and pharmacol. applications; thus, considerable attention has been focused on the discovery of new drugs in the fields of drug invention and development.  Some benzofuran derivs., such as psoralen, 8-methoxypsoralen and angelicin have been used in the treatment of skin diseases such as cancer or psoriasis.  The unique structural features of benzofuran and its wide array of biol. activities make it a privileged structure in the field of drug discovery, esp. in the search for efficient antimicrobial candidates.  Recently, this scaffold has emerged as a pharmacophore of choice for designing antimicrobial agents that are active toward different clin. approved targets.  To pave the way for future research, there is a need to collect the latest information in this promising area.  In the present review, we collated the published reports on this versatile core to provide a deeper insight, so that its full therapeutic potential can be utilized for the treatment of microbial diseases.  This study systematically provides a comprehensive report on current developments in benzofuran-based compds. as antimicrobial agents and is also helpful for the researchers working on a substitution pattern around the nucleus, with an aim to help medicinal chemists to develop structure activity relationships (SAR) on these derivs. as antimicrobial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5jEoZROreO7Vg90H21EOLACvtfcHk0lhFDvnHWQdxRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWktrzJ&md5=f1d95320bfd53a054d8cb80217571b65</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1039%2FC5RA20658H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA20658H%26sid%3Dliteratum%253Aachs%26aulast%3DHiremathad%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DM.%2BR.%26aulast%3DK.%2BR.%26aufirst%3DC.%26aulast%3DChand%26aufirst%3DK.%26aulast%3DSantos%26aufirst%3DM.%2BA.%26aulast%3DKeri%26aufirst%3DR.%2BS.%26atitle%3DBenzofuran%253A%2520an%2520emerging%2520scaffold%2520for%2520antimicrobial%2520agents%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D96809%26epage%3D96828%26doi%3D10.1039%2FC5RA20658H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1111/j.1742-7843.2006.pto_295.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1742-7843.2006.pto_295.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16918708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1egsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=91-95&author=C.+Sanchez&title=The+pharmacology+of+citalopram+enantiomers%3A+the+antagonism+by+R-citalopram+on+the+effect+of+S-citalopram&doi=10.1111%2Fj.1742-7843.2006.pto_295.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram</span></div><div class="casAuthors">Sanchez, Connie</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-95</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent results on the in vivo and in vitro pharmacol. of escitalopram are summarized.  The exact mol. mechanism by which R-citalopram inhibits the effect of S-citalopram on the serotonin transporter remains to be elucidated.  Preliminary evidence indicates an effect of R-citalopram on the assocn. of escitalopram with the high affinity primary site, and on its dissocn. from the serotonin transporter, via an allosteric mechanism.  Escitalopram can be considered as an allosteric serotonin reuptake inhibitor.  This serotonin dual action in binding to two sites on the serotonin transporter (both the primary site and the allosteric site) is hypothesized to be responsible for a longer binding to, and therefore greater inhibition of the serotonin transporter by escitalopram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCxYDiKuN86bVg90H21EOLACvtfcHk0lhFDvnHWQdxRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1egsrk%253D&md5=7ab6c4f4549d521e3fb01a42621fc5e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-7843.2006.pto_295.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-7843.2006.pto_295.x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%26atitle%3DThe%2520pharmacology%2520of%2520citalopram%2520enantiomers%253A%2520the%2520antagonism%2520by%2520R-citalopram%2520on%2520the%2520effect%2520of%2520S-citalopram%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D99%26spage%3D91%26epage%3D95%26doi%3D10.1111%2Fj.1742-7843.2006.pto_295.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meshnick, S. R.</span></span> <span> </span><span class="NLM_article-title">Artemisinin: mechanisms of action, resistance and toxicity</span>. <i>Int. J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1016/S0020-7519(02)00194-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS0020-7519%2802%2900194-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12435450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFCitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=1655-1660&author=S.+R.+Meshnick&title=Artemisinin%3A+mechanisms+of+action%2C+resistance+and+toxicity&doi=10.1016%2FS0020-7519%2802%2900194-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin: mechanisms of action, resistance and toxicity</span></div><div class="casAuthors">Meshnick, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal for Parasitology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1655-1660</span>CODEN:
                <span class="NLM_cas:coden">IJPYBT</span>;
        ISSN:<span class="NLM_cas:issn">0020-7519</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Artemisinin and its derivs. are widely used throughout the world.  The mechanism of action of these compds. appears to involve the heme-mediated decompn. of the endoperoxide bridge to produce carbon-centered free radicals.  The involvement of heme explains why the drugs are selectively toxic to malaria parasites.  The resulting carbon-centered free radicals are alkylate heme and proteins, one of which is the translationally controlled tumor protein.  Clin. relevant artemisinin resistance has not been demonstrated, but it is likely to occur since artemisinin resistance has been obtained in lab. models.  At high doses, artemisinin can be neurotoxic but toxicity has not been found in clin. studies.  The mechanism of neurotoxicity may be similar to the mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyIN982VPC7Vg90H21EOLACvtfcHk0lhFDvnHWQdxRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFCitb0%253D&md5=6d99303ca4b4ba70e70cf4352b10cc1f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0020-7519%2802%2900194-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0020-7519%252802%252900194-7%26sid%3Dliteratum%253Aachs%26aulast%3DMeshnick%26aufirst%3DS.%2BR.%26atitle%3DArtemisinin%253A%2520mechanisms%2520of%2520action%252C%2520resistance%2520and%2520toxicity%26jtitle%3DInt.%2520J.%2520Parasitol.%26date%3D2002%26volume%3D32%26spage%3D1655%26epage%3D1660%26doi%3D10.1016%2FS0020-7519%2802%2900194-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seto, B.</span></span> <span> </span><span class="NLM_article-title">Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer</span>. <i>Clin Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/2001-1326-1-29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2001-1326-1-29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23369283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC3szktlGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=29&author=B.+Seto&title=Rapamycin+and+mTOR%3A+a+serendipitous+discovery+and+implications+for+breast+cancer&doi=10.1186%2F2001-1326-1-29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer</span></div><div class="casAuthors">Seto Belinda</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract"> Rapamycin was discovered more than thirty years ago from a soil sample from the island of Rapa Nui.  It was isolated from Streptomyces hygroscopicus and initial characterization focused on its antifungal activities.  Subsequent characterization showed that it has immunosuppressive properties and has been used successfully to reduce organ rejection with kidney transplantation.  Rapamycin has proven to be a versatile compound with several seemingly unrelated properties, including antifungal, immunosuppressive, and anticancer.  The National Cancer Institute (NCI) Developmental Therapeutics Program demonstrated that rapamycin inhibited cell growth in tumor cell lines.  These observations stimulated research to explore the underlying mechanism of anti-tumor activities.  Cell growth inhibition involves binding to the mammalian Target of Rapamycin (mTOR).  The mTOR signaling pathway is critical to cell growth, proliferation, and survival and rapamycin inhibits these hallmark processes of cancer.  Binding of growth factors activates mTOR signaling, which in turn leads to downstream phosphorylation of protein kinases, e.g., p70S6 kinase and lipid kinases in the phosphorylation of phosphoinositides.  Understanding of mTOR signaling provided the biological basis for targeted chemotherapeutics development, including several rapamycin analogues for treating breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB8nxRBba5AFvAgqb2vdc5fW6udTcc2eZ7LnYTmYKvTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szktlGiug%253D%253D&md5=dbf9e11d3ff4c131131f06324465608c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2F2001-1326-1-29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2001-1326-1-29%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DB.%26atitle%3DRapamycin%2520and%2520mTOR%253A%2520a%2520serendipitous%2520discovery%2520and%2520implications%2520for%2520breast%2520cancer%26jtitle%3DClin%2520Transl%2520Med.%26date%3D2012%26volume%3D1%26spage%3D29%26doi%3D10.1186%2F2001-1326-1-29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G. J.</span></span> <span> </span><span class="NLM_article-title">Immunopharmacology of rapamycin</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.14.1.483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1146%2Fannurev.immunol.14.1.483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=8717522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaK28XitlCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=483-510&author=R.+T.+Abrahamauthor=G.+J.+Wiederrecht&title=Immunopharmacology+of+rapamycin&doi=10.1146%2Fannurev.immunol.14.1.483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Immunopharmacology of rapamycin</span></div><div class="casAuthors">Abraham, Robert T.; Wiederrecht, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">483-510</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 135 refs.  The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth.  The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacol. active complexes with members of a family of intracellular receptors termed the FK506 binding proteins (FKBPs).  The FKBP12·FK506 complex specifically binds to and inhibits calcineurin, a signaling protein required for transcriptional activation of the interleukin (IL)-2 gene in response to T cell antigen receptor engagement.  The FKBP12·rapamycin complex interacts with a recently defined target protein termed the mammalian target of rapamycin (mTOR).  Accumulating data suggest that mTOR functions in a previously unrecognized signal transduction pathway required for the progression of IL-2-stimulated T cells from G1 into the S phase of the cell cycle.  Here we review the immunopharmacol. of rapamycin, with particular emphasis on the characterization of mTOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK9uto6qzk57Vg90H21EOLACvtfcHk0lguPWBmYUUEgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitlCgtb0%253D&md5=90d82e8b704b9fd06c906738b1349bf3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.14.1.483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.14.1.483%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DWiederrecht%26aufirst%3DG.%2BJ.%26atitle%3DImmunopharmacology%2520of%2520rapamycin%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1996%26volume%3D14%26spage%3D483%26epage%3D510%26doi%3D10.1146%2Fannurev.immunol.14.1.483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimmock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garside, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">516</span>, <span class="refDoi"> DOI: 10.1136/bmj.38376.439653.D3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1136%2Fbmj.38376.439653.D3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=516&author=D.+M.+Ashcroftauthor=P.+Dimmockauthor=R.+Garsideauthor=K.+Steinauthor=H.+C.+Williams&title=Efficacy+and+tolerability+of+topical+pimecrolimus+and+tacrolimus+in+the+treatment+of+atopic+dermatitis%3A+meta-analysis+of+randomised+controlled+trials&doi=10.1136%2Fbmj.38376.439653.D3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38376.439653.D3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38376.439653.D3%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26aulast%3DDimmock%26aufirst%3DP.%26aulast%3DGarside%26aufirst%3DR.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520topical%2520pimecrolimus%2520and%2520tacrolimus%2520in%2520the%2520treatment%2520of%2520atopic%2520dermatitis%253A%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBMJ.%26date%3D2005%26volume%3D330%26spage%3D516%26doi%3D10.1136%2Fbmj.38376.439653.D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongiovanni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fausti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatali, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miserocchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, T.</span></span> <span> </span><span class="NLM_article-title">Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.2147/OTT.S127955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FOTT.S127955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28260930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFamurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1155-1164&author=F.+Recineauthor=A.+Bongiovanniauthor=N.+Rivaauthor=V.+Faustiauthor=A.+De+Vitaauthor=L.+Mercataliauthor=C.+Liveraniauthor=G.+Miserocchiauthor=D.+Amadoriauthor=T.+Ibrahim&title=Update+on+the+role+of+trabectedin+in+the+treatment+of+intractable+soft+tissue+sarcomas&doi=10.2147%2FOTT.S127955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas</span></div><div class="casAuthors">Recine, Federica; Bongiovanni, Alberto; Riva, Nada; Fausti, Valentina; De Vita, Alessandro; Mercatali, Laura; Liverani, Chiara; Miserocchi, Giacomo; Amadori, Dino; Ibrahim, Toni</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1155-1164</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers.  This group of tumors comprises over 60 different histotypes with different biol. showing different sensitivity to therapeutic agents.  For decades, the std. first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy.  Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined.  Trabectedin is one of the new mols. approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents.  The compd. is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunol. effects.  This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp27aQwLkKWY7Vg90H21EOLACvtfcHk0lguPWBmYUUEgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFamurvE&md5=8a5313f5ca66382281c331738eed6482</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2147%2FOTT.S127955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S127955%26sid%3Dliteratum%253Aachs%26aulast%3DRecine%26aufirst%3DF.%26aulast%3DBongiovanni%26aufirst%3DA.%26aulast%3DRiva%26aufirst%3DN.%26aulast%3DFausti%26aufirst%3DV.%26aulast%3DDe%2BVita%26aufirst%3DA.%26aulast%3DMercatali%26aufirst%3DL.%26aulast%3DLiverani%26aufirst%3DC.%26aulast%3DMiserocchi%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DD.%26aulast%3DIbrahim%26aufirst%3DT.%26atitle%3DUpdate%2520on%2520the%2520role%2520of%2520trabectedin%2520in%2520the%2520treatment%2520of%2520intractable%2520soft%2520tissue%2520sarcomas%26jtitle%3DOncoTargets%2520Ther.%26date%3D2017%26volume%3D10%26spage%3D1155%26epage%3D1164%26doi%3D10.2147%2FOTT.S127955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderMolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlies, N. H.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (Istodax®, NSC 630176, FR901228, FK228, Depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/ja.2011.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fja.2011.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21587264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=525-531&author=K.+M.+VanderMolenauthor=W.+McCullochauthor=C.+J.+Pearceauthor=N.+H.+Oberlies&title=Romidepsin+%28Istodax%C2%AE%2C+NSC+630176%2C+FR901228%2C+FK228%2C+Depsipeptide%29%3A+a+natural+product+recently+approved+for+cutaneous+T-cell+lymphoma&doi=10.1038%2Fja.2011.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span></div><div class="casAuthors">VanderMolen Karen M; McCulloch William; Pearce Cedric J; Oberlies Nicholas H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">525-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration.  This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample.  This bicyclic compound acts as a prodrug, its disulfide bridge being reduced by glutathione on uptake into the cell, allowing the free thiol groups to interact with Zn ions in the active site of class I and II HDAC enzymes.  Due to the synthetic complexity of the compound, as well as the low yield from the producing organism, analogs are sought to create synthetically accessible alternatives.  As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6-aG7G4t02v69nzq6467DfW6udTcc2ebjXkVJvkyyHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D&md5=7d9d400857a6cf11cfe1f58acf5c1558</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.35%26sid%3Dliteratum%253Aachs%26aulast%3DVanderMolen%26aufirst%3DK.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DC.%2BJ.%26aulast%3DOberlies%26aufirst%3DN.%2BH.%26atitle%3DRomidepsin%2520%2528Istodax%25C2%25AE%252C%2520NSC%2520630176%252C%2520FR901228%252C%2520FK228%252C%2520Depsipeptide%2529%253A%2520a%2520natural%2520product%2520recently%2520approved%2520for%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fja.2011.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1231</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1230-1231&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1230%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voaklander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1351295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1080%2F17474124.2017.1351295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28673106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GgtLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=789-795&author=R.+Voaklanderauthor=I.+M.+Jacobson&title=Sofosbuvir%2C+velpatasvir+and+voxilaprevir+combination+for+the+treatment+of+hepatitis+C&doi=10.1080%2F17474124.2017.1351295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C</span></div><div class="casAuthors">Voaklander, Rebecca; Jacobson, Ira M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">789-795</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The advent of direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infection has dramatically increased rates of cure.  However, there remain difficult-to-treat populations, including patients with genotype 3 infection and cirrhosis, and limited salvage treatment options for those that have failed first-line DAA therapy.  This is a review of the preclin. and clin. development of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pangenotypic treatment for chronic HCV infection.  All relevant literature from 2015 through June of 2017 is included.  Voxilaprevir, a second-generation HCV protease inhibitor, in combination with the already approved combination of sofosbuvir and velpatasvir, was evaluated in the POLARIS trials and found to be a safe and effective regimen.  Patients with prior DAA treatment failure, genotype 3, cirrhosis and/or unfavorable resistance profiles all achieved cure rates of 96% or greater.  The most distinctive role for this potent regimen may prove to be as a salvage regimen for patients who have failed previous DAA therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTwrcUuIHzrVg90H21EOLACvtfcHk0lj788N-PS7yXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GgtLzM&md5=f29dce08c1f55ecfb232a82b51a4ff72</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1351295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1351295%26sid%3Dliteratum%253Aachs%26aulast%3DVoaklander%26aufirst%3DR.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26atitle%3DSofosbuvir%252C%2520velpatasvir%2520and%2520voxilaprevir%2520combination%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26spage%3D789%26epage%3D795%26doi%3D10.1080%2F17474124.2017.1351295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, T.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular blocking drugs: discovery and development</span>. <i>J. R. Soc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1177/014107680209500713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1177%2F014107680209500713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12091515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2002&pages=363-367&author=T.+Raghavendra&title=Neuromuscular+blocking+drugs%3A+discovery+and+development&doi=10.1177%2F014107680209500713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular blocking drugs: discovery and development</span></div><div class="casAuthors">Raghavendra, Thandla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">363-367</span>CODEN:
                <span class="NLM_cas:coden">JRSMD9</span>;
        ISSN:<span class="NLM_cas:issn">0141-0768</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Medicine Press Ltd.</span>)
        </div><div class="casAbstract">A review, describing the history of the discovery of naturally occurring neuromuscular blocking drugs and the development of synthetic ones.  However, all the currently available agents have their limitations, and the quest continues for an ideal drug.  What is needed is an agent that is rapidly acting, noncumulative, independent of renal or hepatic function for its elimination, free of side effects, and with an easily and rapidly reversed action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEJW44rC1XpbVg90H21EOLACvtfcHk0lj788N-PS7yXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFOqtr0%253D&md5=859e83053612c68cc0ec3150b57ee4c5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1177%2F014107680209500713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F014107680209500713%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DT.%26atitle%3DNeuromuscular%2520blocking%2520drugs%253A%2520discovery%2520and%2520development%26jtitle%3DJ.%2520R.%2520Soc.%2520Med.%26date%3D2002%26volume%3D95%26spage%3D363%26epage%3D367%26doi%3D10.1177%2F014107680209500713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nn.4508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fnn.4508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28192393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisV2kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=497-499&author=D.+R.+Corey&title=Nusinersen%2C+an+antisense+oligonucleotide+drug+for+spinal+muscular+atrophy&doi=10.1038%2Fnn.4508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy</span></div><div class="casAuthors">Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">497-499</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy.  Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as treatments for devastating neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfVaBRLymn7bVg90H21EOLACvtfcHk0lj788N-PS7yXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisV2kt7Y%253D&md5=09738c5d61054b2f7a20a35e3396233b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnn.4508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4508%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DNusinersen%252C%2520an%2520antisense%2520oligonucleotide%2520drug%2520for%2520spinal%2520muscular%2520atrophy%26jtitle%3DNat.%2520Neurosci.%26date%3D2017%26volume%3D20%26spage%3D497%26epage%3D499%26doi%3D10.1038%2Fnn.4508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04469.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1365-2125.2012.04469.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23013161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=269-276&author=S.+T.+Crookeauthor=R.+S.+Geary&title=Clinical+pharmacological+properties+of+mipomersen+%28Kynamro%29%2C+a+second+generation+antisense+inhibitor+of+apolipoprotein+B&doi=10.1111%2Fj.1365-2125.2012.04469.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B</span></div><div class="casAuthors">Crooke, Stanley T.; Geary, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mipomersen is a second generation antisense oligonucleotide that targets apolipoprotein B. It has been studied thoroughly in clin. trials (more than 800 subjects), including four randomized double-blind placebo controlled phase 3 studies involving 391 patients, and is in registration for the treatment of severe hypercholesterolemia.  The pharmacokinetic and pharmacodynamic properties of mipomersen are well characterized.  Mipomersen is rapidly and extensively absorbed after s.c. administration and has an elimination half-life of approx. 30 days across species.  It is cleared by nuclease metab. and renal excretion of the metabolites.  Mipomersen reduces all apolipoprotein B contg. atherogenic particles and displays dose dependent redns. between 50-400 mg week-1, both as a single agent and in the presence of maximal lipid lowering therapy.  No drug-drug interactions have been identified.  Mipomersen is a representative of second generation antisense drugs, all of which have similar properties, and is thus representative of the behavior of the class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXj4NgMtz247Vg90H21EOLACvtfcHk0lg1OpFB_3_EhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLvM&md5=28b5ae402fbe98a8f10829c2a6effcdf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04469.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04469.x%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26atitle%3DClinical%2520pharmacological%2520properties%2520of%2520mipomersen%2520%2528Kynamro%2529%252C%2520a%2520second%2520generation%2520antisense%2520inhibitor%2520of%2520apolipoprotein%2520B%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D269%26epage%3D276%26doi%3D10.1111%2Fj.1365-2125.2012.04469.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, T.</span></span> <span> </span><span class="NLM_article-title">Eteplirsen in the treatment of duchenne muscular dystrophy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S97635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FDDDT.S97635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28280301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=533-545&author=K.+R.+Q.+Limauthor=R.+Maruyamaauthor=T.+Yokota&title=Eteplirsen+in+the+treatment+of+duchenne+muscular+dystrophy&doi=10.2147%2FDDDT.S97635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Eteplirsen in the treatment of Duchenne muscular dystrophy</span></div><div class="casAuthors">Lim, Kenji Rowel Q.; Maruyama, Rika; Yokota, Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-545</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500-5,000 male births that is characterized by progressive muscular deterioration.  It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers.  In Sept. 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin prodn. by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants.  Eteplirsen is applicable for approx. 14% of patients with DMD mutations.  This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacol., efficacy, safety, and tolerability data from preclin. and clin. trials.  Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified.  Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-ziUr-zzsF7Vg90H21EOLACvtfcHk0lg1OpFB_3_EhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7vK&md5=e15f242dc4307bb85413134170dbcd6f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S97635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S97635%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.%2BR.%2BQ.%26aulast%3DMaruyama%26aufirst%3DR.%26aulast%3DYokota%26aufirst%3DT.%26atitle%3DEteplirsen%2520in%2520the%2520treatment%2520of%2520duchenne%2520muscular%2520dystrophy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D533%26epage%3D545%26doi%3D10.2147%2FDDDT.S97635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alquwaizani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanikos, J.</span></span> <span> </span><span class="NLM_article-title">Anticoagulants: a review of the pharmacology, dosing, and complications</span>. <i>Curr. Emerg. Hosp. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1007/s40138-013-0014-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs40138-013-0014-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23687625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpsVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=83-97&author=M.+Alquwaizaniauthor=L.+Buckleyauthor=C.+Adamsauthor=J.+Fanikos&title=Anticoagulants%3A+a+review+of+the+pharmacology%2C+dosing%2C+and+complications&doi=10.1007%2Fs40138-013-0014-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Anticoagulants: A Review of the Pharmacology, Dosing, and Complications</span></div><div class="casAuthors">Alquwaizani Mohammed; Buckley Leo; Adams Christopher; Fanikos John</div><div class="citationInfo"><span class="NLM_cas:title">Current emergency and hospital medicine reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-97</span>
        ISSN:<span class="NLM_cas:issn">2167-4884</span>.
    </div><div class="casAbstract">Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis.  Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring intervention.  Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease of use and more favorable pharmacodynamic profiles.  Hemorrhage is the main concerning adverse event with all anticoagulants.  With their ubiquitous use, it becomes important for clinicians to have a sound understanding of anticoagulant pharmacology, dosing, and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ39MnxRVsc5AHqQV89nF-2fW6udTcc2eaimM2VtebcJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpsVamtA%253D%253D&md5=47a40ab236ca6b0304cd83865f6d496b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs40138-013-0014-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40138-013-0014-6%26sid%3Dliteratum%253Aachs%26aulast%3DAlquwaizani%26aufirst%3DM.%26aulast%3DBuckley%26aufirst%3DL.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DFanikos%26aufirst%3DJ.%26atitle%3DAnticoagulants%253A%2520a%2520review%2520of%2520the%2520pharmacology%252C%2520dosing%252C%2520and%2520complications%26jtitle%3DCurr.%2520Emerg.%2520Hosp.%2520Med.%2520Rep.%26date%3D2013%26volume%3D1%26spage%3D83%26epage%3D97%26doi%3D10.1007%2Fs40138-013-0014-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">835</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666060-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-200666060-00006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=821-835&author=V.+R.+Andersonauthor=C.+M.+Perry&title=Pentosan+polysulfate%3A+a+review+of+its+use+in+the+relief+of+bladder+pain+or+discomfort+in+interstitial+cystitis&doi=10.2165%2F00003495-200666060-00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666060-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666060-00006%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DV.%2BR.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DPentosan%2520polysulfate%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520relief%2520of%2520bladder%2520pain%2520or%2520discomfort%2520in%2520interstitial%2520cystitis%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D821%26epage%3D835%26doi%3D10.2165%2F00003495-200666060-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papakonstantinou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakiulakis, G.</span></span> <span> </span><span class="NLM_article-title">Hyaluronic acid: A key molecule in skin aging</span>. <i>Derm.-Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.4161/derm.21923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4161%2Fderm.21923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=253-258&author=E.+Papakonstantinouauthor=M.+Rothauthor=G.+Karakiulakis&title=Hyaluronic+acid%3A+A+key+molecule+in+skin+aging&doi=10.4161%2Fderm.21923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Hyaluronic acid: A key molecule in skin aging</span></div><div class="casAuthors">Papakonstantinou, Eleni; Roth, Michael; Karakiulakis, George</div><div class="citationInfo"><span class="NLM_cas:title">Dermato-Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-258</span>CODEN:
                <span class="NLM_cas:coden">DERMFJ</span>;
        ISSN:<span class="NLM_cas:issn">1938-1972</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Skin aging is a multifactorial process consisting of two distinct and independent mechanisms: intrinsic and extrinsic aging.  Youthful skin retains its turgor, resilience and pliability, among others, due to its high content of water.  Daily external injury, in addn. to the normal process of aging, causes loss of moisture.  The key mol. involved in skin moisture is hyaluronic acid (HA) that has unique capacity in retaining water.  There are multiple sites for the control of HA synthesis, deposition, cell and protein assocn. and degrdn., reflecting the complexity of HA metab.  The enzymes that synthesize or catabolize HA and HA receptors responsible for many of the functions of HA are all multigene families with distinct patterns of tissue expression.  Understanding the metab. of HA in the different layers of the skin and the interactions of HA with other skin components will facilitate the ability to modulate skin moisture in a rational manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxtFo068TDgLVg90H21EOLACvtfcHk0liYvYTh9O0JNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSgsLs%253D&md5=5990c9c07a878a75c167089b5282cd52</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4161%2Fderm.21923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fderm.21923%26sid%3Dliteratum%253Aachs%26aulast%3DPapakonstantinou%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DKarakiulakis%26aufirst%3DG.%26atitle%3DHyaluronic%2520acid%253A%2520A%2520key%2520molecule%2520in%2520skin%2520aging%26jtitle%3DDerm.-Endocrinol.%26date%3D2012%26volume%3D4%26spage%3D253%26epage%3D258%26doi%3D10.4161%2Fderm.21923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triplett, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miloslavsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span> <span> </span><span class="NLM_article-title">Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome: interim results from a treatment IND study</span>. <i>Biol. Blood Marrow Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1016/j.bbmt.2017.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.bbmt.2017.03.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=997-1004&author=P.+G.+Richardsonauthor=A.+R.+Smithauthor=B.+M.+Triplettauthor=N.+A.+Kernanauthor=S.+A.+Gruppauthor=J.+H.+Antinauthor=L.+Lehmannauthor=T.+Shoreauthor=M.+Iacobelliauthor=M.+Miloslavskyauthor=R.+Humeauthor=A.+L.+Hannahauthor=B.+Nejadnikauthor=R.+J.+Soiffer&title=Defibrotide+for+patients+with+hepatic+veno-occlusive+disease%2Fsinusoidal+obstruction+syndrome%3A+interim+results+from+a+treatment+IND+study&doi=10.1016%2Fj.bbmt.2017.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bbmt.2017.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbmt.2017.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSmith%26aufirst%3DA.%2BR.%26aulast%3DTriplett%26aufirst%3DB.%2BM.%26aulast%3DKernan%26aufirst%3DN.%2BA.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DShore%26aufirst%3DT.%26aulast%3DIacobelli%26aufirst%3DM.%26aulast%3DMiloslavsky%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DR.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DNejadnik%26aufirst%3DB.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26atitle%3DDefibrotide%2520for%2520patients%2520with%2520hepatic%2520veno-occlusive%2520disease%252Fsinusoidal%2520obstruction%2520syndrome%253A%2520interim%2520results%2520from%2520a%2520treatment%2520IND%2520study%26jtitle%3DBiol.%2520Blood%2520Marrow%2520Transplant.%26date%3D2017%26volume%3D23%26spage%3D997%26epage%3D1004%26doi%3D10.1016%2Fj.bbmt.2017.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, P.</span></span> <span> </span><span class="NLM_article-title">Not boring at all. Boron is the new carbon in the quest for novel drug candidates</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/embor.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fembor.2009.2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-128&author=P.+Hunter&title=Not+boring+at+all.+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates&doi=10.1038%2Fembor.2009.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all.%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3D128%26doi%3D10.1038%2Fembor.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González Soto, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.jaad.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25956661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=62-69&author=B.+E.+Elewskiauthor=R.+Alyauthor=S.+L.+Baldwinauthor=R.+F.+Gonz%C3%A1lez+Sotoauthor=P.+Richauthor=M.+Weisfeldauthor=H.+Wiltzauthor=L.+T.+Zaneauthor=R.+Pollak&title=Efficacy+and+safety+of+tavaborole+topical+solution%2C+5%25%2C+a+novel+boron-based+antifungal+agent%2C+for+the+treatment+of+toenail+onychomycosis%3A+Results+from+2+randomized+phase-III+studies&doi=10.1016%2Fj.jaad.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span></div><div class="casAuthors">Elewski, Boni E.; Aly, Raza; Baldwin, Sheryl L.; Gonzalez Soto, Remigio F.; Rich, Phoebe; Weisfeld, Max; Wiltz, Hector; Zane, Lee T.; Pollak, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Onychomycosis, a fungal nail infection, can impact quality of life.  We sought to evaluate the efficacy and safety of tavaborole topical soln., 5% for treatment of toenail onychomycosis.  In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 wk.  The primary end point was complete cure of the target great toenail (completely clear nail with neg. mycol.) at week 52.  Secondary end points included completely or almost clear nail, neg. mycol., completely or almost clear nail plus neg. mycol., and safety.  Rates of neg. mycol. (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole vs. vehicle (P ≤ .001).  Completely or almost clear nail rates also significantly favored tavaborole vs. vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001).  Rates of completely or almost clear nail plus neg. mycol. (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole vs. vehicle (P < .001).  Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).  Duration of follow-up is a limitation.  Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57HESc8Cdt7Vg90H21EOLACvtfcHk0liYvYTh9O0JNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D&md5=ce2bd25a222bec52157508b38f9971f9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DElewski%26aufirst%3DB.%2BE.%26aulast%3DAly%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DS.%2BL.%26aulast%3DGonz%25C3%25A1lez%2BSoto%26aufirst%3DR.%2BF.%26aulast%3DRich%26aufirst%3DP.%26aulast%3DWeisfeld%26aufirst%3DM.%26aulast%3DWiltz%26aufirst%3DH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DPollak%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520tavaborole%2520topical%2520solution%252C%25205%2525%252C%2520a%2520novel%2520boron-based%2520antifungal%2520agent%252C%2520for%2520the%2520treatment%2520of%2520toenail%2520onychomycosis%253A%2520Results%2520from%25202%2520randomized%2520phase-III%2520studies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2015%26volume%3D73%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.jaad.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, L. S.</span></span> <span> </span><span class="NLM_article-title">Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2217%2Fimt-2016-0023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=853-866&author=L.+T.+Zaneauthor=S.+Chandaauthor=K.+Jarnaginauthor=D.+B.+Nelsonauthor=L.+Spelmanauthor=L.+S.+Gold&title=Crisaborole+and+its+potential+role+in+treating+atopic+dermatitis%3A+overview+of+early+clinical+studies&doi=10.2217%2Fimt-2016-0023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0023%26sid%3Dliteratum%253Aachs%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DJarnagin%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DD.%2BB.%26aulast%3DSpelman%26aufirst%3DL.%26aulast%3DGold%26aufirst%3DL.%2BS.%26atitle%3DCrisaborole%2520and%2520its%2520potential%2520role%2520in%2520treating%2520atopic%2520dermatitis%253A%2520overview%2520of%2520early%2520clinical%2520studies%26jtitle%3DImmunotherapy%26date%3D2016%26volume%3D8%26spage%3D853%26epage%3D866%26doi%3D10.2217%2Fimt-2016-0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangani, S.</span></span> <span> </span><span class="NLM_article-title">An update on β-lactamase inhibitor discovery and development</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2017.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.drup.2017.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29499835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrnt1Srtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=13-29&author=J.+D.+Docquierauthor=S.+Mangani&title=An+update+on+%CE%B2-lactamase+inhibitor+discovery+and+development&doi=10.1016%2Fj.drup.2017.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">An update on β-lactamase inhibitor discovery and development</span></div><div class="casAuthors">Docquier Jean-Denis; Mangani Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibiotic resistance, and the emergence of pan-resistant clinical isolates, seriously threatens our capability to treat bacterial diseases, including potentially deadly hospital-acquired infections.  This growing issue certainly requires multiple adequate responses, including the improvement of both diagnosis methods and use of antibacterial agents, and obviously the development of novel antibacterial drugs, especially active against Gram-negative pathogens, which represent an urgent medical need.  Considering the clinical relevance of both β-lactam antibiotics and β-lactamase-mediated resistance, the discovery and development of combinations including a β-lactamase inhibitor seems to be particularly attractive, despite being extremely challenging due to the enormous diversity, both structurally and mechanistically, of the potential β-lactamase targets.  This review will cover the evolution of currently available β-lactamase inhibitors along with the most recent research leading to new β-lactamase inhibitors of potential clinical interest or already in the stage of clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsXMDgBdiPxe2qxNLjzXe8fW6udTcc2eacNWklgO1y5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrnt1Srtw%253D%253D&md5=540d110de464506f4a4f4053e5ab4014</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2017.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DDocquier%26aufirst%3DJ.%2BD.%26aulast%3DMangani%26aufirst%3DS.%26atitle%3DAn%2520update%2520on%2520%25CE%25B2-lactamase%2520inhibitor%2520discovery%2520and%2520development%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2018%26volume%3D36%26spage%3D13%26epage%3D29%26doi%3D10.1016%2Fj.drup.2017.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woynarowski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaney, S. G.</span></span> <span> </span><span class="NLM_article-title">Oxaliplatin: mechanism of action and antineoplastic activity</span>. <i>Semin Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2, Suppl. 5</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=9609103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVCkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1998&pages=4-12&issue=2%2C+Suppl.+5&author=E.+Raymondauthor=S.+Faivreauthor=J.+M.+Woynarowskiauthor=S.+G.+Chaney&title=Oxaliplatin%3A+mechanism+of+action+and+antineoplastic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin: mechanism of action and antineoplastic activity</span></div><div class="casAuthors">Raymond, Eric; Faivre, Sandrine; Woynarowski, Jan M.; Chaney, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2, Suppl. 5</span>),
    <span class="NLM_cas:pages">4-12</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with 53 refs.  Oxaliplatin, a platinum-based chemotherapeutic agent with a 1,2-diaminocyclohexane (DACH) carrier ligand, has shown in vitro and in vivo efficacy against many tumor cell lines, including some that are resistant to cisplatin and carboplatin.  The retention of the bulky DACH ring by activated oxaliplatin is thought to result in the formation of platinum-DNA adducts, which appear to be more effective at blocking DNA replication and are more cytotoxic than adducts formed from cisplatin.  Studies by the National Cancer Institute (NCI) have suggested that oxaliplatin has a spectrum of activity different from that of either cisplatin or carboplatin, suggesting that it has different mol. targets and/or mechanisms of resistance.  Oxaliplatin has been demonstrated to differ in some mechanisms assocd. with the development of cisplatin resistance.  Compared with cisplatin-conditioned cells, deficiencies in mismatch repair (MMR) and increases in replicative bypass, which appear to contribute to cisplatin resistance, have not been shown to induce a similar resistance to oxaliplatin.  A decreased likelihood of resistance development makes oxaliplatin a good candidate for first-line therapy.  Studies also demonstrate additive and/or synergistic activity with a no. of other compds., however, suggesting the possible use of oxaliplatin in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocQ9VzgmgYerVg90H21EOLACvtfcHk0lgcxUfDijHlKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVCkt70%253D&md5=2efebcd0a89dbf7be44302650e5ac755</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DWoynarowski%26aufirst%3DJ.%2BM.%26aulast%3DChaney%26aufirst%3DS.%2BG.%26atitle%3DOxaliplatin%253A%2520mechanism%2520of%2520action%2520and%2520antineoplastic%2520activity%26jtitle%3DSemin%2520Oncol.%26date%3D1998%26volume%3D25%26issue%3D2%252C%2520Suppl.%25205%26spage%3D4%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroussent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paci, A.</span></span> <span> </span><span class="NLM_article-title">Oxazaphosphorines: new therapeutic strategies for an old class of drugs</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">938</span>, <span class="refDoi"> DOI: 10.1517/17425255.2010.487861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1517%2F17425255.2010.487861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=20446865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=919-938&author=B.+Giraudauthor=G.+Hebertauthor=A.+Deroussentauthor=G.+J.+Vealauthor=G.+Vassalauthor=A.+Paci&title=Oxazaphosphorines%3A+new+therapeutic+strategies+for+an+old+class+of+drugs&doi=10.1517%2F17425255.2010.487861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazaphosphorines: new therapeutic strategies for an old class of drugs</span></div><div class="casAuthors">Giraud, Berenice; Hebert, Guillaume; Deroussent, Alain; Veal, Gareth J.; Vassal, Gilles; Paci, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">919-938</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The oxazaphosphorines (cyclophosphamide, ifosfamide and trofosfamide) are widely used in clin. practice for their antitumor and immunomodulatory activities.  However, their use is assocd. with toxicities.  The metab. of oxazaphosphorines involves cytochrome P 450 biotransformations, leading to highly reactive metabolites such as acrolein and chloroacetaldehyde responsible for urotoxicity, neurotoxicity and nephrotoxicity.  While the mechanisms behind these toxicities remain under investigation, some advances have been made, as exemplified by the use of mesna to limit acrolein related urotoxicity.  Areas covered in this review: This review highlights potential strategies for limiting side effects commonly assocd. with the oxazaphosphorine drugs, through pharmacol. or medicinal chem.-based approaches.  What the reader will gain: The readers will gain a comprehensive review of these approaches to treatment in terms of: (i) pharmacol.: use of antidotes and modification of metab. through inhibition/induction of CYP enzymes or use of gene therapy; and (ii) medicinal chem.: the design of new drugs to target cancer cells and avoid CYP biotransformation with pre-activated prodrugs or with side-chain substituted analogs.Take home message: An increased knowledge of oxazaphosphorines' metab. and toxicity may allow the development of new anticancer drugs combined with drug delivery systems to circumvent drug toxicity, providing increased tumoral specificity and greater anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH90kS_9RgXLVg90H21EOLACvtfcHk0lgcxUfDijHlKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSqurY%253D&md5=88cefc6ffb275ee5257a61b34f8100b7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.487861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.487861%26sid%3Dliteratum%253Aachs%26aulast%3DGiraud%26aufirst%3DB.%26aulast%3DHebert%26aufirst%3DG.%26aulast%3DDeroussent%26aufirst%3DA.%26aulast%3DVeal%26aufirst%3DG.%2BJ.%26aulast%3DVassal%26aufirst%3DG.%26aulast%3DPaci%26aufirst%3DA.%26atitle%3DOxazaphosphorines%253A%2520new%2520therapeutic%2520strategies%2520for%2520an%2520old%2520class%2520of%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26spage%3D919%26epage%3D938%26doi%3D10.1517%2F17425255.2010.487861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antman, K. H.</span></span> <span> </span><span class="NLM_article-title">Introduction: the history of arsenic trioxide in cancer therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.6-suppl_2-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1634%2Ftheoncologist.6-suppl_2-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=1-2&issue=Suppl.+2&author=K.+H.+Antman&title=Introduction%3A+the+history+of+arsenic+trioxide+in+cancer+therapy&doi=10.1634%2Ftheoncologist.6-suppl_2-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.6-suppl_2-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.6-suppl_2-1%26sid%3Dliteratum%253Aachs%26aulast%3DAntman%26aufirst%3DK.%2BH.%26atitle%3DIntroduction%253A%2520the%2520history%2520of%2520arsenic%2520trioxide%2520in%2520cancer%2520therapy%26jtitle%3DOncologist%26date%3D2001%26volume%3D6%26issue%3DSuppl.%25202%26spage%3D1%26epage%3D2%26doi%3D10.1634%2Ftheoncologist.6-suppl_2-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, O.</span></span> <span> </span><span class="NLM_article-title">Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease</span>. <i>Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 10</span>),  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16985930" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=S3-S12&issue=Suppl.+10&author=O.+Sartor&title=Overview+of+samarium+Sm+153+lexidronam+in+the+treatment+of+painful+metastatic+bone+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSartor%26aufirst%3DO.%26atitle%3DOverview%2520of%2520samarium%2520Sm%2520153%2520lexidronam%2520in%2520the%2520treatment%2520of%2520painful%2520metastatic%2520bone%2520disease%26jtitle%3DRev.%2520Urol.%26date%3D2004%26volume%3D6%26issue%3DSuppl.%252010%26spage%3DS3%26epage%3DS12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 85 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Sarah M. Anthony, Laura G. Wonilowicz, Matthew S. McVeigh, <span class="NLM_string-name hlFld-ContribAuthor">Neil K. Garg</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Fleeting Strained Intermediates to Access Complex Scaffolds. </span><span class="cited-content_cbyCitation_journal-name">JACS Au</span><span> <strong>2021,</strong> <em>1 </em>
                                    (7)
                                     , 897-912. <a href="https://doi.org/10.1021/jacsau.1c00214" title="DOI URL">https://doi.org/10.1021/jacsau.1c00214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacsau.1c00214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacsau.1c00214%26sid%3Dliteratum%253Aachs%26jtitle%3DJACS%2520Au%26atitle%3DLeveraging%252BFleeting%252BStrained%252BIntermediates%252Bto%252BAccess%252BComplex%252BScaffolds%26aulast%3DAnthony%26aufirst%3DSarah%2BM.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D14052021%26date%3D23062021%26volume%3D1%26issue%3D7%26spage%3D897%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael D. Delost, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">Mild Darzens Annulations for the Assembly of Trifluoromethylthiolated (SCF3) Aziridine and Cyclopropane Structures. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c02204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c02204%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMild%252BDarzens%252BAnnulations%252Bfor%252Bthe%252BAssembly%252Bof%252BTrifluoromethylthiolated%252B%252528SCF3%252529%252BAziridine%252Band%252BCyclopropane%252BStructures%26aulast%3DDelost%26aufirst%3DMichael%2BD.%26date%3D2021%26date%3D2021%26date%3D02072021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ibakyntiew D. Marpna, O. Risuklang Shangpliang, Kmendashisha Wanniang, Baskhemlang Kshiar, Tyrchain Mitre Lipon, Badaker M. Laloo, <span class="NLM_string-name hlFld-ContribAuthor">Bekington Myrboh</span>. </span><span class="cited-content_cbyCitation_article-title">Trifluoroacetic Acid-Mediated Oxidative Self-Condensation of Acetophenones in the Presence of SeO2: A Serendipitous Approach for the Synthesis of Fused [1,3]Dioxolo[4,5-d][1,3]dioxoles. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (22)
                                     , 14518-14524. <a href="https://doi.org/10.1021/acsomega.1c01466" title="DOI URL">https://doi.org/10.1021/acsomega.1c01466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.1c01466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.1c01466%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DTrifluoroacetic%252BAcid-Mediated%252BOxidative%252BSelf-Condensation%252Bof%252BAcetophenones%252Bin%252Bthe%252BPresence%252Bof%252BSeO2%25253A%252BA%252BSerendipitous%252BApproach%252Bfor%252Bthe%252BSynthesis%252Bof%252BFused%252B%25255B1%25252C3%25255DDioxolo%25255B4%25252C5-d%25255D%25255B1%25252C3%25255Ddioxoles%26aulast%3DMarpna%26aufirst%3DIbakyntiew%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D19052021%26date%3D28052021%26volume%3D6%26issue%3D22%26spage%3D14518%26epage%3D14524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chao-Huan Zhang, Qing Gao, Meng Li, Jian-Fei Wang, Chuan-Ming Yu, <span class="NLM_string-name hlFld-ContribAuthor">Bin Mao</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetic Resolution of Tertiary Allylic Alcohols: Highly Enantioselective Access to Cyclic Ethers Bearing an α-Tetrasubstituted Stereocenter. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (10)
                                     , 3949-3954. <a href="https://doi.org/10.1021/acs.orglett.1c01110" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01110%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DKinetic%252BResolution%252Bof%252BTertiary%252BAllylic%252BAlcohols%25253A%252BHighly%252BEnantioselective%252BAccess%252Bto%252BCyclic%252BEthers%252BBearing%252Ban%252B%2525CE%2525B1-Tetrasubstituted%252BStereocenter%26aulast%3DZhang%26aufirst%3DChao-Huan%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D31032021%26date%3D30042021%26volume%3D23%26issue%3D10%26spage%3D3949%26epage%3D3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhuo Wang, Tao Chen, Hua Liu, Xiao-Li Zhao, Wei-Bo Hu, Hui Yang, Yahu A. Liu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Wen</span>. </span><span class="cited-content_cbyCitation_article-title">Pillar[5]arene-Derived endo-Functionalized Molecular Tube for Mimicking Protein–Ligand Interactions. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (9)
                                     , 6467-6477. <a href="https://doi.org/10.1021/acs.joc.1c00314" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00314%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPillar%25255B5%25255Darene-Derived%252Bendo-Functionalized%252BMolecular%252BTube%252Bfor%252BMimicking%252BProtein%2525E2%252580%252593Ligand%252BInteractions%26aulast%3DWang%26aufirst%3DZhuo%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08022021%26date%3D19042021%26volume%3D86%26issue%3D9%26spage%3D6467%26epage%3D6477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eun Chae Son, Seung Yeon Kim, <span class="NLM_string-name hlFld-ContribAuthor">Sung-Gon Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Squaramide-Catalyzed Asymmetric Intramolecular Oxa-Michael Reaction of α,β-Unsaturated Carbonyls Containing Benzyl Alcohol: Construction of Chiral 1-Substituted Phthalans. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (9)
                                     , 6826-6839. <a href="https://doi.org/10.1021/acs.joc.1c00715" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00715%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSquaramide-Catalyzed%252BAsymmetric%252BIntramolecular%252BOxa-Michael%252BReaction%252Bof%252B%2525CE%2525B1%25252C%2525CE%2525B2-Unsaturated%252BCarbonyls%252BContaining%252BBenzyl%252BAlcohol%25253A%252BConstruction%252Bof%252BChiral%252B1-Substituted%252BPhthalans%26aulast%3DSon%26aufirst%3DEun%2BChae%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26032021%26date%3D27042021%26volume%3D86%26issue%3D9%26spage%3D6826%26epage%3D6839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Leandro A. Bozzini, Thiago dos Santos, Valter E. Murie, Murilo B. M. de Mello, Ricardo Vessecchi, <span class="NLM_string-name hlFld-ContribAuthor">Giuliano C. Clososki</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective Functionalization of Ester-, Amide-, Carbonate-, and Carbamate-Substituted 2-Phenyl-2-oxazolines with Mixed Lithium–Magnesium Amides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (1)
                                     , 1204-1215. <a href="https://doi.org/10.1021/acs.joc.0c02369" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02369%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRegioselective%252BFunctionalization%252Bof%252BEster-%25252C%252BAmide-%25252C%252BCarbonate-%25252C%252Band%252BCarbamate-Substituted%252B2-Phenyl-2-oxazolines%252Bwith%252BMixed%252BLithium%2525E2%252580%252593Magnesium%252BAmides%26aulast%3DBozzini%26aufirst%3DLeandro%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D06102020%26date%3D09122020%26volume%3D86%26issue%3D1%26spage%3D1204%26epage%3D1215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Houng Kang, <span class="NLM_string-name hlFld-ContribAuthor">Christopher Uyeda</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Vinylidene Insertions into O–H Bonds. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 193-198. <a href="https://doi.org/10.1021/acscatal.0c04713" title="DOI URL">https://doi.org/10.1021/acscatal.0c04713</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c04713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c04713%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DNickel-Catalyzed%252BVinylidene%252BInsertions%252Binto%252BO%2525E2%252580%252593H%252BBonds%26aulast%3DKang%26aufirst%3DHoung%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29102020%26date%3D04122020%26date%3D15122020%26volume%3D11%26issue%3D1%26spage%3D193%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kevin A. Scott, M. Haziq Qureshi, Philip B. Cox, Christopher M. Marshall, Bailey C. Bellaire, Michael Wilcox, Bradey A. R. Stuart, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">A Structural Analysis of the FDA Green Book-Approved Veterinary Drugs and Roles in Human Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15449-15482. <a href="https://doi.org/10.1021/acs.jmedchem.0c01502" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01502%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BStructural%252BAnalysis%252Bof%252Bthe%252BFDA%252BGreen%252BBook-Approved%252BVeterinary%252BDrugs%252Band%252BRoles%252Bin%252BHuman%252BMedicine%26aulast%3DScott%26aufirst%3DKevin%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27082020%26date%3D30102020%26volume%3D63%26issue%3D24%26spage%3D15449%26epage%3D15482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aleksandra Nilova, Louis-Charles Campeau, Edward C. Sherer, <span class="NLM_string-name hlFld-ContribAuthor">David R. Stuart</span>. </span><span class="cited-content_cbyCitation_article-title">Analysis of Benzenoid Substitution Patterns in Small Molecule Active Pharmaceutical Ingredients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13389-13396. <a href="https://doi.org/10.1021/acs.jmedchem.0c00915" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00915%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAnalysis%252Bof%252BBenzenoid%252BSubstitution%252BPatterns%252Bin%252BSmall%252BMolecule%252BActive%252BPharmaceutical%252BIngredients%26aulast%3DNilova%26aufirst%3DAleksandra%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D31082020%26date%3D13082020%26volume%3D63%26issue%3D22%26spage%3D13389%26epage%3D13396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maheshwerreddy Chilamari, Jacob R. Immel, <span class="NLM_string-name hlFld-ContribAuthor">Steven Bloom</span>. </span><span class="cited-content_cbyCitation_article-title">General Access to C-Centered Radicals: Combining a Bioinspired Photocatalyst with Boronic Acids in Aqueous Media. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (21)
                                     , 12727-12737. <a href="https://doi.org/10.1021/acscatal.0c03422" title="DOI URL">https://doi.org/10.1021/acscatal.0c03422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c03422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c03422%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DGeneral%252BAccess%252Bto%252BC-Centered%252BRadicals%25253A%252BCombining%252Ba%252BBioinspired%252BPhotocatalyst%252Bwith%252BBoronic%252BAcids%252Bin%252BAqueous%252BMedia%26aulast%3DChilamari%26aufirst%3DMaheshwerreddy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05082020%26date%3D06102020%26date%3D19102020%26volume%3D10%26issue%3D21%26spage%3D12727%26epage%3D12737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Narasimharao Mukku, Prabhakara Madivalappa Davanagere, Kaushik Chanda, <span class="NLM_string-name hlFld-ContribAuthor">Barnali Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">A Facile Microwave-Assisted Synthesis of Oxazoles and Diastereoselective Oxazolines Using Aryl-Aldehydes, p-Toluenesulfonylmethyl Isocyanide under Controlled Basic Conditions. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (43)
                                     , 28239-28248. <a href="https://doi.org/10.1021/acsomega.0c04130" title="DOI URL">https://doi.org/10.1021/acsomega.0c04130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04130%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DA%252BFacile%252BMicrowave-Assisted%252BSynthesis%252Bof%252BOxazoles%252Band%252BDiastereoselective%252BOxazolines%252BUsing%252BAryl-Aldehydes%25252C%252Bp-Toluenesulfonylmethyl%252BIsocyanide%252Bunder%252BControlled%252BBasic%252BConditions%26aulast%3DMukku%26aufirst%3DNarasimharao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D06102020%26date%3D20102020%26volume%3D5%26issue%3D43%26spage%3D28239%26epage%3D28248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Deyun Qian, <span class="NLM_string-name hlFld-ContribAuthor">Junliang Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Yne–Enones Enable Diversity-Oriented Catalytic Cascade Reactions: A Rapid Assembly of Complexity. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2020,</strong> <em>53 </em>
                                    (10)
                                     , 2358-2371. <a href="https://doi.org/10.1021/acs.accounts.0c00466" title="DOI URL">https://doi.org/10.1021/acs.accounts.0c00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.0c00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.0c00466%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DYne%2525E2%252580%252593Enones%252BEnable%252BDiversity-Oriented%252BCatalytic%252BCascade%252BReactions%25253A%252BA%252BRapid%252BAssembly%252Bof%252BComplexity%26aulast%3DQian%26aufirst%3DDeyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21072020%26date%3D01102020%26volume%3D53%26issue%3D10%26spage%3D2358%26epage%3D2371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vincent Davenel, Christian Nisole, Fabien Fontaine-Vive, Jean-Marie Fourquez, Anne-Marie Chollet, <span class="NLM_string-name hlFld-ContribAuthor">Véronique Michelet</span>. </span><span class="cited-content_cbyCitation_article-title">Gold-Catalyzed Cycloisomerization of 1,6-Cyclohexenylalkyne: An Efficient Entry to Bicyclo[3.2.1]oct-2-ene and Bicyclo[3.3.1]nonadiene. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (19)
                                     , 12657-12669. <a href="https://doi.org/10.1021/acs.joc.0c01841" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01841%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DGold-Catalyzed%252BCycloisomerization%252Bof%252B1%25252C6-Cyclohexenylalkyne%25253A%252BAn%252BEfficient%252BEntry%252Bto%252BBicyclo%25255B3.2.1%25255Doct-2-ene%252Band%252BBicyclo%25255B3.3.1%25255Dnonadiene%26aulast%3DDavenel%26aufirst%3DVincent%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31072020%26date%3D11092020%26date%3D02092020%26volume%3D85%26issue%3D19%26spage%3D12657%26epage%3D12669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">Essential Medicinal Chemistry of Essential Medicines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10170-10187. <a href="https://doi.org/10.1021/acs.jmedchem.0c00415" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00415%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEssential%252BMedicinal%252BChemistry%252Bof%252BEssential%252BMedicines%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11032020%26date%3D12052020%26date%3D30042020%26volume%3D63%26issue%3D18%26spage%3D10170%26epage%3D10187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Munenori Inoue, Yuji Sumii, <span class="NLM_string-name hlFld-ContribAuthor">Norio Shibata</span>. </span><span class="cited-content_cbyCitation_article-title">Contribution of Organofluorine Compounds to Pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (19)
                                     , 10633-10640. <a href="https://doi.org/10.1021/acsomega.0c00830" title="DOI URL">https://doi.org/10.1021/acsomega.0c00830</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c00830%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DContribution%252Bof%252BOrganofluorine%252BCompounds%252Bto%252BPharmaceuticals%26aulast%3DInoue%26aufirst%3DMunenori%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D25022020%26date%3D10042020%26date%3D22042020%26volume%3D5%26issue%3D19%26spage%3D10633%26epage%3D10640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kieran D. Jones, Michael J. Nutt, Elena Comninos, Alexandre N. Sobolev, Stephen A. Moggach, Tomoya Miura, Masahiro Murakami, <span class="NLM_string-name hlFld-ContribAuthor">Scott G. Stewart</span>. </span><span class="cited-content_cbyCitation_article-title">A One-Pot Reaction of α-Imino Rhodium Carbenoids and Halohydrins: Access to 2,6-Substituted Dihydro-2H-1,4-oxazines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     , 3490-3494. <a href="https://doi.org/10.1021/acs.orglett.0c00947" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00947%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252BOne-Pot%252BReaction%252Bof%252B%2525CE%2525B1-Imino%252BRhodium%252BCarbenoids%252Band%252BHalohydrins%25253A%252BAccess%252Bto%252B2%25252C6-Substituted%252BDihydro-2H-1%25252C4-oxazines%26aulast%3DJones%26aufirst%3DKieran%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14032020%26date%3D13042020%26volume%3D22%26issue%3D9%26spage%3D3490%26epage%3D3494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sofiane Hocine, Gilles Berger, <span class="NLM_string-name hlFld-ContribAuthor">Stephen Hanessian</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline Chimeras. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (6)
                                     , 4237-4247. <a href="https://doi.org/10.1021/acs.joc.9b03413" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03413%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBackbone-Fused%25252C%252BConformationally%252BConstrained%252BMorpholine-Proline%252BChimeras%26aulast%3DHocine%26aufirst%3DSofiane%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18122019%26date%3D05032020%26volume%3D85%26issue%3D6%26spage%3D4237%26epage%3D4247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shuming Chen, Jonathan J. Wong, <span class="NLM_string-name hlFld-ContribAuthor">K. N. Houk</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of the Manolikakes Enamide-Based Domino Reaction for the Stereospecific Construction of Tetrahydropyrans. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (5)
                                     , 3806-3811. <a href="https://doi.org/10.1021/acs.joc.9b03440" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03440%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMechanism%252Bof%252Bthe%252BManolikakes%252BEnamide-Based%252BDomino%252BReaction%252Bfor%252Bthe%252BStereospecific%252BConstruction%252Bof%252BTetrahydropyrans%26aulast%3DChen%26aufirst%3DShuming%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D12022020%26date%3D04022020%26volume%3D85%26issue%3D5%26spage%3D3806%26epage%3D3811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kosuke Yamamoto, Masami Kuriyama, <span class="NLM_string-name hlFld-ContribAuthor">Osamu Onomura</span>. </span><span class="cited-content_cbyCitation_article-title">Anodic Oxidation for the Stereoselective Synthesis of Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Accounts of Chemical Research</span><span> <strong>2020,</strong> <em>53 </em>
                                    (1)
                                     , 105-120. <a href="https://doi.org/10.1021/acs.accounts.9b00513" title="DOI URL">https://doi.org/10.1021/acs.accounts.9b00513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.accounts.9b00513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.accounts.9b00513%26sid%3Dliteratum%253Aachs%26jtitle%3DAccounts%2520of%2520Chemical%2520Research%26atitle%3DAnodic%252BOxidation%252Bfor%252Bthe%252BStereoselective%252BSynthesis%252Bof%252BHeterocycles%26aulast%3DYamamoto%26aufirst%3DKosuke%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D30092019%26date%3D24122019%26volume%3D53%26issue%3D1%26spage%3D105%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kavoos Kolahdouzan, Ryan Khalaf, Jessica M. Grandner, Yongsheng Chen, Jack A. Terrett, <span class="NLM_string-name hlFld-ContribAuthor">Malcolm P. Huestis</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Photoredox/Nickel-Catalyzed Conversion of Aryl Halides to Aryl Aminooxetanes: Computational Evidence for a Substrate-Dependent Switch in Mechanism. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     , 405-411. <a href="https://doi.org/10.1021/acscatal.9b03596" title="DOI URL">https://doi.org/10.1021/acscatal.9b03596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.9b03596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.9b03596%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DDual%252BPhotoredox%25252FNickel-Catalyzed%252BConversion%252Bof%252BAryl%252BHalides%252Bto%252BAryl%252BAminooxetanes%25253A%252BComputational%252BEvidence%252Bfor%252Ba%252BSubstrate-Dependent%252BSwitch%252Bin%252BMechanism%26aulast%3DKolahdouzan%26aufirst%3DKavoos%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22082019%26date%3D17102019%26date%3D11122019%26date%3D08112019%26volume%3D10%26issue%3D1%26spage%3D405%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jonathan Cramer, Christoph P. Sager, <span class="NLM_string-name hlFld-ContribAuthor">Beat Ernst</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8915-8930. <a href="https://doi.org/10.1021/acs.jmedchem.9b00179" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00179%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxyl%252BGroups%252Bin%252BSynthetic%252Band%252BNatural-Product-Derived%252BTherapeutics%25253A%252BA%252BPerspective%252Bon%252Ba%252BCommon%252BFunctional%252BGroup%26aulast%3DCramer%26aufirst%3DJonathan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D29012019%26date%3D28052019%26date%3D14052019%26volume%3D62%26issue%3D20%26spage%3D8915%26epage%3D8930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jia-Nan Zhu, Wen-Kang Wang, Yuan Zhu, Yin-Qiu Hu, <span class="NLM_string-name hlFld-ContribAuthor">Sheng-Yin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Cascade Functionalization of C(sp3)–Br/C(sp2)–H Bonds: Access to Fused Benzo[e]isoindole-1,3,5-trione via Visible-Light-Induced Reductive Radical Relay Strategy. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (16)
                                     , 6270-6274. <a href="https://doi.org/10.1021/acs.orglett.9b02153" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02153%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCascade%252BFunctionalization%252Bof%252BC%252528sp3%252529%2525E2%252580%252593Br%25252FC%252528sp2%252529%2525E2%252580%252593H%252BBonds%25253A%252BAccess%252Bto%252BFused%252BBenzo%25255Be%25255Disoindole-1%25252C3%25252C5-trione%252Bvia%252BVisible-Light-Induced%252BReductive%252BRadical%252BRelay%252BStrategy%26aulast%3DZhu%26aufirst%3DJia-Nan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21062019%26date%3D26072019%26volume%3D21%26issue%3D16%26spage%3D6270%26epage%3D6274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Oliver F. Brandenberg, Kai Chen, <span class="NLM_string-name hlFld-ContribAuthor">Frances H. Arnold</span>. </span><span class="cited-content_cbyCitation_article-title">Directed Evolution of a Cytochrome P450 Carbene Transferase for Selective Functionalization of Cyclic Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (22)
                                     , 8989-8995. <a href="https://doi.org/10.1021/jacs.9b02931" title="DOI URL">https://doi.org/10.1021/jacs.9b02931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b02931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b02931%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDirected%252BEvolution%252Bof%252Ba%252BCytochrome%252BP450%252BCarbene%252BTransferase%252Bfor%252BSelective%252BFunctionalization%252Bof%252BCyclic%252BCompounds%26aulast%3DBrandenberg%26aufirst%3DOliver%2BF.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17032019%26date%3D22052019%26date%3D09052019%26volume%3D141%26issue%3D22%26spage%3D8989%26epage%3D8995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniel
M. Flores, <span class="NLM_string-name hlFld-ContribAuthor">Valerie A. Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Intermolecular 2 + 2 Carbonyl–Olefin Photocycloadditions Enabled by Cu(I)–Norbornene MLCT. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (22)
                                     , 8741-8745. <a href="https://doi.org/10.1021/jacs.9b03775" title="DOI URL">https://doi.org/10.1021/jacs.9b03775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b03775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b03775%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIntermolecular%252B2%252B%25252B%252B2%252BCarbonyl%2525E2%252580%252593Olefin%252BPhotocycloadditions%252BEnabled%252Bby%252BCu%252528I%252529%2525E2%252580%252593Norbornene%252BMLCT%26aulast%3DFlores%26aufirst%3DDaniel%2BM.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08042019%26date%3D24052019%26date%3D22052019%26volume%3D141%26issue%3D22%26spage%3D8741%26epage%3D8745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Pradipta Das, Michael D. Delost, Munaum H. Qureshi, David T. Smith, <span class="NLM_string-name hlFld-ContribAuthor">Jon T. Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">A Survey of the Structures of US FDA Approved Combination Drugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4265-4311. <a href="https://doi.org/10.1021/acs.jmedchem.8b01610" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01610%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BStructures%252Bof%252BUS%252BFDA%252BApproved%252BCombination%252BDrugs%26aulast%3DDas%26aufirst%3DPradipta%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D16102018%26date%3D30112018%26date%3D16112018%26volume%3D62%26issue%3D9%26spage%3D4265%26epage%3D4311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miao-Miao  Li</span>, <span class="hlFld-ContribAuthor ">Bao-Le  Qu</span>, <span class="hlFld-ContribAuthor ">Yu-Qing  Xiao</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Xiao</span>, <span class="hlFld-ContribAuthor ">Liang-Qiu  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Enantioselective trapping of palladium-stabilized oxo-1,4-dipoles with photochemically generated ketenes. </span><span class="cited-content_cbyCitation_journal-name">Science Bulletin</span><span> <strong>2021,</strong> <em>66 </em>
                                    (17)
                                     , 1719-1722. <a href="https://doi.org/10.1016/j.scib.2021.04.037" title="DOI URL">https://doi.org/10.1016/j.scib.2021.04.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.scib.2021.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.scib.2021.04.037%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Bulletin%26atitle%3DEnantioselective%252Btrapping%252Bof%252Bpalladium-stabilized%252Boxo-1%25252C4-dipoles%252Bwith%252Bphotochemically%252Bgenerated%252Bketenes%26aulast%3DLi%26aufirst%3DMiao-Miao%26date%3D2021%26volume%3D66%26issue%3D17%26spage%3D1719%26epage%3D1722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Gao</span>, <span class="hlFld-ContribAuthor ">Yanshu  Luo</span>, <span class="hlFld-ContribAuthor ">Qianlan  Xu</span>, <span class="hlFld-ContribAuthor ">Yukun  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiangnan  Gong</span>, <span class="hlFld-ContribAuthor ">Yuanzhi  Xia</span>, <span class="hlFld-ContribAuthor ">Lin  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">A Unified Catalytic Asymmetric (4+1) and (5+1) Annulation Strategy to Access Chiral Spirooxindole‐Fused Oxacycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/anie.202105282" title="DOI URL">https://doi.org/10.1002/anie.202105282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202105282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202105282%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BUnified%252BCatalytic%252BAsymmetric%252B%2525284%25252B1%252529%252Band%252B%2525285%25252B1%252529%252BAnnulation%252BStrategy%252Bto%252BAccess%252BChiral%252BSpirooxindole%2525E2%252580%252590Fused%252BOxacycles%26aulast%3DGao%26aufirst%3DMin%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Gao</span>, <span class="hlFld-ContribAuthor ">Yanshu  Luo</span>, <span class="hlFld-ContribAuthor ">Qianlan  Xu</span>, <span class="hlFld-ContribAuthor ">Yukun  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiangnan  Gong</span>, <span class="hlFld-ContribAuthor ">Yuanzhi  Xia</span>, <span class="hlFld-ContribAuthor ">Lin  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">A Unified Catalytic Asymmetric (4+1) and (5+1) Annulation Strategy to Access Chiral Spirooxindole‐Fused Oxacycles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>105 </em><a href="https://doi.org/10.1002/ange.202105282" title="DOI URL">https://doi.org/10.1002/ange.202105282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202105282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202105282%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DA%252BUnified%252BCatalytic%252BAsymmetric%252B%2525284%25252B1%252529%252Band%252B%2525285%25252B1%252529%252BAnnulation%252BStrategy%252Bto%252BAccess%252BChiral%252BSpirooxindole%2525E2%252580%252590Fused%252BOxacycles%26aulast%3DGao%26aufirst%3DMin%26date%3D2021%26date%3D2021%26volume%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yong‐Qin  He</span>, <span class="hlFld-ContribAuthor ">Wan‐Fa  Tian</span>, <span class="hlFld-ContribAuthor ">Mei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhao‐Zhao  Zhou</span>, <span class="hlFld-ContribAuthor ">Xian‐Rong  Song</span>, <span class="hlFld-ContribAuthor ">Hai‐Xin  Ding</span>, <span class="hlFld-ContribAuthor ">Qiang  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Cobalt and Photoredox Catalysis Enabled Redox‐Neutral Annulation of 2‐Propynolphenols. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (13)
                                     , 3372-3377. <a href="https://doi.org/10.1002/adsc.202100221" title="DOI URL">https://doi.org/10.1002/adsc.202100221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100221%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DDual%252BCobalt%252Band%252BPhotoredox%252BCatalysis%252BEnabled%252BRedox%2525E2%252580%252590Neutral%252BAnnulation%252Bof%252B2%2525E2%252580%252590Propynolphenols%26aulast%3DZhu%26aufirst%3DYao%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D13%26spage%3D3372%26epage%3D3377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Xiang</span>, <span class="hlFld-ContribAuthor ">Chen‐Yi  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ying  Zou</span>, <span class="hlFld-ContribAuthor ">Zhi‐Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Wen‐Sheng  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Fang  Tian</span>, <span class="hlFld-ContribAuthor ">Li‐Xin  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Organocatalyst‐promoted Diastereoselective and Enantioselective Michael Addition/Hemiketalization Reaction between Hydroxymaleimide and Quinone. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>10 </em>
                                    (7)
                                     , 1713-1717. <a href="https://doi.org/10.1002/ajoc.202100291" title="DOI URL">https://doi.org/10.1002/ajoc.202100291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202100291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202100291%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOrganocatalyst%2525E2%252580%252590promoted%252BDiastereoselective%252Band%252BEnantioselective%252BMichael%252BAddition%25252FHemiketalization%252BReaction%252Bbetween%252BHydroxymaleimide%252Band%252BQuinone%26aulast%3DXiang%26aufirst%3DMin%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D7%26spage%3D1713%26epage%3D1717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanumay  Sarkar</span>, <span class="hlFld-ContribAuthor ">Tariq A.  Shah</span>, <span class="hlFld-ContribAuthor ">Prabhat Kumar  Maharana</span>, <span class="hlFld-ContribAuthor ">Kangkan  Talukdar</span>, <span class="hlFld-ContribAuthor ">Bijay Ketan  Das</span>, <span class="hlFld-ContribAuthor ">Tharmalingam  Punniyamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">Transition‐Metal‐Catalyzed Directing Group Assisted (Hetero)aryl C−H Functionalization: Construction of C−C/C‐Heteroatom Bonds. </span><span class="cited-content_cbyCitation_journal-name">The Chemical Record</span><span> <strong>2021,</strong> <em>40 </em><a href="https://doi.org/10.1002/tcr.202100143" title="DOI URL">https://doi.org/10.1002/tcr.202100143</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tcr.202100143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftcr.202100143%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Chemical%2520Record%26atitle%3DTransition%2525E2%252580%252590Metal%2525E2%252580%252590Catalyzed%252BDirecting%252BGroup%252BAssisted%252B%252528Hetero%252529aryl%252BC%2525E2%252588%252592H%252BFunctionalization%25253A%252BConstruction%252Bof%252BC%2525E2%252588%252592C%25252FC%2525E2%252580%252590Heteroatom%252BBonds%26aulast%3DSarkar%26aufirst%3DTanumay%26date%3D2021%26date%3D2021%26volume%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabrielle  Robert‐Scott</span>, <span class="hlFld-ContribAuthor ">Jacob  St‐Gelais</span>, <span class="hlFld-ContribAuthor ">Denis  Giguère</span>. </span><span class="cited-content_cbyCitation_article-title">Annulative Dimerization of Carbohydrates: Synthesis of Complex
              C
              2
              ‐Symmetrical 1,4‐Dioxane‐Sugar Hybrids. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (22)
                                     , 3322-3330. <a href="https://doi.org/10.1002/ejoc.202100411" title="DOI URL">https://doi.org/10.1002/ejoc.202100411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100411%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAnnulative%252BDimerization%252Bof%252BCarbohydrates%25253A%252BSynthesis%252Bof%252BComplex%252BC%252B2%252B%2525E2%252580%252590Symmetrical%252B1%25252C4%2525E2%252580%252590Dioxane%2525E2%252580%252590Sugar%252BHybrids%26aulast%3DRobert%25E2%2580%2590Scott%26aufirst%3DGabrielle%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D22%26spage%3D3322%26epage%3D3330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu‐Hong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao‐Yu  He</span>, <span class="hlFld-ContribAuthor ">Qing‐Qing  Yang</span>, <span class="hlFld-ContribAuthor ">Amina  Boucherif</span>, <span class="hlFld-ContribAuthor ">Jun  Xuan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Organocatalytic Asymmetric Cycloaddition Reactions Through
              Ortho
              ‐Quinone Methide Scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1233-1250. <a href="https://doi.org/10.1002/ajoc.202100141" title="DOI URL">https://doi.org/10.1002/ajoc.202100141</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202100141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202100141%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252BOrganocatalytic%252BAsymmetric%252BCycloaddition%252BReactions%252BThrough%252BOrtho%252B%2525E2%252580%252590Quinone%252BMethide%252BScaffolds%26aulast%3DMa%26aufirst%3DYu%25E2%2580%2590Hong%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1233%26epage%3D1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liangliang  Luo</span>, <span class="hlFld-ContribAuthor ">Xiao-Pan  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-Feng  Li</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhou</span>, <span class="hlFld-ContribAuthor ">You-Cai  Xiao</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium(
              ii
              )-catalyzed aerobic oxidative O–H/C–H isocyanide insertion: facile access to pyrrolo[2,1-
              c
              ][1,4]benzoxazine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (19)
                                     , 4364-4368. <a href="https://doi.org/10.1039/D1OB00393C" title="DOI URL">https://doi.org/10.1039/D1OB00393C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00393C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00393C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DPalladium%252528%252Bii%252B%252529-catalyzed%252Baerobic%252Boxidative%252BO%2525E2%252580%252593H%25252FC%2525E2%252580%252593H%252Bisocyanide%252Binsertion%25253A%252Bfacile%252Baccess%252Bto%252Bpyrrolo%25255B2%25252C1-%252Bc%252B%25255D%25255B1%25252C4%25255Dbenzoxazine%252Bderivatives%26aulast%3DLuo%26aufirst%3DLiangliang%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D19%26spage%3D4364%26epage%3D4368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Shengjia  Lin</span>, <span class="hlFld-ContribAuthor ">Yawei  Zhu</span>, <span class="hlFld-ContribAuthor ">Daniel  Ferrante</span>, <span class="hlFld-ContribAuthor ">Timaf  Ishak</span>, <span class="hlFld-ContribAuthor ">Yuki  Baba</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">α-Hydroxy boron-enabled regioselective access to bifunctional halo-boryl alicyclic ethers and α-halo borons. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (37)
                                     , 4564-4567. <a href="https://doi.org/10.1039/D1CC00336D" title="DOI URL">https://doi.org/10.1039/D1CC00336D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC00336D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC00336D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3D%2525CE%2525B1-Hydroxy%252Bboron-enabled%252Bregioselective%252Baccess%252Bto%252Bbifunctional%252Bhalo-boryl%252Balicyclic%252Bethers%252Band%252B%2525CE%2525B1-halo%252Bborons%26aulast%3DWang%26aufirst%3DLucia%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D37%26spage%3D4564%26epage%3D4567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sagar S.  Thorat</span>, <span class="hlFld-ContribAuthor ">Ravindar  Kontham</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the synthesis of furo-pyranones and their application in the total synthesis of related natural products. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (9)
                                     , 2110-2162. <a href="https://doi.org/10.1039/D0QO01421D" title="DOI URL">https://doi.org/10.1039/D0QO01421D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01421D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01421D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DStrategies%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bfuro-pyranones%252Band%252Btheir%252Bapplication%252Bin%252Bthe%252Btotal%252Bsynthesis%252Bof%252Brelated%252Bnatural%252Bproducts%26aulast%3DThorat%26aufirst%3DSagar%2BS.%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D9%26spage%3D2110%26epage%3D2162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jagram  Anterbedy</span>, <span class="hlFld-ContribAuthor ">Sudhakar  Mokenapelli</span>, <span class="hlFld-ContribAuthor ">Gangadhar  Thalari</span>. </span><span class="cited-content_cbyCitation_article-title">Facial synthesis of novel 3-(2-methylbenzofuran-3-yl)-5-((4-(phenoxymethyl)-1H-1,2,3-triazole-1-yl)methyl)-1,2,4-oxadiazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2021,</strong> <em>51 </em>
                                    (9)
                                     , 1417-1424. <a href="https://doi.org/10.1080/00397911.2021.1884881" title="DOI URL">https://doi.org/10.1080/00397911.2021.1884881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2021.1884881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2021.1884881%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DFacial%252Bsynthesis%252Bof%252Bnovel%252B3-%2525282-methylbenzofuran-3-yl%252529-5-%252528%2525284-%252528phenoxymethyl%252529-1H-1%25252C2%25252C3-triazole-1-yl%252529methyl%252529-1%25252C2%25252C4-oxadiazole%252Bderivatives%26aulast%3DAnterbedy%26aufirst%3DJagram%26date%3D2021%26date%3D2021%26volume%3D51%26issue%3D9%26spage%3D1417%26epage%3D1424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shan‐Shan  Zhu</span>, <span class="hlFld-ContribAuthor ">Heng  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Fu</span>, <span class="hlFld-ContribAuthor ">Wen‐Juan  Hao</span>, <span class="hlFld-ContribAuthor ">Shu‐Liang  Wang</span>, <span class="hlFld-ContribAuthor ">Shu‐Jiang  Tu</span>, <span class="hlFld-ContribAuthor ">Bo  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Regio‐ and Stereoselective Synthesis of Rotationally Hindered C
              12
              ‐Naphthylated Tribenzo[
              a,c,j
              ]xanthenes through Catalytic Tricyclization of Yne‐Allenones. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (8)
                                     , 2199-2204. <a href="https://doi.org/10.1002/adsc.202100061" title="DOI URL">https://doi.org/10.1002/adsc.202100061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100061%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DRegio%2525E2%252580%252590%252Band%252BStereoselective%252BSynthesis%252Bof%252BRotationally%252BHindered%252BC%252B12%252B%2525E2%252580%252590Naphthylated%252BTribenzo%25255B%252Ba%25252Cc%25252Cj%252B%25255Dxanthenes%252Bthrough%252BCatalytic%252BTricyclization%252Bof%252BYne%2525E2%252580%252590Allenones%26aulast%3DZhu%26aufirst%3DShan%25E2%2580%2590Shan%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D8%26spage%3D2199%26epage%3D2204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roman  Abrams</span>, <span class="hlFld-ContribAuthor ">Mehul H.  Jesani</span>, <span class="hlFld-ContribAuthor ">Alex  Browning</span>, <span class="hlFld-ContribAuthor ">Jonathan  Clayden</span>. </span><span class="cited-content_cbyCitation_article-title">Triarylmethanes and their Medium‐Ring Analogues by Unactivated Truce–Smiles Rearrangement of Benzanilides. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/ange.202102192" title="DOI URL">https://doi.org/10.1002/ange.202102192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202102192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202102192%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DTriarylmethanes%252Band%252Btheir%252BMedium%2525E2%252580%252590Ring%252BAnalogues%252Bby%252BUnactivated%252BTruce%2525E2%252580%252593Smiles%252BRearrangement%252Bof%252BBenzanilides%26aulast%3DAbrams%26aufirst%3DRoman%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roman  Abrams</span>, <span class="hlFld-ContribAuthor ">Mehul H.  Jesani</span>, <span class="hlFld-ContribAuthor ">Alex  Browning</span>, <span class="hlFld-ContribAuthor ">Jonathan  Clayden</span>. </span><span class="cited-content_cbyCitation_article-title">Triarylmethanes and their Medium‐Ring Analogues by Unactivated Truce–Smiles Rearrangement of Benzanilides. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/anie.202102192" title="DOI URL">https://doi.org/10.1002/anie.202102192</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202102192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202102192%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DTriarylmethanes%252Band%252Btheir%252BMedium%2525E2%252580%252590Ring%252BAnalogues%252Bby%252BUnactivated%252BTruce%2525E2%252580%252593Smiles%252BRearrangement%252Bof%252BBenzanilides%26aulast%3DAbrams%26aufirst%3DRoman%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yulei  Wang</span>, <span class="hlFld-ContribAuthor ">João C. A.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Lin</span>, <span class="hlFld-ContribAuthor ">Lutz  Ackermann</span>. </span><span class="cited-content_cbyCitation_article-title">Elektrooxidative Rhodium‐katalysierte [5+2]‐Anellierung durch C‐H/O‐H‐Aktivierung. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (12)
                                     , 6490-6495. <a href="https://doi.org/10.1002/ange.202016895" title="DOI URL">https://doi.org/10.1002/ange.202016895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202016895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202016895%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DElektrooxidative%252BRhodium%2525E2%252580%252590katalysierte%252B%25255B5%25252B2%25255D%2525E2%252580%252590Anellierung%252Bdurch%252BC%2525E2%252580%252590H%25252FO%2525E2%252580%252590H%2525E2%252580%252590Aktivierung%26aulast%3DWang%26aufirst%3DYulei%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D12%26spage%3D6490%26epage%3D6495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yulei  Wang</span>, <span class="hlFld-ContribAuthor ">João C. A.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Lin</span>, <span class="hlFld-ContribAuthor ">Lutz  Ackermann</span>. </span><span class="cited-content_cbyCitation_article-title">Electrooxidative Rhodium‐Catalyzed [5+2] Annulations via C−H/O−H Activations. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (12)
                                     , 6419-6424. <a href="https://doi.org/10.1002/anie.202016895" title="DOI URL">https://doi.org/10.1002/anie.202016895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202016895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202016895%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DElectrooxidative%252BRhodium%2525E2%252580%252590Catalyzed%252B%25255B5%25252B2%25255D%252BAnnulations%252Bvia%252BC%2525E2%252588%252592H%25252FO%2525E2%252588%252592H%252BActivations%26aulast%3DWang%26aufirst%3DYulei%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D12%26spage%3D6419%26epage%3D6424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farrukh  Sajjad</span>, <span class="hlFld-ContribAuthor ">Yanmei  Chen</span>, <span class="hlFld-ContribAuthor ">Xue  Tian</span>, <span class="hlFld-ContribAuthor ">Suzhen  Dong</span>, <span class="hlFld-ContribAuthor ">Alavala  Gopi Krishna Reddy</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Dong  Xing</span>. </span><span class="cited-content_cbyCitation_article-title">Facile synthesis of 1,4-oxazines by ruthenium-catalyzed tandem N–H insertion/cyclization of α-arylamino ketones and diazo pyruvates. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (8)
                                     , 1769-1772. <a href="https://doi.org/10.1039/D0OB01913E" title="DOI URL">https://doi.org/10.1039/D0OB01913E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB01913E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB01913E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DFacile%252Bsynthesis%252Bof%252B1%25252C4-oxazines%252Bby%252Bruthenium-catalyzed%252Btandem%252BN%2525E2%252580%252593H%252Binsertion%25252Fcyclization%252Bof%252B%2525CE%2525B1-arylamino%252Bketones%252Band%252Bdiazo%252Bpyruvates%26aulast%3DSajjad%26aufirst%3DFarrukh%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D8%26spage%3D1769%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laxmidhar  Rout</span>, <span class="hlFld-ContribAuthor ">Tharmalingam  Punniyamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in transition-metal-mediated Csp2-B and Csp2-P cross-coupling reactions. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>431 </em>, 213675. <a href="https://doi.org/10.1016/j.ccr.2020.213675" title="DOI URL">https://doi.org/10.1016/j.ccr.2020.213675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2020.213675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2020.213675%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Btransition-metal-mediated%252BCsp2-B%252Band%252BCsp2-P%252Bcross-coupling%252Breactions%26aulast%3DRout%26aufirst%3DLaxmidhar%26date%3D2021%26volume%3D431%26spage%3D213675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makenzie J.  Millward</span>, <span class="hlFld-ContribAuthor ">Emily  Ellis</span>, <span class="hlFld-ContribAuthor ">John W.  Ward</span>, <span class="hlFld-ContribAuthor ">Jonathan  Clayden</span>. </span><span class="cited-content_cbyCitation_article-title">Hydantoin-bridged medium ring scaffolds by migratory insertion of urea-tethered nitrile anions into aromatic C–N bonds. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     , 2091-2096. <a href="https://doi.org/10.1039/D0SC06188C" title="DOI URL">https://doi.org/10.1039/D0SC06188C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC06188C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC06188C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DHydantoin-bridged%252Bmedium%252Bring%252Bscaffolds%252Bby%252Bmigratory%252Binsertion%252Bof%252Burea-tethered%252Bnitrile%252Banions%252Binto%252Baromatic%252BC%2525E2%252580%252593N%252Bbonds%26aulast%3DMillward%26aufirst%3DMakenzie%2BJ.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6%26spage%3D2091%26epage%3D2096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weida  Liang</span>, <span class="hlFld-ContribAuthor ">Xinpei  Cai</span>, <span class="hlFld-ContribAuthor ">Mingji  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-catalyzed hydroxycyclopropanol ring-opening cyclization to tetrahydrofurans and tetrahydropyrans: short total syntheses of hyperiones. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 1311-1316. <a href="https://doi.org/10.1039/D0SC05556E" title="DOI URL">https://doi.org/10.1039/D0SC05556E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC05556E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC05556E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DCu-catalyzed%252Bhydroxycyclopropanol%252Bring-opening%252Bcyclization%252Bto%252Btetrahydrofurans%252Band%252Btetrahydropyrans%25253A%252Bshort%252Btotal%252Bsyntheses%252Bof%252Bhyperiones%26aulast%3DLiang%26aufirst%3DWeida%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D1311%26epage%3D1316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hossam  Nada</span>, <span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Activity Relationship of Key Heterocyclic Anti-Angiogenic Leads of Promising Potential in the Fight against Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 553. <a href="https://doi.org/10.3390/molecules26030553" title="DOI URL">https://doi.org/10.3390/molecules26030553</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030553%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStructure%252BActivity%252BRelationship%252Bof%252BKey%252BHeterocyclic%252BAnti-Angiogenic%252BLeads%252Bof%252BPromising%252BPotential%252Bin%252Bthe%252BFight%252Bagainst%252BCancer%26aulast%3DNada%26aufirst%3DHossam%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victoria  Dimakos</span>, <span class="hlFld-ContribAuthor ">Mark S.  Taylor</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the direct
              O
              -arylation of carbohydrates. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (3)
                                     , 514-524. <a href="https://doi.org/10.1039/D0OB02009E" title="DOI URL">https://doi.org/10.1039/D0OB02009E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02009E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02009E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdirect%252BO%252B-arylation%252Bof%252Bcarbohydrates%26aulast%3DDimakos%26aufirst%3DVictoria%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D3%26spage%3D514%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan  Yuan</span>, <span class="hlFld-ContribAuthor ">Dong‐Mei  Yan</span>, <span class="hlFld-ContribAuthor ">Pan‐Pan  Gao</span>, <span class="hlFld-ContribAuthor ">De‐Qing  Shi</span>, <span class="hlFld-ContribAuthor ">Wen‐Jing  Xiao</span>, <span class="hlFld-ContribAuthor ">Jia‐Rong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Photoredox‐Catalyzed Multicomponent Cyclization of 2‐Vinyl Phenols,
              N
              ‐Alkoxypyridinium Salts, and Sulfur Ylides for Synthesis of Dihydrobenzofurans. </span><span class="cited-content_cbyCitation_journal-name">ChemCatChem</span><span> <strong>2021,</strong> <em>13 </em>
                                    (2)
                                     , 543-547. <a href="https://doi.org/10.1002/cctc.202001589" title="DOI URL">https://doi.org/10.1002/cctc.202001589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cctc.202001589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcctc.202001589%26sid%3Dliteratum%253Aachs%26jtitle%3DChemCatChem%26atitle%3DPhotoredox%2525E2%252580%252590Catalyzed%252BMulticomponent%252BCyclization%252Bof%252B2%2525E2%252580%252590Vinyl%252BPhenols%25252C%252BN%252B%2525E2%252580%252590Alkoxypyridinium%252BSalts%25252C%252Band%252BSulfur%252BYlides%252Bfor%252BSynthesis%252Bof%252BDihydrobenzofurans%26aulast%3DYuan%26aufirst%3DFan%26date%3D2021%26date%3D2020%26volume%3D13%26issue%3D2%26spage%3D543%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean R.  Barlow</span>, <span class="hlFld-ContribAuthor ">Lily J.  Callaghan</span>, <span class="hlFld-ContribAuthor ">Vilius  Franckevičius</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of the palladium-catalysed cyclisation of α-amido malonates with propargylic compounds. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>80 </em>, 131866. <a href="https://doi.org/10.1016/j.tet.2020.131866" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131866%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DInvestigation%252Bof%252Bthe%252Bpalladium-catalysed%252Bcyclisation%252Bof%252B%2525CE%2525B1-amido%252Bmalonates%252Bwith%252Bpropargylic%252Bcompounds%26aulast%3DBarlow%26aufirst%3DSean%2BR.%26date%3D2021%26volume%3D80%26spage%3D131866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanumay  Sarkar</span>, <span class="hlFld-ContribAuthor ">Kangkan  Talukdar</span>, <span class="hlFld-ContribAuthor ">Bijay Ketan  Das</span>, <span class="hlFld-ContribAuthor ">Tariq A.  Shah</span>, <span class="hlFld-ContribAuthor ">Bijoy  Debnath</span>, <span class="hlFld-ContribAuthor ">Tharmalingam  Punniyamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">The transition-metal-catalyzed stereoselective ring-expansion of vinylaziridines and vinyloxiranes. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>14 </em><a href="https://doi.org/10.1039/D1OB00259G" title="DOI URL">https://doi.org/10.1039/D1OB00259G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00259G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00259G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DThe%252Btransition-metal-catalyzed%252Bstereoselective%252Bring-expansion%252Bof%252Bvinylaziridines%252Band%252Bvinyloxiranes%26aulast%3DSarkar%26aufirst%3DTanumay%26date%3D2021%26date%3D2021%26volume%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David P.  Rotella</span>. </span><span class="cited-content_cbyCitation_article-title">Heterocycles in drug discovery: Properties and preparation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 149-183. <a href="https://doi.org/10.1016/bs.aihch.2020.10.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.10.002%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocycles%252Bin%252Bdrug%252Bdiscovery%25253A%252BProperties%252Band%252Bpreparation%26aulast%3DRotella%26aufirst%3DDavid%2BP.%26date%3D2021%26spage%3D149%26epage%3D183%26pub%3DElsevier%26atitle%3DApplications%252Bof%252BHeterocycles%252Bin%252Bthe%252BDesign%252Bof%252BDrugs%252Band%252BAgricultural%252BProducts%26date%3D2021%26volume%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ben  Niu</span>, <span class="hlFld-ContribAuthor ">Yin  Wei</span>, <span class="hlFld-ContribAuthor ">Min  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in annulation reactions based on zwitterionic π-allyl palladium and propargyl palladium complexes. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>4 </em><a href="https://doi.org/10.1039/D1QO00273B" title="DOI URL">https://doi.org/10.1039/D1QO00273B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00273B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00273B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRecent%252Badvances%252Bin%252Bannulation%252Breactions%252Bbased%252Bon%252Bzwitterionic%252B%2525CF%252580-allyl%252Bpalladium%252Band%252Bpropargyl%252Bpalladium%252Bcomplexes%26aulast%3DNiu%26aufirst%3DBen%26date%3D2021%26date%3D2021%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Shan  Kong</span>, <span class="hlFld-ContribAuthor ">Xing-Long  Li</span>, <span class="hlFld-ContribAuthor ">Hua-Jian  Xu</span>, <span class="hlFld-ContribAuthor ">Yao  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Conversion of 5-hydroxymethylfurfural to chemicals: A review of catalytic routes and product applications. </span><span class="cited-content_cbyCitation_journal-name">Fuel Processing Technology</span><span> <strong>2020,</strong> <em>209 </em>, 106528. <a href="https://doi.org/10.1016/j.fuproc.2020.106528" title="DOI URL">https://doi.org/10.1016/j.fuproc.2020.106528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fuproc.2020.106528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fuproc.2020.106528%26sid%3Dliteratum%253Aachs%26jtitle%3DFuel%2520Processing%2520Technology%26atitle%3DConversion%252Bof%252B5-hydroxymethylfurfural%252Bto%252Bchemicals%25253A%252BA%252Breview%252Bof%252Bcatalytic%252Broutes%252Band%252Bproduct%252Bapplications%26aulast%3DKong%26aufirst%3DQing-Shan%26date%3D2020%26volume%3D209%26spage%3D106528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengchu  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Trapping of Transient Carboxylic Oxonium Ylides with α,β‐Unsaturated 2‐Acyl Imidazoles. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (21)
                                     , 4662-4667. <a href="https://doi.org/10.1002/adsc.202000701" title="DOI URL">https://doi.org/10.1002/adsc.202000701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000701%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DDiastereoselective%252BTrapping%252Bof%252BTransient%252BCarboxylic%252BOxonium%252BYlides%252Bwith%252B%2525CE%2525B1%25252C%2525CE%2525B2%2525E2%252580%252590Unsaturated%252B2%2525E2%252580%252590Acyl%252BImidazoles%26aulast%3DZhang%26aufirst%3DMengchu%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D21%26spage%3D4662%26epage%3D4667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sofia  Oliveira-Pinto</span>, <span class="hlFld-ContribAuthor ">Olívia  Pontes</span>, <span class="hlFld-ContribAuthor ">Fátima  Baltazar</span>, <span class="hlFld-ContribAuthor ">Marta  Costa</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo efficacy studies of chromene-based compounds in triple-negative breast cancer – A systematic review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2020,</strong> <em>887 </em>, 173452. <a href="https://doi.org/10.1016/j.ejphar.2020.173452" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173452%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DIn%252Bvivo%252Befficacy%252Bstudies%252Bof%252Bchromene-based%252Bcompounds%252Bin%252Btriple-negative%252Bbreast%252Bcancer%252B%2525E2%252580%252593%252BA%252Bsystematic%252Breview%26aulast%3DOliveira-Pinto%26aufirst%3DSofia%26date%3D2020%26volume%3D887%26spage%3D173452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Zhong</span>, <span class="hlFld-ContribAuthor ">Qi  Yin</span>, <span class="hlFld-ContribAuthor ">Yukun  Zhao</span>, <span class="hlFld-ContribAuthor ">Qinfeng  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Formal [5+1] annulation reactions of dielectrophilic peroxides: facile access to functionalized dihydropyrans. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (86)
                                     , 13189-13192. <a href="https://doi.org/10.1039/D0CC05565D" title="DOI URL">https://doi.org/10.1039/D0CC05565D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC05565D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC05565D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DFormal%252B%25255B5%25252B1%25255D%252Bannulation%252Breactions%252Bof%252Bdielectrophilic%252Bperoxides%25253A%252Bfacile%252Baccess%252Bto%252Bfunctionalized%252Bdihydropyrans%26aulast%3DZhong%26aufirst%3DChen%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D86%26spage%3D13189%26epage%3D13192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonio  Del Vecchio</span>, <span class="hlFld-ContribAuthor ">Alex  Talbot</span>, <span class="hlFld-ContribAuthor ">Fabien  Caillé</span>, <span class="hlFld-ContribAuthor ">Arnaud  Chevalier</span>, <span class="hlFld-ContribAuthor ">Antoine  Sallustrau</span>, <span class="hlFld-ContribAuthor ">Olivier  Loreau</span>, <span class="hlFld-ContribAuthor ">Gianluca  Destro</span>, <span class="hlFld-ContribAuthor ">Frédéric  Taran</span>, <span class="hlFld-ContribAuthor ">Davide  Audisio</span>. </span><span class="cited-content_cbyCitation_article-title">Carbon isotope labeling of carbamates by late-stage [
              11
              C], [
              13
              C] and [
              14
              C]carbon dioxide incorporation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (78)
                                     , 11677-11680. <a href="https://doi.org/10.1039/D0CC05031H" title="DOI URL">https://doi.org/10.1039/D0CC05031H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC05031H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC05031H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCarbon%252Bisotope%252Blabeling%252Bof%252Bcarbamates%252Bby%252Blate-stage%252B%25255B%252B11%252BC%25255D%25252C%252B%25255B%252B13%252BC%25255D%252Band%252B%25255B%252B14%252BC%25255Dcarbon%252Bdioxide%252Bincorporation%26aulast%3DDel%2BVecchio%26aufirst%3DAntonio%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D78%26spage%3D11677%26epage%3D11680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fotini  Moschona</span>, <span class="hlFld-ContribAuthor ">Ioanna  Savvopoulou</span>, <span class="hlFld-ContribAuthor ">Maria  Tsitopoulou</span>, <span class="hlFld-ContribAuthor ">Despoina  Tataraki</span>, <span class="hlFld-ContribAuthor ">Gerasimos  Rassias</span>. </span><span class="cited-content_cbyCitation_article-title">Epoxide Syntheses and Ring-Opening Reactions in Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2020,</strong> <em>10 </em>
                                    (10)
                                     , 1117. <a href="https://doi.org/10.3390/catal10101117" title="DOI URL">https://doi.org/10.3390/catal10101117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal10101117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal10101117%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DEpoxide%252BSyntheses%252Band%252BRing-Opening%252BReactions%252Bin%252BDrug%252BDevelopment%26aulast%3DMoschona%26aufirst%3DFotini%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D10%26spage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tejas M.  Dhameliya</span>, <span class="hlFld-ContribAuthor ">Hiren A.  Donga</span>, <span class="hlFld-ContribAuthor ">Punit V.  Vaghela</span>, <span class="hlFld-ContribAuthor ">Bhoomi G.  Panchal</span>, <span class="hlFld-ContribAuthor ">Dipen K.  Sureja</span>, <span class="hlFld-ContribAuthor ">Kunjan B.  Bodiwala</span>, <span class="hlFld-ContribAuthor ">Mahesh T.  Chhabria</span>. </span><span class="cited-content_cbyCitation_article-title">A decennary update on applications of metal nanoparticles (MNPs) in the synthesis of nitrogen- and oxygen-containing heterocyclic scaffolds. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (54)
                                     , 32740-32820. <a href="https://doi.org/10.1039/D0RA02272A" title="DOI URL">https://doi.org/10.1039/D0RA02272A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA02272A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA02272A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DA%252Bdecennary%252Bupdate%252Bon%252Bapplications%252Bof%252Bmetal%252Bnanoparticles%252B%252528MNPs%252529%252Bin%252Bthe%252Bsynthesis%252Bof%252Bnitrogen-%252Band%252Boxygen-containing%252Bheterocyclic%252Bscaffolds%26aulast%3DDhameliya%26aufirst%3DTejas%2BM.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D54%26spage%3D32740%26epage%3D32820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudhakar Mokenapelli</span>, <span class="hlFld-ContribAuthor ">Madhu  Gutam</span>, <span class="hlFld-ContribAuthor ">Jayaprakash Rao  Yerrabelli</span>, <span class="hlFld-ContribAuthor ">Vamshi Krishna  Irlapati</span>, <span class="hlFld-ContribAuthor ">Neelima  Gorityala</span>, <span class="hlFld-ContribAuthor ">Someswar Rao  Sagurthi</span>, <span class="hlFld-ContribAuthor ">Prasad Rao  Chitneni</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel 2-Substituted-Benzyl-5-(2-Methylbenzofuran-3-yl)-2H-Tetrazoles: Anti-Proliferative Activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>46 </em>
                                    (5)
                                     , 845-855. <a href="https://doi.org/10.1134/S1068162020050179" title="DOI URL">https://doi.org/10.1134/S1068162020050179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162020050179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162020050179%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252B2-Substituted-Benzyl-5-%2525282-Methylbenzofuran-3-yl%252529-2H-Tetrazoles%25253A%252BAnti-Proliferative%252BActivity%26aulast%3DSudhakar%2BMokenapelli%26date%3D2020%26date%3D2020%26volume%3D46%26issue%3D5%26spage%3D845%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Fang  Yang</span>, <span class="hlFld-ContribAuthor ">Weiwei  Hu</span>, <span class="hlFld-ContribAuthor ">Bo  Ren</span>, <span class="hlFld-ContribAuthor ">Zi-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kegong  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">Gold(
              i
              )-catalyzed tandem cyclization of cyclopropylidene-tethered propargylic alcohols: an approach to functionalized naphtho[2,3-
              c
              ]pyrans. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (64)
                                     , 9154-9157. <a href="https://doi.org/10.1039/D0CC03285A" title="DOI URL">https://doi.org/10.1039/D0CC03285A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC03285A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC03285A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DGold%252528%252Bi%252B%252529-catalyzed%252Btandem%252Bcyclization%252Bof%252Bcyclopropylidene-tethered%252Bpropargylic%252Balcohols%25253A%252Ban%252Bapproach%252Bto%252Bfunctionalized%252Bnaphtho%25255B2%25252C3-%252Bc%252B%25255Dpyrans%26aulast%3DLi%26aufirst%3DJian%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D64%26spage%3D9154%26epage%3D9157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengfen  Liu</span>, <span class="hlFld-ContribAuthor ">Minyan  Li</span>, <span class="hlFld-ContribAuthor ">Guogang  Deng</span>, <span class="hlFld-ContribAuthor ">Wanshi  Wei</span>, <span class="hlFld-ContribAuthor ">Ping  Feng</span>, <span class="hlFld-ContribAuthor ">Quanxing  Zi</span>, <span class="hlFld-ContribAuthor ">Tiantian  Li</span>, <span class="hlFld-ContribAuthor ">Hongbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Yang</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Walsh</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-metal-free C(sp
              3
              )–H/C(sp
              3
              )–H dehydrogenative coupling of saturated heterocycles with
              N
              -benzyl imines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (29)
                                     , 7619-7625. <a href="https://doi.org/10.1039/D0SC00031K" title="DOI URL">https://doi.org/10.1039/D0SC00031K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC00031K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC00031K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DTransition-metal-free%252BC%252528sp%252B3%252B%252529%2525E2%252580%252593H%25252FC%252528sp%252B3%252B%252529%2525E2%252580%252593H%252Bdehydrogenative%252Bcoupling%252Bof%252Bsaturated%252Bheterocycles%252Bwith%252BN%252B-benzyl%252Bimines%26aulast%3DLiu%26aufirst%3DZhengfen%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D29%26spage%3D7619%26epage%3D7625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudhakar  Mokenapelli</span>, <span class="hlFld-ContribAuthor ">Gangadhar  Thalari</span>, <span class="hlFld-ContribAuthor ">Naveen  Vadiyaala</span>, <span class="hlFld-ContribAuthor ">Jayaprakash R.  Yerrabelli</span>, <span class="hlFld-ContribAuthor ">Vamshi K.  Irlapati</span>, <span class="hlFld-ContribAuthor ">Neelima  Gorityala</span>, <span class="hlFld-ContribAuthor ">Someswar R.  Sagurthi</span>, <span class="hlFld-ContribAuthor ">Prasad R.  Chitneni</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, cytotoxicity, and molecular docking of substituted 3‐(2‐methylbenzofuran‐3‐yl)‐5‐(phenoxymethyl)‐1,2,4‐oxadiazoles. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (6)
                                     , 2000006. <a href="https://doi.org/10.1002/ardp.202000006" title="DOI URL">https://doi.org/10.1002/ardp.202000006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000006%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%25252C%252Bcytotoxicity%25252C%252Band%252Bmolecular%252Bdocking%252Bof%252Bsubstituted%252B3%2525E2%252580%252590%2525282%2525E2%252580%252590methylbenzofuran%2525E2%252580%2525903%2525E2%252580%252590yl%252529%2525E2%252580%2525905%2525E2%252580%252590%252528phenoxymethyl%252529%2525E2%252580%2525901%25252C2%25252C4%2525E2%252580%252590oxadiazoles%26aulast%3DMokenapelli%26aufirst%3DSudhakar%26date%3D2020%26date%3D2020%26volume%3D353%26issue%3D6%26spage%3D2000006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takoua  Ben Issa</span>, <span class="hlFld-ContribAuthor ">Abir  Sagaama</span>, <span class="hlFld-ContribAuthor ">Noureddine  Issaoui</span>. </span><span class="cited-content_cbyCitation_article-title">Computational study of 3-thiophene acetic acid: Molecular docking, electronic and intermolecular interactions investigations. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2020,</strong> <em>86 </em>, 107268. <a href="https://doi.org/10.1016/j.compbiolchem.2020.107268" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2020.107268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2020.107268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2020.107268%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DComputational%252Bstudy%252Bof%252B3-thiophene%252Bacetic%252Bacid%25253A%252BMolecular%252Bdocking%25252C%252Belectronic%252Band%252Bintermolecular%252Binteractions%252Binvestigations%26aulast%3DBen%2BIssa%26aufirst%3DTakoua%26date%3D2020%26volume%3D86%26spage%3D107268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna V.  Listratova</span>, <span class="hlFld-ContribAuthor ">Najoua  Sbei</span>, <span class="hlFld-ContribAuthor ">Leonid G.  Voskressensky</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Electrosynthesis of
              N
              ,
              O
              -Heterocycles - Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (14)
                                     , 2012-2027. <a href="https://doi.org/10.1002/ejoc.201901635" title="DOI URL">https://doi.org/10.1002/ejoc.201901635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901635%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCatalytic%252BElectrosynthesis%252Bof%252BN%252B%25252C%252BO%252B-Heterocycles%252B-%252BRecent%252BAdvances%26aulast%3DListratova%26aufirst%3DAnna%2BV.%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D14%26spage%3D2012%26epage%3D2027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Jun-Long  Li</span>, <span class="hlFld-ContribAuthor ">Qi-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Wen-Lin  Zou</span>, <span class="hlFld-ContribAuthor ">Yan-Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Qiang  Jia</span>, <span class="hlFld-ContribAuthor ">Fu  Peng</span>, <span class="hlFld-ContribAuthor ">Bo  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Regiodivergent construction of medium-sized heterocycles from vinylethylene carbonates and allylidenemalononitriles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2888-2894. <a href="https://doi.org/10.1039/C9SC06377C" title="DOI URL">https://doi.org/10.1039/C9SC06377C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC06377C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC06377C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DRegiodivergent%252Bconstruction%252Bof%252Bmedium-sized%252Bheterocycles%252Bfrom%252Bvinylethylene%252Bcarbonates%252Band%252Ballylidenemalononitriles%26aulast%3DZhang%26aufirst%3DXiang%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D11%26spage%3D2888%26epage%3D2894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sudhakar  Mokenapelli</span>, <span class="hlFld-ContribAuthor ">Jayaprakash Rao  Yerrabelli</span>, <span class="hlFld-ContribAuthor ">Neeladrisingha  Das</span>, <span class="hlFld-ContribAuthor ">Partha  Roy</span>, <span class="hlFld-ContribAuthor ">Prasad Rao  Chitneni</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and cytotoxicity of novel 14α-
              O
              -(andrographolide-3-subsitutedisoxazole-5-carboxylate) derivatives. </span><span class="cited-content_cbyCitation_journal-name">Natural Product Research</span><span> <strong>2020,</strong> <em>155 </em>, 1-7. <a href="https://doi.org/10.1080/14786419.2020.1736060" title="DOI URL">https://doi.org/10.1080/14786419.2020.1736060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14786419.2020.1736060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14786419.2020.1736060%26sid%3Dliteratum%253Aachs%26jtitle%3DNatural%2520Product%2520Research%26atitle%3DSynthesis%252Band%252Bcytotoxicity%252Bof%252Bnovel%252B14%2525CE%2525B1-%252BO%252B-%252528andrographolide-3-subsitutedisoxazole-5-carboxylate%252529%252Bderivatives%26aulast%3DMokenapelli%26aufirst%3DSudhakar%26date%3D2020%26date%3D2020%26volume%3D155%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew D.  Chen</span>, <span class="hlFld-ContribAuthor ">James H.  Herbort</span>, <span class="hlFld-ContribAuthor ">Ethan A.  Wappes</span>, <span class="hlFld-ContribAuthor ">Kohki M.  Nakafuku</span>, <span class="hlFld-ContribAuthor ">Darsheed N.  Mustafa</span>, <span class="hlFld-ContribAuthor ">David A.  Nagib</span>. </span><span class="cited-content_cbyCitation_article-title">Radical cascade synthesis of azoles
              via
              tandem hydrogen atom transfer. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 2479-2486. <a href="https://doi.org/10.1039/C9SC06239D" title="DOI URL">https://doi.org/10.1039/C9SC06239D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC06239D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC06239D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DRadical%252Bcascade%252Bsynthesis%252Bof%252Bazoles%252Bvia%252Btandem%252Bhydrogen%252Batom%252Btransfer%26aulast%3DChen%26aufirst%3DAndrew%2BD.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D9%26spage%3D2479%26epage%3D2486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Fu</span>, <span class="hlFld-ContribAuthor ">Lianhui  Wang</span>, <span class="hlFld-ContribAuthor ">Zi  Yang</span>, <span class="hlFld-ContribAuthor ">Jiang-Shan  Shen</span>, <span class="hlFld-ContribAuthor ">Fei  Tang</span>, <span class="hlFld-ContribAuthor ">Jiayi  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiuling  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Facile access to versatile aza-macrolides through iridium-catalysed cascade allyl-amination/macrolactonization. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (6)
                                     , 960-963. <a href="https://doi.org/10.1039/C9CC07372H" title="DOI URL">https://doi.org/10.1039/C9CC07372H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC07372H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC07372H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DFacile%252Baccess%252Bto%252Bversatile%252Baza-macrolides%252Bthrough%252Biridium-catalysed%252Bcascade%252Ballyl-amination%25252Fmacrolactonization%26aulast%3DFu%26aufirst%3DWei%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D6%26spage%3D960%26epage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vitalii A.  Palchykov</span>, <span class="hlFld-ContribAuthor ">Alexandr A.  Gaponov</span>. </span><span class="cited-content_cbyCitation_article-title">1,3-Amino alcohols and their phenol analogs in heterocyclization reactions. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 285-350. <a href="https://doi.org/10.1016/bs.aihch.2019.06.001" title="DOI URL">https://doi.org/10.1016/bs.aihch.2019.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2019.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2019.06.001%26sid%3Dliteratum%253Aachs%26atitle%3D1%25252C3-Amino%252Balcohols%252Band%252Btheir%252Bphenol%252Banalogs%252Bin%252Bheterocyclization%252Breactions%26aulast%3DPalchykov%26aufirst%3DVitalii%2BA.%26date%3D2020%26spage%3D285%26epage%3D350%26pub%3DElsevier%26date%3D2020%26volume%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Run  Wang</span>, <span class="hlFld-ContribAuthor ">Xiong  Xie</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(III)-Catalyzed C–H Bond Activation for the Construction of Heterocycles with sp3-Carbon Centers. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 823. <a href="https://doi.org/10.3390/catal9100823" title="DOI URL">https://doi.org/10.3390/catal9100823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal9100823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal9100823%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DRh%252528III%252529-Catalyzed%252BC%2525E2%252580%252593H%252BBond%252BActivation%252Bfor%252Bthe%252BConstruction%252Bof%252BHeterocycles%252Bwith%252Bsp3-Carbon%252BCenters%26aulast%3DWang%26aufirst%3DRun%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosemary A.  Croft</span>, <span class="hlFld-ContribAuthor ">Maryne A. J.  Dubois</span>, <span class="hlFld-ContribAuthor ">Alexander J.  Boddy</span>, <span class="hlFld-ContribAuthor ">Camille  Denis</span>, <span class="hlFld-ContribAuthor ">Anna  Lazaridou</span>, <span class="hlFld-ContribAuthor ">Anne Sophie  Voisin-Chiret</span>, <span class="hlFld-ContribAuthor ">Ronan  Bureau</span>, <span class="hlFld-ContribAuthor ">Chulho  Choi</span>, <span class="hlFld-ContribAuthor ">James J.  Mousseau</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Catalytic Friedel-Crafts Reactions on Saturated Heterocycles and Small Rings for sp
              3
              -sp
              2
              Coupling of Medicinally Relevant Fragments. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (31-32)
                                     , 5385-5395. <a href="https://doi.org/10.1002/ejoc.201900498" title="DOI URL">https://doi.org/10.1002/ejoc.201900498</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900498%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCatalytic%252BFriedel-Crafts%252BReactions%252Bon%252BSaturated%252BHeterocycles%252Band%252BSmall%252BRings%252Bfor%252Bsp%252B3%252B-sp%252B2%252BCoupling%252Bof%252BMedicinally%252BRelevant%252BFragments%26aulast%3DCroft%26aufirst%3DRosemary%2BA.%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D31-32%26spage%3D5385%26epage%3D5395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christiane  Schultze</span>, <span class="hlFld-ContribAuthor ">Bernd  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalized Benzofurans via Microwave‐Promoted Tandem Claisen‐Rearrangement/5‐
              
                endo
              
              ‐dig Cyclization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2019,</strong> <em>56 </em>
                                    (9)
                                     , 2619-2629. <a href="https://doi.org/10.1002/jhet.3671" title="DOI URL">https://doi.org/10.1002/jhet.3671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3671%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DFunctionalized%252BBenzofurans%252Bvia%252BMicrowave%2525E2%252580%252590Promoted%252BTandem%252BClaisen%2525E2%252580%252590Rearrangement%25252F5%2525E2%252580%252590%252Bendo%252B%2525E2%252580%252590dig%252BCyclization%26aulast%3DSchultze%26aufirst%3DChristiane%26date%3D2019%26date%3D2019%26volume%3D56%26issue%3D9%26spage%3D2619%26epage%3D2629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Qing  Wu</span>, <span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Mani  Arulkumar</span>, <span class="hlFld-ContribAuthor ">Neng  Wang</span>, <span class="hlFld-ContribAuthor ">Si-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A 3,4-dihalo-2(5
              H
              )-furanone initiated ring-opening reaction of DABCO in the absence of a metal catalyst and additive and its application in a one-pot two-step reaction. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 3782-3788. <a href="https://doi.org/10.1039/C9GC01740B" title="DOI URL">https://doi.org/10.1039/C9GC01740B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC01740B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC01740B%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DA%252B3%25252C4-dihalo-2%2525285%252BH%252B%252529-furanone%252Binitiated%252Bring-opening%252Breaction%252Bof%252BDABCO%252Bin%252Bthe%252Babsence%252Bof%252Ba%252Bmetal%252Bcatalyst%252Band%252Badditive%252Band%252Bits%252Bapplication%252Bin%252Ba%252Bone-pot%252Btwo-step%252Breaction%26aulast%3DWu%26aufirst%3DHan-Qing%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D14%26spage%3D3782%26epage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bu‐Zheng  Tang</span>, <span class="hlFld-ContribAuthor ">Jia‐Zhuo  Li</span>, <span class="hlFld-ContribAuthor ">Ai‐Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen‐Juan  Hao</span>, <span class="hlFld-ContribAuthor ">Shu‐Jiang  Tu</span>, <span class="hlFld-ContribAuthor ">Bo  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Merging [2+2] Cycloaddition with 1,6‐/1,4‐Aza‐Binucleophilic Additions toward Unprecedented Indazole‐Containing Polycycles. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (14)
                                     , 3394-3402. <a href="https://doi.org/10.1002/adsc.201900401" title="DOI URL">https://doi.org/10.1002/adsc.201900401</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900401%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DMerging%252B%25255B2%25252B2%25255D%252BCycloaddition%252Bwith%252B1%25252C6%2525E2%252580%252590%25252F1%25252C4%2525E2%252580%252590Aza%2525E2%252580%252590Binucleophilic%252BAdditions%252Btoward%252BUnprecedented%252BIndazole%2525E2%252580%252590Containing%252BPolycycles%26aulast%3DTang%26aufirst%3DBu%25E2%2580%2590Zheng%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D14%26spage%3D3394%26epage%3D3402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daiki  Kuwana</span>, <span class="hlFld-ContribAuthor ">Benjamin  Ovadia</span>, <span class="hlFld-ContribAuthor ">Daigo  Kamimura</span>, <span class="hlFld-ContribAuthor ">Masanori  Nagatomo</span>, <span class="hlFld-ContribAuthor ">Masayuki  Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">Installation of O‐Heterocycles to N‐Heteroarenes via an Et
              3
              B/O
              2
              ‐Mediated Radical Reaction of α‐Alkoxy and α‐Alkoxyacyl Tellurides. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (7)
                                     , 1088-1091. <a href="https://doi.org/10.1002/ajoc.201900170" title="DOI URL">https://doi.org/10.1002/ajoc.201900170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900170%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DInstallation%252Bof%252BO%2525E2%252580%252590Heterocycles%252Bto%252BN%2525E2%252580%252590Heteroarenes%252Bvia%252Ban%252BEt%252B3%252BB%25252FO%252B2%252B%2525E2%252580%252590Mediated%252BRadical%252BReaction%252Bof%252B%2525CE%2525B1%2525E2%252580%252590Alkoxy%252Band%252B%2525CE%2525B1%2525E2%252580%252590Alkoxyacyl%252BTellurides%26aulast%3DKuwana%26aufirst%3DDaiki%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D7%26spage%3D1088%26epage%3D1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koji  Kubota</span>, <span class="hlFld-ContribAuthor ">Minami  Uesugi</span>, <span class="hlFld-ContribAuthor ">Shun  Osaki</span>, <span class="hlFld-ContribAuthor ">Hajime  Ito</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-alkyl-2-boryl-substituted-tetrahydrofurans
              via
              copper(
              i
              )-catalysed borylative cyclization of aliphatic ketones. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (23)
                                     , 5680-5683. <a href="https://doi.org/10.1039/C9OB00962K" title="DOI URL">https://doi.org/10.1039/C9OB00962K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB00962K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB00962K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2-alkyl-2-boryl-substituted-tetrahydrofurans%252Bvia%252Bcopper%252528%252Bi%252B%252529-catalysed%252Bborylative%252Bcyclization%252Bof%252Baliphatic%252Bketones%26aulast%3DKubota%26aufirst%3DKoji%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D23%26spage%3D5680%26epage%3D5683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wes  Lee</span>, <span class="hlFld-ContribAuthor ">Mingbin  Yuan</span>, <span class="hlFld-ContribAuthor ">Christopher  Acha</span>, <span class="hlFld-ContribAuthor ">Ashley  Onwu</span>, <span class="hlFld-ContribAuthor ">Osvaldo  Gutierrez</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of nitrones and allenoates cascade reactions for the synthesis of dihydro[1,2-
              a
              ]indoles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (7)
                                     , 1767-1772. <a href="https://doi.org/10.1039/C8OB02346H" title="DOI URL">https://doi.org/10.1039/C8OB02346H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02346H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02346H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DMechanism%252Bof%252Bnitrones%252Band%252Ballenoates%252Bcascade%252Breactions%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bdihydro%25255B1%25252C2-%252Ba%252B%25255Dindoles%26aulast%3DLee%26aufirst%3DWes%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D7%26spage%3D1767%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Long  Ji</span>, <span class="hlFld-ContribAuthor ">Yao  Pan</span>, <span class="hlFld-ContribAuthor ">Fang-Zhou  Geng</span>, <span class="hlFld-ContribAuthor ">Wen-Juan  Hao</span>, <span class="hlFld-ContribAuthor ">Shu-Jiang  Tu</span>, <span class="hlFld-ContribAuthor ">Bo  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic silver/scandium catalytic spiroketalization of β-alkynyl ketones for the atom economical synthesis of skeletally diverse spirocyclic isochromenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (4)
                                     , 474-479. <a href="https://doi.org/10.1039/C8QO01277F" title="DOI URL">https://doi.org/10.1039/C8QO01277F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO01277F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO01277F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DSynergistic%252Bsilver%25252Fscandium%252Bcatalytic%252Bspiroketalization%252Bof%252B%2525CE%2525B2-alkynyl%252Bketones%252Bfor%252Bthe%252Batom%252Beconomical%252Bsynthesis%252Bof%252Bskeletally%252Bdiverse%252Bspirocyclic%252Bisochromenes%26aulast%3DJi%26aufirst%3DCheng-Long%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D4%26spage%3D474%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael Dominic  Delost</span>, <span class="hlFld-ContribAuthor ">Jon Tryggvi  Njardarson</span>. </span><span class="cited-content_cbyCitation_article-title">Oxiranes and Oxirenes: Monocyclic. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14758-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14758-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14758-4%26sid%3Dliteratum%253Aachs%26atitle%3DOxiranes%252Band%252BOxirenes%25253A%252BMonocyclic%26aulast%3DDelost%26aufirst%3DMichael%2BDominic%26date%3D2019%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Distribution of oxygen heterocycles according to ring size and aromaticity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Frequency and structural content of oxygen heterocycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Most frequent oxygen heterocycles in U.S. FDA approved drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Pharmaceuticals containing oxiranes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmaceuticals containing oxetanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmaceuticals containing furanose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Pharmaceuticals containing dioxolanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Pharmaceuticals containing dihydrofuran-2(3<i>H</i>)-one (γ<b>-</b>lactones).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Pharmaceuticals containing furan-2(5<i>H</i>)-one (butenolides).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Pharmaceuticals containing oxazolidinones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pharmaceuticals containing tetrahydrofurans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pharmaceuticals containing 1,3-oxathiolane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Pharmaceuticals containing furans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Pharmaceuticals containing isoxazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pharmaceuticals containing oxazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Pharmaceuticals containing oxadiazoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Pharmaceuticals containing pyranoses (part I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Pharmaceuticals containing pyranoses (part II).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Pharmaceuticals containing pyranoses (part III).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Pharmaceuticals containing morpholines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Pharmaceuticals containing dihydropyran.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Pharmaceuticals containing tetrahydropyran.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Pharmaceuticals containing δ-lactones.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Pharmaceuticals containing 1,3-oxazinanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Pharmaceuticals containing chromanes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0027.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Pharmaceuticals containing chromenes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0028.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Pharmaceuticals containing morphinan alkaloids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0029.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Pharmaceuticals containing benzofurans.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Pharmaceuticals containing various seven-membered rings.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0031.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Pharmaceuticals containing macro-lactones (part I).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0032.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Pharmaceuticals containing macro-lactones (part 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0033.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Pharmaceuticals containing macrocyclic ethers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0034.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Pharmaceuticals containing oligomers and polymers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/medium/jm-2018-00876u_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0035.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Pharmaceuticals containing boron, phosphorus, and metal oxacycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-24/acs.jmedchem.8b00876/20181226/images/large/jm-2018-00876u_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00876&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 97 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10257</span>– <span class="NLM_lpage">10274</span>, <span class="refDoi"> DOI: 10.1021/jm501100b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501100b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10257-10274&author=E.+Vitakuauthor=D.+T.+Smithauthor=J.+T.+Njardarson&title=Analysis+of+the+structural+diversity%2C+substitution+patterns%2C+and+frequency+of+nitrogen+heterocycles+among+U.S.+FDA+approved+pharmaceuticals&doi=10.1021%2Fjm501100b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</span></div><div class="casAuthors">Vitaku, Edon; Smith, David T.; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10257-10274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nitrogen heterocycles are among the most significant structural components of pharmaceuticals.  Anal. of our database of U.S. FDA approved drugs reveals that 59% of unique small-mol. drugs contain a nitrogen heterocycle.  In this review we report on the top 25 most commonly utilized nitrogen heterocycles found in pharmaceuticals.  The main part of our anal. is divided into seven sections: (1) three- and four-membered heterocycles, (2) five-, (3) six-, and (4) seven- and eight-membered heterocycles, as well as (5) fused, (6) bridged bicyclic, and (7) macrocyclic nitrogen heterocycles.  Each section reveals the top nitrogen heterocyclic structures and their relative impact for that ring type.  For the most commonly used nitrogen heterocycles, we report detailed substitution patterns, highlight common architectural cores, and discuss unusual or rare structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cUk9KxUSkbVg90H21EOLACvtfcHk0ljlXqy0RHtYTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wlu7%252FP&md5=7065b3b2fc6f69cede0f87479c7cf472</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm501100b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501100b%26sid%3Dliteratum%253Aachs%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DD.%2BT.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DAnalysis%2520of%2520the%2520structural%2520diversity%252C%2520substitution%2520patterns%252C%2520and%2520frequency%2520of%2520nitrogen%2520heterocycles%2520among%2520U.S.%2520FDA%2520approved%2520pharmaceuticals%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10257%26epage%3D10274%26doi%3D10.1021%2Fjm501100b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilardi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug Design and discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2832</span>– <span class="NLM_lpage">2842</span>, <span class="refDoi"> DOI: 10.1021/jm401375q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401375q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2832-2842&author=E.+A.+Ilardiauthor=E.+Vitakuauthor=J.+T.+Njardarson&title=Data-mining+for+sulfur+and+fluorine%3A+an+evaluation+of+pharmaceuticals+to+reveal+opportunities+for+drug+Design+and+discovery&doi=10.1021%2Fjm401375q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery</span></div><div class="casAuthors">Ilardi, Elizabeth A.; Vitaku, Edon; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2832-2842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Among carbon, hydrogen, oxygen, and nitrogen, sulfur and fluorine are both leading constituents of the pharmaceuticals that comprise our medicinal history.  In efforts to stimulate the minds of both the general public and expert scientist, statistics were collected from the trends assocd. with therapeutics spanning 12 disease categories (a total of 1969 drugs) from our new graphical montage compilation: disease focused pharmaceuticals posters.  Each poster is a vibrant display of a collection of pharmaceuticals (including structural image, Food and Drug Administration (FDA) approval date, international nonproprietary name (INN), initial market name, and a color-coded subclass of function) organized chronol. and classified according to an assocn. with a particular clin. indication.  Specifically, the evolution and structural diversity of sulfur and the popular integration of fluorine into drugs introduced over the past 50 years are evaluated.  The presented qual. conclusions in this article aim to promote innovative insights into drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvH3H0yeaywrVg90H21EOLACvtfcHk0lg9Bat_3DxvGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyksb%252FE&md5=b684f76341311979d0100ed68cffe714</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm401375q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401375q%26sid%3Dliteratum%253Aachs%26aulast%3DIlardi%26aufirst%3DE.%2BA.%26aulast%3DVitaku%26aufirst%3DE.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DData-mining%2520for%2520sulfur%2520and%2520fluorine%253A%2520an%2520evaluation%2520of%2520pharmaceuticals%2520to%2520reveal%2520opportunities%2520for%2520drug%2520Design%2520and%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2832%26epage%3D2842%26doi%3D10.1021%2Fjm401375q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brichacek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njardarson, J. T.</span></span> <span> </span><span class="NLM_article-title">A Graphical journey of innovative organic architectures that have improved our lives</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1348</span>– <span class="NLM_lpage">1349</span>, <span class="refDoi"> DOI: 10.1021/ed1003806</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed1003806" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=1348-1349&author=N.+A.+McGrathauthor=M.+Brichacekauthor=J.+T.+Njardarson&title=A+Graphical+journey+of+innovative+organic+architectures+that+have+improved+our+lives&doi=10.1021%2Fed1003806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives</span></div><div class="casAuthors">McGrath, Nicholas A.; Brichacek, Matthew; Njardarson, Jon T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1348-1349</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society and Division of Chemical Education, Inc.</span>)
        </div><div class="casAbstract">A new free graphical teaching tool that highlights the beautiful org. architectures of the top selling pharmaceuticals is detailed on two posters.  In addn. to the multitude of teaching and data-mining opportunities these posters offer, they were also created to emphasize the central role org. chemists play in the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPDa7XFu1jBLVg90H21EOLACvtfcHk0lg9Bat_3DxvGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqsb%252FP&md5=abaab52626cc29b94b88389f39727513</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fed1003806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed1003806%26sid%3Dliteratum%253Aachs%26aulast%3DMcGrath%26aufirst%3DN.%2BA.%26aulast%3DBrichacek%26aufirst%3DM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DA%2520Graphical%2520journey%2520of%2520innovative%2520organic%2520architectures%2520that%2520have%2520improved%2520our%2520lives%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D2010%26volume%3D87%26spage%3D1348%26epage%3D1349%26doi%3D10.1021%2Fed1003806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ZuWallack, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ZuWallack, R. L.</span></span> <span> </span><span class="NLM_article-title">Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1835</span>, <span class="refDoi"> DOI: 10.1517/14656566.5.8.1827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1517%2F14656566.5.8.1827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15264997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Olt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=1827-1835&author=A.+R.+ZuWallackauthor=R.+L.+ZuWallack&title=Tiotropium+bromide%2C+a+new%2C+once-daily+inhaled+anticholinergic+bronchodilator+for+chronic-obstructive+pulmonary+disease&doi=10.1517%2F14656566.5.8.1827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease</span></div><div class="casAuthors">ZuWallack, Alicia R.; ZuWallack, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1827-1835</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Tiotropium bromide is a quaternary ammonium compd. structurally related to ipratropium and has recently been approved in the US for the long-term, once-daily, maintenance treatment of bronchospasm assocd. with chronic-obstructive pulmonary disease (COPD).  It is available in a dry powder form, where 18 mg of the drug is inhaled once-daily through a device, the HandiHaler.  The potency and long duration of effect of this anticholinergic bronchodilator result primarily from a prolonged blockade of the M1 and M3 muscarinic receptors in the airways and a relatively more rapid dissocn. from the M2 receptor (which provides inhibitory feedback).  Multiple studies of up to a duration of 1 yr have demonstrated its effectiveness as a bronchodilator for COPD, with a trough increase (measured ∼ 24 h after administration of the drug) in forced expiratory vol. in 1 s of ∼ 0.12 l and a peak increase of ∼ 0.25 l.  Tiotropium inhalation also leads to a significant redn. in static lung vols. in hyperinflated patients with COPD; this probably contributes to the redn. in dyspnoea that is assocd. with long-term use of this maintenance bronchodilator.  Regular use of the drug was assocd. with clin. meaningful increases in the Transitional Dyspnea Index, which indicate redns. in dyspnea assocd. with daily activities.  Improvement in the respiratory-specific health status questionnaire, the St George's Respiratory Questionnaire component and total scores was also documented.  Finally, pooled data from two 1-yr studies and two 6-mo studies documented 20 and 28% redns. in the no. of exacerbations per patient per yr.  Side effects have been relatively minimal, with dry mouth the most common symptom, ranging 6-16% of patients and rarely leading to discontinuation of the study drug.  Limited comparisons of efficacy with other bronchodilators are available.  Once-daily tiotropium has been demonstrated to be clearly superior to ipratropium four times daily as a bronchodilator for COPD.  Combined results from two studies comparing once-daily tiotropium to twice-daily inhalation of std. doses of salmeterol, indicate a magnitude of the bronchodilator response similar in the two drugs early in the study.  However, by 6 mo, the bronchodilator effect of tiotropium was somewhat greater than that of the long-acting β-agonist.  Preliminary data suggest that combining tiotropium with long-acting β-agonists may produce addnl. bronchodilator action in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYqgepEqrbmLVg90H21EOLACvtfcHk0lg9Bat_3DxvGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Olt7c%253D&md5=90c3f5babe9fbb4436482ececa4569c0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14656566.5.8.1827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.5.8.1827%26sid%3Dliteratum%253Aachs%26aulast%3DZuWallack%26aufirst%3DA.%2BR.%26aulast%3DZuWallack%26aufirst%3DR.%2BL.%26atitle%3DTiotropium%2520bromide%252C%2520a%2520new%252C%2520once-daily%2520inhaled%2520anticholinergic%2520bronchodilator%2520for%2520chronic-obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2004%26volume%3D5%26spage%3D1827%26epage%3D1835%26doi%3D10.1517%2F14656566.5.8.1827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grynkiewicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadzikowska, M.</span></span> <span> </span><span class="NLM_article-title">Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs</span>. <i>Pharmacol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">463</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=18799813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWgsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=439-463&author=G.+Grynkiewiczauthor=M.+Gadzikowska&title=Tropane+alkaloids+as+medicinally+useful+natural+products+and+their+synthetic+derivatives+as+new+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugs</span></div><div class="casAuthors">Grynkiewicz, Grzegorz; Gadzikowska, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">439-463</span>CODEN:
                <span class="NLM_cas:coden">PRHEDU</span>;
        ISSN:<span class="NLM_cas:issn">1734-1140</span>.
    
            (<span class="NLM_cas:orgname">Polish Academy of Sciences, Institute of Pharmacology</span>)
        </div><div class="casAbstract">A review.  Secondary metabolites of Solanaceae plants sharing a tropane skeleton as a common structural feature are sharply divided into two classes: tropine and ecgonine derivs.  The first group, represented by well known alkaloids: atropine and scopolamine, which are considered to be model anticholinergic drugs (cholinergic antagonists), continues to provide inspiration in the search for more selective muscarinic receptor antagonists.  The second class accommodates one of the principal drugs of abuse, cocaine.  Synthesis of much needed cocaine antagonists, despite extensive research, has not been particularly successful.  Therefore, new concepts of cocaine abuse treatment resort to immunotherapy and biotechnol.  The contemporary pharmaceutical industry manufs. over 20 active pharmaceutical substances contg. tropane moiety in their structure, which are applied as mydriatics (nervous system agents), antiemetics, antispasmodic agents (muscle relaxants, spasmolytics), anesthetics and bronchodilators.  There are two sources of starting materials for this industrial activity: natural products isolated from cultivated transgenic plants (mainly scopolamine and atropine from Australian Duboisia) and chem. synthesis based on common intermediate: tropinone, which can be further transformed by synthetic means to the following classes of compds.: tropine and its esters (tropeines), scopine and nortropine derivs., and tropane quaternary ammonium salts.  This survey focuses on new developments in chem. and pharmacol. of tropane derivs., particularly in view of their prospective industrial applications as therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY2vRlzsQ-OLVg90H21EOLACvtfcHk0ljAswv9yXSbJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWgsrvO&md5=f59773c74944524fbd41938e15eb3ae7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrynkiewicz%26aufirst%3DG.%26aulast%3DGadzikowska%26aufirst%3DM.%26atitle%3DTropane%2520alkaloids%2520as%2520medicinally%2520useful%2520natural%2520products%2520and%2520their%2520synthetic%2520derivatives%2520as%2520new%2520drugs%26jtitle%3DPharmacol.%2520Rep.%26date%3D2008%26volume%3D60%26spage%3D439%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raz, R.</span></span> <span> </span><span class="NLM_article-title">Fosfomycin: an old–new antibiotic</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1111/j.1469-0691.2011.03636.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1469-0691.2011.03636.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21914036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslyqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4-7&author=R.+Raz&title=Fosfomycin%3A+an+old%E2%80%93new+antibiotic&doi=10.1111%2Fj.1469-0691.2011.03636.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fosfomycin: an old-new antibiotic</span></div><div class="casAuthors">Raz, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-7</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fosfomycin is a broad-spectrum antibiotic discovered in Spain in 1969.  It has bactericidal activity against a wide range of bacteria, including gram-neg. micro-organisms and some gram-pos. bacteria, such as staphylococci.  Initially fosfomycin was administered parenterally and only to patients with severe infections.  Today it is often dispensed as fosfomycin-trometamol, an oral formula recommended in the treatment of urinary tract infections.  Fosfomycin-trometamol in a single dose is indicated for the treatment of women with uncomplicated urinary tract infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFTGAabxBhQLVg90H21EOLACvtfcHk0ljAswv9yXSbJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslyqs7Y%253D&md5=b01415c2f4698138f5a00a0cb36f0a6a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2011.03636.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2011.03636.x%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DR.%26atitle%3DFosfomycin%253A%2520an%2520old%25E2%2580%2593new%2520antibiotic%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2012%26volume%3D18%26spage%3D4%26epage%3D7%26doi%3D10.1111%2Fj.1469-0691.2011.03636.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomoda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozoe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of cerulenin on fatty acid synthetase. Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity</span>. <i>J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1093/oxfordjournals.jbchem.a133933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1093%2Foxfordjournals.jbchem.a133933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=6749834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaL38Xks1KjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1982&pages=7-12&author=A.+Kawaguchiauthor=H.+Tomodaauthor=S.+Nozoeauthor=S.+Omuraauthor=S.+Okuda&title=Mechanism+of+action+of+cerulenin+on+fatty+acid+synthetase.+Effect+of+cerulenin+on+iodoacetamide-induced+malonyl-CoA+decarboxylase+activity&doi=10.1093%2Foxfordjournals.jbchem.a133933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of cerulenin on fatty acid synthetase.  Effect of cerulenin on iodoacetamide-induced malonyl-CoA decarboxylase activity</span></div><div class="casAuthors">Kawaguchi, Akihiko; Tomoda, Hiroshi; Nozoe, Shigeo; Omura, Satoshi; Okuda, Shigenobu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biochemistry </span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-12</span>CODEN:
                <span class="NLM_cas:coden">JOBIAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-924X</span>.
    </div><div class="casAbstract">The antibiotic cerulenin (I)  [17397-89-6] irreversibly inactivates yeast fatty acid synthetase  [9045-77-6].  Of all catalytic activities of the synthetase, only the condensation reaction is inhibited by cerulenin.  At 0° and pH 6.5, the second-order rate const. of k = 88 M-1·s-1 was obtained for the inactivation by cerulenin.  This value was ∼90-times greater than the rate const. for the inactivation of the enzyme by iodoacetamide  [144-48-9].  The enzyme was protected against the action of cerulenin by prior treatment with acetyl-CoA but not malonyl-CoA.  Treatment of the enzyme with iodoacetamide, while impairing the synthetase activity, induced malonyl-CoA decarboxylase  [9024-99-1] activity.  Cerulenin had no effect on the malonyl-CoA decarboxylase activity of the iodoacetamide-treated enzyme.  N-Ethylmaleimide, in contrast, inhibited the iodoacetamide-induced malonyl-CoA decarboxylase activity.  When the enzyme was preincubated with cerulenin, malonyl-CoA decarboxylase activity could not be detected even after treatment of the enzyme with iodoacetamide.  These results indicated that the reaction of cerulenin with the peripheral SH-groups of the synthetase is responsible for the inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgbtzg55-j7Vg90H21EOLACvtfcHk0ljAswv9yXSbJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xks1KjtLs%253D&md5=f15e1ebe0efc898afb775f3f375f43cb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Foxfordjournals.jbchem.a133933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Foxfordjournals.jbchem.a133933%26sid%3Dliteratum%253Aachs%26aulast%3DKawaguchi%26aufirst%3DA.%26aulast%3DTomoda%26aufirst%3DH.%26aulast%3DNozoe%26aufirst%3DS.%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DOkuda%26aufirst%3DS.%26atitle%3DMechanism%2520of%2520action%2520of%2520cerulenin%2520on%2520fatty%2520acid%2520synthetase.%2520Effect%2520of%2520cerulenin%2520on%2520iodoacetamide-induced%2520malonyl-CoA%2520decarboxylase%2520activity%26jtitle%3DJ.%2520Biochem.%26date%3D1982%26volume%3D92%26spage%3D7%26epage%3D12%26doi%3D10.1093%2Foxfordjournals.jbchem.a133933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arenas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melián, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Alenza, M.
D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily</span>. <i>J. Vet. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1485</span>, <span class="refDoi"> DOI: 10.1111/jvim.12207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fjvim.12207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=24118316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252Fkt12qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=1478-1485&author=C.+Arenasauthor=C.+Meli%C3%A1nauthor=M.%0AD.+P%C3%A9rez-Alenza&title=Evaluation+of+2+trilostane+protocols+for+the+treatment+of+canine+pituitary-dependent+hyperadrenocorticism%3A+twice+daily+versus+once+daily&doi=10.1111%2Fjvim.12207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily</span></div><div class="casAuthors">Arenas C; Melian C; Perez-Alenza M D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of veterinary internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1478-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Trilostane is the drug of choice to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs, but there is still controversy about which protocol best controls the clinical signs and results of adrenal functioning test.  OBJECTIVES:  To compare the efficacy of twice daily (BID) versus once daily (SID) trilostane administration and to compare the safety of both protocols in the treatment of dogs with PDH.  ANIMALS:  Thirty-two client-owned dogs diagnosed with PDH between 2008 and 2010 and treated with trilostane either BID or SID.  METHODS:  In this prospective randomized study, 2 trilostane protocols were evaluated on the basis of the owner's perception of clinical signs, on the results of laboratory tests, and on the results of the ACTH stimulation test in dogs with PDH.  Dogs were followed up for a period of 1 year.  RESULTS:  During the study, more dogs in the BID group had complete clinical recovery than in the SID group.  However, there was no significant difference in the mean post-ACTH cortisol concentration between groups.  Basal cortisol concentration at 6 months was higher in animals treated SID compared with animals treated BID.  Mean total daily doses of trilostane used to control PDH, as well as adverse effects observed in the course of the study, in both groups were not statistically different.  CONCLUSION AND CLINICAL IMPORTANCE:  Adverse effects were mild using either protocol of treatment.  Using trilostane BID might increase the number of dogs with a good clinical response compared with using trilostane SID.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzJn3YTky2dresJRIHUP1ofW6udTcc2eYwNnlaYdlwRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252Fkt12qtA%253D%253D&md5=fb425b5fadde0bc5e3e216100e023411</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fjvim.12207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvim.12207%26sid%3Dliteratum%253Aachs%26aulast%3DArenas%26aufirst%3DC.%26aulast%3DMeli%25C3%25A1n%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez-Alenza%26aufirst%3DM.%2BD.%26atitle%3DEvaluation%2520of%25202%2520trilostane%2520protocols%2520for%2520the%2520treatment%2520of%2520canine%2520pituitary-dependent%2520hyperadrenocorticism%253A%2520twice%2520daily%2520versus%2520once%2520daily%26jtitle%3DJ.%2520Vet.%2520Intern.%2520Med.%26date%3D2013%26volume%3D27%26spage%3D1478%26epage%3D1485%26doi%3D10.1111%2Fjvim.12207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullinan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geddes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span> <span> </span><span class="NLM_article-title">Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma</span>. <i>Cochrane Database Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">Cd002987</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD002987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2F14651858.CD002987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=Cd002987&author=D.+J.+Evansauthor=P.+Cullinanauthor=D.+M.+Geddesauthor=E.+H.+Waltersauthor=S.+J.+Milanauthor=P.+Jones&title=Troleandomycin+as+an+oral+corticosteroid+steroid+sparing+agent+in+stable+asthma&doi=10.1002%2F14651858.CD002987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD002987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD002987%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DD.%2BJ.%26aulast%3DCullinan%26aufirst%3DP.%26aulast%3DGeddes%26aufirst%3DD.%2BM.%26aulast%3DWalters%26aufirst%3DE.%2BH.%26aulast%3DMilan%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DTroleandomycin%2520as%2520an%2520oral%2520corticosteroid%2520steroid%2520sparing%2520agent%2520in%2520stable%2520asthma%26jtitle%3DCochrane%2520Database%2520Syst.%2520Rev.%26date%3D2000%26volume%3D2%26spage%3DCd002987%26doi%3D10.1002%2F14651858.CD002987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; p  <span class="NLM_fpage">1163</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1163&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">600</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1039/c3np20126k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2Fc3np20126k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23575525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=600-604&author=K.+B.+Kimauthor=C.+M.+Crews&title=From+epoxomicin+to+carfilzomib%3A+chemistry%2C+biology%2C+and+medical+outcomes&doi=10.1039%2Fc3np20126k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes</span></div><div class="casAuthors">Kim, Kyung Bo; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">600-604</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: 1992 to 2012The initial enthusiasm following the discovery of a pharmacol. active natural product is often fleeting due to the poor prospects for its ultimate clin. application.  Despite this, the ever-changing landscape of modern biol. has a const. need for mol. probes that can aid in our understanding of biol. processes.  After its initial discovery by Bristol-Myers Squibb as a microbial anti-tumor natural product, epoxomicin was deemed unfit for development due to its peptide structure and potentially labile epoxyketone pharmacophore.  Despite its drawbacks, epoxomicin's pharmacophore was found to provide unprecedented selectivity for the proteasome.  Epoxomicin also served as a scaffold for the generation of a synthetic tetrapeptide epoxyketone with improved activity, YU-101, which became the parent lead compd. of carfilzomib (Kyprolis®), the recently approved therapeutic agent for multiple myeloma.  In this era of rational drug design and high-throughput screening, the prospects for turning an active natural product into an approved therapy are often slim.  However, by understanding the journey that began with the discovery of epoxomicin and ended with the successful use of carfilzomib in the clinic, we may find new insights into the keys for success in natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ZmojYh4VybVg90H21EOLACvtfcHk0lilj3sF2muJew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWqsrY%253D&md5=fa9d90ac327e5383f6d80512ecec8db4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1039%2Fc3np20126k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np20126k%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DFrom%2520epoxomicin%2520to%2520carfilzomib%253A%2520chemistry%252C%2520biology%252C%2520and%2520medical%2520outcomes%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2013%26volume%3D30%26spage%3D600%26epage%3D604%26doi%3D10.1039%2Fc3np20126k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wuitschik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreira, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span> <span> </span><span class="NLM_article-title">Oxetanes in drug discovery: structural and synthetic insights</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3227</span>– <span class="NLM_lpage">3246</span>, <span class="refDoi"> DOI: 10.1021/jm9018788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3227-3246&author=G.+Wuitschikauthor=E.+M.+Carreiraauthor=B.+Wagnerauthor=H.+Fischerauthor=I.+Parrillaauthor=F.+Schulerauthor=M.+Rogers-Evansauthor=K.+M%C3%BCller&title=Oxetanes+in+drug+discovery%3A+structural+and+synthetic+insights&doi=10.1021%2Fjm9018788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes in Drug Discovery: Structural and Synthetic Insights</span></div><div class="casAuthors">Wuitschik, Georg; Carreira, Erick M.; Wagner, Bjorn; Fischer, Holger; Parrilla, Isabelle; Schuler, Franz; Rogers-Evans, Mark; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3227-3246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of oxetanes as replacements for gem-di-Me or carbonyl groups and their effects on the aq. soly., lipophilicity, metabolic stability, and conformation for various compds. are studied; methods for the prepn. of a variety of substituted oxetanes are given.  The magnitude of changes in properties and in metabolic stability with oxetane substitution depends on the structural context; for example, substitution of a gem-di-Me group with an oxetane, aq. soly. may increase by a factor of 4 to more than 4000 while reducing the rate of metabolic degrdn. in most cases.  Incorporation of an oxetane into an aliph. chain increases in some cases the preference for synclinal conformations rather than antiplanar conformations of the chain.  Spirocyclic oxetanes such as an oxazaspiroheptane resemble commonly used fragments in drug discovery, such as morpholines, and in some cases increase aq. soly. more effectively than morpholines.  An improved chemoselective oxidn. of 3-oxetanol to 3-oxetanone is disclosed; olefination of 3-oxetanone by a variety of methods yields alkylideneoxetanes I [R = (EtO)2P(:O), OHC, O2N, EtO2C, NC, PhO2S, MeCO, 1-(4-chlorophenyl)-1-cyclobutanecarbonyl].  I (R = EtO2C, OHC, O2N) undergo addn. reactions with nucleophiles such as amines, carbonyl compds., and arylboronic acids to give oxetanes such as II.  The crystal structures of a variety of oxetanes are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbJqJGrlPJrVg90H21EOLACvtfcHk0lilj3sF2muJew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D&md5=e95742d38e933c2fb0d76d638ccc773c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm9018788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018788%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DOxetanes%2520in%2520drug%2520discovery%253A%2520structural%2520and%2520synthetic%2520insights%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3227%26epage%3D3246%26doi%3D10.1021%2Fjm9018788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gueritte, F.</span></span> <span> </span><span class="NLM_article-title">General and recent aspects of the chemistry and structure activity relationships of taxoids</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.2174/1381612013397429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2174%2F1381612013397429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=1229-1249&author=F.+Gueritte&title=General+and+recent+aspects+of+the+chemistry+and+structure+activity+relationships+of+taxoids&doi=10.2174%2F1381612013397429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1381612013397429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612013397429%26sid%3Dliteratum%253Aachs%26aulast%3DGueritte%26aufirst%3DF.%26atitle%3DGeneral%2520and%2520recent%2520aspects%2520of%2520the%2520chemistry%2520and%2520structure%2520activity%2520relationships%2520of%2520taxoids%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2001%26volume%3D7%26spage%3D1229%26epage%3D1249%26doi%3D10.2174%2F1381612013397429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hadvary, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfer, H.</span></span> <span> </span><span class="NLM_article-title">The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">2021</span>– <span class="NLM_lpage">2027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1991&pages=2021-2027&author=P.+Hadvaryauthor=W.+Sidlerauthor=W.+Meisterauthor=W.+Vetterauthor=H.+Wolfer&title=The+lipase+inhibitor+tetrahydrolipstatin+binds+covalently+to+the+putative+active+site+serine+of+pancreatic+lipase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHadvary%26aufirst%3DP.%26aulast%3DSidler%26aufirst%3DW.%26aulast%3DMeister%26aufirst%3DW.%26aulast%3DVetter%26aufirst%3DW.%26aulast%3DWolfer%26aufirst%3DH.%26atitle%3DThe%2520lipase%2520inhibitor%2520tetrahydrolipstatin%2520binds%2520covalently%2520to%2520the%2520putative%2520active%2520site%2520serine%2520of%2520pancreatic%2520lipase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1991%26volume%3D266%26spage%3D2021%26epage%3D2027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span> <span> </span><span class="NLM_article-title">Oral vitamin B12 replacement for the treatment of pernicious anemia</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">38</span>, <span class="refDoi"> DOI: 10.3389/fmed.2016.00038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.3389%2Ffmed.2016.00038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2szotl2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=38&author=C.+Q.+H.+Chanauthor=L.+L.+Lowauthor=K.+H.+Lee&title=Oral+vitamin+B12+replacement+for+the+treatment+of+pernicious+anemia&doi=10.3389%2Ffmed.2016.00038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia</span></div><div class="casAuthors">Chan Catherine Qiu Hua; Low Lian Leng; Lee Kheng Hock</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">Many patients with pernicious anemia are treated with lifelong intramuscular (IM) vitamin B12 replacement.  As early as the 1950s, there were studies suggesting that oral vitamin B12 replacement may provide adequate absorption.  Nevertheless, oral vitamin B12 replacement in patients with pernicious anemia remains uncommon in clinical practice.  The objective of this review is to provide an update on the effectiveness of oral vitamin B12 for the treatment of pernicious anemia, the recommended dosage, and the required frequency of laboratory test and clinical monitoring.  Relevant articles were identified by PubMed search from January 1, 1980 to March 31, 2016 and through hand search of relevant reference articles.  Two randomized controlled trials, three prospective papers, one systematic review, and three clinical reviews fulfilled our inclusion criteria.  We found that oral vitamin B12 replacement at 1000 μg daily was adequate to replace vitamin B12 levels in patients with pernicious anemia.  We conclude that oral vitamin B12 is an effective alternative to vitamin B12 IM injections.  Patients should be offered this alternative after an informed discussion on the advantages and disadvantages of both treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxUyB8QnYOiTW1zwg2yUK5fW6udTcc2eZ6lp_cUl18hrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szotl2msw%253D%253D&md5=ce0b914b7a322260eb064f718be3c578</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2016.00038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2016.00038%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DC.%2BQ.%2BH.%26aulast%3DLow%26aufirst%3DL.%2BL.%26aulast%3DLee%26aufirst%3DK.%2BH.%26atitle%3DOral%2520vitamin%2520B12%2520replacement%2520for%2520the%2520treatment%2520of%2520pernicious%2520anemia%26jtitle%3DFront.%2520Med.%26date%3D2016%26volume%3D3%26spage%3D38%26doi%3D10.3389%2Ffmed.2016.00038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen</span>. <i>Med. Gas Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1186/2045-9912-2-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2045-9912-2-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22309834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFert7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=3-6&author=X.+Chenauthor=X.+Zhaiauthor=Z.+Kangauthor=X.+Sun&title=Lactulose%3A+an+effective+preventive+and+therapeutic+option+for+ischemic+stroke+by+production+of+hydrogen&doi=10.1186%2F2045-9912-2-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Lactulose: an effective preventive and therapeutic option for ischemic stroke by production of hydrogen</span></div><div class="casAuthors">Chen, Xiao; Zhai, Xiao; Kang, Zhimin; Sun, Xuejun</div><div class="citationInfo"><span class="NLM_cas:title">Medical Gas Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">MGREB2</span>;
        ISSN:<span class="NLM_cas:issn">2045-9912</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Lactulose, a synthetic sugar not able to be digested and absorbed by human beings, is widely used to treat constipation and hepatic encephalopathy clin.  Through fermn. by the bacteria in the gastrointestinal tract, lactulose can produce considerable amt. of hydrogen, which is protective for ischemic stroke as a unique antioxidant.  We propose that lactulose can induce the prodn. of endogenous hydrogen that in turn reduces oxidative stress and ameliorate the stroke damage in human beings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrasvdTF-sfKbVg90H21EOLACvtfcHk0lgG59jrgRrOCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFert7o%253D&md5=4d6fcd9801efa1cde26d9aa289d36fdd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F2045-9912-2-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2045-9912-2-3%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DKang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DLactulose%253A%2520an%2520effective%2520preventive%2520and%2520therapeutic%2520option%2520for%2520ischemic%2520stroke%2520by%2520production%2520of%2520hydrogen%26jtitle%3DMed.%2520Gas%2520Res.%26date%3D2012%26volume%3D2%26spage%3D3%26epage%3D6%26doi%3D10.1186%2F2045-9912-2-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp 924, 1165–1168, 1221–1224.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nugent, C. A.</span></span> <span> </span><span class="NLM_article-title">Guanadrel Sulfate: A Postganglionic sympathetic inhibitor for the treatment of mild to moderate hypertension</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1983.tb03257.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fj.1875-9114.1983.tb03257.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1983&pages=220-227&author=J.+D.+Palmerauthor=C.+A.+Nugent&title=Guanadrel+Sulfate%3A+A+Postganglionic+sympathetic+inhibitor+for+the+treatment+of+mild+to+moderate+hypertension&doi=10.1002%2Fj.1875-9114.1983.tb03257.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1983.tb03257.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1983.tb03257.x%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DJ.%2BD.%26aulast%3DNugent%26aufirst%3DC.%2BA.%26atitle%3DGuanadrel%2520Sulfate%253A%2520A%2520Postganglionic%2520sympathetic%2520inhibitor%2520for%2520the%2520treatment%2520of%2520mild%2520to%2520moderate%2520hypertension%26jtitle%3DPharmacotherapy%26date%3D1983%26volume%3D3%26spage%3D220%26epage%3D227%26doi%3D10.1002%2Fj.1875-9114.1983.tb03257.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterfalvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournex, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvol, P.</span></span> <span> </span><span class="NLM_article-title">Importance of the lactonic ring in the activity of steroidal antialdosterones</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90513-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2F0006-2952%2880%2990513-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=353-357&author=M.+Peterfalviauthor=V.+Torelliauthor=R.+Fournexauthor=G.+Rousseauauthor=M.+Claireauthor=A.+Michaudauthor=P.+Corvol&title=Importance+of+the+lactonic+ring+in+the+activity+of+steroidal+antialdosterones&doi=10.1016%2F0006-2952%2880%2990513-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990513-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990513-4%26sid%3Dliteratum%253Aachs%26aulast%3DPeterfalvi%26aufirst%3DM.%26aulast%3DTorelli%26aufirst%3DV.%26aulast%3DFournex%26aufirst%3DR.%26aulast%3DRousseau%26aufirst%3DG.%26aulast%3DClaire%26aufirst%3DM.%26aulast%3DMichaud%26aufirst%3DA.%26aulast%3DCorvol%26aufirst%3DP.%26atitle%3DImportance%2520of%2520the%2520lactonic%2520ring%2520in%2520the%2520activity%2520of%2520steroidal%2520antialdosterones%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D353%26epage%3D357%26doi%3D10.1016%2F0006-2952%2880%2990513-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykow, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamanda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agans-Fantuzzi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chintala, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3061</span>– <span class="NLM_lpage">3064</span>, <span class="refDoi"> DOI: 10.1021/jm800180e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800180e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3061-3064&author=S.+Chackalamannilauthor=Y.+Wangauthor=W.+J.+Greenleeauthor=Z.+Huauthor=Y.+Xiaauthor=H.-S.+Ahnauthor=G.+Boykowauthor=Y.+Hsiehauthor=J.+Palamandaauthor=J.+Agans-Fantuzziauthor=S.+Kurowskiauthor=M.+Grazianoauthor=M.+Chintala&title=Discovery+of+a+novel%2C+orally+active+himbacine-based+thrombin+receptor+antagonist+%28SCH+530348%29+with+potent+antiplatelet+activity&doi=10.1021%2Fjm800180e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity</span></div><div class="casAuthors">Chackalamannil, Samuel; Wang, Yuguang; Greenlee, William J.; Hu, Zhiyong; Xia, Yan; Ahn, Ho-Sam; Boykow, George; Hsieh, Yunsheng; Palamanda, Jairam; Agans-Fantuzzi, Jacqueline; Kurowski, Stan; Graziano, Michael; Chintala, Madhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3061-3064</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described.  Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clin. trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKpr_OJqfuEbVg90H21EOLACvtfcHk0lh8SbYgm8x-5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ghu70%253D&md5=228c224e173cdb77b448943bdbec6838</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm800180e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800180e%26sid%3Dliteratum%253Aachs%26aulast%3DChackalamannil%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DH.-S.%26aulast%3DBoykow%26aufirst%3DG.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DPalamanda%26aufirst%3DJ.%26aulast%3DAgans-Fantuzzi%26aufirst%3DJ.%26aulast%3DKurowski%26aufirst%3DS.%26aulast%3DGraziano%26aufirst%3DM.%26aulast%3DChintala%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%252C%2520orally%2520active%2520himbacine-based%2520thrombin%2520receptor%2520antagonist%2520%2528SCH%2520530348%2529%2520with%2520potent%2520antiplatelet%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3061%26epage%3D3064%26doi%3D10.1021%2Fjm800180e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arev-Fishelzon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, Y.</span></span> <span> </span><span class="NLM_article-title">The effect of a single dose of oral pilocarpine (Salagen) on the intraocular pressure and pupil diameter in glaucoma Patients</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=448&author=O.+Geyerauthor=A.+Wolfauthor=T.+Arev-Fishelzonauthor=E.+Levingerauthor=Y.+Wolfson&title=The+effect+of+a+single+dose+of+oral+pilocarpine+%28Salagen%29+on+the+intraocular+pressure+and+pupil+diameter+in+glaucoma+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DO.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DArev-Fishelzon%26aufirst%3DT.%26aulast%3DLevinger%26aufirst%3DE.%26aulast%3DWolfson%26aufirst%3DY.%26atitle%3DThe%2520effect%2520of%2520a%2520single%2520dose%2520of%2520oral%2520pilocarpine%2520%2528Salagen%2529%2520on%2520the%2520intraocular%2520pressure%2520and%2520pupil%2520diameter%2520in%2520glaucoma%2520Patients%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2006%26volume%3D47%26spage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allison, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eugui, E. M.</span></span> <span> </span><span class="NLM_article-title">Mycophenolate mofetil and its mechanisms of action</span>. <i>Immunopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/S0162-3109(00)00188-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS0162-3109%2800%2900188-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10878285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=85-118&author=A.+C.+Allisonauthor=E.+M.+Eugui&title=Mycophenolate+mofetil+and+its+mechanisms+of+action&doi=10.1016%2FS0162-3109%2800%2900188-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Mycophenolate mofetil and its mechanisms of action</span></div><div class="casAuthors">Allison, A. C.; Eugui, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Immunopharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">85-118</span>CODEN:
                <span class="NLM_cas:coden">IMMUDP</span>;
        ISSN:<span class="NLM_cas:issn">0162-3109</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with many refs.  Mycophenolate mofetil (MMF, CellCept) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase (IMPDH).  This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides.  T- and B-lymphocytes are more dependent on this pathway than other cell types are.  Moreover, MPA is a fivefold more potent inhibitor of the type II isoform of IMPDH, which is expressed in activated lymphocytes, than of the type I isoform of IMPDH, which is expressed in most cell types.  MPA has therefore a more potent cytostatic effect on lymphocytes than on other cell types.  This is the principal mechanism by which MPA exerts immunosuppressive effects.  Three other mechanisms may also contribute to the efficacy of MPA in preventing allograft rejection and other applications.  First, MPA can induce apoptosis of activated T-lymphocytes, which may eliminate clones of cells responding to antigenic stimulation.  Second, by depleting guanosine nucleotides, MPA suppresses glycosylation and the expression of some adhesion mols., thereby decreasing the recruitment of lymphocytes and monocytes into sites of inflammation and graft rejection.  Third, by depleting guanosine nucleotides MPA also depletes tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase (iNOS).  MPA therefore suppresses the prodn. by iNOS of NO, and consequent tissue damage mediated by peroxynitrite.  CellCept suppresses T-lymphocytic responses to allogeneic cells and other antigens.  The drug also suppresses primary, but not secondary, antibody responses.  The efficacy of regimes including CellCept in preventing allograft rejection, and in the treatment of rejection, is now firmly established.  CellCept is also efficacious in several exptl. animal models of chronic rejection, and it is hoped that the drug will have the same effect in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLog1LqM9WU7Vg90H21EOLACvtfcHk0lgfzBzu9WBqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlKkt7o%253D&md5=0d254ab2a991bf5be727fcf8e38371e3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0162-3109%2800%2900188-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0162-3109%252800%252900188-0%26sid%3Dliteratum%253Aachs%26aulast%3DAllison%26aufirst%3DA.%2BC.%26aulast%3DEugui%26aufirst%3DE.%2BM.%26atitle%3DMycophenolate%2520mofetil%2520and%2520its%2520mechanisms%2520of%2520action%26jtitle%3DImmunopharmacology%26date%3D2000%26volume%3D47%26spage%3D85%26epage%3D118%26doi%3D10.1016%2FS0162-3109%2800%2900188-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauptman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. A.</span></span> <span> </span><span class="NLM_article-title">Digitalis</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1265</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.99.9.1265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1161%2F01.CIR.99.9.1265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=1265-1270&author=P.+J.+Hauptmanauthor=R.+A.+Kelly&title=Digitalis&doi=10.1161%2F01.CIR.99.9.1265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.9.1265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.9.1265%26sid%3Dliteratum%253Aachs%26aulast%3DHauptman%26aufirst%3DP.%2BJ.%26aulast%3DKelly%26aufirst%3DR.%2BA.%26atitle%3DDigitalis%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D1265%26epage%3D1270%26doi%3D10.1161%2F01.CIR.99.9.1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bozdogan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appelbaum, P. C.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones: activity, mode of action, and mechanism of resistance</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2003.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ijantimicag.2003.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=113-119&author=B.+Bozdoganauthor=P.+C.+Appelbaum&title=Oxazolidinones%3A+activity%2C+mode+of+action%2C+and+mechanism+of+resistance&doi=10.1016%2Fj.ijantimicag.2003.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones: activity, mode of action, and mechanism of resistance</span></div><div class="casAuthors">Bozdogan, Bulent; Appelbaum, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-119</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Oxazolidinones are a new group of antibiotics.  These synthetic drugs are active against a large spectrum of Gram-pos. bacteria, including methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes.  Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit.  Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, assocd. with 23S rRNA alterations during treatment were reported.  Linezolid, the 1st oxazolidinone available, has already taken its place in the clinic for treatment of Gram-pos. infections.  Pharmacokinetic properties as well as its good penetration and accumulation in the tissue including bone, lung, vegetations, hematoma and cerebrospinal fluid, allow its use for surgical infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjtJXxgnCjTbVg90H21EOLACvtfcHk0lgfzBzu9WBqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOnug%253D%253D&md5=3ce55290e07811bb846ba5a8fcc99073</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2003.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2003.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DBozdogan%26aufirst%3DB.%26aulast%3DAppelbaum%26aufirst%3DP.%2BC.%26atitle%3DOxazolidinones%253A%2520activity%252C%2520mode%2520of%2520action%252C%2520and%2520mechanism%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2004%26volume%3D23%26spage%3D113%26epage%3D119%26doi%3D10.1016%2Fj.ijantimicag.2003.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, W.</span></span> <span> </span><span class="NLM_article-title">D-Cycloserine in neuropsychiatric diseases: a systematic review</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyv102</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyv102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1093%2Fijnp%2Fpyv102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26364274" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyv102&author=S.+Schadeauthor=W.+Paulus&title=D-Cycloserine+in+neuropsychiatric+diseases%3A+a+systematic+review&doi=10.1093%2Fijnp%2Fpyv102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyv102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyv102%26sid%3Dliteratum%253Aachs%26aulast%3DSchade%26aufirst%3DS.%26aulast%3DPaulus%26aufirst%3DW.%26atitle%3DD-Cycloserine%2520in%2520neuropsychiatric%2520diseases%253A%2520a%2520systematic%2520review%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyv102%26doi%3D10.1093%2Fijnp%2Fpyv102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.68</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4155%2Ffmc.11.68" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21806380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFeisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1181-1197&author=A.+K.+Ghoshauthor=D.+D.+Anderson&title=Tetrahydrofuran%2C+tetrahydropyran%2C+triazoles+and+related+heterocyclic+derivatives+as+HIV+protease+inhibitors&doi=10.4155%2Ffmc.11.68"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors</span></div><div class="casAuthors">Ghosh, Arun K.; Anderson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1181-1197</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  HIV/AIDS remains a formidable disease with millions of individuals inflicted worldwide.  Although treatment regimens have improved considerably, drug resistance brought on by viral mutation continues to erode their effectiveness.  Intense research efforts are currently underway in search of new and improved therapies.  This review is concerned with the design of novel HIV-1 protease inhibitors that incorporate heterocyclic scaffolds and which have been reported within the recent literature (2005--2010).  Various examples in this review showcase the essential role heterocycles play as scaffolds and bioisosteres in HIV-1 protease inhibitor drug development.  This review will hopefully stimulate the widespread application of these heterocycles in the design of other therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWRpKhwnPK7LVg90H21EOLACvtfcHk0lgfzBzu9WBqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFeisbw%253D&md5=c5c7ac273b57adae7b8c18cabaee2c49</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.68%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DAnderson%26aufirst%3DD.%2BD.%26atitle%3DTetrahydrofuran%252C%2520tetrahydropyran%252C%2520triazoles%2520and%2520related%2520heterocyclic%2520derivatives%2520as%2520HIV%2520protease%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1181%26epage%3D1197%26doi%3D10.4155%2Ffmc.11.68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramu Sridhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaragurubaran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fcmdc.200600103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16927344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVCmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=939-950&author=A.+K.+Ghoshauthor=P.+Ramu+Sridharauthor=N.+Kumaragurubaranauthor=Y.+Kohauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Bis-tetrahydrofuran%3A+a+privileged+ligand+for+darunavir+and+a+new+generation+of+hiv+protease+inhibitors+that+combat+drug+resistance&doi=10.1002%2Fcmdc.200600103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Sridhar, Perali Ramu; Kumaragurubaran, Nagaswamy; Koh, Yasuhiro; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-950</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The structure-based design of bis-tetrahydrofuranyl urethane has emerged as a privileged nonpeptide P2 ligand for a variety of highly potent HIV-1 protease inhibitors.  Incorporation of this ligand provided HIV protease inhibitors with exceedingly potent antiviral activity and superior activity against multi-PI-resistant variants relative to other FDA-approved PIs.  Recently, TMC-114 (darunavir) was approved by the FDA for treatment of drug-resistant HIV.  GW640385 (brecanavir), which incorporates bis-THF as the P2 ligand, is currently in Phase-III clin. development.  The bis-THF ligand was specifically designed to fill in the hydrophobic S2 pocket effectively and to promote extensive hydrogen bonding with the protein backbone in the enzyme S2 site.  The protein-ligand x-ray crystal structures with TMC-114 and other inhibitors with the bis-THF ligand revealed extensive interactions with the backbone of residues Asp29 and Asp30 at the S2 site.  The current design concept targeting the protein backbone may serve as an important guide to combat drug resistance.  Further design and synthesis of conceptually novel inhibitors are in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpT49sY24kLVg90H21EOLACvtfcHk0livXBHHPG4tOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVCmu7w%253D&md5=e9826330e807476b916d69e86ff55a40</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600103%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DRamu%2BSridhar%26aufirst%3DP.%26aulast%3DKumaragurubaran%26aufirst%3DN.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DBis-tetrahydrofuran%253A%2520a%2520privileged%2520ligand%2520for%2520darunavir%2520and%2520a%2520new%2520generation%2520of%2520hiv%2520protease%2520inhibitors%2520that%2520combat%2520drug%2520resistance%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D939%26epage%3D950%26doi%3D10.1002%2Fcmdc.200600103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. K.</span></span> <span> </span><span class="NLM_article-title">Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.2146/ajhp110237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2146%2Fajhp110237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22517020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOmsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=745-755&author=A.+McBrideauthor=S.+K.+Butler&title=Eribulin+mesylate%3A+a+novel+halichondrin+B+analogue+for+the+treatment+of+metastatic+breast+cancer&doi=10.2146%2Fajhp110237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer</span></div><div class="casAuthors">McBride, Ali; Butler, Sara K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">745-755</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose. The pharmacol., pharmacokinetics, clin. efficacy, safety, and administration of eribulin in patients with metastatic breast cancer are reviewed.  Summary. Classical chemotherapeutic agents for breast cancer have dominated treatment regimens even in the era of targeted therapy.  Disease progression through these agents is often due to the development of resistance or lack of efficacy with these agents.  Recently, a new nontaxane agent, eribulin mesylate, was approved for the treatment of metastatic breast cancer in patients who have received at least two prior chemotherapeutic agents.  Eribulin is a member of a new class of synthetic cytotoxic agents derived from the Japanese sea sponge Halichondria okadai.  Eribulin differs from other antimicrotubule agents in that it can bind to the microtubule cap and inhibit tubulin polymn., leading to microtubule arrest.  In Phase II clin. trials, eribulin demonstrated activity in extensively pretreated patients who had previously received an anthracycline, taxane, and capecitabine and had shown disease progression within the last six months of treatment.  In a pivotal Phase III clin. trial of heavily pretreated patients, patients who received eribulin vs. the physician's treatment of choice showed a significant increase in overall and progression-free survival.  Eribulin has a manageable adverse-effect profile, consisting mainly of neutropenia and fatigue.  Eribulin has been assocd. with a low incidence of peripheral neuropathy.  Conclusion. Eribulin, a novel synthetic antimicrotubule agent that binds to the vinca domain of tubulin and inhibits the polymn. of tubulin, offers a new treatment option for metastatic breast cancer or locally advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolsBGRs5gqkLVg90H21EOLACvtfcHk0livXBHHPG4tOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOmsb%252FL&md5=26be9deaf43ca2950e61b2371d6fa4bb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2146%2Fajhp110237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp110237%26sid%3Dliteratum%253Aachs%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DS.%2BK.%26atitle%3DEribulin%2520mesylate%253A%2520a%2520novel%2520halichondrin%2520B%2520analogue%2520for%2520the%2520treatment%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D745%26epage%3D755%26doi%3D10.2146%2Fajhp110237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachem, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemaly, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kontoyiannis, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raad, I. I.</span></span> <span> </span><span class="NLM_article-title">Posaconazole: a broad-spectrum triazole antifungal</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(05)70297-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS1473-3099%2805%2970297-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16310149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlelu7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=775-785&author=H.+A.+Torresauthor=R.+Y.+Hachemauthor=R.+F.+Chemalyauthor=D.+P.+Kontoyiannisauthor=I.+I.+Raad&title=Posaconazole%3A+a+broad-spectrum+triazole+antifungal&doi=10.1016%2FS1473-3099%2805%2970297-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Posaconazole: A broad-spectrum triazole antifungal</span></div><div class="casAuthors">Torres, Harrys A.; Hachem, Ray Y.; Chemaly, Roy F.; Kontoyiannis, Dimitrios P.; Raad, Issam I.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Posaconazole is a new triazole drug being investigated in phase III clin. trials for the treatment and prevention of invasive fungal infections.  In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species, Fusarium species, zygomycetes, and endemic fungi.  Posaconazole is given orally two to four times daily.  This triazole is widely distributed in the body, metabolized mainly by the liver, and is well tolerated, even in long-term courses.  Adverse events are generally mild and include headache and gastrointestinal complaints.  Posaconazole has shown promising clin. efficacy against life-threatening fungal infections that are often refractory to the currently available antifungal therapies-eg, invasive aspergillosis, fusariosis, and the emerging zygomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4X-P2eEDtKbVg90H21EOLACvtfcHk0livXBHHPG4tOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlelu7jE&md5=e762181fe91a9df86697eb42d7e574be</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2805%2970297-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252805%252970297-8%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DH.%2BA.%26aulast%3DHachem%26aufirst%3DR.%2BY.%26aulast%3DChemaly%26aufirst%3DR.%2BF.%26aulast%3DKontoyiannis%26aufirst%3DD.%2BP.%26aulast%3DRaad%26aufirst%3DI.%2BI.%26atitle%3DPosaconazole%253A%2520a%2520broad-spectrum%2520triazole%2520antifungal%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2005%26volume%3D5%26spage%3D775%26epage%3D785%26doi%3D10.1016%2FS1473-3099%2805%2970297-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, H.</span></span> <span> </span><span class="NLM_article-title">Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with sjogren’s syndrome</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.2165/00044011-200222020-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00044011-200222020-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23315394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XitV2htLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=67-73&author=H.+Yasudaauthor=H.+Niki&title=Review+of+the+pharmacological+properties+and+clinical+usefulness+of+muscarinic+agonists+for+xerostomia+in+patients+with+sjogren%E2%80%99s+syndrome&doi=10.2165%2F00044011-200222020-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjogren's syndrome</span></div><div class="casAuthors">Yasuda, Hiroshi; Niki, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  The anti-xerostomia effects of muscarinic agonists (cholinomimetics) are reviewed.  Cevimeline (cevimeline monohydrochloride hemihydrate) is a novel muscarinic agonist that stimulates salivary secretion in animals and humans both with normal salivary gland function and with impaired salivary secretion (xerostomia or oral dryness) as effectively as pilocarpine.  Other classic and non-selective muscarinic agonists, such as arecoline, carbachol, muscarine and oxotremorine, as well as acetylcholine, failed to exhibit a sufficient salivation effect even at sublethal doses in animals.  Oral administration of cevimeline 30mg to humans induces a moderate and lasting increase in salivary flow, and the effect is maintained for at least 4 to 6 h, longer than with pilocarpine.  Mean increases in salivary flow rates after cevimeline treatment were 2-fold higher than after placebo, and no evidence of tolerance of the pharmacol. effect has been obsd. during prolonged administration for up to 12 mo.  The clin. efficacy of cevimeline in relieving symptoms of xerostomia, including oral dryness and difficulties in chewing, swallowing and speaking, has been demonstrated by placebo-controlled, double-blind, randomized clin. trials in the USA and Japan.  In these studies, cevimeline 30mg three times daily increased salivary flow and improved the symptoms of xerostomia in a significantly higher percentage of patients compared with placebo.  Some patients receiving cevimeline therapy for xerostomia experienced adverse events such as sweating, gastrointestinal symptoms (nausea, diarrhea, abdominal pain and vomiting), dizziness and rigors; these effects were related to muscarinic activity and were generally mild and tolerable in comparison with those of pilocarpine.  These findings suggest that muscarinic M3 agonists are suitable for the treatment of xerostomia.  Cevimeline in particular has a long-lasting salivation effect with fewer adverse events than pilocarpine, and so is expected to be more useful for the treatment of xerostomia in patients with Sjogren's syndrome, reducing symptom severity and improving their quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTTV8eQzUMt7Vg90H21EOLACvtfcHk0livXBHHPG4tOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitV2htLg%253D&md5=1e1ce23c558ae2c0f692b72e1af1e890</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2165%2F00044011-200222020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00044011-200222020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DH.%26atitle%3DReview%2520of%2520the%2520pharmacological%2520properties%2520and%2520clinical%2520usefulness%2520of%2520muscarinic%2520agonists%2520for%2520xerostomia%2520in%2520patients%2520with%2520sjogren%25E2%2580%2599s%2520syndrome%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2002%26volume%3D22%26spage%3D67%26epage%3D73%26doi%3D10.2165%2F00044011-200222020-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shubber, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitoria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span> <span> </span><span class="NLM_article-title">comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e79981</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0079981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1371%2Fjournal.pone.0079981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e79981&author=N.+Fordauthor=Z.+Shubberauthor=A.+Hillauthor=M.+Vitoriaauthor=M.+Dohertyauthor=E.+J.+Millsauthor=A.+Gray&title=comparative+efficacy+of+lamivudine+and+emtricitabine%3A+a+systematic+review+and+meta-analysis+of+randomized+trials&doi=10.1371%2Fjournal.pone.0079981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0079981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0079981%26sid%3Dliteratum%253Aachs%26aulast%3DFord%26aufirst%3DN.%26aulast%3DShubber%26aufirst%3DZ.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DVitoria%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DM.%26aulast%3DMills%26aufirst%3DE.%2BJ.%26aulast%3DGray%26aufirst%3DA.%26atitle%3Dcomparative%2520efficacy%2520of%2520lamivudine%2520and%2520emtricitabine%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520randomized%2520trials%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De79981%26doi%3D10.1371%2Fjournal.pone.0079981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvaris, M.</span></span> <span> </span><span class="NLM_article-title">Treatment of urinary infections with nitrofurantoin (furadantin)</span>. <i>BJU Int.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1111/j.1464-410X.1958.tb03521.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1464-410X.1958.tb03521.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1958&pages=303-309&author=M.+Salvaris&title=Treatment+of+urinary+infections+with+nitrofurantoin+%28furadantin%29&doi=10.1111%2Fj.1464-410X.1958.tb03521.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.1958.tb03521.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.1958.tb03521.x%26sid%3Dliteratum%253Aachs%26aulast%3DSalvaris%26aufirst%3DM.%26atitle%3DTreatment%2520of%2520urinary%2520infections%2520with%2520nitrofurantoin%2520%2528furadantin%2529%26jtitle%3DBJU%2520Int.%26date%3D1958%26volume%3D30%26spage%3D303%26epage%3D309%26doi%3D10.1111%2Fj.1464-410X.1958.tb03521.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P.</span></span> <span> </span><span class="NLM_article-title">Lapatinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd2332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fnrd2332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17633789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=431&author=B.+Moyauthor=P.+Kirkpatrickauthor=S.+Karauthor=P.+Goss&title=Lapatinib&doi=10.1038%2Fnrd2332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib</span></div><div class="casAuthors">Moy, Beverly; Kirkpatrick, Peter; Kar, Santwana; Goss, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">431-432</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lapatinib is a small-mol. kinase inhibitor that targets the epidermal growth factor receptor and the human epidermal growth factor receptor 2 (HER2).  In March 2007, lapatinib distosylate monohydrate (Tykerb; GlaxoSmithKline) was approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2hpzYynvxLbVg90H21EOLACvtfcHk0lh0qeRJPdwF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVSmur8%253D&md5=e1fc2433a41b935d4dcfd72e8e12be59</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd2332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2332%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26aulast%3DKar%26aufirst%3DS.%26aulast%3DGoss%26aufirst%3DP.%26atitle%3DLapatinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D431%26doi%3D10.1038%2Fnrd2332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinel, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapid, M. I.</span></span> <span> </span><span class="NLM_article-title">Treatment of nightmares with prazosin: A systematic review</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/j.mayocp.2012.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.mayocp.2012.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=22883741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2012&pages=890-900&author=S.+Kungauthor=Z.+Espinelauthor=M.+I.+Lapid&title=Treatment+of+nightmares+with+prazosin%3A+A+systematic+review&doi=10.1016%2Fj.mayocp.2012.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of nightmares with prazosin: a systematic review</span></div><div class="casAuthors">Kung, Simon; Espinel, Zelde; Lapid, Maria I.</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">890-900</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Nightmares, frequently assocd. with posttraumatic stress disorder and clin. relevant in today's world of violence, are difficult to treat, with few pharmacol. options.  We performed a systematic review to evaluate the evidence for the use of prazosin in the treatment of nightmares.  A comprehensive search was performed using the databases EMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systematic Reviews, from their inception to March 9, 2012, using keywords prazosin and nightmares/PTSD or assocd. terms (see text).  Two authors independently reviewed titles and abstrs. and selected relevant studies.  Descriptive data and outcomes of interest from eligible studies were extd. by 1 author, and checked by 2 others.  The risk of bias of randomized controlled trials (RCTs) was assessed independently by 2 reviewers.  Articles met criteria for inclusion if prazosin was used to treat nightmares, and outcome measures included nightmares or related symptoms of sleep disorders.  Our search yielded 21 studies, consisting of 4 RCTs, 4 open-label studies, 4 retrospective chart reviews, and 9 single case reports.  The prazosin dose ranged from 1 to 16 mg/d.  Results were mixed for the 4 RCTs: 3 reported significant improvement in the no. of nightmares, and 1 found no redn. in the no. of nightmares.  Reduced nightmare severity with use of prazosin was consistently reported in the open-label trials, retrospective chart reviews, and single case reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFs7_H89PSJ7Vg90H21EOLACvtfcHk0lh0qeRJPdwF_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlaqsA%253D%253D&md5=fe853863fd7f14c86ff51077b7739bbf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2012.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2012.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DS.%26aulast%3DEspinel%26aufirst%3DZ.%26aulast%3DLapid%26aufirst%3DM.%2BI.%26atitle%3DTreatment%2520of%2520nightmares%2520with%2520prazosin%253A%2520A%2520systematic%2520review%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2012%26volume%3D87%26spage%3D890%26epage%3D900%26doi%3D10.1016%2Fj.mayocp.2012.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, R.</span></span> <span> </span><span class="NLM_article-title">How Zantac became the best-selling drug in history</span>. <i>J. Health Care Mark.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10169076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADyaK2svgsFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=24-29&author=R.+Wright&title=How+Zantac+became+the+best-selling+drug+in+history"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">How Zantac became the best-selling drug in history</span></div><div class="casAuthors">Wright R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of health care marketing</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">24-9</span>
        ISSN:<span class="NLM_cas:issn">0737-3252</span>.
    </div><div class="casAbstract">Glaxo's Zantac began its dominance of the acid/peptic marketplace with a launch strategy, taking advantage of the established Roche sales force to rapidly promote the product.  Educational symposia for physicians were instrumental in disseminating both disease and product information to primary care physicians and specialists.  This technique not only pleased physicians (more referrals), but also increased public awareness of gastrointestinal disease, further expanding the patient market.  Several novel marketing strategies contributed to Zantac's success, including the public-service announcements, celebrity media tours, and consumer-awareness bulletins, which brought the drug to the lay public and encouraged individuals to seek advice from their physicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUKOV4dA-MuEodMGTatQ7LfW6udTcc2ebMEk2u8pnK17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2svgsFGmsA%253D%253D&md5=74637455d07a98f3bf713e35a7e65765</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DR.%26atitle%3DHow%2520Zantac%2520became%2520the%2520best-selling%2520drug%2520in%2520history%26jtitle%3DJ.%2520Health%2520Care%2520Mark.%26date%3D1996%26volume%3D16%26spage%3D24%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schauer, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekant, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mally, A.</span></span> <span> </span><span class="NLM_article-title">Hepatobiliary toxicity of furan: identification of furan metabolites in bile of male f344/n rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1698</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.031781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1124%2Fdmd.109.031781" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1698-1706&author=C.+Hambergerauthor=M.+Kellertauthor=U.+M.+Schauerauthor=W.+Dekantauthor=A.+Mally&title=Hepatobiliary+toxicity+of+furan%3A+identification+of+furan+metabolites+in+bile+of+male+f344%2Fn+rats&doi=10.1124%2Fdmd.109.031781"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.031781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.031781%26sid%3Dliteratum%253Aachs%26aulast%3DHamberger%26aufirst%3DC.%26aulast%3DKellert%26aufirst%3DM.%26aulast%3DSchauer%26aufirst%3DU.%2BM.%26aulast%3DDekant%26aufirst%3DW.%26aulast%3DMally%26aufirst%3DA.%26atitle%3DHepatobiliary%2520toxicity%2520of%2520furan%253A%2520identification%2520of%2520furan%2520metabolites%2520in%2520bile%2520of%2520male%2520f344%252Fn%2520rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1698%26epage%3D1706%26doi%3D10.1124%2Fdmd.109.031781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. A.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolites in the biotransformation of molecules containing a furan ring</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1021/tx3003824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=6-25&author=L.+A.+Peterson&title=Reactive+metabolites+in+the+biotransformation+of+molecules+containing+a+furan+ring&doi=10.1021%2Ftx3003824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring</span></div><div class="casAuthors">Peterson, Lisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-25</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many xenobiotics contg. a furan ring are toxic and/or carcinogenic.  The harmful effects of these compds. require furan ring oxidn.  This reaction generates an electrophilic intermediate.  Depending on the furan ring substituents, the intermediate is either an epoxide or a cis-enedione with more ring substitution favoring epoxide formation.  Either intermediate reacts with cellular nucleophiles such as protein or DNA to trigger toxicities.  The reactivity of the metabolite dets. which cellular nucleophiles are targeted.  The toxicity of a particular furan is also influenced by the presence of competing metabolic pathways or efficient detoxification routes.  GSH plays an important role in modulating the harmful effects of this class of compd. by reacting with the reactive metabolite.  However, this may not represent a detoxification step in all cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp4Dr5stLUSrVg90H21EOLACvtfcHk0lhwH-jkMQDLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qsrbN&md5=fe3a280d0b7a99a436ec619abc1e1fa0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Ftx3003824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003824%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DL.%2BA.%26atitle%3DReactive%2520metabolites%2520in%2520the%2520biotransformation%2520of%2520molecules%2520containing%2520a%2520furan%2520ring%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D6%26epage%3D25%26doi%3D10.1021%2Ftx3003824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barmade, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murumkar, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, M. R.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry perspective of fused isoxazole derivatives</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2863</span>– <span class="NLM_lpage">2883</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160506145700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2174%2F1568026616666160506145700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=27150366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWht7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2863-2883&author=M.+A.+Barmadeauthor=P.+R.+Murumkarauthor=M.+K.+Sharmaauthor=M.+R.+Yadav&title=Medicinal+chemistry+perspective+of+fused+isoxazole+derivatives&doi=10.2174%2F1568026616666160506145700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry Perspective of Fused Isoxazole Derivatives</span></div><div class="casAuthors">Barmade, Mahesh A.; Murumkar, Prashant R.; Sharma, Mayank Kumar; Yadav, Mange Ram</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2863-2883</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitrogen contg. heterocyclic rings with an oxygen atom is considered as one of the best combination in medicinal chem. due to their diversified biol. activities.  Isoxazole, a five membered heterocyclic azole ring is found in naturally occurring ibetonic acid along with some of the marketed drugs such as valdecoxib, flucloxacillin, cloxacillin, dicloxacillin, and danazol.  It is also significant for showing antipsychotic activity in risperidone and anticonvulsant activity in zonisamide, the marketed drugs.  This review article covers research articles reported till date covering biol. activity along with SAR of fused isoxazole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB2RkEKpFxPbVg90H21EOLACvtfcHk0lhwH-jkMQDLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWht7zF&md5=774b6118d2b3440f33c52fa3cc93584d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160506145700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160506145700%26sid%3Dliteratum%253Aachs%26aulast%3DBarmade%26aufirst%3DM.%2BA.%26aulast%3DMurumkar%26aufirst%3DP.%2BR.%26aulast%3DSharma%26aufirst%3DM.%2BK.%26aulast%3DYadav%26aufirst%3DM.%2BR.%26atitle%3DMedicinal%2520chemistry%2520perspective%2520of%2520fused%2520isoxazole%2520derivatives%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2863%26epage%3D2883%26doi%3D10.2174%2F1568026616666160506145700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.-H.</span></span> <span> </span><span class="NLM_article-title">Recent advance in oxazole-based medicinal chemistry</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.12.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ejmech.2017.12.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29288945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2018&pages=444-492&author=H.-Z.+Zhangauthor=Z.-L.+Zhaoauthor=C.-H.+Zhou&title=Recent+advance+in+oxazole-based+medicinal+chemistry&doi=10.1016%2Fj.ejmech.2017.12.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advance in oxazole-based medicinal chemistry</span></div><div class="casAuthors">Zhang, Hui-Zhen; Zhao, Zhi-Long; Zhou, Cheng-He</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">444-492</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Oxazole compds. contg. nitrogen and oxygen atoms in the five-membered arom. ring are readily able to bind with a variety of enzymes and receptors in biol. systems via diverse non-covalent interactions, and thus display versatile biol. activities.  The related researches in oxazole-based derivs. including oxazoles, isoxazoles, oxazolines, oxadiazoles, oxazolidones, benzoxazoles and so on, as medicinal drugs have been an extremely active topic, and numerous excellent achievements have been acquired.  Noticeably, a large no. of oxazole compds. as clin. drugs or candidates have been frequently employed for the treatment of various types of diseases, which have shown their large development value and wide potential as medicinal agents.  This work systematically reviewed the recent researches and developments of the whole range of oxazole compds. as medicinal drugs, including antibacterial, antifungal, antiviral, antitubercular, anticancer, anti-inflammatory and analgesic, antidiabetic, antiparasitic, anti-obesitic, anti-neuropathic, antioxidative as well as other biol. activities.  The perspectives of the foreseeable future in the research and development of oxazole-based compds. as medicinal drugs are also presented.  It is hoped that this review will serve as a stimulant for new thoughts in the quest for rational designs of more active and less toxic oxazole medicinal drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB0ZFICNzJ_LVg90H21EOLACvtfcHk0li7jMnVzsNakA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Kluw%253D%253D&md5=4b4b3a3db4b5bdae78aa385db3c6f263</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.12.044%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-Z.%26aulast%3DZhao%26aufirst%3DZ.-L.%26aulast%3DZhou%26aufirst%3DC.-H.%26atitle%3DRecent%2520advance%2520in%2520oxazole-based%2520medicinal%2520chemistry%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D144%26spage%3D444%26epage%3D492%26doi%3D10.1016%2Fj.ejmech.2017.12.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinàs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&author=J.+Bostr%C3%B6mauthor=A.+Hognerauthor=A.+Llin%C3%A0sauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2ebqp4wPcW-dQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlin%25C3%25A0s%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yellon, D. M.</span></span> <span> </span><span class="NLM_article-title">Anthracycline chemotherapy and cardiotoxicity</span>. <i>Cardiovasc. Drugs Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1007/s10557-016-6711-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs10557-016-6711-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28185035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlOqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=63-75&author=J.+V.+McGowanauthor=R.+Chungauthor=A.+Maulikauthor=I.+Piotrowskaauthor=J.+M.+Walkerauthor=D.+M.+Yellon&title=Anthracycline+chemotherapy+and+cardiotoxicity&doi=10.1007%2Fs10557-016-6711-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Anthracycline Chemotherapy and Cardiotoxicity</span></div><div class="casAuthors">McGowan, John V.; Chung, Robin; Maulik, Angshuman; Piotrowska, Izabela; Walker, J. Malcolm; Yellon, Derek M.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drugs and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-75</span>CODEN:
                <span class="NLM_cas:coden">CDTHET</span>;
        ISSN:<span class="NLM_cas:issn">0920-3206</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.  Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality.  The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways.  Cardioprotective treatments are few and those that have been examd. include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane.  New treatments exploiting the ErbB or other novel pro-survival pathways, such as conditioning, are on the cardioprotection horizon.  Even in the forthcoming era of targeted cancer therapies, the substantial proportion of today's anthracycline-treated cancer patients may become tomorrow's cardiac patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD-ITlhJanQbVg90H21EOLACvtfcHk0li7jMnVzsNakA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlOqtLs%253D&md5=a13263360269429a434337fb46c44b23</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs10557-016-6711-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10557-016-6711-0%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DJ.%2BV.%26aulast%3DChung%26aufirst%3DR.%26aulast%3DMaulik%26aufirst%3DA.%26aulast%3DPiotrowska%26aufirst%3DI.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26aulast%3DYellon%26aufirst%3DD.%2BM.%26atitle%3DAnthracycline%2520chemotherapy%2520and%2520cardiotoxicity%26jtitle%3DCardiovasc.%2520Drugs%2520Ther.%26date%3D2017%26volume%3D31%26spage%3D63%26epage%3D75%26doi%3D10.1007%2Fs10557-016-6711-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eleazu, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleazu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chukwuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essien, U. N.</span></span> <span> </span><span class="NLM_article-title">Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans</span>. <i>J. Diabetes Metab. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">60</span>, <span class="refDoi"> DOI: 10.1186/2251-6581-12-60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2251-6581-12-60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=24364898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSgtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=60&author=C.+O.+Eleazuauthor=K.+C.+Eleazuauthor=S.+Chukwumaauthor=U.+N.+Essien&title=Review+of+the+mechanism+of+cell+death+resulting+from+streptozotocin+challenge+in+experimental+animals%2C+its+practical+use+and+potential+risk+to+humans&doi=10.1186%2F2251-6581-12-60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans</span></div><div class="casAuthors">Eleazu, Chinedum Ogbonnaya; Eleazu, Kate Chinedum; Chukwuma, Sonia; Essien, Udeme Nelson</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Diabetes and Metabolic Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60/1-60/7, 7</span>CODEN:
                <span class="NLM_cas:coden">JDMDAL</span>;
        ISSN:<span class="NLM_cas:issn">2251-6581</span>.
    
            (<span class="NLM_cas:orgname">Tehran University of Medical Sciences, Endocrinology & Metabolism Research Center</span>)
        </div><div class="casAbstract">A review.  Streptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose) is a naturally occurring diabetogenic compd., produced by the soil bacterium streptomyces achromogenes, that exhibits broad spectrum of antibacterial properties.  Streptozotocin functions as a DNA synthesis inhibitor in both bacterial and mammalian cells.  In mammalian cells, the actual mechanism and metabolic targets of STZ toxicity that results in cell death is not known.  This review identifies four key areas that explain the mechanism of the cytotoxicity of STZ in mammalian cell lines, investigates the practical aspects of using STZ in exptl. animals and the potential risks of its exposure to human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKMm4ggmSHRrVg90H21EOLACvtfcHk0li7jMnVzsNakA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSgtrvL&md5=7b5fa0bad8c6e07c9eec53201cfc507d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F2251-6581-12-60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2251-6581-12-60%26sid%3Dliteratum%253Aachs%26aulast%3DEleazu%26aufirst%3DC.%2BO.%26aulast%3DEleazu%26aufirst%3DK.%2BC.%26aulast%3DChukwuma%26aufirst%3DS.%26aulast%3DEssien%26aufirst%3DU.%2BN.%26atitle%3DReview%2520of%2520the%2520mechanism%2520of%2520cell%2520death%2520resulting%2520from%2520streptozotocin%2520challenge%2520in%2520experimental%2520animals%252C%2520its%2520practical%2520use%2520and%2520potential%2520risk%2520to%2520humans%26jtitle%3DJ.%2520Diabetes%2520Metab.%2520Disord.%26date%3D2013%26volume%3D12%26spage%3D60%26doi%3D10.1186%2F2251-6581-12-60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, J. A.</span></span> <span> </span><span class="NLM_article-title">Indolocarbazole natural products: occurrence, biosynthesis, and biological activity</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1045</span>, <span class="refDoi"> DOI: 10.1039/B601930G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2FB601930G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17119643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivFahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=1007-1045&author=C.+Sanchezauthor=C.+Mendezauthor=J.+A.+Salas&title=Indolocarbazole+natural+products%3A+occurrence%2C+biosynthesis%2C+and+biological+activity&doi=10.1039%2FB601930G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Indolocarbazole natural products: occurrence, biosynthesis, and biological activity</span></div><div class="casAuthors">Sanchez, Cesar; Mendez, Carmen; Salas, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1007-1045</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The indolocarbazole family of natural products, including the biosynthetically related bisindolylmaleimides, is reviewed (with 316 refs. cited).  The isolation of indolocarbazoles from natural sources and the biosynthesis of this class of compds. are thoroughly reviewed, including recent developments in mol. genetics, enzymol. and metabolic engineering.  The biol. activities and underlying modes of action displayed by natural and synthetic indolocarbazoles is also presented, with an emphasis on the development of analogs that have entered clin. trials for its future use against cancer or other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYX-bxZmjEA7Vg90H21EOLACvtfcHk0lhx6OP9PQ95pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivFahsQ%253D%253D&md5=7634cd7a7078adbeb5be7bd6fa12a862</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1039%2FB601930G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB601930G%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DMendez%26aufirst%3DC.%26aulast%3DSalas%26aufirst%3DJ.%2BA.%26atitle%3DIndolocarbazole%2520natural%2520products%253A%2520occurrence%252C%2520biosynthesis%252C%2520and%2520biological%2520activity%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2006%26volume%3D23%26spage%3D1007%26epage%3D1045%26doi%3D10.1039%2FB601930G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, M. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of DNA-bound Co(III)·bleomycin B(2): Insights on intercalation and minor groove binding</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">5052</span>– <span class="NLM_lpage">5056</span>, <span class="refDoi"> DOI: 10.1073/pnas.0708143105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1073%2Fpnas.0708143105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5052-5056&author=K.+D.+Goodwinauthor=M.+A.+Lewisauthor=E.+C.+Longauthor=M.+M.+Georgiadis&title=Crystal+structure+of+DNA-bound+Co%28III%29%C2%B7bleomycin+B%282%29%3A+Insights+on+intercalation+and+minor+groove+binding&doi=10.1073%2Fpnas.0708143105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708143105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708143105%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DK.%2BD.%26aulast%3DLewis%26aufirst%3DM.%2BA.%26aulast%3DLong%26aufirst%3DE.%2BC.%26aulast%3DGeorgiadis%26aufirst%3DM.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520DNA-bound%2520Co%2528III%2529%25C2%25B7bleomycin%2520B%25282%2529%253A%2520Insights%2520on%2520intercalation%2520and%2520minor%2520groove%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D5052%26epage%3D5056%26doi%3D10.1073%2Fpnas.0708143105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">701</span>– <span class="NLM_lpage">705</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=701-705&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D701%26epage%3D705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J. P. H.</span></span> <span> </span><span class="NLM_article-title">Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1210/jc.2009-0473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1210%2Fjc.2009-0473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=19892839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2010&pages=34-42&author=S.+Nairauthor=J.+P.+H.+Wilding&title=Sodium+glucose+cotransporter+2+inhibitors+as+a+new+treatment+for+diabetes+mellitus&doi=10.1210%2Fjc.2009-0473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus</span></div><div class="casAuthors">Nair, Sunil; Wilding, John P. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-42</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Sodium-glucose cotransporter 2 (SGLT2) expressed in the proximal renal tubules accounts for about 90% of the reabsorption of glucose from tubular fluid.  Genetic defects of SGLT2 result in a benign familial renal glucosuria.  Pharmacol. agents that block SGLT2 are being tested as potential treatment for type 2 diabetes mellitus.  A Pubmed search was used to identify all relevant articles on the physiol. of SGLTs as well as published preclin. and clin. exptl. studies with SGLT2 inhibitors; a ref. search of all retrieved articles was also undertaken.  SGLT2 is almost exclusively expressed in the proximal renal tubules.  Preclin. studies with selective SLGT2 inhibitors show dose-dependent glucosuria and lowering of blood glucose in models of type 2 diabetes.  Preliminary clin. studies of ≤ 3-mo duration show dose-dependent lowering of glycosylated Hb ≤ 0.9% along with modest wt. loss.  Side effects include an increase in genital fungal infection compared to placebo, increased urine vol. (300-400 mL/24 h), and evidence of vol. depletion consistent with mild diuretic effect.  SGLT2 inhibitors are showing promise as a useful addn. to the current therapeutic options in type 2 diabetes mellitus.  Results of ongoing phase III clin. trials are awaited and will det. whether the risk-benefit ratio will allow approval of this new class of drug for the management of type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVmHLfjABp1bVg90H21EOLACvtfcHk0lhx6OP9PQ95pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGhsr0%253D&md5=d99ac28d42f3b3869b61fb98d53587f6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1210%2Fjc.2009-0473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2009-0473%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DS.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DSodium%2520glucose%2520cotransporter%25202%2520inhibitors%2520as%2520a%2520new%2520treatment%2520for%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2010%26volume%3D95%26spage%3D34%26epage%3D42%26doi%3D10.1210%2Fjc.2009-0473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanefeld, M.</span></span> <span> </span><span class="NLM_article-title">The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus</span>. <i>J. Diabetes Complicat.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/S1056-8727(97)00123-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS1056-8727%2897%2900123-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=9647342" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=228-237&author=M.+Hanefeld&title=The+role+of+acarbose+in+the+treatment+of+non-insulin-dependent+diabetes+mellitus&doi=10.1016%2FS1056-8727%2897%2900123-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS1056-8727%2897%2900123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1056-8727%252897%252900123-2%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520acarbose%2520in%2520the%2520treatment%2520of%2520non-insulin-dependent%2520diabetes%2520mellitus%26jtitle%3DJ.%2520Diabetes%2520Complicat.%26date%3D1998%26volume%3D12%26spage%3D228%26epage%3D237%26doi%3D10.1016%2FS1056-8727%2897%2900123-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruniera, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviolli, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacci, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Luz Goncalves Pedreira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorgini
Peterlini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzalis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos Junqueira, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, F. L.</span></span> <span> </span><span class="NLM_article-title">The use of vancomycin with its therapeutic and adverse effects: a review</span>. <i>Eur. Rev. Med. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25753888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2MnislSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=694-700&author=F.+R.+Brunieraauthor=F.+M.+Ferreiraauthor=L.+R.+Saviolliauthor=M.+R.+Bacciauthor=D.+Federauthor=M.+da+Luz+Goncalves+Pedreiraauthor=M.+A.+Sorgini%0APeterliniauthor=L.+A.+Azzalisauthor=V.+B.+Campos+Junqueiraauthor=F.+L.+Fonseca&title=The+use+of+vancomycin+with+its+therapeutic+and+adverse+effects%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The use of vancomycin with its therapeutic and adverse effects: a review</span></div><div class="casAuthors">Bruniera F R; Ferreira F M; Saviolli L R M; Bacci M R; Feder D; da Luz Goncalves Pedreira M; Sorgini Peterlini M A; Azzalis L A; Campos Junqueira V B; Fonseca F L A</div><div class="citationInfo"><span class="NLM_cas:title">European review for medical and pharmacological sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">694-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Vancomycin (VCM) is a tricyclic glycopeptide antibiotic produced by Streptococcus orientalis.  Widely used in hospitals, it is indicated to fight severe infections caused by Gram-positive bacteria, especially with the advent of MRSA (methicillin-resistant Staphylococcus aureus), penicillin-resistant pneumococci among others.  Furthermore, it is indicated for the treatment of patients allergic to penicillins and cephalosporins.  Dose recommendations, dilution rates and types of infusion are controversial and also result in toxic effects.  Aim of this paper was to perform a literature review showing the therapeutic and adverse effects of vancomycin.  MATERIALS AND METHODS:  This is a literature review of recent articles published on MEDLINE and SciELO databases in English, Portuguese and Spanish.  RESULTS:  The main adverse effects of vancomycin are: hypotension, phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red man syndrome, neutropenia, chills, fever, interstitial nephritis.  CONCLUSIONS:  The use of vancomycin is still very common; however, inadequate doses and prolonged therapy pose a risk of increasing minimum inhibitory concentrations (MICs), resulting in subtherapeutic levels, treatment failures and toxicity.  Therefore, further studies should be conducted to optimize the administration of vancomycin, monitoring treatments from the beginning in order to ensure a safe and effective use of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlQswSuSEi7MSzjBFCN0BJfW6udTcc2ebucCQ-AdxG-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnislSlsQ%253D%253D&md5=b257c0b6ed5eb2984b2ef531c51814c7</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruniera%26aufirst%3DF.%2BR.%26aulast%3DFerreira%26aufirst%3DF.%2BM.%26aulast%3DSaviolli%26aufirst%3DL.%2BR.%26aulast%3DBacci%26aufirst%3DM.%2BR.%26aulast%3DFeder%26aufirst%3DD.%26aulast%3Dda%2BLuz%2BGoncalves%2BPedreira%26aufirst%3DM.%26aulast%3DSorgini%2BPeterlini%26aufirst%3DM.%2BA.%26aulast%3DAzzalis%26aufirst%3DL.%2BA.%26aulast%3DCampos%2BJunqueira%26aufirst%3DV.%2BB.%26aulast%3DFonseca%26aufirst%3DF.%2BL.%26atitle%3DThe%2520use%2520of%2520vancomycin%2520with%2520its%2520therapeutic%2520and%2520adverse%2520effects%253A%2520a%2520review%26jtitle%3DEur.%2520Rev.%2520Med.%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D19%26spage%3D694%26epage%3D700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arsic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mladenovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stankovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, P.</span></span> <span> </span><span class="NLM_article-title">16-membered macrolide antibiotics: a review</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2017.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ijantimicag.2017.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28668674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12iu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=283-298&author=B.+Arsicauthor=J.+Barberauthor=A.+Cikosauthor=M.+Mladenovicauthor=N.+Stankovicauthor=P.+Novak&title=16-membered+macrolide+antibiotics%3A+a+review&doi=10.1016%2Fj.ijantimicag.2017.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">16-Membered macrolide antibiotics: a review</span></div><div class="casAuthors">Arsic, Biljana; Barber, Jill; Cikos, Ana; Mladenovic, Milan; Stankovic, Nevena; Novak, Predrag</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-298</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The 16-membered macrolide antibiotics (e.g. tylosin A and josamycin) are mainly used in veterinary medicine, and are much less studied than their 14- and 15-membered erythromycin-based cousins.  Although these antibiotics have similar antibacterial profiles, with activity primarily against Gram-pos. and a limited range of Gram-neg. organisms, the 16-membered macrolides show some advantages.  These include better gastrointestinal tolerance, lack of drug-drug interactions, and activity against certain resistant bacterial strains by extension of the peptide tunnel reach allowing addnl. interactions.  In addn. to antibacterial activity, the most famous representative of the class, tylosin A, as well as some derivs. of desmycosin (tylosin B), have shown antimalarial activity.  Such activity has also been obsd. in the 14-membered macrolide antibiotics, azithromycin, solithromycin and clindamycin.  This antimalarial activity provides the opportunity to investigate these drugs as cheap and effective antimalarials.  This is an overview of the latest research on biosynthesis, structure, chem. properties and mode of action of 16-membered macrolides, with special emphasis on their most explored members: tylosin A and josamycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiw9SfzlKkx7Vg90H21EOLACvtfcHk0liFDRwdx66x3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12iu74%253D&md5=b58e545077ba9ed63b3d5494766141c8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2017.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2017.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DArsic%26aufirst%3DB.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DCikos%26aufirst%3DA.%26aulast%3DMladenovic%26aufirst%3DM.%26aulast%3DStankovic%26aufirst%3DN.%26aulast%3DNovak%26aufirst%3DP.%26atitle%3D16-membered%2520macrolide%2520antibiotics%253A%2520a%2520review%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2018%26volume%3D51%26spage%3D283%26epage%3D298%26doi%3D10.1016%2Fj.ijantimicag.2017.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Fidaxomicin: A novel agent for the treatment of clostridium difficile infection</span>. <i>Can. J. Infect. Dis. Med. Micriobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1155/2015/934594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1155%2F2015%2F934594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26744587" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=305-312&author=G.+G.+Zhanelauthor=A.+J.+Walktyauthor=J.+A.+Karlowsky&title=Fidaxomicin%3A+A+novel+agent+for+the+treatment+of+clostridium+difficile+infection&doi=10.1155%2F2015%2F934594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1155%2F2015%2F934594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F934594%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DWalkty%26aufirst%3DA.%2BJ.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DFidaxomicin%253A%2520A%2520novel%2520agent%2520for%2520the%2520treatment%2520of%2520clostridium%2520difficile%2520infection%26jtitle%3DCan.%2520J.%2520Infect.%2520Dis.%2520Med.%2520Micriobiol.%26date%3D2015%26volume%3D26%26spage%3D305%26epage%3D312%26doi%3D10.1155%2F2015%2F934594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, T.</span></span> <span> </span><span class="NLM_article-title">Aminoglycoside antibiotics: old drugs and new therapeutic approaches</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1852</span>, <span class="refDoi"> DOI: 10.1007/s00018-007-7034-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs00018-007-7034-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17447006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFagtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=1841-1852&author=T.+Hermann&title=Aminoglycoside+antibiotics%3A+old+drugs+and+new+therapeutic+approaches&doi=10.1007%2Fs00018-007-7034-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoglycoside antibiotics: old drugs and new therapeutic approaches</span></div><div class="casAuthors">Hermann, T.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1841-1852</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Aminoglycoside antibiotics kill bacteria by binding to the ribosomal decoding site and reducing fidelity of protein synthesis.  Since the discovery of these natural products over 50 years ago, aminoglycosides have provided a mainstay of antibacterial therapy of serious Gram-neg. infections.  In recent years, aminoglycosides have become important tools to study mol. recognition of RNA (RNA).  In an ingenious exploitation of the aminoglycosides' mechanism of action, it has been speculated that drug-induced readthrough of premature stop codons in mutated mRNAs might be used to treat patients suffering from certain heritable genetic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEI1QmZiN5qbVg90H21EOLACvtfcHk0liFDRwdx66x3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFagtLg%253D&md5=64e217c8a48b551551d3278fa203d8f3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00018-007-7034-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-007-7034-x%26sid%3Dliteratum%253Aachs%26aulast%3DHermann%26aufirst%3DT.%26atitle%3DAminoglycoside%2520antibiotics%253A%2520old%2520drugs%2520and%2520new%2520therapeutic%2520approaches%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2007%26volume%3D64%26spage%3D1841%26epage%3D1852%26doi%3D10.1007%2Fs00018-007-7034-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busscher, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutjes, F. P. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Delft, F. L.</span></span> <span> </span><span class="NLM_article-title">2-Deoxystreptamine: central scaffold of aminoglycoside antibiotics</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/cr0404085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr0404085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=775-792&author=G.+F.+Busscherauthor=F.+P.+J.+T.+Rutjesauthor=F.+L.+van+Delft&title=2-Deoxystreptamine%3A+central+scaffold+of+aminoglycoside+antibiotics&doi=10.1021%2Fcr0404085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">2-Deoxystreptamine: Central Scaffold of Aminoglycoside Antibiotics</span></div><div class="casAuthors">Busscher, Guuske F.; Rutjes, Floris P. J. T.; Van Delft, Floris L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-791</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses mechanism of action, toxicity, synthesis and resistance to aminoglycoside antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBApxOro0DKrVg90H21EOLACvtfcHk0lgjzgHx5UQnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsrg%253D&md5=531133e96e3397673a084b60341b04fe</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fcr0404085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0404085%26sid%3Dliteratum%253Aachs%26aulast%3DBusscher%26aufirst%3DG.%2BF.%26aulast%3DRutjes%26aufirst%3DF.%2BP.%2BJ.%2BT.%26aulast%3Dvan%2BDelft%26aufirst%3DF.%2BL.%26atitle%3D2-Deoxystreptamine%253A%2520central%2520scaffold%2520of%2520aminoglycoside%2520antibiotics%26jtitle%3DChem.%2520Rev.%26date%3D2005%26volume%3D105%26spage%3D775%26epage%3D792%26doi%3D10.1021%2Fcr0404085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Structure and mechanism of the lincosamide antibiotic adenylyltransferase LinB</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1659</span>, <span class="refDoi"> DOI: 10.1016/j.str.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.str.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=20004168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFantbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1649-1659&author=M.+Morarauthor=K.+Bhullarauthor=D.+W.+Hughesauthor=M.+Junopauthor=G.+D.+Wright&title=Structure+and+mechanism+of+the+lincosamide+antibiotic+adenylyltransferase+LinB&doi=10.1016%2Fj.str.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Mechanism of the Lincosamide Antibiotic Adenylyltransferase LinB</span></div><div class="casAuthors">Morar, Mariya; Bhullar, Kirandeep; Hughes, Donald W.; Junop, Murray; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1649-1659</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Lincosamides make up an important class of antibiotics used against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus.  Predictably, lincosamide-resistant microorganisms have emerged with antibiotic modification as one of their major resistance strategies.  Inactivating enzymes LinB/A catalyze adenylylation of the drug; however, little is known about their mechanistic and structural properties.  We detd. two x-ray structures of LinB: ternary substrate- and binary product-bound complexes.  Structural and kinetic characterization of LinB, mutagenesis, solvent isotope effect, and product inhibition studies are consistent with a mechanism involving direct in-line nucleotidyl transfer.  The characterization of LinB enabled its classification as a member of a nucleotidyltransferase superfamily, along with nucleotide polymerases and aminoglycoside nucleotidyltransferases, and this relationship offers further support for the LinB mechanism.  The LinB structure provides an evolutionary link to ancient nucleotide polymerases and suggests that, like protein kinases and acetyltransferases, these are proto-resistance elements from which drug resistance can evolve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTfPk0pQXU7Vg90H21EOLACvtfcHk0lgjzgHx5UQnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFantbrL&md5=16a3b5173a48a5b1492e541d835331c6</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DMorar%26aufirst%3DM.%26aulast%3DBhullar%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DD.%2BW.%26aulast%3DJunop%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DStructure%2520and%2520mechanism%2520of%2520the%2520lincosamide%2520antibiotic%2520adenylyltransferase%2520LinB%26jtitle%3DStructure%26date%3D2009%26volume%3D17%26spage%3D1649%26epage%3D1659%26doi%3D10.1016%2Fj.str.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetti, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivashanmugam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parthasarathy, S.</span></span> <span> </span><span class="NLM_article-title">Sugammadex: A revolutionary drug in neuromuscular pharmacology</span>. <i>Anesth. Essays Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.4103/0259-1162.123211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4103%2F0259-1162.123211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25885973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlsVeqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=302-306&author=K.+Nagauthor=D.+R.+Singhauthor=A.+N.+Shettiauthor=H.+Kumarauthor=T.+Sivashanmugamauthor=S.+Parthasarathy&title=Sugammadex%3A+A+revolutionary+drug+in+neuromuscular+pharmacology&doi=10.4103%2F0259-1162.123211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Sugammadex: A revolutionary drug in neuromuscular pharmacology</span></div><div class="casAuthors">Nag Kusha; Singh Dewan Roshan; Kumar Hemanth; Sivashanmugam T; Parthasarathy S; Shetti Akshaya N</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia, essays and researches</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">302-6</span>
        ISSN:<span class="NLM_cas:issn">0259-1162</span>.
    </div><div class="casAbstract">Sugammadex (ORG 25969) is a unique neuromuscular reversal drug; a novel cyclodextrin, the first in a new class of selective relaxant binding agents, which reverse neuromuscular blockade (NMB) with the aminosteroid non-depolarizing muscle relaxants rocuronium and vecuronium.  Sugammadex can reverse moderate or deep NMB.  The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQEv8ir77jTc25P7XSLhESfW6udTcc2eb8Tp9gKuJJsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlsVeqtQ%253D%253D&md5=ffdf88b898eb1f4578b0929929010aaf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.4103%2F0259-1162.123211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0259-1162.123211%26sid%3Dliteratum%253Aachs%26aulast%3DNag%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%2BR.%26aulast%3DShetti%26aufirst%3DA.%2BN.%26aulast%3DKumar%26aufirst%3DH.%26aulast%3DSivashanmugam%26aufirst%3DT.%26aulast%3DParthasarathy%26aufirst%3DS.%26atitle%3DSugammadex%253A%2520A%2520revolutionary%2520drug%2520in%2520neuromuscular%2520pharmacology%26jtitle%3DAnesth.%2520Essays%2520Res.%26date%3D2013%26volume%3D7%26spage%3D302%26epage%3D306%26doi%3D10.4103%2F0259-1162.123211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roder, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, M. J.</span></span> <span> </span><span class="NLM_article-title">Auranofin: repurposing an old drug for a golden new age</span>. <i>Drugs R&D</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1007/s40268-015-0083-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs40268-015-0083-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25698589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsF2htL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=13-20&author=C.+Roderauthor=M.+J.+Thomson&title=Auranofin%3A+repurposing+an+old+drug+for+a+golden+new+age&doi=10.1007%2Fs40268-015-0083-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin: Repurposing an Old Drug for a Golden New Age</span></div><div class="casAuthors">Roder, Christine; Thomson, Melanie J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs in R&D</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">DRDDFD</span>;
        ISSN:<span class="NLM_cas:issn">1174-5886</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Drug discovery, development and registration is an expensive and time-consuming process assocd. with a high failure rate [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Woodcock and Woosley (Annu Rev Med 59:1-12, 2008)].  Drug 'repurposing' is the identification of new therapeutic purposes for already approved drugs and is more affordable and achievable than novel drug discovery [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013)].  Auranofin is a drug that is approved for the treatment of rheumatoid arthritis but is being investigated for potential therapeutic application in a no. of other diseases including cancer, neurodegenerative disorders, HIV/AIDS, parasitic infections and bacterial infections [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)].  The main mechanism of action of auranofin is through the inhibition of redn./oxidn. (redox) enzymes that are essential for maintaining intracellular levels of reactive oxygen species.  Inhibition of these enzymes leads to cellular oxidative stress and intrinsic apoptosis [Pessetto et al. (Mol Cancer Ther 12:1299-1309, 2013), Fan et al. (Cell Death Dis 5:e1191, 2014), Fiskus et al. (Cancer Res 74:2520-2532, 2014), Marzano et al. (Free Radic Biol Med 42:872-881, 2007)].  Drugs such as auranofin that have already been approved for human use [Tejman-Yarden et al. (Antimicrob Agents Chemother 57:2029-2035, 2013)] can be brought into clin. use for other diseases relatively quickly and for a fraction of the cost of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqitmjCdCXIoLVg90H21EOLACvtfcHk0lj_4mEIWNW9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsF2htL8%253D&md5=86020bc2c56f02d36384f65a5062de35</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs40268-015-0083-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40268-015-0083-y%26sid%3Dliteratum%253Aachs%26aulast%3DRoder%26aufirst%3DC.%26aulast%3DThomson%26aufirst%3DM.%2BJ.%26atitle%3DAuranofin%253A%2520repurposing%2520an%2520old%2520drug%2520for%2520a%2520golden%2520new%2520age%26jtitle%3DDrugs%2520R%2526D%26date%3D2015%26volume%3D15%26spage%3D13%26epage%3D20%26doi%3D10.1007%2Fs40268-015-0083-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gissendanner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruthers, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slone, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. R.</span></span> <span> </span><span class="NLM_article-title">Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs</span>. <i>Vet. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1016/j.vetpar.2007.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.vetpar.2007.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=17980490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGjtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2007&pages=345-351&author=D.+E.+Snyderauthor=J.+Meyerauthor=A.+G.+Zimmermannauthor=M.+Qiaoauthor=S.+J.+Gissendannerauthor=L.+R.+Cruthersauthor=R.+L.+Sloneauthor=D.+R.+Young&title=Preliminary+studies+on+the+effectiveness+of+the+novel+pulicide%2C+spinosad%2C+for+the+treatment+and+control+of+fleas+on+dogs&doi=10.1016%2Fj.vetpar.2007.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs</span></div><div class="casAuthors">Snyder, Daniel E.; Meyer, Jeffery; Zimmermann, Alan G.; Qiao, Meihua; Gissendanner, Sonya J.; Cruthers, Larry R.; Slone, Robyn L.; Young, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Parasitology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">345-351</span>CODEN:
                <span class="NLM_cas:coden">VPARDI</span>;
        ISSN:<span class="NLM_cas:issn">0304-4017</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Spinosad is a novel mode-of-action insecticide produced from a family of natural products derived from fermn. of the actinomycete, Saccharopolyspora spinosa.  Sep. studies were undertaken to det. the min. ED of spinosad given orally for the treatment of exptl. induced flea infestations (Ctenocephalides felis) on dogs, and to assess any potential impacts of feeding canned or dry food at the time of dosing.  Both were randomized block (blocked by gender and pre-treatment flea counts), blinded parallel-arm studies, with dogs selected on health and ability to maintain pre-treatment flea populations.  For dose selection, 48 dogs were allocated among six groups (8 dogs/group; 4 males, 4 females): placebo-treated neg. control, spinosad in gelatin capsules at 15, 20, 30 and 40 mg/kg administered per os; and topical imidacloprid (10 mg/kg) as a pos. control.  Placebo and spinosad treatments were administered on Days 0, 30 and 60, imidacloprid only on Day 0.  In a second study to assess the impact of food type at the time of dosing, three groups were formed: placebo-treated control (8 dogs; 4 males, 4 females), spinosad (30 mg/kg) administered with canned food (8 male dogs, 8 females); and spinosad (30 mg/kg) with dry food (8 males, 8 females).  Treatments were administered on Days 0 and 30.  To assess post-treatment persistent efficacy, flea infestations were repeated at regular post-treatment intervals, beginning on Day 5 through Day 89 in the dose selection study and Day 58 in the impact of food type and dosing study.  Flea counts were performed 48 h post-infestation by study personnel who were blinded to treatments.  In the dose selection study, compared to geometric mean live flea counts in the control group, each spinosad dose was highly effective (99.8-100%) at 7, 14 and 21 days after treatment.  Only the 30 and 40 mg/kg doses maintained high efficacy (97.2-100%) until 30 days after treatment, with no difference between the two.  Imidacloprid was highly effective at Day 30, with significant difference only from the 15 mg/kg spinosad group.  Because there was no significant difference between the higher spinosad rates, 30 mg/kg was selected as the optimal min. ED.  In the second study, spinosad was highly effective at all post-treatment flea counts (98-100%).  Taken together, these studies demonstrate that repeated monthly oral treatments with spinosad at 30 mg/kg provide sustained control of C. felis on dogs.  There were no treatment-related adverse events in either study, indicating that spinosad has potential to be used monthly as a safe and effective flea adulticide, providing sustained activity that matches that of currently used topical products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgbO7Qe47X4rVg90H21EOLACvtfcHk0lj_4mEIWNW9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGjtr%252FM&md5=a2369bbcce41576611189b4e29f47494</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.vetpar.2007.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vetpar.2007.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DD.%2BE.%26aulast%3DMeyer%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DA.%2BG.%26aulast%3DQiao%26aufirst%3DM.%26aulast%3DGissendanner%26aufirst%3DS.%2BJ.%26aulast%3DCruthers%26aufirst%3DL.%2BR.%26aulast%3DSlone%26aufirst%3DR.%2BL.%26aulast%3DYoung%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520studies%2520on%2520the%2520effectiveness%2520of%2520the%2520novel%2520pulicide%252C%2520spinosad%252C%2520for%2520the%2520treatment%2520and%2520control%2520of%2520fleas%2520on%2520dogs%26jtitle%3DVet.%2520Parasitol.%26date%3D2007%26volume%3D150%26spage%3D345%26epage%3D351%26doi%3D10.1016%2Fj.vetpar.2007.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crump, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span> <span> </span><span class="NLM_article-title">Ivermectin, “wonder drug” from Japan: the human use perspective</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2183/pjab.87.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2183%2Fpjab.87.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2011&pages=13-28&author=A.+Crumpauthor=S.+Omura&title=Ivermectin%2C+%E2%80%9Cwonder+drug%E2%80%9D+from+Japan%3A+the+human+use+perspective&doi=10.2183%2Fpjab.87.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ivermectin 'Wonder drug' from Japan: the human use perspective</span></div><div class="casAuthors">Crump, Andy; Omura, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">13-28</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro deriv. of avermectin-originating solely from a single microorganism isolated at the Kitasato Institute, Tokyo, Japan from Japanese soil-has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world.  Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in com. livestock and companion animals.  It was quickly discovered to be ideal in combating two of the world's most devastating and disfiguring diseases which have plagued the world's poor throughout the tropics for centuries.  It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally.  It has also been used to successfully overcome several other human diseases and new uses for it are continually being found.  This paper looks in depth at the events surrounding ivermectin's passage from being a huge success in Animal Health into its widespread use in humans, a development which has led many to describe it as a "wonder" drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgTCraCUeJ7Vg90H21EOLACvtfcHk0lj_4mEIWNW9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt1alsL4%253D&md5=6eabcfcd3ef1a97aa7165b35d9eb0eef</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.2183%2Fpjab.87.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.87.13%26sid%3Dliteratum%253Aachs%26aulast%3DCrump%26aufirst%3DA.%26aulast%3DOmura%26aufirst%3DS.%26atitle%3DIvermectin%252C%2520%25E2%2580%259Cwonder%2520drug%25E2%2580%259D%2520from%2520Japan%253A%2520the%2520human%2520use%2520perspective%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2011%26volume%3D87%26spage%3D13%26epage%3D28%26doi%3D10.2183%2Fpjab.87.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tambo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khater, E. I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergquist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. N.</span></span> <span> </span><span class="NLM_article-title">Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty</span>. <i>Infect. Dis. Poverty</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1186/s40249-015-0091-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2Fs40249-015-0091-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26708575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC28rlsFajtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=58-65&author=E.+Tamboauthor=E.+I.+M.+Khaterauthor=J.+H.+Chenauthor=R.+Bergquistauthor=X.+N.+Zhou&title=Nobel+prize+for+the+artemisinin+and+ivermectin+discoveries%3A+a+great+boost+towards+elimination+of+the+global+infectious+diseases+of+poverty&doi=10.1186%2Fs40249-015-0091-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty</span></div><div class="casAuthors">Tambo Ernest; Tambo Ernest; Tambo Ernest; Tambo Ernest; Khater Emad I M; Zhou Xiao-Nong; Khater Emad I M; Zhou Xiao-Nong; Chen Jun-Hu; Zhou Xiao-Nong; Chen Jun-Hu; Chen Jun-Hu; Bergquist Robert</div><div class="citationInfo"><span class="NLM_cas:title">Infectious diseases of poverty</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58</span>
        ISSN:<span class="NLM_cas:issn">2095-5162</span>.
    </div><div class="casAbstract">The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to inflict a disproportionate global public health burden with associated consequences, thereby contributing to the vicious cycle of poverty and inequity.  However, the effectiveness and large-scale coverage of artemisinin combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives.  The paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the Nobel Prize in Physiology or Medicine in 2015.  However, the story would not be complete without mentioning praziquantel.  The huge contribution of this drug in modernizing the control of schistosomiasis and also some intestinal helminth infections had already shifted the focus from control to potential elimination of this disease.  Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious diseases that humans have lived with since time immemorial.  These drugs all have broad-spectrum effects, yet they are very safe and can even be packaged together in various combinations.  The strong effect on so many of the great infectious scourges in the developing countries has not only had a remarkable influence on many endemic diseases, but also contributed to improving the cost structure of healthcare.  Significant benefits include improved quality of preventive and curative medicine, promotion of community-based interventions, universal health coverage and the fostering of global partnerships.  The laudable progress and benefits achieved are indispensable in championing, strengthening and moving forward elimination of the IDoPs.  However, there is an urgent need for further innovative, contextual and integrated approaches along with the advent of the Sustainable Development Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzwIcPiz2m6Fw2ofyr07jXfW6udTcc2eYhiB_O_rRtwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rlsFajtw%253D%253D&md5=b9c00c0d744d3216ea9404ed73d56850</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs40249-015-0091-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40249-015-0091-8%26sid%3Dliteratum%253Aachs%26aulast%3DTambo%26aufirst%3DE.%26aulast%3DKhater%26aufirst%3DE.%2BI.%2BM.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DBergquist%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DX.%2BN.%26atitle%3DNobel%2520prize%2520for%2520the%2520artemisinin%2520and%2520ivermectin%2520discoveries%253A%2520a%2520great%2520boost%2520towards%2520elimination%2520of%2520the%2520global%2520infectious%2520diseases%2520of%2520poverty%26jtitle%3DInfect.%2520Dis.%2520Poverty%26date%3D2015%26volume%3D4%26spage%3D58%26epage%3D65%26doi%3D10.1186%2Fs40249-015-0091-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava, N.</span></span> <span> </span><span class="NLM_article-title">A review on pharmacological profile of Morpholine derivatives</span>. <i>Int. J. Pharmacol. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=40-51&author=M.+Naimauthor=O.+Alamauthor=J.+Alamauthor=P.+Alamauthor=N.+Shrivastava&title=A+review+on+pharmacological+profile+of+Morpholine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaim%26aufirst%3DM.%26aulast%3DAlam%26aufirst%3DO.%26aulast%3DAlam%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DP.%26aulast%3DShrivastava%26aufirst%3DN.%26atitle%3DA%2520review%2520on%2520pharmacological%2520profile%2520of%2520Morpholine%2520derivatives%26jtitle%3DInt.%2520J.%2520Pharmacol.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D3%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rupak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulichi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suman, K.</span></span> <span> </span><span class="NLM_article-title">Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance</span>. <i>Int. J. Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1777</span>– <span class="NLM_lpage">1788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=1777-1788&author=K.+Rupakauthor=S.+R.+Vulichiauthor=K.+Suman&title=Emphasizing+morpholine+and+its+derivatives+%28MAID%29%3A+typical+candidate+of+pharmaceutical+importance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance</span></div><div class="casAuthors">Rupak, Kumar; Vulichi, Srinivasa R.; Suman, Kapur</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chemical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1777-1788</span>CODEN:
                <span class="NLM_cas:coden">IJCSIL</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sadguru Publications</span>)
        </div><div class="casAbstract">The use of chems. (drugs) for both medical and recreational purposes is hardly new.  In fact, drug use seems to have been a part of human science prehistory.  Morpholine (C4H9NO, 1-oxa-4-azacyclohexane) is a synthetic simple heterocyclic org. compd. having characteristic functional groups of amine and ether and great industrial importance.  Chem. manipulations on morpholine based mols. through structure - activity relationship strategy could help developing many interesting candidates of therapeutic significance to tackle broad range of medical ailments.  Feasible physicochem. properties (polarity and soly.), low cost and wide availability make it a suitable candidate for the synthesis of many potent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT0rs1eUYwRbVg90H21EOLACvtfcHk0lhHZtc8JILY7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFantLs%253D&md5=5ebc0d446a0813a9ff55edccb0ef62ee</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRupak%26aufirst%3DK.%26aulast%3DVulichi%26aufirst%3DS.%2BR.%26aulast%3DSuman%26aufirst%3DK.%26atitle%3DEmphasizing%2520morpholine%2520and%2520its%2520derivatives%2520%2528MAID%2529%253A%2520typical%2520candidate%2520of%2520pharmaceutical%2520importance%26jtitle%3DInt.%2520J.%2520Chem.%2520Sci.%26date%3D2016%26volume%3D14%26spage%3D1777%26epage%3D1788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiver, G.</span></span> <span> </span><span class="NLM_article-title">The treatment of influenza with antiviral drugs</span>. <i>Can. Med. Assoc. J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">57</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12515786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FgvFCmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2003&pages=49-57&author=G.+Stiver&title=The+treatment+of+influenza+with+antiviral+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The treatment of influenza with antiviral drugs</span></div><div class="casAuthors">Stiver Grant</div><div class="citationInfo"><span class="NLM_cas:title">CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-56</span>
        ISSN:<span class="NLM_cas:issn">0820-3946</span>.
    </div><div class="casAbstract">Influenza vaccination with current inactivated vaccines homologous to the prevalent wild-type virus can reduce influenza illness in 75%-80% of healthy adults.  Vaccine is recommended for all individuals with chronic underlying diseases and for those aged 65 years or older.  Although influenza vaccination is still advocated for patients with blunted immunity, protection rates are not as high, running at 40% for frail institutionalized elderly people.  The influenza antiviral agents amantadine or rimantadine, zanamivir and oseltamivir can modify the severity of illness and reduce the duration of illness by about 1.5-2.5 days.  Amantadine inhibits only influenza A.  Resistant virus may emerge in up to 33% of amantadine-treated patients in the first 5 days of treatment and be transmitted to susceptible close contacts.  Side effects are usually mild in short courses of treatment.  The neuraminidase inhibitor drugs zanamivir and oseltamivir act on both influenza A and B.  Treatment is most effective when given within 30-36 hours after the onset of illness, and the earlier the better.  Influenza should be treated with antiviral drugs in unvaccinated and vaccinated high-risk patients, as well as immunosuppressed patients with influenza-like illness, in periods of confirmed influenza prevalence.  These drugs may be of great value in the event of a major viral antigenic shift that causes pandemic influenza, if an adequate supply can be sustained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8Urfbou99qTEwO064Z95rfW6udTcc2eYUUgAtdf25jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FgvFCmtQ%253D%253D&md5=8343e074c01f0ffdcfeed864852cff50</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStiver%26aufirst%3DG.%26atitle%3DThe%2520treatment%2520of%2520influenza%2520with%2520antiviral%2520drugs%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2003%26volume%3D168%26spage%3D49%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martelli, A.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buontempo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCubrey, J. A.</span></span> <span> </span><span class="NLM_article-title">Drug discovery targeting the mTOR pathway</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1042/CS20171158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1042%2FCS20171158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29523752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1Gnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=543-568&author=A.%0AM.+Martelliauthor=F.+Buontempoauthor=J.+A.+McCubrey&title=Drug+discovery+targeting+the+mTOR+pathway&doi=10.1042%2FCS20171158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Drug discovery targeting the mTOR pathway</span></div><div class="casAuthors">Martelli, Alberto M.; Buontempo, Francesca; McCubrey, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-568</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) and mTORC2. mTORC1 and mTORC2 play key physiol. roles as they control anabolic and catabolic processes in response to external cues in a variety of tissues and organs.  However, mTORC1 and mTORC2 activities are deregulated in widespread human diseases, including cancer.  Cancer cells take advantage of mTOR oncogenic signaling to drive their proliferation, survival, metabolic transformation, and metastatic potential.  Therefore, mTOR lends itself very well as a therapeutic target for innovative cancer treatment. mTOR was initially identified as the target of the antibiotic rapamycin that displayed remarkable antitumor activity in vitro.  Promising preclin. studies using rapamycin and its derivs. (rapalogs) demonstrated efficacy in many human cancer types, hence supporting the launch of numerous clin. trials aimed to evaluate the real effectiveness of mTOR-targeted therapies.  However, rapamycin and rapalogs have shown very limited activity in most clin. contexts, also when combined with other drugs.  Thus, novel classes of mTOR inhibitors with a stronger antineoplastic potency have been developed.  Nevertheless, emerging clin. data suggest that also these novel mTOR-targeting drugs may have a weak antitumor activity.  Here, we summarize the current status of available mTOR inhibitors and highlight the most relevant results from both preclin. and clin. studies that have provided valuable insights into both their efficacy and failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyW8DmOPSirrVg90H21EOLACvtfcHk0lhHZtc8JILY7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1Gnsrk%253D&md5=4cb101292276ef49baefa197915e306e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1042%2FCS20171158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171158%26sid%3Dliteratum%253Aachs%26aulast%3DMartelli%26aufirst%3DA.%2BM.%26aulast%3DBuontempo%26aufirst%3DF.%26aulast%3DMcCubrey%26aufirst%3DJ.%2BA.%26atitle%3DDrug%2520discovery%2520targeting%2520the%2520mTOR%2520pathway%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D543%26epage%3D568%26doi%3D10.1042%2FCS20171158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majewski, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner
Enschede, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span> <span> </span><span class="NLM_article-title">The bcl2 selective inhibitor venetoclax induces rapid onset apoptosis of cll cells in patients via a tp53-independent mechanism</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3215</span>– <span class="NLM_lpage">3224</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-01-688796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1182%2Fblood-2016-01-688796" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=3215-3224&author=M.+A.+Andersonauthor=J.+Dengauthor=J.+F.+Seymourauthor=C.+Tamauthor=S.+Y.+Kimauthor=J.+Feinauthor=L.+Yuauthor=J.+R.+Brownauthor=D.+Westermanauthor=E.+G.+Siauthor=I.+J.+Majewskiauthor=D.+Segalauthor=S.+L.+Heitner%0AEnschedeauthor=D.+C.+S.+Huangauthor=M.+S.+Davidsauthor=A.+Letaiauthor=A.+W.+Roberts&title=The+bcl2+selective+inhibitor+venetoclax+induces+rapid+onset+apoptosis+of+cll+cells+in+patients+via+a+tp53-independent+mechanism&doi=10.1182%2Fblood-2016-01-688796"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-01-688796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-01-688796%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DWesterman%26aufirst%3DD.%26aulast%3DSi%26aufirst%3DE.%2BG.%26aulast%3DMajewski%26aufirst%3DI.%2BJ.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DHeitner%2BEnschede%26aufirst%3DS.%2BL.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26atitle%3DThe%2520bcl2%2520selective%2520inhibitor%2520venetoclax%2520induces%2520rapid%2520onset%2520apoptosis%2520of%2520cll%2520cells%2520in%2520patients%2520via%2520a%2520tp53-independent%2520mechanism%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D3215%26epage%3D3224%26doi%3D10.1182%2Fblood-2016-01-688796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogeeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirumurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bal, T. R.</span></span> <span> </span><span class="NLM_article-title">Camptothecin and its analogues: a review on their chemotherapeutic potential</span>. <i>Nat. Prod. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1080/14786410412331299005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1080%2F14786410412331299005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=15938148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFajsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=393-412&author=D.+Sriramauthor=P.+Yogeeswariauthor=R.+Thirumuruganauthor=T.+R.+Bal&title=Camptothecin+and+its+analogues%3A+a+review+on+their+chemotherapeutic+potential&doi=10.1080%2F14786410412331299005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin and its analogues: a review on their chemotherapeutic potential</span></div><div class="casAuthors">Sriram, Dharmarajan; Yogeeswari, Perumal; Thirumurugan, Rathinasabapathy; Ratan Bal, Tanushree</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-412</span>CODEN:
                <span class="NLM_cas:coden">NPRAAT</span>;
        ISSN:<span class="NLM_cas:issn">1478-6419</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Topoisomerase I (Topo-I) is a major target for anticancer drug discovery and design.  As a result, Topo-I inhibitors constitute an important class of the current anticancer drugs.  To date, all of the Topo-I inhibitors that have been clin. evaluated are analogs of camptothecin (CPT), an ext. of the Chinese tree Camptotheca acuminata.  CPT has shown significant antitumor activity to lung, ovarian, breast, pancreas and stomach cancers.  In this article the, phytochem. aspect, and various structural modifications are comprehensively reviewed as in rings A, B, C, D and E. Biol. activity of camptothecin, other than anticancer, reported till the year 2003 has also been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6NIkdIrNjA7Vg90H21EOLACvtfcHk0lg_imEVMoq4uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFajsrY%253D&md5=7149d979a0e7915678cce4ba5ea8aabb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1080%2F14786410412331299005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14786410412331299005%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DD.%26aulast%3DYogeeswari%26aufirst%3DP.%26aulast%3DThirumurugan%26aufirst%3DR.%26aulast%3DBal%26aufirst%3DT.%2BR.%26atitle%3DCamptothecin%2520and%2520its%2520analogues%253A%2520a%2520review%2520on%2520their%2520chemotherapeutic%2520potential%26jtitle%3DNat.%2520Prod.%2520Res.%26date%3D2005%26volume%3D19%26spage%3D393%26epage%3D412%26doi%3D10.1080%2F14786410412331299005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzeeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shashikumar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullangi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies</span>. <i>Biomed. Chromatogr.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1002/bmc.561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1002%2Fbmc.561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16143964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=282-293&author=M.+K.+Pashaauthor=S.+Muzeebauthor=S.+J.+Bashaauthor=D.+Shashikumarauthor=R.+Mullangiauthor=N.+R.+Srinivas&title=Analysis+of+five+HMG-CoA+reductase+inhibitors%2D%2D+atorvastatin%2C+lovastatin%2C+pravastatin%2C+rosuvastatin+and+simvastatin%3A+pharmacological%2C+pharmacokinetic+and+analytical+overview+and+development+of+a+new+method+for+use+in+pharmaceutical+formulations+analysis+and+in+vitro+metabolism+studies&doi=10.1002%2Fbmc.561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of 5 HMG-CoA reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies</span></div><div class="casAuthors">Pasha, Md. Khalid; Muzeeb, Syed; Basha, Shaik Jafar Sadik; Shashikumar, Dhanya; Mullangi, Ramesh; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedical Chromatography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BICHE2</span>;
        ISSN:<span class="NLM_cas:issn">0269-3879</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A specific, accurate, precise and reproducible high-performance liq. chromatog. (HPLC) method was developed and validated for the simultaneous quantitation of 5 3-hydroxy-3-methyglutaryl CoA (HMG-CoA) reductase inhibitors, viz. atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin, in pharmaceutical formulations and extended the application to in vitro metab. studies of these statins.  Ternary gradient elution at a flow rate of 1 mL/min was employed on an Intertisl ODS 3V column (4.6 × 250 mm, 5 μm) at ambient temp.  The mobile phase consisted of 0.01 M ammonium acetate (pH 5.0), acetonitrile and methanol.  Theophylline was used as an internal std. (IS).  The HMG-CoA reductase inhibitors and their metabolites were monitored at a wavelength of 237 nm.  Drugs were found to be 89.6-105.6% of their label's claim in the pharmaceutical formulations.  For in vitro metab. studies the reaction mixts. were extd. with simple liq.-liq. extn. using Et acetate.  Baseline sepn. of statins and their metabolites along with IS free from endogenous interferences was achieved.  Nominal retention times of IS, atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin were 7.5, 17.2, 21.6, 28.5, 33.5, and 35.5 min, resp.  The proposed method is simple, selective, and could be applicable for routine anal. of HMG-CoA reductase inhibitors in pharmaceutical prepns. as well as in vitro metab. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpwmedQVQ007Vg90H21EOLACvtfcHk0lg_imEVMoq4uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlKlsr8%253D&md5=b095fd040f79ebdf5fa3bff5e9d51e30</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fbmc.561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.561%26sid%3Dliteratum%253Aachs%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DMuzeeb%26aufirst%3DS.%26aulast%3DBasha%26aufirst%3DS.%2BJ.%26aulast%3DShashikumar%26aufirst%3DD.%26aulast%3DMullangi%26aufirst%3DR.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DAnalysis%2520of%2520five%2520HMG-CoA%2520reductase%2520inhibitors--%2520atorvastatin%252C%2520lovastatin%252C%2520pravastatin%252C%2520rosuvastatin%2520and%2520simvastatin%253A%2520pharmacological%252C%2520pharmacokinetic%2520and%2520analytical%2520overview%2520and%2520development%2520of%2520a%2520new%2520method%2520for%2520use%2520in%2520pharmaceutical%2520formulations%2520analysis%2520and%2520in%2520vitro%2520metabolism%2520studies%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2006%26volume%3D20%26spage%3D282%26epage%3D293%26doi%3D10.1002%2Fbmc.561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunkel, L.</span></span> <span> </span><span class="NLM_article-title">Use of aromatase inhibitors to increase final height</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>254–255</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2006.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.mce.2006.04.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16766117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254%E2%80%93255&publication_year=2006&pages=207-216&author=L.+Dunkel&title=Use+of+aromatase+inhibitors+to+increase+final+height&doi=10.1016%2Fj.mce.2006.04.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Use of aromatase inhibitors to increase final height</span></div><div class="casAuthors">Dunkel, Leo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">254-255</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  During puberty in both sexes, the mechanism involved in epiphyseal fusion is mediated by the action of estrogen through a cascade of events including proliferation, differentiation, and apoptosis of chondrocytes.  The enzyme P 450 aromatase catalyzes the aromatization of C19 androgens (androstenedione and testosterone) to C18 estrogens (estrone and estradiol).  Inhibition of estrogen action by aromatase inhibitors (AIs) appears to decelerate the process of growth plate fusion, and thus AIs may be used therapeutically to increase adult height.  The clin. experience with AIs in the pediatric setting is limited to testolactone, fadrozole, letrozole, and anastrozole.  Testolactone, a nonselective steroidal AI, was used successfully as an adjunct to antiandrogen and gonadotropin-releasing hormone analog (GnRHa), therapy for children with familial male-limited precocious puberty (FMPP) and congenital adrenal hyperplasia (CAH), and with some success in girls with McCune-Albright syndrome.  The limitations of testolactone include its relatively low potency and the need for frequent dosing.  Results of a randomized placebo-controlled trial in boys with delayed puberty treated with letrozole, a selective nonsteroidal AI, found that boys treated with letrozole + testosterone experienced delayed bone maturation and good growth response and achieved an increase in predicted adult height.  In this study, only minor differences in bone d. were seen between the placebo and letrozole treatment groups, both of which were receiving concomitant testosterone therapy.  No adverse effects on testis size or inhibin B concn. were noted.  The therapeutic value of AIs in growth promotion now remains to be substantiated in future controlled clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd6lh7ASnlPLVg90H21EOLACvtfcHk0lg19QUEH5t3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFSjtro%253D&md5=c5294ae019b717b8619e84367f7fdd33</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2006.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2006.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DL.%26atitle%3DUse%2520of%2520aromatase%2520inhibitors%2520to%2520increase%2520final%2520height%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2006%26volume%3D254%25E2%2580%2593255%26spage%3D207%26epage%3D216%26doi%3D10.1016%2Fj.mce.2006.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandel, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span> <span> </span><span class="NLM_article-title">Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3547</span>– <span class="NLM_lpage">3555</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S84850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FDDDT.S84850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26185421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=3547-3555&author=C.+E.+Kandelauthor=S.+L.+Walmsley&title=Dolutegravir+%E2%80%93+a+review+of+the+pharmacology%2C+efficacy%2C+and+safety+in+the+treatment+of+HIV&doi=10.2147%2FDDDT.S84850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV</span></div><div class="casAuthors">Kandel, Christopher E.; Walmsley, Sharon L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3547-3555</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection.  Dolutegravir is equiv. or superior to existing treatment regimens in both treatment-na.ovrddot.ive and treatment-experienced patients including those with previous raltegravir or elvitegravir failure.  The consistent efficacy coupled with excellent tolerability and infrequent drug-drug interactions makes the co-formulation of dolutegravir with two nucleotide reverse-transcriptase inhibitors an attractive treatment option.  This review summarizes the pharmacokinetics, adverse event profile, and efficacy of dolutegravir in the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowDC2XTWz-H7Vg90H21EOLACvtfcHk0lg19QUEH5t3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOjtLs%253D&md5=3c19253c813435554b78db89949fbb13</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S84850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S84850%26sid%3Dliteratum%253Aachs%26aulast%3DKandel%26aufirst%3DC.%2BE.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26atitle%3DDolutegravir%2520%25E2%2580%2593%2520a%2520review%2520of%2520the%2520pharmacology%252C%2520efficacy%252C%2520and%2520safety%2520in%2520the%2520treatment%2520of%2520HIV%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D3547%26epage%3D3555%26doi%3D10.2147%2FDDDT.S84850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D. H.</span></span> <span> </span><span class="NLM_article-title">(1994). Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.2165/00003495-199448040-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-199448040-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1994&pages=599-616&author=R.+N.+Brogdenauthor=D.+H.+Peters&title=%281994%29.+Dirithromycin.+A+review+of+its+antimicrobial+activity%2C+pharmacokinetic+properties+and+therapeutic+efficacy&doi=10.2165%2F00003495-199448040-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2165%2F00003495-199448040-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199448040-00008%26sid%3Dliteratum%253Aachs%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26aulast%3DPeters%26aufirst%3DD.%2BH.%26atitle%3D%25281994%2529.%2520Dirithromycin.%2520A%2520review%2520of%2520its%2520antimicrobial%2520activity%252C%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%26jtitle%3DDrugs%26date%3D1994%26volume%3D48%26spage%3D599%26epage%3D616%26doi%3D10.2165%2F00003495-199448040-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhazes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, F.</span></span> <span> </span><span class="NLM_article-title">Chromone as a privileged scaffold in drug discovery: recent advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7941</span>– <span class="NLM_lpage">7957</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1ylsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7941-7957&author=J.+Reisauthor=A.+Gasparauthor=N.+Milhazesauthor=F.+Borges&title=Chromone+as+a+privileged+scaffold+in+drug+discovery%3A+recent+advances&doi=10.1021%2Facs.jmedchem.6b01720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances</span></div><div class="casAuthors">Reis, Joana; Gaspar, Alexandra; Milhazes, Nuno; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7941-7957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of privileged structures in drug discovery has proven to be an effective strategy allowing the generation of innovative hits/leads and successful optimization processes.  Chromone is actually recognized as a privileged structure and a valid template for the design of novel compds. with potential pharmacol. interest, particularly in the field of neurodegenerative, inflammatory and infectious diseases as well as diabetes and cancer.  Within this framework, this review provides the reader with a literature update following the preceding article entitled Chromone: a valid scaffold in Medicinal Chem.  The review is mainly focused on the biol. interest of chromones, including those isolated from natural sources.  Moreover, as drug repurposing is becoming an attractive drug discovery approach, the opening repurposing studies on chromone-based drugs are also reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLXpaiKTmA7Vg90H21EOLACvtfcHk0lg19QUEH5t3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1ylsbY%253D&md5=bb722a050abe9c6203d9d891818d06eb</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01720%26sid%3Dliteratum%253Aachs%26aulast%3DReis%26aufirst%3DJ.%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DMilhazes%26aufirst%3DN.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DChromone%2520as%2520a%2520privileged%2520scaffold%2520in%2520drug%2520discovery%253A%2520recent%2520advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7941%26epage%3D7957%26doi%3D10.1021%2Facs.jmedchem.6b01720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goa, K. L.</span></span> <span> </span><span class="NLM_article-title">Galantamine: a review of its use in Alzheimer’s disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060050-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-200060050-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1095-1122&author=L.+J.+Scottauthor=K.+L.+Goa&title=Galantamine%3A+a+review+of+its+use+in+Alzheimer%E2%80%99s+disease&doi=10.2165%2F00003495-200060050-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060050-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060050-00008%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DGoa%26aufirst%3DK.%2BL.%26atitle%3DGalantamine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26spage%3D1095%26epage%3D1122%26doi%3D10.2165%2F00003495-200060050-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nevagi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. N.</span></span> <span> </span><span class="NLM_article-title">Biological and medicinal significance of benzofuran</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.ejmech.2014.10.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=26015069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFWisr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=561-581&author=R.+J.+Nevagiauthor=S.+N.+Digheauthor=S.+N.+Dighe&title=Biological+and+medicinal+significance+of+benzofuran&doi=10.1016%2Fj.ejmech.2014.10.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Biological and medicinal significance of benzofuran</span></div><div class="casAuthors">Nevagi, Reshma J.; Dighe, Santosh N.; Dighe, Satish N.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">561-581</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  This article emphasizes on the importance of benzofuran as a biol. relevant heterocycle.  It covers most of the physiol. as well as medicinally important compds. contg. benzofuran rings.  This article also covers clin. approved drugs contg. benzofuran scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmk0ugoH_1xLVg90H21EOLACvtfcHk0lhj2-nznNVweg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFWisr3F&md5=d3395a58c2eaf4c068d8e7465a2014d2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.085%26sid%3Dliteratum%253Aachs%26aulast%3DNevagi%26aufirst%3DR.%2BJ.%26aulast%3DDighe%26aufirst%3DS.%2BN.%26aulast%3DDighe%26aufirst%3DS.%2BN.%26atitle%3DBiological%2520and%2520medicinal%2520significance%2520of%2520benzofuran%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D561%26epage%3D581%26doi%3D10.1016%2Fj.ejmech.2014.10.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hiremathad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K. R., C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, R. S.</span></span> <span> </span><span class="NLM_article-title">Benzofuran: an emerging scaffold for antimicrobial agents</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">96809</span>– <span class="NLM_lpage">96828</span>, <span class="refDoi"> DOI: 10.1039/C5RA20658H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1039%2FC5RA20658H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWktrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=96809-96828&author=A.+Hiremathadauthor=M.+R.+Patilauthor=C.+K.+R.author=K.+Chandauthor=M.+A.+Santosauthor=R.+S.+Keri&title=Benzofuran%3A+an+emerging+scaffold+for+antimicrobial+agents&doi=10.1039%2FC5RA20658H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Benzofuran: an emerging scaffold for antimicrobial agents</span></div><div class="casAuthors">Hiremathad, Asha; Patil, Mahadeo R.; Chethana, K. R.; Chand, Karam; Santos, M. Amelia; Keri, Rangappa S.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">117</span>),
    <span class="NLM_cas:pages">96809-96828</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Resistance to antibiotics is a major global problem and there is an urgent need to develop new therapeutic agents.  Although many classes of active compds. have been established as efficient derivs. in diverse fields of antimicrobial therapy, they have not yet found wide application against a few deadly microbes.  In recent years, compds. have been developed that have solved some of the problems posed; for example improved bioavailability is one of the targets achieved with most of the more recent compds., allowing for once-daily dosing.  Benzofuran and its derivs. are found to be suitable structures, existing widely in natural products and unnatural compds. with a wide range of biol. and pharmacol. applications; thus, considerable attention has been focused on the discovery of new drugs in the fields of drug invention and development.  Some benzofuran derivs., such as psoralen, 8-methoxypsoralen and angelicin have been used in the treatment of skin diseases such as cancer or psoriasis.  The unique structural features of benzofuran and its wide array of biol. activities make it a privileged structure in the field of drug discovery, esp. in the search for efficient antimicrobial candidates.  Recently, this scaffold has emerged as a pharmacophore of choice for designing antimicrobial agents that are active toward different clin. approved targets.  To pave the way for future research, there is a need to collect the latest information in this promising area.  In the present review, we collated the published reports on this versatile core to provide a deeper insight, so that its full therapeutic potential can be utilized for the treatment of microbial diseases.  This study systematically provides a comprehensive report on current developments in benzofuran-based compds. as antimicrobial agents and is also helpful for the researchers working on a substitution pattern around the nucleus, with an aim to help medicinal chemists to develop structure activity relationships (SAR) on these derivs. as antimicrobial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5jEoZROreO7Vg90H21EOLACvtfcHk0lhj2-nznNVweg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWktrzJ&md5=f1d95320bfd53a054d8cb80217571b65</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1039%2FC5RA20658H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA20658H%26sid%3Dliteratum%253Aachs%26aulast%3DHiremathad%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DM.%2BR.%26aulast%3DK.%2BR.%26aufirst%3DC.%26aulast%3DChand%26aufirst%3DK.%26aulast%3DSantos%26aufirst%3DM.%2BA.%26aulast%3DKeri%26aufirst%3DR.%2BS.%26atitle%3DBenzofuran%253A%2520an%2520emerging%2520scaffold%2520for%2520antimicrobial%2520agents%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D96809%26epage%3D96828%26doi%3D10.1039%2FC5RA20658H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1111/j.1742-7843.2006.pto_295.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1742-7843.2006.pto_295.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16918708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1egsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=91-95&author=C.+Sanchez&title=The+pharmacology+of+citalopram+enantiomers%3A+the+antagonism+by+R-citalopram+on+the+effect+of+S-citalopram&doi=10.1111%2Fj.1742-7843.2006.pto_295.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram</span></div><div class="casAuthors">Sanchez, Connie</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-95</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent results on the in vivo and in vitro pharmacol. of escitalopram are summarized.  The exact mol. mechanism by which R-citalopram inhibits the effect of S-citalopram on the serotonin transporter remains to be elucidated.  Preliminary evidence indicates an effect of R-citalopram on the assocn. of escitalopram with the high affinity primary site, and on its dissocn. from the serotonin transporter, via an allosteric mechanism.  Escitalopram can be considered as an allosteric serotonin reuptake inhibitor.  This serotonin dual action in binding to two sites on the serotonin transporter (both the primary site and the allosteric site) is hypothesized to be responsible for a longer binding to, and therefore greater inhibition of the serotonin transporter by escitalopram.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCxYDiKuN86bVg90H21EOLACvtfcHk0lhj2-nznNVweg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1egsrk%253D&md5=7ab6c4f4549d521e3fb01a42621fc5e2</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-7843.2006.pto_295.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-7843.2006.pto_295.x%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DC.%26atitle%3DThe%2520pharmacology%2520of%2520citalopram%2520enantiomers%253A%2520the%2520antagonism%2520by%2520R-citalopram%2520on%2520the%2520effect%2520of%2520S-citalopram%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2006%26volume%3D99%26spage%3D91%26epage%3D95%26doi%3D10.1111%2Fj.1742-7843.2006.pto_295.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meshnick, S. R.</span></span> <span> </span><span class="NLM_article-title">Artemisinin: mechanisms of action, resistance and toxicity</span>. <i>Int. J. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1660</span>, <span class="refDoi"> DOI: 10.1016/S0020-7519(02)00194-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2FS0020-7519%2802%2900194-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12435450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFCitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=1655-1660&author=S.+R.+Meshnick&title=Artemisinin%3A+mechanisms+of+action%2C+resistance+and+toxicity&doi=10.1016%2FS0020-7519%2802%2900194-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin: mechanisms of action, resistance and toxicity</span></div><div class="casAuthors">Meshnick, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal for Parasitology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1655-1660</span>CODEN:
                <span class="NLM_cas:coden">IJPYBT</span>;
        ISSN:<span class="NLM_cas:issn">0020-7519</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Artemisinin and its derivs. are widely used throughout the world.  The mechanism of action of these compds. appears to involve the heme-mediated decompn. of the endoperoxide bridge to produce carbon-centered free radicals.  The involvement of heme explains why the drugs are selectively toxic to malaria parasites.  The resulting carbon-centered free radicals are alkylate heme and proteins, one of which is the translationally controlled tumor protein.  Clin. relevant artemisinin resistance has not been demonstrated, but it is likely to occur since artemisinin resistance has been obtained in lab. models.  At high doses, artemisinin can be neurotoxic but toxicity has not been found in clin. studies.  The mechanism of neurotoxicity may be similar to the mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEyIN982VPC7Vg90H21EOLACvtfcHk0lgJzHwY5ZcmNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFCitb0%253D&md5=6d99303ca4b4ba70e70cf4352b10cc1f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0020-7519%2802%2900194-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0020-7519%252802%252900194-7%26sid%3Dliteratum%253Aachs%26aulast%3DMeshnick%26aufirst%3DS.%2BR.%26atitle%3DArtemisinin%253A%2520mechanisms%2520of%2520action%252C%2520resistance%2520and%2520toxicity%26jtitle%3DInt.%2520J.%2520Parasitol.%26date%3D2002%26volume%3D32%26spage%3D1655%26epage%3D1660%26doi%3D10.1016%2FS0020-7519%2802%2900194-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seto, B.</span></span> <span> </span><span class="NLM_article-title">Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer</span>. <i>Clin Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/2001-1326-1-29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1186%2F2001-1326-1-29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23369283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC3szktlGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=29&author=B.+Seto&title=Rapamycin+and+mTOR%3A+a+serendipitous+discovery+and+implications+for+breast+cancer&doi=10.1186%2F2001-1326-1-29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer</span></div><div class="casAuthors">Seto Belinda</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract"> Rapamycin was discovered more than thirty years ago from a soil sample from the island of Rapa Nui.  It was isolated from Streptomyces hygroscopicus and initial characterization focused on its antifungal activities.  Subsequent characterization showed that it has immunosuppressive properties and has been used successfully to reduce organ rejection with kidney transplantation.  Rapamycin has proven to be a versatile compound with several seemingly unrelated properties, including antifungal, immunosuppressive, and anticancer.  The National Cancer Institute (NCI) Developmental Therapeutics Program demonstrated that rapamycin inhibited cell growth in tumor cell lines.  These observations stimulated research to explore the underlying mechanism of anti-tumor activities.  Cell growth inhibition involves binding to the mammalian Target of Rapamycin (mTOR).  The mTOR signaling pathway is critical to cell growth, proliferation, and survival and rapamycin inhibits these hallmark processes of cancer.  Binding of growth factors activates mTOR signaling, which in turn leads to downstream phosphorylation of protein kinases, e.g., p70S6 kinase and lipid kinases in the phosphorylation of phosphoinositides.  Understanding of mTOR signaling provided the biological basis for targeted chemotherapeutics development, including several rapamycin analogues for treating breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB8nxRBba5AFvAgqb2vdc5fW6udTcc2eZMyGAlJo5AW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szktlGiug%253D%253D&md5=dbf9e11d3ff4c131131f06324465608c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2F2001-1326-1-29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2001-1326-1-29%26sid%3Dliteratum%253Aachs%26aulast%3DSeto%26aufirst%3DB.%26atitle%3DRapamycin%2520and%2520mTOR%253A%2520a%2520serendipitous%2520discovery%2520and%2520implications%2520for%2520breast%2520cancer%26jtitle%3DClin%2520Transl%2520Med.%26date%3D2012%26volume%3D1%26spage%3D29%26doi%3D10.1186%2F2001-1326-1-29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederrecht, G. J.</span></span> <span> </span><span class="NLM_article-title">Immunopharmacology of rapamycin</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.14.1.483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1146%2Fannurev.immunol.14.1.483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=8717522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaK28XitlCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=483-510&author=R.+T.+Abrahamauthor=G.+J.+Wiederrecht&title=Immunopharmacology+of+rapamycin&doi=10.1146%2Fannurev.immunol.14.1.483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Immunopharmacology of rapamycin</span></div><div class="casAuthors">Abraham, Robert T.; Wiederrecht, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">483-510</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 135 refs.  The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth.  The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacol. active complexes with members of a family of intracellular receptors termed the FK506 binding proteins (FKBPs).  The FKBP12·FK506 complex specifically binds to and inhibits calcineurin, a signaling protein required for transcriptional activation of the interleukin (IL)-2 gene in response to T cell antigen receptor engagement.  The FKBP12·rapamycin complex interacts with a recently defined target protein termed the mammalian target of rapamycin (mTOR).  Accumulating data suggest that mTOR functions in a previously unrecognized signal transduction pathway required for the progression of IL-2-stimulated T cells from G1 into the S phase of the cell cycle.  Here we review the immunopharmacol. of rapamycin, with particular emphasis on the characterization of mTOR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK9uto6qzk57Vg90H21EOLACvtfcHk0lgJzHwY5ZcmNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitlCgtb0%253D&md5=90d82e8b704b9fd06c906738b1349bf3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.14.1.483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.14.1.483%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DWiederrecht%26aufirst%3DG.%2BJ.%26atitle%3DImmunopharmacology%2520of%2520rapamycin%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D1996%26volume%3D14%26spage%3D483%26epage%3D510%26doi%3D10.1146%2Fannurev.immunol.14.1.483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimmock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garside, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials</span>. <i>BMJ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">516</span>, <span class="refDoi"> DOI: 10.1136/bmj.38376.439653.D3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1136%2Fbmj.38376.439653.D3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2005&pages=516&author=D.+M.+Ashcroftauthor=P.+Dimmockauthor=R.+Garsideauthor=K.+Steinauthor=H.+C.+Williams&title=Efficacy+and+tolerability+of+topical+pimecrolimus+and+tacrolimus+in+the+treatment+of+atopic+dermatitis%3A+meta-analysis+of+randomised+controlled+trials&doi=10.1136%2Fbmj.38376.439653.D3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1136%2Fbmj.38376.439653.D3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.38376.439653.D3%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DD.%2BM.%26aulast%3DDimmock%26aufirst%3DP.%26aulast%3DGarside%26aufirst%3DR.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DH.%2BC.%26atitle%3DEfficacy%2520and%2520tolerability%2520of%2520topical%2520pimecrolimus%2520and%2520tacrolimus%2520in%2520the%2520treatment%2520of%2520atopic%2520dermatitis%253A%2520meta-analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DBMJ.%26date%3D2005%26volume%3D330%26spage%3D516%26doi%3D10.1136%2Fbmj.38376.439653.D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Recine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongiovanni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fausti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatali, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miserocchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, T.</span></span> <span> </span><span class="NLM_article-title">Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1164</span>, <span class="refDoi"> DOI: 10.2147/OTT.S127955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FOTT.S127955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28260930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFamurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=1155-1164&author=F.+Recineauthor=A.+Bongiovanniauthor=N.+Rivaauthor=V.+Faustiauthor=A.+De+Vitaauthor=L.+Mercataliauthor=C.+Liveraniauthor=G.+Miserocchiauthor=D.+Amadoriauthor=T.+Ibrahim&title=Update+on+the+role+of+trabectedin+in+the+treatment+of+intractable+soft+tissue+sarcomas&doi=10.2147%2FOTT.S127955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas</span></div><div class="casAuthors">Recine, Federica; Bongiovanni, Alberto; Riva, Nada; Fausti, Valentina; De Vita, Alessandro; Mercatali, Laura; Liverani, Chiara; Miserocchi, Giacomo; Amadori, Dino; Ibrahim, Toni</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1155-1164</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers.  This group of tumors comprises over 60 different histotypes with different biol. showing different sensitivity to therapeutic agents.  For decades, the std. first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy.  Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined.  Trabectedin is one of the new mols. approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents.  The compd. is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunol. effects.  This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp27aQwLkKWY7Vg90H21EOLACvtfcHk0ljw5qZ27Bt7-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFamurvE&md5=8a5313f5ca66382281c331738eed6482</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2147%2FOTT.S127955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S127955%26sid%3Dliteratum%253Aachs%26aulast%3DRecine%26aufirst%3DF.%26aulast%3DBongiovanni%26aufirst%3DA.%26aulast%3DRiva%26aufirst%3DN.%26aulast%3DFausti%26aufirst%3DV.%26aulast%3DDe%2BVita%26aufirst%3DA.%26aulast%3DMercatali%26aufirst%3DL.%26aulast%3DLiverani%26aufirst%3DC.%26aulast%3DMiserocchi%26aufirst%3DG.%26aulast%3DAmadori%26aufirst%3DD.%26aulast%3DIbrahim%26aufirst%3DT.%26atitle%3DUpdate%2520on%2520the%2520role%2520of%2520trabectedin%2520in%2520the%2520treatment%2520of%2520intractable%2520soft%2520tissue%2520sarcomas%26jtitle%3DOncoTargets%2520Ther.%26date%3D2017%26volume%3D10%26spage%3D1155%26epage%3D1164%26doi%3D10.2147%2FOTT.S127955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderMolen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberlies, N. H.</span></span> <span> </span><span class="NLM_article-title">Romidepsin (Istodax®, NSC 630176, FR901228, FK228, Depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">531</span>, <span class="refDoi"> DOI: 10.1038/ja.2011.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fja.2011.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=21587264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=525-531&author=K.+M.+VanderMolenauthor=W.+McCullochauthor=C.+J.+Pearceauthor=N.+H.+Oberlies&title=Romidepsin+%28Istodax%C2%AE%2C+NSC+630176%2C+FR901228%2C+FK228%2C+Depsipeptide%29%3A+a+natural+product+recently+approved+for+cutaneous+T-cell+lymphoma&doi=10.1038%2Fja.2011.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma</span></div><div class="casAuthors">VanderMolen Karen M; McCulloch William; Pearce Cedric J; Oberlies Nicholas H</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antibiotics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">525-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration.  This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample.  This bicyclic compound acts as a prodrug, its disulfide bridge being reduced by glutathione on uptake into the cell, allowing the free thiol groups to interact with Zn ions in the active site of class I and II HDAC enzymes.  Due to the synthetic complexity of the compound, as well as the low yield from the producing organism, analogs are sought to create synthetically accessible alternatives.  As a T-cell lymphoma drug, romidepsin offers a valuable new treatment for diseases with few effective therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6-aG7G4t02v69nzq6467DfW6udTcc2eYuZP7PgoPHQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjptFWqtg%253D%253D&md5=7d9d400857a6cf11cfe1f58acf5c1558</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.35%26sid%3Dliteratum%253Aachs%26aulast%3DVanderMolen%26aufirst%3DK.%2BM.%26aulast%3DMcCulloch%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DC.%2BJ.%26aulast%3DOberlies%26aufirst%3DN.%2BH.%26atitle%3DRomidepsin%2520%2528Istodax%25C2%25AE%252C%2520NSC%2520630176%252C%2520FR901228%252C%2520FK228%252C%2520Depsipeptide%2529%253A%2520a%2520natural%2520product%2520recently%2520approved%2520for%2520cutaneous%2520T-cell%2520lymphoma%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D525%26epage%3D531%26doi%3D10.1038%2Fja.2011.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, T. L.</span>; <span class="NLM_string-name">Williams, D. A.</span>; <span class="NLM_string-name">Roche, V. F.</span>; <span class="NLM_string-name">Zito, S. W.</span></span> <i>Foye’s Principles of Medicinal Chemistry</i>, <span class="NLM_edition">7</span>th ed.; <span class="NLM_publisher-name">Lippincott Williams & Wilkins</span>: <span class="NLM_publisher-loc">Baltimore, MD</span>, <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1231</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1230-1231&author=T.+L.+Lemke&author=D.+A.+Williams&author=V.+F.+Roche&author=S.+W.+Zito&title=Foye%E2%80%99s+Principles+of+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DT.%2BL.%26btitle%3DFoye%25E2%2580%2599s%2520Principles%2520of%2520Medicinal%2520Chemistry%26pub%3DLippincott%2520Williams%2520%2526%2520Wilkins%26date%3D2013%26spage%3D1230%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voaklander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C</span>. <i>Expert Rev. Gastroenterol. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">789</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1080/17474124.2017.1351295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1080%2F17474124.2017.1351295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28673106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GgtLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=789-795&author=R.+Voaklanderauthor=I.+M.+Jacobson&title=Sofosbuvir%2C+velpatasvir+and+voxilaprevir+combination+for+the+treatment+of+hepatitis+C&doi=10.1080%2F17474124.2017.1351295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C</span></div><div class="casAuthors">Voaklander, Rebecca; Jacobson, Ira M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">789-795</span>CODEN:
                <span class="NLM_cas:coden">ERGHBD</span>;
        ISSN:<span class="NLM_cas:issn">1747-4124</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The advent of direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infection has dramatically increased rates of cure.  However, there remain difficult-to-treat populations, including patients with genotype 3 infection and cirrhosis, and limited salvage treatment options for those that have failed first-line DAA therapy.  This is a review of the preclin. and clin. development of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pangenotypic treatment for chronic HCV infection.  All relevant literature from 2015 through June of 2017 is included.  Voxilaprevir, a second-generation HCV protease inhibitor, in combination with the already approved combination of sofosbuvir and velpatasvir, was evaluated in the POLARIS trials and found to be a safe and effective regimen.  Patients with prior DAA treatment failure, genotype 3, cirrhosis and/or unfavorable resistance profiles all achieved cure rates of 96% or greater.  The most distinctive role for this potent regimen may prove to be as a salvage regimen for patients who have failed previous DAA therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTwrcUuIHzrVg90H21EOLACvtfcHk0li0Unbqd1NBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GgtLzM&md5=f29dce08c1f55ecfb232a82b51a4ff72</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F17474124.2017.1351295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474124.2017.1351295%26sid%3Dliteratum%253Aachs%26aulast%3DVoaklander%26aufirst%3DR.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26atitle%3DSofosbuvir%252C%2520velpatasvir%2520and%2520voxilaprevir%2520combination%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2017%26volume%3D11%26spage%3D789%26epage%3D795%26doi%3D10.1080%2F17474124.2017.1351295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghavendra, T.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular blocking drugs: discovery and development</span>. <i>J. R. Soc. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1177/014107680209500713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1177%2F014107680209500713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=12091515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2002&pages=363-367&author=T.+Raghavendra&title=Neuromuscular+blocking+drugs%3A+discovery+and+development&doi=10.1177%2F014107680209500713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular blocking drugs: discovery and development</span></div><div class="casAuthors">Raghavendra, Thandla</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">363-367</span>CODEN:
                <span class="NLM_cas:coden">JRSMD9</span>;
        ISSN:<span class="NLM_cas:issn">0141-0768</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Medicine Press Ltd.</span>)
        </div><div class="casAbstract">A review, describing the history of the discovery of naturally occurring neuromuscular blocking drugs and the development of synthetic ones.  However, all the currently available agents have their limitations, and the quest continues for an ideal drug.  What is needed is an agent that is rapidly acting, noncumulative, independent of renal or hepatic function for its elimination, free of side effects, and with an easily and rapidly reversed action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEJW44rC1XpbVg90H21EOLACvtfcHk0li0Unbqd1NBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFOqtr0%253D&md5=859e83053612c68cc0ec3150b57ee4c5</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1177%2F014107680209500713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F014107680209500713%26sid%3Dliteratum%253Aachs%26aulast%3DRaghavendra%26aufirst%3DT.%26atitle%3DNeuromuscular%2520blocking%2520drugs%253A%2520discovery%2520and%2520development%26jtitle%3DJ.%2520R.%2520Soc.%2520Med.%26date%3D2002%26volume%3D95%26spage%3D363%26epage%3D367%26doi%3D10.1177%2F014107680209500713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nn.4508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fnn.4508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28192393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisV2kt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2017&pages=497-499&author=D.+R.+Corey&title=Nusinersen%2C+an+antisense+oligonucleotide+drug+for+spinal+muscular+atrophy&doi=10.1038%2Fnn.4508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy</span></div><div class="casAuthors">Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">497-499</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy.  Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as treatments for devastating neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfVaBRLymn7bVg90H21EOLACvtfcHk0li0Unbqd1NBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisV2kt7Y%253D&md5=09738c5d61054b2f7a20a35e3396233b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fnn.4508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn.4508%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DNusinersen%252C%2520an%2520antisense%2520oligonucleotide%2520drug%2520for%2520spinal%2520muscular%2520atrophy%26jtitle%3DNat.%2520Neurosci.%26date%3D2017%26volume%3D20%26spage%3D497%26epage%3D499%26doi%3D10.1038%2Fnn.4508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooke, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04469.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1111%2Fj.1365-2125.2012.04469.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23013161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=269-276&author=S.+T.+Crookeauthor=R.+S.+Geary&title=Clinical+pharmacological+properties+of+mipomersen+%28Kynamro%29%2C+a+second+generation+antisense+inhibitor+of+apolipoprotein+B&doi=10.1111%2Fj.1365-2125.2012.04469.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B</span></div><div class="casAuthors">Crooke, Stanley T.; Geary, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">269-276</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Mipomersen is a second generation antisense oligonucleotide that targets apolipoprotein B. It has been studied thoroughly in clin. trials (more than 800 subjects), including four randomized double-blind placebo controlled phase 3 studies involving 391 patients, and is in registration for the treatment of severe hypercholesterolemia.  The pharmacokinetic and pharmacodynamic properties of mipomersen are well characterized.  Mipomersen is rapidly and extensively absorbed after s.c. administration and has an elimination half-life of approx. 30 days across species.  It is cleared by nuclease metab. and renal excretion of the metabolites.  Mipomersen reduces all apolipoprotein B contg. atherogenic particles and displays dose dependent redns. between 50-400 mg week-1, both as a single agent and in the presence of maximal lipid lowering therapy.  No drug-drug interactions have been identified.  Mipomersen is a representative of second generation antisense drugs, all of which have similar properties, and is thus representative of the behavior of the class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXj4NgMtz247Vg90H21EOLACvtfcHk0li0Unbqd1NBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLvM&md5=28b5ae402fbe98a8f10829c2a6effcdf</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04469.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04469.x%26sid%3Dliteratum%253Aachs%26aulast%3DCrooke%26aufirst%3DS.%2BT.%26aulast%3DGeary%26aufirst%3DR.%2BS.%26atitle%3DClinical%2520pharmacological%2520properties%2520of%2520mipomersen%2520%2528Kynamro%2529%252C%2520a%2520second%2520generation%2520antisense%2520inhibitor%2520of%2520apolipoprotein%2520B%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D269%26epage%3D276%26doi%3D10.1111%2Fj.1365-2125.2012.04469.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. R. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, T.</span></span> <span> </span><span class="NLM_article-title">Eteplirsen in the treatment of duchenne muscular dystrophy</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S97635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2147%2FDDDT.S97635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=28280301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=533-545&author=K.+R.+Q.+Limauthor=R.+Maruyamaauthor=T.+Yokota&title=Eteplirsen+in+the+treatment+of+duchenne+muscular+dystrophy&doi=10.2147%2FDDDT.S97635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Eteplirsen in the treatment of Duchenne muscular dystrophy</span></div><div class="casAuthors">Lim, Kenji Rowel Q.; Maruyama, Rika; Yokota, Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-545</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500-5,000 male births that is characterized by progressive muscular deterioration.  It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers.  In Sept. 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin prodn. by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants.  Eteplirsen is applicable for approx. 14% of patients with DMD mutations.  This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacol., efficacy, safety, and tolerability data from preclin. and clin. trials.  Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified.  Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-ziUr-zzsF7Vg90H21EOLACvtfcHk0lhkQTWem8rfzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOgs7vK&md5=e15f242dc4307bb85413134170dbcd6f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S97635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S97635%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DK.%2BR.%2BQ.%26aulast%3DMaruyama%26aufirst%3DR.%26aulast%3DYokota%26aufirst%3DT.%26atitle%3DEteplirsen%2520in%2520the%2520treatment%2520of%2520duchenne%2520muscular%2520dystrophy%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D533%26epage%3D545%26doi%3D10.2147%2FDDDT.S97635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alquwaizani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanikos, J.</span></span> <span> </span><span class="NLM_article-title">Anticoagulants: a review of the pharmacology, dosing, and complications</span>. <i>Curr. Emerg. Hosp. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1007/s40138-013-0014-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1007%2Fs40138-013-0014-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=23687625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpsVamtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=83-97&author=M.+Alquwaizaniauthor=L.+Buckleyauthor=C.+Adamsauthor=J.+Fanikos&title=Anticoagulants%3A+a+review+of+the+pharmacology%2C+dosing%2C+and+complications&doi=10.1007%2Fs40138-013-0014-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Anticoagulants: A Review of the Pharmacology, Dosing, and Complications</span></div><div class="casAuthors">Alquwaizani Mohammed; Buckley Leo; Adams Christopher; Fanikos John</div><div class="citationInfo"><span class="NLM_cas:title">Current emergency and hospital medicine reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-97</span>
        ISSN:<span class="NLM_cas:issn">2167-4884</span>.
    </div><div class="casAbstract">Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis.  Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring intervention.  Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease of use and more favorable pharmacodynamic profiles.  Hemorrhage is the main concerning adverse event with all anticoagulants.  With their ubiquitous use, it becomes important for clinicians to have a sound understanding of anticoagulant pharmacology, dosing, and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ39MnxRVsc5AHqQV89nF-2fW6udTcc2eZyi6Mf7qVyl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpsVamtA%253D%253D&md5=47a40ab236ca6b0304cd83865f6d496b</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1007%2Fs40138-013-0014-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40138-013-0014-6%26sid%3Dliteratum%253Aachs%26aulast%3DAlquwaizani%26aufirst%3DM.%26aulast%3DBuckley%26aufirst%3DL.%26aulast%3DAdams%26aufirst%3DC.%26aulast%3DFanikos%26aufirst%3DJ.%26atitle%3DAnticoagulants%253A%2520a%2520review%2520of%2520the%2520pharmacology%252C%2520dosing%252C%2520and%2520complications%26jtitle%3DCurr.%2520Emerg.%2520Hosp.%2520Med.%2520Rep.%26date%3D2013%26volume%3D1%26spage%3D83%26epage%3D97%26doi%3D10.1007%2Fs40138-013-0014-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">835</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666060-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2165%2F00003495-200666060-00006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=821-835&author=V.+R.+Andersonauthor=C.+M.+Perry&title=Pentosan+polysulfate%3A+a+review+of+its+use+in+the+relief+of+bladder+pain+or+discomfort+in+interstitial+cystitis&doi=10.2165%2F00003495-200666060-00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666060-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666060-00006%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DV.%2BR.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DPentosan%2520polysulfate%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520relief%2520of%2520bladder%2520pain%2520or%2520discomfort%2520in%2520interstitial%2520cystitis%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D821%26epage%3D835%26doi%3D10.2165%2F00003495-200666060-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papakonstantinou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakiulakis, G.</span></span> <span> </span><span class="NLM_article-title">Hyaluronic acid: A key molecule in skin aging</span>. <i>Derm.-Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.4161/derm.21923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.4161%2Fderm.21923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslSgsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=253-258&author=E.+Papakonstantinouauthor=M.+Rothauthor=G.+Karakiulakis&title=Hyaluronic+acid%3A+A+key+molecule+in+skin+aging&doi=10.4161%2Fderm.21923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Hyaluronic acid: A key molecule in skin aging</span></div><div class="casAuthors">Papakonstantinou, Eleni; Roth, Michael; Karakiulakis, George</div><div class="citationInfo"><span class="NLM_cas:title">Dermato-Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-258</span>CODEN:
                <span class="NLM_cas:coden">DERMFJ</span>;
        ISSN:<span class="NLM_cas:issn">1938-1972</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Skin aging is a multifactorial process consisting of two distinct and independent mechanisms: intrinsic and extrinsic aging.  Youthful skin retains its turgor, resilience and pliability, among others, due to its high content of water.  Daily external injury, in addn. to the normal process of aging, causes loss of moisture.  The key mol. involved in skin moisture is hyaluronic acid (HA) that has unique capacity in retaining water.  There are multiple sites for the control of HA synthesis, deposition, cell and protein assocn. and degrdn., reflecting the complexity of HA metab.  The enzymes that synthesize or catabolize HA and HA receptors responsible for many of the functions of HA are all multigene families with distinct patterns of tissue expression.  Understanding the metab. of HA in the different layers of the skin and the interactions of HA with other skin components will facilitate the ability to modulate skin moisture in a rational manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxtFo068TDgLVg90H21EOLACvtfcHk0lhkQTWem8rfzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslSgsLs%253D&md5=5990c9c07a878a75c167089b5282cd52</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4161%2Fderm.21923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fderm.21923%26sid%3Dliteratum%253Aachs%26aulast%3DPapakonstantinou%26aufirst%3DE.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DKarakiulakis%26aufirst%3DG.%26atitle%3DHyaluronic%2520acid%253A%2520A%2520key%2520molecule%2520in%2520skin%2520aging%26jtitle%3DDerm.-Endocrinol.%26date%3D2012%26volume%3D4%26spage%3D253%26epage%3D258%26doi%3D10.4161%2Fderm.21923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triplett, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miloslavsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span> <span> </span><span class="NLM_article-title">Defibrotide for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome: interim results from a treatment IND study</span>. <i>Biol. Blood Marrow Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1016/j.bbmt.2017.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.bbmt.2017.03.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=997-1004&author=P.+G.+Richardsonauthor=A.+R.+Smithauthor=B.+M.+Triplettauthor=N.+A.+Kernanauthor=S.+A.+Gruppauthor=J.+H.+Antinauthor=L.+Lehmannauthor=T.+Shoreauthor=M.+Iacobelliauthor=M.+Miloslavskyauthor=R.+Humeauthor=A.+L.+Hannahauthor=B.+Nejadnikauthor=R.+J.+Soiffer&title=Defibrotide+for+patients+with+hepatic+veno-occlusive+disease%2Fsinusoidal+obstruction+syndrome%3A+interim+results+from+a+treatment+IND+study&doi=10.1016%2Fj.bbmt.2017.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bbmt.2017.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbmt.2017.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DSmith%26aufirst%3DA.%2BR.%26aulast%3DTriplett%26aufirst%3DB.%2BM.%26aulast%3DKernan%26aufirst%3DN.%2BA.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DShore%26aufirst%3DT.%26aulast%3DIacobelli%26aufirst%3DM.%26aulast%3DMiloslavsky%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DR.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DNejadnik%26aufirst%3DB.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26atitle%3DDefibrotide%2520for%2520patients%2520with%2520hepatic%2520veno-occlusive%2520disease%252Fsinusoidal%2520obstruction%2520syndrome%253A%2520interim%2520results%2520from%2520a%2520treatment%2520IND%2520study%26jtitle%3DBiol.%2520Blood%2520Marrow%2520Transplant.%26date%3D2017%26volume%3D23%26spage%3D997%26epage%3D1004%26doi%3D10.1016%2Fj.bbmt.2017.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, P.</span></span> <span> </span><span class="NLM_article-title">Not boring at all. Boron is the new carbon in the quest for novel drug candidates</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1038/embor.2009.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1038%2Fembor.2009.2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=125-128&author=P.+Hunter&title=Not+boring+at+all.+Boron+is+the+new+carbon+in+the+quest+for+novel+drug+candidates&doi=10.1038%2Fembor.2009.2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fembor.2009.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2009.2%26sid%3Dliteratum%253Aachs%26aulast%3DHunter%26aufirst%3DP.%26atitle%3DNot%2520boring%2520at%2520all.%2520Boron%2520is%2520the%2520new%2520carbon%2520in%2520the%2520quest%2520for%2520novel%2520drug%2520candidates%26jtitle%3DEMBO%2520Rep.%26date%3D2009%26volume%3D10%26spage%3D125%26epage%3D128%26doi%3D10.1038%2Fembor.2009.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aly, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González Soto, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollak, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.jaad.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=25956661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2015&pages=62-69&author=B.+E.+Elewskiauthor=R.+Alyauthor=S.+L.+Baldwinauthor=R.+F.+Gonz%C3%A1lez+Sotoauthor=P.+Richauthor=M.+Weisfeldauthor=H.+Wiltzauthor=L.+T.+Zaneauthor=R.+Pollak&title=Efficacy+and+safety+of+tavaborole+topical+solution%2C+5%25%2C+a+novel+boron-based+antifungal+agent%2C+for+the+treatment+of+toenail+onychomycosis%3A+Results+from+2+randomized+phase-III+studies&doi=10.1016%2Fj.jaad.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies</span></div><div class="casAuthors">Elewski, Boni E.; Aly, Raza; Baldwin, Sheryl L.; Gonzalez Soto, Remigio F.; Rich, Phoebe; Weisfeld, Max; Wiltz, Hector; Zane, Lee T.; Pollak, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Onychomycosis, a fungal nail infection, can impact quality of life.  We sought to evaluate the efficacy and safety of tavaborole topical soln., 5% for treatment of toenail onychomycosis.  In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 wk.  The primary end point was complete cure of the target great toenail (completely clear nail with neg. mycol.) at week 52.  Secondary end points included completely or almost clear nail, neg. mycol., completely or almost clear nail plus neg. mycol., and safety.  Rates of neg. mycol. (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs 0.5% and 1.5%) significantly favored tavaborole vs. vehicle (P ≤ .001).  Completely or almost clear nail rates also significantly favored tavaborole vs. vehicle (26.1%-27.5% vs 9.3%-14.6%; P < .001).  Rates of completely or almost clear nail plus neg. mycol. (15.3%-17.9% vs 1.5%-3.9%) were significantly greater for tavaborole vs. vehicle (P < .001).  Application-site reactions with tavaborole included exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).  Duration of follow-up is a limitation.  Tavaborole demonstrates a favorable benefit-risk profile in treatment of toenail onychomycosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq57HESc8Cdt7Vg90H21EOLACvtfcHk0ljHiSNV3NZHmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFSqtrs%253D&md5=ce2bd25a222bec52157508b38f9971f9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DElewski%26aufirst%3DB.%2BE.%26aulast%3DAly%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DS.%2BL.%26aulast%3DGonz%25C3%25A1lez%2BSoto%26aufirst%3DR.%2BF.%26aulast%3DRich%26aufirst%3DP.%26aulast%3DWeisfeld%26aufirst%3DM.%26aulast%3DWiltz%26aufirst%3DH.%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DPollak%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520tavaborole%2520topical%2520solution%252C%25205%2525%252C%2520a%2520novel%2520boron-based%2520antifungal%2520agent%252C%2520for%2520the%2520treatment%2520of%2520toenail%2520onychomycosis%253A%2520Results%2520from%25202%2520randomized%2520phase-III%2520studies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2015%26volume%3D73%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.jaad.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zane, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnagin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, L. S.</span></span> <span> </span><span class="NLM_article-title">Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies</span>. <i>Immunotherapy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.2217/imt-2016-0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.2217%2Fimt-2016-0023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=853-866&author=L.+T.+Zaneauthor=S.+Chandaauthor=K.+Jarnaginauthor=D.+B.+Nelsonauthor=L.+Spelmanauthor=L.+S.+Gold&title=Crisaborole+and+its+potential+role+in+treating+atopic+dermatitis%3A+overview+of+early+clinical+studies&doi=10.2217%2Fimt-2016-0023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.2217%2Fimt-2016-0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fimt-2016-0023%26sid%3Dliteratum%253Aachs%26aulast%3DZane%26aufirst%3DL.%2BT.%26aulast%3DChanda%26aufirst%3DS.%26aulast%3DJarnagin%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DD.%2BB.%26aulast%3DSpelman%26aufirst%3DL.%26aulast%3DGold%26aufirst%3DL.%2BS.%26atitle%3DCrisaborole%2520and%2520its%2520potential%2520role%2520in%2520treating%2520atopic%2520dermatitis%253A%2520overview%2520of%2520early%2520clinical%2520studies%26jtitle%3DImmunotherapy%26date%3D2016%26volume%3D8%26spage%3D853%26epage%3D866%26doi%3D10.2217%2Fimt-2016-0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Docquier, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangani, S.</span></span> <span> </span><span class="NLM_article-title">An update on β-lactamase inhibitor discovery and development</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2017.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1016%2Fj.drup.2017.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=29499835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrnt1Srtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=13-29&author=J.+D.+Docquierauthor=S.+Mangani&title=An+update+on+%CE%B2-lactamase+inhibitor+discovery+and+development&doi=10.1016%2Fj.drup.2017.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">An update on β-lactamase inhibitor discovery and development</span></div><div class="casAuthors">Docquier Jean-Denis; Mangani Stefano</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibiotic resistance, and the emergence of pan-resistant clinical isolates, seriously threatens our capability to treat bacterial diseases, including potentially deadly hospital-acquired infections.  This growing issue certainly requires multiple adequate responses, including the improvement of both diagnosis methods and use of antibacterial agents, and obviously the development of novel antibacterial drugs, especially active against Gram-negative pathogens, which represent an urgent medical need.  Considering the clinical relevance of both β-lactam antibiotics and β-lactamase-mediated resistance, the discovery and development of combinations including a β-lactamase inhibitor seems to be particularly attractive, despite being extremely challenging due to the enormous diversity, both structurally and mechanistically, of the potential β-lactamase targets.  This review will cover the evolution of currently available β-lactamase inhibitors along with the most recent research leading to new β-lactamase inhibitors of potential clinical interest or already in the stage of clinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsXMDgBdiPxe2qxNLjzXe8fW6udTcc2eb4XoBlog9cJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrnt1Srtw%253D%253D&md5=540d110de464506f4a4f4053e5ab4014</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2017.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DDocquier%26aufirst%3DJ.%2BD.%26aulast%3DMangani%26aufirst%3DS.%26atitle%3DAn%2520update%2520on%2520%25CE%25B2-lactamase%2520inhibitor%2520discovery%2520and%2520development%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2018%26volume%3D36%26spage%3D13%26epage%3D29%26doi%3D10.1016%2Fj.drup.2017.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woynarowski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaney, S. G.</span></span> <span> </span><span class="NLM_article-title">Oxaliplatin: mechanism of action and antineoplastic activity</span>. <i>Semin Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2, Suppl. 5</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=9609103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADyaK1cXjvVCkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1998&pages=4-12&issue=2%2C+Suppl.+5&author=E.+Raymondauthor=S.+Faivreauthor=J.+M.+Woynarowskiauthor=S.+G.+Chaney&title=Oxaliplatin%3A+mechanism+of+action+and+antineoplastic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Oxaliplatin: mechanism of action and antineoplastic activity</span></div><div class="casAuthors">Raymond, Eric; Faivre, Sandrine; Woynarowski, Jan M.; Chaney, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2, Suppl. 5</span>),
    <span class="NLM_cas:pages">4-12</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review with 53 refs.  Oxaliplatin, a platinum-based chemotherapeutic agent with a 1,2-diaminocyclohexane (DACH) carrier ligand, has shown in vitro and in vivo efficacy against many tumor cell lines, including some that are resistant to cisplatin and carboplatin.  The retention of the bulky DACH ring by activated oxaliplatin is thought to result in the formation of platinum-DNA adducts, which appear to be more effective at blocking DNA replication and are more cytotoxic than adducts formed from cisplatin.  Studies by the National Cancer Institute (NCI) have suggested that oxaliplatin has a spectrum of activity different from that of either cisplatin or carboplatin, suggesting that it has different mol. targets and/or mechanisms of resistance.  Oxaliplatin has been demonstrated to differ in some mechanisms assocd. with the development of cisplatin resistance.  Compared with cisplatin-conditioned cells, deficiencies in mismatch repair (MMR) and increases in replicative bypass, which appear to contribute to cisplatin resistance, have not been shown to induce a similar resistance to oxaliplatin.  A decreased likelihood of resistance development makes oxaliplatin a good candidate for first-line therapy.  Studies also demonstrate additive and/or synergistic activity with a no. of other compds., however, suggesting the possible use of oxaliplatin in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocQ9VzgmgYerVg90H21EOLACvtfcHk0ljvqwwsy83n8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjvVCkt70%253D&md5=2efebcd0a89dbf7be44302650e5ac755</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaymond%26aufirst%3DE.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DWoynarowski%26aufirst%3DJ.%2BM.%26aulast%3DChaney%26aufirst%3DS.%2BG.%26atitle%3DOxaliplatin%253A%2520mechanism%2520of%2520action%2520and%2520antineoplastic%2520activity%26jtitle%3DSemin%2520Oncol.%26date%3D1998%26volume%3D25%26issue%3D2%252C%2520Suppl.%25205%26spage%3D4%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroussent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veal, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paci, A.</span></span> <span> </span><span class="NLM_article-title">Oxazaphosphorines: new therapeutic strategies for an old class of drugs</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">938</span>, <span class="refDoi"> DOI: 10.1517/17425255.2010.487861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1517%2F17425255.2010.487861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=20446865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=919-938&author=B.+Giraudauthor=G.+Hebertauthor=A.+Deroussentauthor=G.+J.+Vealauthor=G.+Vassalauthor=A.+Paci&title=Oxazaphosphorines%3A+new+therapeutic+strategies+for+an+old+class+of+drugs&doi=10.1517%2F17425255.2010.487861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazaphosphorines: new therapeutic strategies for an old class of drugs</span></div><div class="casAuthors">Giraud, Berenice; Hebert, Guillaume; Deroussent, Alain; Veal, Gareth J.; Vassal, Gilles; Paci, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">919-938</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The oxazaphosphorines (cyclophosphamide, ifosfamide and trofosfamide) are widely used in clin. practice for their antitumor and immunomodulatory activities.  However, their use is assocd. with toxicities.  The metab. of oxazaphosphorines involves cytochrome P 450 biotransformations, leading to highly reactive metabolites such as acrolein and chloroacetaldehyde responsible for urotoxicity, neurotoxicity and nephrotoxicity.  While the mechanisms behind these toxicities remain under investigation, some advances have been made, as exemplified by the use of mesna to limit acrolein related urotoxicity.  Areas covered in this review: This review highlights potential strategies for limiting side effects commonly assocd. with the oxazaphosphorine drugs, through pharmacol. or medicinal chem.-based approaches.  What the reader will gain: The readers will gain a comprehensive review of these approaches to treatment in terms of: (i) pharmacol.: use of antidotes and modification of metab. through inhibition/induction of CYP enzymes or use of gene therapy; and (ii) medicinal chem.: the design of new drugs to target cancer cells and avoid CYP biotransformation with pre-activated prodrugs or with side-chain substituted analogs.Take home message: An increased knowledge of oxazaphosphorines' metab. and toxicity may allow the development of new anticancer drugs combined with drug delivery systems to circumvent drug toxicity, providing increased tumoral specificity and greater anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH90kS_9RgXLVg90H21EOLACvtfcHk0ljvqwwsy83n8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSqurY%253D&md5=88cefc6ffb275ee5257a61b34f8100b7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1517%2F17425255.2010.487861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2010.487861%26sid%3Dliteratum%253Aachs%26aulast%3DGiraud%26aufirst%3DB.%26aulast%3DHebert%26aufirst%3DG.%26aulast%3DDeroussent%26aufirst%3DA.%26aulast%3DVeal%26aufirst%3DG.%2BJ.%26aulast%3DVassal%26aufirst%3DG.%26aulast%3DPaci%26aufirst%3DA.%26atitle%3DOxazaphosphorines%253A%2520new%2520therapeutic%2520strategies%2520for%2520an%2520old%2520class%2520of%2520drugs%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2010%26volume%3D6%26spage%3D919%26epage%3D938%26doi%3D10.1517%2F17425255.2010.487861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antman, K. H.</span></span> <span> </span><span class="NLM_article-title">Introduction: the history of arsenic trioxide in cancer therapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">2</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.6-suppl_2-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=10.1634%2Ftheoncologist.6-suppl_2-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2001&pages=1-2&issue=Suppl.+2&author=K.+H.+Antman&title=Introduction%3A+the+history+of+arsenic+trioxide+in+cancer+therapy&doi=10.1634%2Ftheoncologist.6-suppl_2-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.6-suppl_2-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.6-suppl_2-1%26sid%3Dliteratum%253Aachs%26aulast%3DAntman%26aufirst%3DK.%2BH.%26atitle%3DIntroduction%253A%2520the%2520history%2520of%2520arsenic%2520trioxide%2520in%2520cancer%2520therapy%26jtitle%3DOncologist%26date%3D2001%26volume%3D6%26issue%3DSuppl.%25202%26spage%3D1%26epage%3D2%26doi%3D10.1634%2Ftheoncologist.6-suppl_2-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, O.</span></span> <span> </span><span class="NLM_article-title">Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease</span>. <i>Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">Suppl. 10</span>),  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S12</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;key=16985930" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=S3-S12&issue=Suppl.+10&author=O.+Sartor&title=Overview+of+samarium+Sm+153+lexidronam+in+the+treatment+of+painful+metastatic+bone+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSartor%26aufirst%3DO.%26atitle%3DOverview%2520of%2520samarium%2520Sm%2520153%2520lexidronam%2520in%2520the%2520treatment%2520of%2520painful%2520metastatic%2520bone%2520disease%26jtitle%3DRev.%2520Urol.%26date%3D2004%26volume%3D6%26issue%3DSuppl.%252010%26spage%3DS3%26epage%3DS12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00876&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-24%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00876%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00876" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b26819e8f1252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
